question stringlengths 14 1.69M | answer stringlengths 1 40.5k | meat_tokens int64 1 8.18k |
|---|---|---|
The company is incorporated as an Agricultural Cooperative, governed by the General Law of Cooperatives, its statutes and internal regulations.
Established in the year 2007 with 47 partners, all small farmers from the Choapa province, Coquimbo Region.
Because of their actions, by the year<|fim_middle|> small farmers from the system of the Agrarian Reform are located in different places of the Salamanca, Illapel and Los Vilos communes, Choapa province, Coquimbo Region. In terms of gender, there are 79 men and 11 women.
The company is constituted as Agricultural Cooperative, governed by the General Law of Cooperatives, its Statutes and Internal Regulation.
Plant: RESTO RESERVA CORA F, LOTE H, PERALILLO COMUNA ILLAPEL, REGION DE COQUIMBO CHILE.
Get our lattest updates by suscribing to our Newsletter. | 2014, the number of partners grew up to 90, with a surface between the partners of 164 acres, planted with walnuts, divided in three varieties: Serr variety (80%), Chandler variety (13%) and California type nut or seed (8%).
All | 64 |
We have heard a lot lately about the technology which could allow self driving cars on the road and the latest news from Oxford University certainly seems to make it seem like something which could happen soon.
The car in question uses a mixture of small cameras and lasers to let it work out when<|fim_middle|> they are "working with" the Department of Transport in order to try and get some testing done on the UK roads. At the moment they are giving it a try in a specially built testing centre at the Begbroke Science Park in Oxfordshire which the professor described as being a "light industrial site with road markings" where the car's navigation and control can be tested.
The key is that the vehicle simply recognises its surroundings and can take over when it is on a route it is already familiar with. A touch on the brake pedal will give full control back to the human driver.
* environmental conditions allowing it.
* the price of the technical features needed. | it is following a familiar route. It then memorises the trip. This means that it could potentially be let loose on its own for your commute to work or the daily trip to school.
The idea has been designed to cost little money and to take some of the "strain" off drivers. Of course, researchers at Google have been looking at producing something similar and have even pushed for a change to the law in California so that they can try out their car in the real world.
The Oxford version is the result of the Oxford RobotCar UK project and one of the key players is called Professor Paul Newman, who works in the university's department of engineering science.
Prof Newman said that | 137 |
Curious about New East Side condos in Chicago? See New East Side real estate listings below or keep reading about this wonderful community. You can also use our free registration, allowing you to save your favorite properties to view later, customize your searches and to sign up for email alerts when New East Side<|fim_middle|> lakefront. And given this optimal location in the city, buildings like The Aqua, The Lancaster, The Regatta, and The Chandler nicely combine lavish interior spaces with fabulous common amenities and the convenience of being close to a number of attractions, like Michigan Avenue and Millennium Park just to name a couple, as well as Chicago's major business and financial hub in The Loop. A limited number of luxury townhomes are also part of the high-end real estate market around the New Eastside, but inventory for these very highly-sought after properties can be extremely limited!
Contact Helaine Cohen to learn more about available properties in the New East Side neighborhood of Chicago. | homes become available that meet your criteria.
Home buyers will find everything they need in close proximity, with a full service grocery store and Mariano's Fresh Market on-hand, along with salons, restaurants, and other conveniences at the Village Market Center. Also within the community is Lakeshore East, a planned development featuring 5,000+ units, commercial space and a 6-acre park. Several of the individual buildings in Lakeshore East have won awards for their architecture and urban planning.
New East Side real estate is within walking distance of the Chicago River, Lake Michigan, DuSable Harbor, Michigan Avenue, the downtown loop, Grant Park and Millennium Park, as well as numerous shopping, dining and cultural venues.
The New Eastside part of downtown Chicago is know for its luxury high-rises and award winning architecture, especially given its one of the newly developed parts of the | 181 |
Representing the Commonwealth, Secretary-General Patricia Scotland said the event was a prime opportunity to shift the global spotlight onto countries that are still suffering the aftermath of Hurricanes Maria and Irma that devastated Antigua and Barbuda, Dominica, Puerto Rico, the Virgin Islands and others in 2017.
The Secretary-General continued, "But there is a lot more work to do politically, socially and economically. For example, we still have to address the issue of absorptive capacity, which is the ability to effectively access and<|fim_middle|> far £4.1 million has been mobilised for Commonwealth members from an initial investment of AU$1 million, with a further £201 million in the pipeline.
A world-class debt management programme to help countries create effective debt management strategies.
Opening the event, President Bill Clinton commended the Commonwealth and others for continuing to support the countries affected by Hurricanes Maria and Irma.
Dominican Foreign Minister Francine Baron, reiterated the Secretary-General's call for a 'resilience lab' in countries like Dominica to learn from countries' response to the diverse climatic and other challenges inherent in post-disaster recovery.
She said, "We heard the Secretary-General of the Commonwealth talk about 31 states that have similar challenges to Dominica, and we are hoping we can develop systems, procedures, toolkits that can be replicated in other countries that will be facing similar challenges. | use donated development assistance - particularly as a preliminary Commonwealth study shows that vulnerable countries failed to receive and use US$4.5 billion worth of development assistance donated between 2010 and 2016.
The Secretary-General said that commitments made will ensure Antigua and Barbuda, Dominica and all the countries affected by Hurricanes Maria and Irma can continue to rebuild economies, infrastructure, communities and homes that are strong enough to withstand the onslaught of future natural disasters.
In 2016, the Commonwealth Secretariat launched the Commonwealth Climate Finance Access Hub, which installs experts in its developing member countries to ensure that their applications for climate-related funding are successful. So | 135 |
How Facebook Can Make Museums More Social (And Why Jewish Organizations Should Pay Attention)
By Rachel Jarman Myers | August 30, 2016
From the Collection: I See / I Think / I Wonder
Finding Jewish Life in Unexpected Places<|fim_middle|> Southern Jewish Communities
I find the PBDM charming because it breaks most of the typical formats of an online collection. The albums are not classified chronologically, not by theme, not by any means as far as I can tell. There is no search tool to find something specific to the history of Pine Bluff you may be interested in. That's where I find the surprising beauty of this Desktop Museum. It somehow produces that feeling of opening a box of old photos, sorting through each one quickly checking the backside for a handwritten note identifying the faces and places. It produces a museum experience that facilitates the joy of discovery. As a Jewish museum professional, I was looking for an image of old Jewish stores, but I ended up delighted by so much more.
The site is focuses on connecting the "Pine Bluff Diaspora" — people of all generations who have a connection to Pine Bluff but are no longer there can now walk down memory lane together. The comments on the photos provide a warm sense of familiarity, and personal connections to each of the museums' items on exhibit. I spent time looking for some Jewish content but was immediately drawn in by the variety. I don't have a personal connection to Pine Bluff (although I wrote about a photo in the ISJL's collection from Pine Bluff) but I now have a real appreciation for their unique Zebra mascot!
This summer, the remaining Jewish community in Pine Bluff held their final service at Anshe Emeth. The congregation worked with the Jewish Community Legacy Project to develop plans to deconsecrate the building and a few items were donated to the Museum of the Southern Jewish Experience.
Jewish museums can learn a lot from the Pine Bluff Diaspora. Actually, all Jewish organizations can learn from this model! We certainly understand the term "Diaspora," and we are part of many diasporas. Congregations could have albums from each decade to connect even kids who have grown and moved away with their home congregations; museums can have virtual album-exhibits; the possibilities for connection are exciting and engaging, and I encourage you to check out the Pine Bluff Desktop Museum, and be inspired by how you might share the memorabilia and memories from your communities in the social space.
Jewish food, holidays, Torah, Shabbat, history, blogs and more in your inbox – sign up now!
Getting to Know (Jewish) Natchez
Last week, I was on the road with TENT, a week-long traveling seminar on culture, history, and social justice for ...
Reflections on Remembrance: Memorial Day and More
Memorial Day is approaching, and while I'm usually swept up in the parades, beach trips and community cookouts, this year ...
What Makes A House A (Jewish) Home?
The mezuzah isn't a finishing touch, but a starting point. |
My Jewish Learning is a not-for-profit and relies on your help
Southern & Jewish celebrates the stories, people, and experiences – past and present – of Jewish life in the American South. Hosted by the Goldring/Woldenberg Institute of Southern Jewish Life, posts come from educators, students, rabbis, parents, artists, and many other "visitors-to and daily-livers-of" the Southern Jewish experience. From road trips to recipes to reflections, we'll explore a little bit of everything – well, at least all things Southern and/or Jewish. Shalom, y'all!
I've been active on Facebook since 2004. Right before I started college, Brandeis University was added to the then-still-exclusive site, and I was able to connect with my future classmates. More than a decade later, Facebook has evolved and become a huge force in most of our lives. Today my feed is crowded with baby photos, and I'm grateful for the ability to connect with friends and family across the country. It's become something we all take for granted.
But occasionally the power of the site still manages to surprise me.
The Pine Bluff Desktop Museum
I got a tip recently from a friend, Gary, who shared the online link to Paul Perdue's albums constituting the Pine Bluff Desktop Museum with me. I was confused at first, and tried to overcome my initial skepticism– I'm not sure how I feel about online museums, in general. Often their static materials and limited interactive elements leave much to be desired (I already knew of a few exceptions, of course, like Jewish Women's Archive and 82nd & 5th) but Gary explained to me that this was different: This museum's exhibits are actually hosted on Facebook.
Paul Perdue, the curator of the PBDM, has been collecting any and all material from Pine Bluff, Arkansas. He uses the intuitive, interactive nature of Facebook to get around the failures of a traditional online exhibit. He uses what people are already familiar with and are using, and it works: People love his albums of Pine Bluff memories and memorabilia. Each album contains 200 "pieces," and more than 40 albums have been created thus far.
This project truly embraces some of the current trends that major museums and historic sites are integrating into their practices. As databases are moved online, museum professionals are reimagining the empirical authoritative system of classification but allowing for objects to be described and classified from more inclusive perspectives. Curators are creating more user-friendly web interfaces for collection databases, "folksonomies" are emerging in the classification of collections information, and sites are placing collections information outside the confines of an institution's own web spaces and inviting user input.
The Risenberg Brothers. Source: ISJL Encyclopedia of | 574 |
PressClub Middle East · Article.
The new BMW M5 and BMW M5 Competition.
17.06.2020 Press Kit
The arrival of the new BMW M5 and BMW M5 Competition sees the high-performance sedans from BMW M GmbH returning to the stage in even sharper form.
M Cars
Osama El-Sherif
Tel: +971-4-3129-964
Attachments(<|fim_middle|> g/km). The new BMW M5 Competition (fuel consumption combined: 10.6 – 10.5 l/100 km [26.6 – 26.9 mpg imp]; CO2 emissions combined: 242 – 239 g/km).
Highlights - BMW M5 and BMW M5 Competition PDF, EN, 1.71 MB
Short Version - BMW M5 and BMW M5 Competition PDF, EN, 115.18 KB
Long Version - BMW M5 and BMW M5 Competition PDF, EN, 163.77 KB
Specifications - BMW M5 and BMW M5 Competition PDF, EN, 203.96 KB
Article Media Material.
TV Footage
CO2 emission information.
The following applies to consumption figures for vehicles with new type approval, September 2017 onward: The figures for fuel consumption, CO2 emissions and energy consumption are obtained in accordance with the specified measuring procedure (EC Regulation No. 715/2007), as issued and amended. The figures are for a basic-version vehicle in Germany. The bandwidths allow for differences in the choice of wheel and tire sizes and items of optional equipment and can be changed by the configuration.
Obtained on the basis of the new "Worldwide harmonized Light vehicles Test Procedure" (WLTP), the figures are converted back to the "New European Driving Cycle" (NEDC) for the sake of comparability. Values other than those stated here may be used for the purposes of taxation and for other vehicle-related duties relating to CO2 emissions.
More information about official fuel consumption figures and the official specific CO2 emissions of new passenger cars can be obtained from the "guideline on fuel consumption, CO2 emissions and current consumption of new passenger cars", available here: https://www.dat.de/co2/.
BMW Group confirms outlook for 2020 – significantly improved performance in third quarter
Corporate Finance, Facts, Figures
BMW Group Quarterly Statement to 30 September 2020
Ad-hoc announcement: Preliminary free cash flow for the Automotive segment of BMW AG in the third...
BMW Group Quarterly Report to 30 June 2020
BMW Group reaffirms outlook for full year 2020
Further News for: F90 · M Cars · M5 | 4x, ~2.18 MB)
Photos(101x, ~1,004.61 MB)
BMW M GmbH has made its BMW M5 and BMW M5 Competition high-performance sedans better than ever with some stylistic fine-tuning and a skilfully honed operating concept. The 4.4‑litre V8 engine with BMW M TwinPower Turbo technology generates 441 kW/600 hp in the BMW M5 and 460 kW/625 hp in the BMW M5 Competition. The eight‑speed M Steptronic transmission with Drivelogic comes as standard, as does M xDrive all-wheel drive, which also includes a 2WD setting for pure rear-wheel drive.
Featuring new shock absorbers from the BMW M8 Gran Coupé and a retuned chassis, the BMW M5 Competition offers even better driveability and handling at the limit, combined with superior comfort levels. The BMW M5 Competition sits seven millimetres lower than the BMW M5 and includes other well-conceived tweaks to the suspension and springs. This setup makes allowance for the car's extra power and truly comes into its own on the race track.
The BMW M5 sprints from 0 – 100 km/h (62 mph) in only 3.4 seconds and passes 200 km/h (124 mph) with just 11.1 seconds on the clock. The BMW M5 Competition reaches both marks a fraction more quickly: 100 km/h (62 mph) is up in 3.3 seconds, 200 km/h (124 mph) in 10.8 seconds.
As on the BMW 5 Series range, the updated BMW kidney grille drops down further into the front apron; its chrome surround now has a one-piece design framing both kidney elements, which sport M‑specific double bars and an M badge.
The restyled front apron has bolder contouring and larger air intakes at the sides, while the large central air intake is hexagonal in shape and incorporates the oil cooler along with the radar sensor for the Active Cruise Control (ACC) system.
New L‑shaped light tubes searing in narrow streaks towards the kidney grille add a dynamic flourish to the newly designed LED headlights. The new option of BMW Individual lights Shadowline adds a dark-tinted accent to the Adaptive LED Headlights and BMW Laserlight.
The LED rear lights now have a three-dimensional feel to them and provide a fresh take on the familiar BMW L shape with their precise light graphic.
The larger central display with a diagonal of 12.3 inches makes it easier than ever to keep a clear eye on the myriad functions of the driving dynamics systems and BMW M xDrive.
The new two-button operating concept in the centre console originates from the BMW M8. The M Mode button lets the driver toggle swiftly between the ROAD and SPORT settings. The Setup button takes them straight to the central display's menu, where they can select an individual configuration for the powertrain and chassis options. The BMW M5 Competition also offers TRACK mode, for an undiluted M feeling on race circuits.
The Brands Hatch Grey and Motegi Red metallic colours are both new, as are the BMW Individual finishes Tanzanite Blue II metallic, Aventurine Red II metallic and matt Frozen Bluestone metallic. Champagne Quartz metallic has been renamed Alvit Grey metallic.
The 20-inch M double-spoke wheels in polished Orbit Grey familiar from the BMW M8 are now available as an option.
The standard M Compound brakes can now be specified with callipers painted in High-gloss Black or High-gloss Red as an alternative to the existing blue finish.
Prices in Germany will start at €120,900 for the BMW M5 and €129,900 for the BMW M5 Competition.
CO2 EMISSIONS & CONSUMPTION.
The new BMW M5 (fuel consumption combined: 10.6 – 10.5 l/100 km [26.6 – 26.9 mpg imp]; CO2 emissions combined: 242 – 239 | 877 |
30 years at your service with all the choice pieces that made us famous among our clients. Our philosophy is to try to be always up to date, keeping up with fashion to satisfy all requests. We are in<|fim_middle|> Servizio; Villas such as Palazzo Giovio and Villa Giovio; Churches such as Santa Cecilia and Basilica di Sant'Abbondio; Museums such as Civic Art Gallery and History Museum G. Garibaldi. | constant search of novelty and originality that go hand in hand with good fit, for all those customers who love elegance and sophistication even under a suit. Since we took over the reins of this historic street shop in Milan, in 2011, we tried to give it that added value that plays on youth, yet retains the friendliness and helpfulness of all time.
Nearby Things to Do include: Towns such as Brunate and Blevio; Castles & Ruins such as Como Gate Tower and Broletto; Monuments such as Statue of Alessandro Volta and Monumento ai Caduti per | 126 |
An Updated 16th-Century French Château Seven Years in the Making
23rd October, 2018
When Didier Benderli arrived at a charming 16th-century château in the Parisian countryside, he was expecting a quick intervention. "Originally, the client asked me to come and change the paintwork in some of the rooms and put up curtains in the bedrooms," says the French interior designer behind Paris-based firm Kerylos Intérieurs. But what followed was a total design overhaul. "We ended up breaking down and changing almost everything—and there is not a single pair of curtains in the château."
Though a 19th-century renovation lovingly preserved its intricate boiserie, the property had fallen into disrepair—the château's lifetime has spanned several ownership changes, religious wars, and the French Revolution—and Benderli found the house and its surrounding outbuildings in need of an update that married their history and his client's contemporary lifestyle. "I wanted to restore the original identity of the château, which had faded with time, and consequently create a connection between the original architecture and new interior design," he says.
Over the next seven years, he gutted the place, introducing new heating, ventilation, plumbing, and electrical systems and applying era-appropriate cosmetic fixes across the board: He restored fireplaces, installed antique parquet floors, and replaced windows and roofing tiles. He maintained the gilded accents that appear throughout the home—"We commissioned a cabinetmaker, stonemason, iron craftsman, and painter, among others, all of whom used traditional techniques in their work during the renovation," the designer says—but in the kitchen, he removed partitions to create an airy Calacatta marble-and-steel gathering space for entertaining family-style in the 21st century.
Benderli's genre-bending aesthetic naturally extends to the furnishings and accessories, a mix of antique-store finds and modern-design classics. "We started by choosing pieces that matched our respective tastes but also possessed the elegance that would match the environment," he says. "The Danish design of Finn Juhl, Kaare Klint, and Alvar Aalto, and lighting by Angelo Lelli seemed to fit well." That contemporary current is also highlighted by the artwork, a collection that ranges from a colorful Gaston Chaissac in the living room to a stark Lu Chao diptych in the master bedroom. The result is a home that will no doubt stand the test of time for another five centuries.
For the renovation of a 16th-century château in the Parisian countryside, French designer Didier Benderli maintained the home's sense of history while introducing modern touches in keeping with the homeowner's contemporary lifestyle. Asymmetrical furniture dominates in the library, where a midcentury sofa by Carlo de Carli and chairs by Ico Parisi surround a cocktail table by Gabriella Crespi. The floor lamps are by Philippe Hiquily, and the ashtray is by Fontana Arte Editeur.
A Peter Schoolwerth painting sets the palette for the piano room. A smoked glass-and-brass lighting fixture by Hans Agne Jakobsson hangs above a vignette composed of a midcentury sofa, a Vladimir Kagan chaise, and an Ado Chale cocktail table.
In the living room, the playful lines of a Carlo de Carli sofa mirror the abstract shapes in a custom rug designed by Benderli. The woodwork was painted gray to add depth and dimension.
A Finn Juhl sofa joins wood shelves by Gio Ponti, a Gino Sarfatti floor lamp, and a cast-aluminum cocktail table by Ado Chale in another corner of the living room.
"The dining room is my favorite room," the designer says. "We commissioned sculptor Philippe Anthonioz to create a bronze-and-marble table anchored in the ground, which is in opposition to the light and magnetic spiral of the Poul Hennigsen chandelier." The chairs are by Gio Ponti, and the rug is a custom creation by Benderli.
In a hallway, the classic checkerboard flooring creates graphic contrast to the gray walls and vintage leather-bound mirrors. An Arne Jacobsen Egg chair serves as a modern counterpoint to the original stone fireplace.
Rather than restore the original kitchen, Benderli removed walls and created a contemporary marble-and-steel gathering space designed for entertaining, with a La Cornue stove, Hainaut stone flooring, and custom French walnut marquetry.
Lighting by Olgoj Chorchoj plays<|fim_middle|>, and the chair is by Helge Vestergaard Jensen
Deck chairs from the 1940s were restored and placed around an inviting swim area that's part of a park designed by the English landscape architect Russell Page. "The grounds were restored and reinvented in the areas where there were no traces of the original design," says Benderli
In a patio area, a pair of folding deck chairs by Preben Fabricius sits with side tables by Albert Larsson on natural teak flooring.
« Perth Market Snapshot for the week ending 14th October
Perth Market Snapshot for the week ending 21 October » | off angular furnishings by Grete Jalk and Hans Olsen.
A 1930s Italian sofa by Guglielmo Ulrich, chairs by Gigi Radice, and a cocktail table by Fernando and Humberto Campana combine to create an elegant seating area in a bedroom dominated by artwork by Lu Chao.
Stilnovo sconces mirror lighting fixtures by Angelo Lelli.
Stenciled flooring makes a bold statement in a guest bedroom. Artwork by Mickalene Thomas hangs in place of a headboard, and linens by Caravane and Maison de Vacances echo the palette
A pair of Vladimir Kagan sofas, a polished copper Kam Tin cocktail table, and hanging lights by Poul Henningsen elevate the pool house. The floor lamp is by Silvio Bilangione | 167 |
I was rather exited when i received a very orangey invitation this week in my inbox.
No other then Netflix asked me to join them at the Orange Is The New Black Season 3 Launch.
So on Thursday i stepped foot into the very own London version of Litchfield Federal P. who just happen to hold some special Visiting Hours at The Tardis in Waterloo.
I was greeted by the lovely Netflix Team and after having my Mugshot taken i ventured to the Bar where a delicious and fruity Pimms was calling my name!
Then I headed to the Benefit Make up Stand to get beautified for a very natural "Piper" look and after tucking into some delicious miniature prison food like prison porridge served in a sardine tin (which turned out to be rather nice risotto with veggies) and a beetroot lipstick.
Now i wish<|fim_middle|> but its brilliant and defiantly worth loosing sleep over because you cant stop after just 1 episode even though its way past midnight already, am i right??
On the way out we couldn't help but have a group mugshot together!
We make quite a good bunch of inmates don't you think??
The only thing missing where those orange jumpsuits!
Moi, Lauren (Mummy Is A Gadget Geek) and Pauly (Gifts from the Pirates) who brought along his awesome OITNB Phone Cover which you HAVE to check out here!
seconds after this picture was taken!!
Litchfield Federal Penitentiary with Piper & Co.! | i took some pictures of the gorgeous drinks and food as well as my make up after the Benefit Lady worked her magic on me but i was just too busy enjoying myself!
2 episodes and they certainly did deliver!
2 seasons and Nicky is one of my favourite characters.
I won't give you any spoilers | 61 |
AITech Interview with Marcus Fowler, SVP, Strategic Engagements, and Threats at Darktrace
by AI TechPark March 21, 2022 August 3, 2022
1. Tell us about your role at Darktrace. What are the cyber threat issues you work on in a typical day?
As SVP of Strategic Engagements and Threats, I speak with senior and C-suite leaders daily about what matters most to their businesses and operations and help outline risk and cybersecurity strategies to strengthen business resilience. I focus on explaining current threat trends and emerging and next-generation threats, working closely with the Darktrace Subject Matter Experts team.
Today, one of my main projects is growing and maturing Darktrace's Federal Division, which launched earlier this month. I am very excited to be bringing AI-based cyber defense capabilities to the U.S. government.
I also engage with the broader security leadership community through Executive Roundtables by participating or moderating. Last week, I led a webinar discussing the cyber impacts of the Ukraine-Russia conflict moving forward, including what the everyday CISO needs to consider and what our customers most need to know.
2. You are a former CIA Operations Chief. Let us in on what you have learned from that experience of yours.
The most critical lesson I learned at the CIA is how to work and collaborate as a team. I learned the importance of communications across an organization, both north-south and east-west. I have always been drawn to applying next-generation technologies to maximize business potential, not just creating the next cool, shiny thing. However, to be successful in this, as a public or private sector technology leader, you need to be able to serve as a liaison between the teams developing<|fim_middle|> about protecting sensitive personal and company data, securing national security information and critical infrastructure, and ensuring public and private sector operations. The most exciting part of my job across all these components is working closely with senior security leaders.
I enjoy learning about our customers' experiences and helping them improve their defenses. I like talking about how advanced technologies, like AI and ML, allow security to develop new and more effective security strategies. Cybersecurity is not just about building perimeter defenses or relying on threat intelligence anymore. Defenses are not just focused on trying and likely failing to be left of the breach constantly. Now, you need to have defensives to the right of the breach… as long as they're still to the left of business disruption.
9. What is your advice to the tech professionals who want to choose cybersecurity as their career path?
There is a range of roles within the cybersecurity space for many different people, from highly technical to less technically minded. There are many great voices and mentors out there, offering great advice and working to bring in new talent; use them. If curated appropriately, the social media infosec community is so active, and there is so much that you can learn online and teach yourself without getting a degree in cybersecurity.
10. What is your life's motto that has stayed with you throughout your professional career?
I don't think I get to claim this as my motto, but it was one I often heard at the CIA, and it resonates with me and is very relevant to security leaders: "Mission First, People Always." We need to be constantly focused on the security mission as we often hear, "We have to be right every minute of every day while attackers only need a moment." However, we can't forget our people and the stress it puts on them. As leaders, we need to be looking out for them.
Marcus Fowler
SVP, Strategic Engagements, and Threats at Darktrace
Marcus Fowler spent 15 years at the Central Intelligence Agency developing global cyber operations and technical strategies, until joining Darktrace in 2019. He has led cyber efforts with various US Intelligence Community elements and global partners and has extensive experience advising senior leaders on cyber efforts. He is recognized as a leader in developing and deploying innovative cyber solutions. Prior to serving at the CIA, Marcus was an officer in the United States Marine Corps. Marcus has an engineering degree from the United States Naval Academy and a Masters' Degree in International Security Studies from The Fletcher School. He also completed Harvard Business School's Executive Education Advanced Management Program.
AItech interviewsAItech newsbusiness interviewsDarktraceInterview
Calix ProtectIQ To Stop Hundreds of Monthly Cyberattacks Per Home
Vectra Appoints David Sajoto as Vice President of APJ Region
AI TechPark
Artificial Intelligence (AI) is penetrating the enterprise in an overwhelming way, and the only choice organizations have is to thrive through this advanced tech rather than be deterred by its complications.
Interview with Stephan Jou, CTO of Interset at Micro Focus
AI TechPark February 23, 2021 February 23, 2021
AITech Interview with Ioannis Tsamardinos, CEO and Co-founder at JADBio
AI TechPark October 4, 2021 August 3, 2022
Interview with Roger Beadle, Co-founder and CEO at Limitless
AI TechPark August 18, 2020 January 4, 2021 | emerging technologies and national security leaders – translating more technical language to higher-level mission needs, bridging the understanding gap, and allowing tech teams to think more about business impact.
3. Can you describe a few examples of use cases for Darktrace's services in general business terms?
Darktrace helps organizations maintain normal business operations and ensures business resilience. Darktrace uses AI to think about security differently – it moves away from focusing on the attacker to the focus on understanding and enforcing normal behaviors based on its knowledge of the business. Using AI as an enterprise's immune system, Darktrace learns what behaviors are 'normal' – which is unique to each organization – and fights back against attacks with precise autonomous response technology. Using AI to augment a company's human security team allows them to be vastly more efficient and preserve critical human resources while accelerating their investigation process and response times.
4. Recently in the month of February, Darktrace acquired Cybersprint. How do you see this acquisition to shape the future of Darktrace in the world of cybersecurity?
Cybersprint impressed us with the quality of their technology. Their technology adheres to the same design principles we value at Darktrace – reduce complexity, augment human teams, and underpin all of this with AI. Cybersprint has unparalleled access to attack surface data – across the whole internet. Having access to this data and intelligently analyzing it is a huge benefit.
At Darktrace, we already offer our customers the ability to have complete visibility over their internal data – their email environment, SaaS data, operational technology, IoT, network, zero trust, and other coverage areas. Cybersprint's ability to understand the outside-in level of risk via attack surface understanding complements Darktrace's new Prevent efforts to understand attack path vulnerability. Combining those data sets with Cybersprint and deriving its insights will accelerate and drive breakthrough innovation.
5. Regarding Darktrace Prevent, a Continuous Cyber AI Loop component, can you elaborate its relevance to businesses in layman's terms? How is the testing stage going so far?
You cannot protect what you do not know. Our Self-Learning AI helps businesses understand their normal activity, creating a complete picture of "self" for that organization. We are already experts in knowing yourself. The next phase focuses on knowing your enemy. You cannot prevent future attacks without understanding the routes your attacker will take to steal from or hold the business hostage.
AI-based Attack Path Modelling (APM) allows the security team to assess risk, identify vulnerabilities, and protect your most valuable assets or business operations pipelines. APM will enable organizations to simulate the potential paths a bad actor might take. Before an attack, companies can identify vulnerable areas and proactively harden defenses around their environment's most susceptible attack pathways.
This mindset is a significant departure from traditional defenses. All this occurs in the "Continuous AI Loop," where Darktrace's four areas—attack prevention, detection, response, and healing—actually strengthen and improve one another. There is a strong appetite for this across industries. We have customers in beta mode and a long waiting list of customers hoping to test the capability.
6. Can you give us an example of a recent cyber-attack incident and how Darktrace's unique Self-learning AI tackled it?
Groupement Hospitalier Territorial de Dordogne (GHTD) installed Darktrace in May 2021. A few weeks later, the ransomware attack began. Before the attack, the health system only used Darktrace's 'Enterprise Immune System' detection technology. During the attack, GHTD turned on Darktrace's autonomous response technology, Antigena, because the malicious activity was moving too fast for the security team to contain it alone. Darktrace stopped the malicious activity by enforcing normal business operations. These actions meant there was no disruption and no ransom demanded.
Without Antigena, attackers would have encrypted the hospital's data, and it would have lost functionality for days or weeks. That would have caused financial and reputational damage, but it also has the potential to impact patient care. GHTD could continue working, connecting to the internet, and caring for patients even while under attack. Downtime is not tolerable for the healthcare sector.
The algorithms quarantine only the affected devices and investigate the compromise without business disruption. Those not immediately involved would not have known anything was wrong. That's how intelligent this AI can be.
As more employees moved to a hybrid working model, GHTD had to extend VPN access to more users than the equipment could support. The health system also had to permit VPN connections on personal machines, presenting new cybersecurity risks and prompting GHTD to expand Darktrace's autonomous response to cover these devices. Antigena Endpoint can detect anomalous activity and make micro-decisions based on unusual activity, such as out-of-the-ordinary initial file downloads and data exfiltration attempts, command and control traffic, or lateral movement indicative of a cyber-threat.
The AI immediately detects suspicious requests from external equipment through the VPN and stops when the request seems malicious, or the behavior is abnormal. The technology is clever enough to know the difference between unusual behavior that is harmless – like an employee working from a café in the morning – and a malicious attack.
Since the health system started using Self-Learning AI to protect patients, it can be sure there will be no abnormal traffic or behavior without knowing about it, and its security team can finetune the technology to be more protective and more sensitive when it comes to more mission-critical systems. That's the future of cybersecurity.
7. What do you think about the Russia-Ukraine crisis? Will it lead to global cyber warfare?
The cyber chapter of this crisis is yet to be written. However, I might argue that we have been in a global cyber low-intensity conflict for many years. Nation-state use of cyber to leverage geopolitical and national security pressure has been constantly on the rise; the Russia-Ukraine crisis and international economic disruption targeted at Russia could trigger greater use of cyber. Though it is worth noting we have not seen it yet, one can't but feel that for everyone outside of Ukraine, this is the calm before the storm.
Hacktivism and non-state actors' participation is concerning because their actions may be wrongly attributed to another nation and lead to escalation of conflict because of misattribution.
That is what keeps me up at night. One of my biggest concerns would be a non-state actor attack, like on Colonial Pipeline, against Russian infrastructure that causes an unintentional escalation of the conflict or gives Putin enough justification to strike more forcefully outside Ukraine. It is impossible to control the actions of hacktivists, vigilantes, and cyber-criminal groups. If these non-state actors impact Russian infrastructure, these attacks may be misattributed as U.S. government actions.
8. Cybersecurity resembles a continuous process of building high-tech armors for warfare. What is your idea of cybersecurity and the most exciting part of your job as SVP of Strategic threats at Darktrace?
To me, cybersecurity is | 1,426 |
About the Gabber
Get your Gabber
Support the Gabber!
The Gabs
Take the Gabber
Purchase A Classified
Pia's Selected in Top 50 Restaurant List
March 14, 2018 by Debbie Wolfe
Pia Goff, chef and owner of Pia's Trattoria in Gulfport, showcases the regular menu that is offered to each diner in a metal fold-open case with a striking exterior patina. "It's a fun place," said Pia. "If you like people and food like we do, then it's a dream job."
For Pia Goff, chef and owner of Pia's Trattoria in Gulfport, operating a successful restaurant is all about using fresh ingredients, offering unique menus and treating diners as if they are her best friends.
Being selected as one of the top restaurants in Tampa Bay by a newspaper food critic is a bonus. And, this has happened more than once.
Most recently, Laura Reiley of the Tampa Bay Times named Pia's in her 2018 top 50 list for Tampa Bay. Reiley has been the food critic at the paper for about 10 years and Pia's was the first local restaurant she reviewed in April 2007.
"My philosophy is when training new staff, which doesn't happen very often because nobody leaves, is that in the moment when a diner steps through the door that person is my best friend," she said. "The hostess, the bartender and the servers treat everyone as if each person is Pia's best friend. From the hundreds if not thousands of restaurants in the area, when people choose to come here it is an honor. We still love and have passion for what we do after 13 years. It's the whole package."
With an established staff, Pia now mostly concentrates on getting Facebook information published, building and printing menus, hiring when needed, and greeting guests in the dining room.
"I have a great staff and we don't use titles. It's 100 percent teamwork," said Pia<|fim_middle|> Gabber Newspaper | . "Anything I know, they know. We don't have a big turnover. My chefs have been with me for a while. Jonathan Summers has been with me for eight years. He is like my mini-me.
"Three of my chefs are trained in culinary school. With me that's four. That's a big deal."
The regular menu is offered to each diner in a metal fold-open case that has a striking exterior patina.
"Every two weeks, there is also a completely new specials menu that offers two or three different options for soups, salads, appetizers, entrees and desserts," said Pia. "We started doing this two years ago. It allows us to play with food trends without committing to them."
Details also flow through the building's multiple interior and exterior seating options with a variety of Tuscan-themed decorations that are reflective of Pia's homeland – Italy. In addition to owning the restaurant, Pia, her husband Tom, and their four children also make their home in Gulfport.
"I grew up in a little town," she said. "When you get to know the people and the issues, you can't help but care because you live in the community. I feel blessed that we chose Gulfport because it's a wonderful place with wonderful people. When we moved here, I immediately felt at home. I'm not just a business owner, I've also raised my four children here. They all work at the restaurant."
One of the ways Pia gives back to Gulfport is by being the lead organizer for the annual Chefs Table charity fine-dining event that is held down the middle of Beach Boulevard. Started in 2016, the event had to increase seating capacity by 50 percent for 2017. In both years, multiple Gulfport-based restaurants served sold-out crowds. In 2016, the event raised $8,569.75 for the Community Action Stops Abuse (CASA) program in Pinellas County and in 2017, $17,538.50 was given to Gulfport Elementary school to help them fund a new playground that is planned for completion in the spring of 2018.
"Once a year it brings the restaurants and our staffs together," said Pia of Chefs Table. "We get to know each other. That's a good thing."
by Debbie Wolfe
Support the Gabber
Team Gabber brought back the print version of the newspaper, and we've redesigned our website to make it easier for you to get the news. We're not out of the woods yet, and every little bit helps pay our reporters, printer, and other expenses. Support local news and families — donate now to keep The Gabber Newspaper serving the community it loves!
Please support local news and The Gabber Newspaper!
Filed Under: Arts, News
© 2021 All Rights Reserved | The | 602 |
Earth captures the new "mini moon," astronomers say
February 27, 2020 01:20 by Wion NewsDesk
The mass – about 1.9-3.5 meters (6-11 feet) in diameter – was observed by researchers Kacper Wierzchos and Teddy Pruyne in the NASA-funded Catalina Sky Survey in Arizona on the night<|fim_middle|> be around for very long.
"It's moving away from the Earth-Moon system as we speak," Grigori Fedorets, a researcher at Queen's University Belfast in Northern Ireland, told New Scientist and will likely escape in April.
The only other known asteroid in Earth orbit, 2006 RH120, orbited the planet from September 2006 to June 2007.
Get our daily newsletter in your inbox
Thank you for subscribing to our daily newsletter.
Categories Science Post navigation
The Great Barrier Reef remediation project is moving forward
Most amphibians shine Mental thread | of February 15.
By the France-Presse Agency Washington
UPDATED ON 27 FEB 2020 2020 19:38 IST
The Earth has acquired a second "mini-moon" the size of a car, according to astronomers who saw the object surrounding our planet.
"IMPORTANT NEWS. Earth has a new temporarily captured object / a possible mini-moon called 2020 CD3," probably a C-type asteroid, "Wierzchos wrote on Twitter on Wednesday.
The astronomer said it was a "big deal" because "this is only the second known asteroid in Earth orbit (after the 2006 RH120, which was also discovered by Catalina Sky Survey)."
Its trajectory suggests it entered Earth's orbit three years ago, he said.
The Smithsonian Astrophysics Observatory's Minor Planet Center, which collects data on minor planets and asteroids, said in an ad that "no connection was found to a known artificial object," meaning it is likely an asteroid captured by gravity. Earth.
"Orbit integrations indicate that this object is temporarily connected to Earth."
Technical contractor Elon Musk said the object the size of the car was not the Telsa Roadster he launched into space in 2018, which now orbits the Sun.
"It's not mine," he wrote on Twitter.
Earth's new neighbor is not in a stable orbit around the planet and is unlikely to | 297 |
Serfloor Loose Lay is our luxurious natural wood design range of vinyl flooring for all living and commercial spaces. Our Loose Lay is treated with an Anti-Bacterial surface and is water resistant making it a perfect choice for all families and work places.
The floor is an integral element of any space. If you are on the lookout for affordable and convenient flooring options, Serfloor Australia has got you covered for loose lay vinyl plank flooring.
We are the one stop shop for all your vinyl flooring needs. We manufacture and supply a variety of vinyl flooring products such as loose lay, click lock and glue down as well as adhesives.
When you are thinking of renovating a residential or commercial space, you have to harmonise various factors to give your space the desired ambience. You will be taking into consideration the aesthetics, the cost in terms of the product and maintenance, as well as durability of your floors. You may have to analyse foot traffic as well. Our loose lay vinyl flooring is an affordable solution.
We know that deciding on one particular type of flooring can be quite daunting because often people like the combination of hard and soft surfaces in flooring. This is a tricky combination because the thickness of both surfaces is different. However, our loose lay vinyl planks serve as the ideal choice for people who want to combine hard and soft surfaces.<|fim_middle|> manufacture the flooring materials keeping in mind health and safety. We use special techniques and materials to make sure that the tiles remain slip-resistant.
We have almost four decades of industry experience and hence have a thorough understanding of the needs of our customers.
Serfloor Australia is the answer to your flooring challenges so just give us a call at (03) 9796 4626.
Serfloor Loose Lay Vinyl Planks are a premium and elegant option with a realistic wood look design that is a perfect solution for your flooring choice. Designed to be very easy to install over almost any surface without underlay or glue. Serfloor Loose lay flooring is Dimensionally Stable which means it keeps movement in the floor minimal when exposed to extreme temperatures and requires minimal gaps when installing. In addition Serfloor Loose Lay is designed for easy replacement, if a plank gets damaged it can easily be lifted and replaced with a new one. Serfloor Loose Lay is also 100% water resistant making it an ideal solution for all indoor areas including wet areas for Commercial and Domestic environments. Our Loose Lay is backed with a 30 year Domestic Wear Warranty and a 15 Year Commercial Wear Warranty. Serfloor Loose Lay is an incredibly durable yet versatile product for all flooring requirements. | Our floor will harmonise the interior of your living space by integrating seamlessly with your carpet or tile.
When it comes to installation of a floor in large commercial spaces such as retail outlets, open-concept offices or high-rise applications, our loose lay vinyl plank flooring is the best option. The flooring tiles we provide are thicker than conventional a tile, which means that they are quite effective in making the space sound-proof, more comfortable and luxurious.
The loose lay vinyl is an excellent option no matter whether you want the floor to be installed, in a commercial or retail store or in an art museum or any other public area with heavy foot traffic.
The best thing about our service is that we manufacture a number of designs, colours and textures that you can choose from to make sure that your concept is served. You can even choose among a number of chic, classic and modern tiles according to the look and feel of your space. Another thing that makes our tiles the ideal choice is that they are manufactured using the best quality materials and are affordable which makes us the premium choice for flooring.
Our products are treated with a PUR coating that protects against damage from staining, scuffing and scratching. All our products are sold with a generous warranty of 30 years for residential premises and 15 years for commercial premises.
We | 263 |
Home » National University Selects EBSCO Discovery...
National University Selects EBSCO Discovery Service™
posted by kmcevoy on Tue, 02/08/2011 - 12:13
~Improved Access to Full-Text Resources, a Simple Search Interface with Advanced Options and Mobile Access—National University Selects EBSCO Discovery Service~
IPSWICH, Mass. — February 8, 2011 — National University, the second-largest<|fim_middle|> University System, has selected EBSCO Discovery Service™ (EDS) from EBSCO Publishing to provide the University with a way to deliver its large collection to the end user and to make its library resources easier to find.
National University researched a variety of options from next generation catalogs to resource portals as well as discovery services—more than 11 products in all—as it sought to improve access to the library's full-text resources. National University was looking to find an academic library resource that had a simple search interface but still had advanced options to limit search results.
National University's librarians wanted a service that would provide users with more access to the library collection to better support research projects and assignments. Students were asking for a simple search experience that was closer to a traditional Web search. In deciding on EBSCO Discovery Service, the university was able to leverage its large eBook collection (more than 135,000 titles) and search the full-text of its collection alongside research databases and other library resources.
Senior Analyst for Research and Electronic Resources at the National University Library, Betty Kellogg, says EBSCO Discovery Service proved itself in side-by-side trials with other services. "In our trials with test databases we received more full-text relevant results with EBSCO Discovery Service than other products."
While relevancy was an important differentiator, the strong metadata available within EDS, its ease of access and the customizability were also important factors according to Kellogg. "We liked that resources such as JSTOR and LexisNexis Academic could be searched through EBSCO Discovery Service, reducing our silos of separate information and that EDS was available in a mobile version. The option to create links on the search page to preselected databases from any vendor or subject collections to help students focus their results was also appealing."
EDS will be part of a new library website design and a key component of a library initiative to serve students accessing the library via mobile devises. Kellogg says EDS will allow students to search the library without needing to know the names and descriptions of all the databases in the collection. The library is anticipating an increase in database usage since students will be searching across all resources and returning more relevant results from underused or previously hard to find resources.
EBSCO Discovery Service creates a unified, customized index of an institution's information resources, and an easy, yet powerful means of accessing all of that content from a single search box—searching made even more powerful because of the quality of metadata and depth and breadth of coverage.
The Base Index for EBSCO Discovery Service forms the foundation upon which each EDS subscribing library builds out its custom collection. Beginning with the Base Index, each institution extends the reach of EDS by adding appropriate resources including its catalog, institutional repositories, EBSCOhost and other databases, and additional content sources to which it subscribes. It is this combination that allows a single, comprehensive, custom solution for discovering the value of any library's collection.
The EDS Base Index is comprised of metadata from the world's foremost information providers. At present, the EDS Base Index represents content from approximately 20,000 providers in addition to metadata from another 70,000 book publishers. Although constantly growing, today the EDS Base Index provides metadata for nearly 50,000 magazines & journals, approximately 825,000 CDs & DVDs, nearly six million books, more than 100 million newspaper articles, more than 400,000 conference proceedings and hundreds of thousands of additional information sources from various source-types.
About EBSCO Publishing
EBSCO Publishing is the world's premier database aggregator, offering a suite of more than 300 full-text and secondary research databases. Through a library of tens of thousands of full-text journals, magazines, books, monographs, reports and various other publication types from renowned publishers, EBSCO serves the content needs of all researchers (Academic, Medical, K-12, Public Library, Corporate, Government, etc.). The company's product lines include proprietary databases such as Academic Search™, Business Source®, CINAHL®, DynaMed™, Literary Reference Center™, MasterFILE™, NoveList®, SocINDEX™ and SPORTDiscus™ as well as dozens of leading licensed databases such as ATLA Religion Database™, EconLit, Inspec®, MEDLINE®, MLA International Bibliography, The Philosopher's Index™, PsycARTICLES® and PsycINFO®. Databases are powered by EBSCOhost®, the most-used for-fee electronic resource in libraries around the world. EBSCO is the provider of EBSCO Discovery Service™ a core collection of locally-indexed metadata creating a unified index of an institution's resources within a single, customizable search point providing everything the researcher needs in one place—fast, simple access to the library's full text content, deeper indexing and more full-text searching of more journals and magazines than any other discovery service (www.ebscohost.com/discovery). For more information, visit the EBSCO Publishing Web site at: www.ebscohost.com, or contact: [email protected].
EBSCO Publishing is a division of EBSCO Industries Inc., one of the largest privately held companies in the United States.
Kathleen McEvoy
(800) 653-2726 ext. 2594
EBSCO Publishing
discovery solutions | private, nonprofit institution of higher education in California and the flagship university of the National | 16 |
Features a database of thousands of British real-ales from hundreds of breweries, searchable by brewery, beer or location. Also has ale-related links.
Directory of food sites, recipes, links, articles, discussions, competitions, and news. Expert advice on any food-related matter.
Independent body<|fim_middle|> | dedicated to promoting tea and its unique story for the benefit of those who produce, sell and enjoy tea the world over.
A community site for enthusiasts of Real Cider, Scrumpy and Perry. It includes a forum, members' recommendations for pubs and ciders, general history and information.
Directory of Internet cafes, restaurants and reviews, takeaways, and mail-order food sites in the UK, plus contact information and delivery region.
Books on various regions plus recipes, restaurant reviews and people profiles.
Directory of farm shops, speciality food retailers, farmers markets and village stores. Also includes a forum and information about cookery courses.
Offers daily news and articles, cooking tips, recipes, herbs and spices information and a guide to cooking techniques.
Raising awareness and increasing our enjoyment of wild game. Includes recipes and detailed nutritional facts.
Independent web magazine offers advice on 'day trips' buying wine, beer and food from Calais, France.
Fun guide to milk at school, with resources for children and teachers.
Food writer and caterer. Contact details.
Channel 4 series about food, where it comes from, and why that matters. Includes seasonal recipes, news and events, projects and shop.
Promoting the range of French Cheeses available in the UK. Competitions, recipe of the week and tips on buying and storing cheeses. | 268 |
Hillview faces "challenging year" due to weather
Posted by jkeating624 | Apr 2, 2015 | North Reading News | 0 |
By BOB TUROSZ
NORTH READING – The Selectmen burned the late night oil again last week in line by line reviews of town department budgets leading up to the June 1 Town Meeting. Those heard from included the Hillview Commission, Youth Services, Elder Services and Parks and Recreation.
Hillview Commission
The Hillview Commission is submitting a $1 million budget request for fiscal 2016, about 15 percent less than the current budget year. Hillview member Peter Hemme said fiscal 2015 has been a very active year at the Hillview, with a number of improvements made, including a new irrigation system that will be coming on line shortly.
As the Transcript has previously reported, the Hillview and PBL Catering Inc. agreed to terminate PBL's lease to manage the Hillview function hall and Hemme said there have been four responses to the Request For Proposals for a new manager.
In addition to the irrigation system, Hemme said golf course improvements included seven new tee boxes and new sod. Looking forward to the next budget year, Hemme said the spending plan assumes flat revenue growth but that assumption will be challenged by the terrible winter of 2015 and the very tardy arrival of spring.
"We're going to be in a very challenging position this year." Hemme told the Selectmen. For example, in a normal March and April the Hillview<|fim_middle|> grant would be for $125,000 a year for up to 10 years of prevention work among North Reading youth, tackling issues like youth abuse of substances such as tobacco, alcohol, marijuana, prescription drugs and opiates.
In presenting the fiscal 2016 Parks and Recreation budget, Maureen Stevens had two requests: That the town once again assume funding of the Recreation Director's salary of $59,586 and that the department budget itself revert to a Revolving Account rather than an Enterprise Fund.
For fiscal 2016, the department is proposing a budget of $552,464. In fiscal 2009, Stevens said, the town required Parks and Rec to fund the Recreation Director's salary. Recreation Chairman Ron Kern said that since 2008, the department has raised over $2.5 million as a result of fundraising activities the committee has committed to. "We keep challenging the community to grow that amount but we're at the point where we may have reached our peak."
Kern said it takes an "incredible" amount of volunteer man hours to run the events put on by Parks and Recreation. Stevens said there's been a decline in registration in the sports leagues since fiscal 2009, when Recreation was required to assume responsibility for the salaries of the Director and equipment manager. Fees were raised from $15 to $45, she said and since then they've lost 913 registrations.
Recreation member Rita Mullin said the Recreation request was a compromise going back to 2007/08. Since that time, most departments in town have added back many positions that were lost "and Recreation is just asking to be made whole again."
"Let the extra work we do be put into progressive things, not salaries," she added.
Selectman Stephen O'Leary asked: "What's the underlying fear here? Are you anticipating your reserves and retained earnings are going to shrink?"
"They're not getting any bigger and they could possibly shrink," replied Stevens. "We're not seeing any growth."
Selectmen Chairman Robert Maueri said the board will carefully consider Recreation's requests and revenue plan "and make the hard decisions in the coming weeks."
PreviousBurke, Conant named PPS Director finalists
NextTennis team to swing into spring
Person-Centered Planning webinar with NR SEPAC
No new candidates in Town Election; tenant seat open on Housing Authority
Retiring payroll accountant praised for devotion to his craft by School Dept.
Front Page: January 26, 2023
North Reading Community Links | typically can expect to generate between $100,000 and $150,000 in revenue. But right now, "it's anybody's guess when we're going to be able to open up," Hemme said. "This is going to be a very challenging year, we're going to have to manage our expenses very carefully."
The long planned irrigation project is about 80 to 90 percent complete, Hemme reported. And once the ground completely thaws, a few remaining lines will be pulled through and the water will be turned on. "And we'll all keep our fingers crossed." Hemme said they have confidence that the new system will be fine.
The proposed fiscal 2016 budget predicted revenue totaling slightly over $1.5 million. The revenue currently assumes $50,000 of rental income from the function hall. Total expenditures, including debt service, decreases by $138,789 (8.4 percent) from fiscal 2015. The decrease can be attributed to the suspension, for four years, of the Payments In Lieu of Taxes (PILOT) the Hillview has, in the past, made to the town.
Town Administrator Michael Gilleberto's budget recommendation concurs with the Hillview's number of $1,028,909.
"Pray for good weather" for the rest of 2015, Hemme told the Selectmen in wrapping up.
Elder Services
At $159,000, Elder Services is one of the smaller budgets in general government but as Director Mary Prenney pointed out, it serves some of the most vulnerable, poorest and frailest members of the community.
Next year's operating budget has some significant reductions, she said, based on the anticipated purchase of a new elderly van, which will mean less money spent on repairs, she said. The only problem is that they are still in the process of researching this van because the vehicle they proposed at the last Town Meeting is out of production. They're waiting for a finished model of a substitute vehicle to be ready by the end of the month.
Prenney credited the partnership with Mystic Valley Elder Services as the reason the department is able to keep 47 North Reading seniors in their homes instead of in a nursing home. Last year that number was 35.
North Reading has over 3,200 residents over age 60 and that number is only going to grow. People want to continue living in North Reading, she said. "This is their home, where they want to age in place and hopefully with the services offered by our department, they will. These people want to stay connected to the community in the way previous generations did not.
"Building age-friendly communities is the wave of the future" and her budget contains no surprises, she told the Selectmen.
The Youth Services Department budget presented by Amy Luckiewicz was well received, at $55,158. Luckiewicz said there are nine North Reading children receiving social services from her department, all active cases. She said there was an increase in participation among K-12 students in Youth Services programs this year, including four students who continue to come to youth group although they have actually graduated. When she prepared her budget statement, she anticipated an enrollment of 125 students by June and as of March 23 there were already 123 enrolled.
Thirteen students are enrolled in the last session of safety class.
Forty-two are currently enrolled in the mentoring program, (up 47 percent).
Twenty-five are enrolled in the high school youth group (up 27 percent).
Sixteen are enrolled in the middle school youth group. (up 47 percent).
About 12 percent of the currently enrolled students have regular access to transportation.
Luckiewicz reported her department has applied for a Drug Free Community grant and she feels North Reading has a very strong application. "Former Superintendent of Schools Kathy Willis reviewed the grant application multiple times with me and we feel we have the strongest application possible."
Much of the information for the grant application was obtained in partnership with the police, fire and school departments and none of that would have been possible without the town's Community Impact Team, she said.
The grant itself is in response to the epidemic of opiate abuse in the state generally and Middlesex County specifically. If awarded the | 913 |
This weekend I will be attending an Airbrush course at Nait, I am super stoked to learn more about airbrushing and how to expand my knowledge from airbrushing on canvas and people to automobiles, skateboard decks, trailers, other surfaces and more!
I will touch base on how the course went and some of the things learned later this month. Follow me on my social to for real time updates during the weekend!
You have probably seen this event posted/promoted on all my social media & websites, you may have even seen it in the news: Global, CBC, City TV, The Edmonton Sun, The St. Albert Gazette & other social media pages all throughout October.
It was an interesting event, there were many vendors: Halloween fashions, artists, bone throwing & tarot card readings, tea vendors & so much more; there was also a panel on stage with some speakers and demos – I was one of the panelists for both days giving tips and tricks on some special fx make up & face painting – there was a Michael Jackson impersonator, costume contests, special guests and a couple of local authors; one Author by the name of Erika Knudsen, who's books I started reading waaaaay back in high school (2004-2006) & bought from a local hair salon in our small town that she actually managed and probably cut my hair too lol small world!!
It turns out there was another author there by the name of A.D. Ryan, my sister bought me their book "Blood Moon" about werewolves & homicide. She bought it at Night of Fear Fest thinking it was the same author I got my books signed by lol the thought was there 🙂 and I am very excited to read this book as well!
My younger sister Marie helped me out a lot with this booth, she ran out and got me some more halloween decorations, bought an extra box of candy just in case & helped me set up and run my booth. The second Day Marie also came to help again, as did my good friend Hilary, they both helped me run<|fim_middle|> its 3rd year. | my booth, take down all the decorations and load up my truck. Thanks to them everything ran a lot faster & smoother!! I am very grateful & happy to have such awesome help with these venues!
I dressed up in two different costumes for both days & painted my sister as Two Face from the Batman cartoons. Day one I was Sally from Nightmare Before Christmas, Day two I was Jack Skellington & my friend Hilary was Sally 🙂 It is always interesting and fun to see all the decorations & costumes as Halloween is my Christmas lol my favorite time of the year!!
Unfortunately the event was not as busy as we were all hoping it would be; I did not have any customers the first day & did not make my table rent; however, the planner of the event offered to give me a free table next year & was very appreciative of the things I did to help out at the event, etc.
With all the awesome press this event got many vendors were surprised it was not busier, however there were other Halloween events happening on Friday night & Saturday; more well known events that have been occurring annually for many years so there was some fierce competition the event was up against. That being said, my body art business got a lot of media coverage which is good & a fair amount of business cards were taken so hopefully business increases for next Halloween & throughout the year for venues/parties. The planner of the event also offered to give me a free table for next year's event, so I am pretty excited for next years event & how it will evolve for | 313 |
Megan Burtt at the Oriental Theater on Saturday night.
Megan Burtt's release show at the Oriental Theater last weekend demonstrated the Denver music scene at its best. It was a celebration and release of her latest album<|fim_middle|> songs to create the monumental and symphonic feeling this album craves.
Burtt herself, with her sequined guitar strap, red hair and bright smile, can seriously belt the blues. The Berklee School of Music graduate has been honing her skills with a rigorous touring schedule. We're lucky that her travels brought her back home to the Mile High City.
Her favorite songs on The Bargain include "Ain't Seen Nothing Yet," "The Hurricane", and "Was It Love." Buy the new album on iTunes, and see more photos from the amazing night of music below.
Julian Peterson sings at the Oriental Theater.
Strange Americans at the Oriental Theater.
Strange Americans lead man Matt Hoffman sings his heart out at the Oriental Theater.
Megan Burtt serenades the Oriental Theater on Saturday night.
Megan Burtt gets some practice time in the alleyway before her set at the Oriental Theater. | , The Bargain, and the energy was explosive. Burtt has an amazing ability to bring together people who have been really good at music for a long time.
The Oriental Theater takes you back in time, keeping its old charm in spite of the massive growth seen in the surrounding neighborhood over the past few years. The early crowd at last weekend's show comprised friends, family, kids and those on whom Burtt has had an impact.
Next up on the list of talented musicians was Strange Americans. Fresh off a tour of the Midwest, bandmembers Matt Hoffman, Trent Nelson, Murry Mercier, Trevor Sinnard and Michael McKee brought their A-game. They played a seriously heavy rock-and-roll set, with some of the subtle country and dance elements that made the seated crowd finally rise off their feet. Lead singer Hoffman stayed true to the band's self-proclaimed "blue-collar rock and roll," decked out in plaid and a trucker hat.
Megan Burtt at the Oriental Theater.
As Burtt took the stage, the entire crowd seemed to migrate to the front of the room to get closer to the badass energy that she emanates. In content, The Bargain is the account of a trying time in Burtt's life, when she contracted a serious illness while living in Mississippi.
The amazing musicians playing with Burtt relived the experience with her, taking their time to produce The Bargain with "blood, sweat, and tears," as she aptly put it. Members of the Colorado Symphony joined after the first few | 312 |
Race The World
Race the world cycling
A brand new event has landed on the cycling scene called Race The World, a global bike race for amateurs, with the first leg kicking off<|fim_middle|> our tents for the night.
The three aspects of Race The World that get my heart pumping with excitement are;
1. Role of Team Captain
It's a huge honour and responsibility for me to have been asked to take on this role. The team at Limelight Sports behind this event are placing a lot of trust and faith in me to deliver! How did this become my job?! I'm so excited for this next stage of my own journey... I am looking forward to being introduced to my team, getting to know them and understanding and their motivations behind taking on this challenge. I can't wait to develop a personality for our team, to understand everyone's strengths and weaknesses, for us to experience all the highs and lows that will come with a challenge like this and to find a way through whatever we face, as a strong unit.
It feels like the most amazing journey for us to start as eight individual people and see who and what we can become. To form a team, work together, bond, fall apart and bond again, and to create an experience that will change us all.
2. The USA Adventure
I haven't been to the states for 12 years and have ALWAYS dreamt of cycling across it. Everyday I imagine what we will see, feel, hear and experience; the landscapes we'll cycle through, the sunsets and sunrises, the moments that will stay with us forever. I love America and am stoked to create new memories there.
3. The Camp
Each night we will set up camp in a different location and use this as our race village providing the space and time for everyone to rest, recover and get ready to roll again the next day. Having logistics taken care of, means the competitors can focus on themselves and what they need to get into the best shape for the next stage. I'm excited about this part of the trip because I know it's almost as important a part of the adventure as the cycling itself.
Throughout life I find it's always about people and stories and they are undoubtedly what will make this adventure. I can't wait to share it all with you.
This is a chance to make history by being part of something that has big plans to become a prominent race in the cycling calendar.
Read more about what this race means to me in my interview with Race The World here.
Tagged: adventure, Challenge, cycling, Endurance, Race the world, travel, USA
Newer PostSitsum Atlanta: The Power of Social Media
Older PostSeptember: A chance to refocus and renergise | on November 1st from LA and finishing in Miami on the 14th.
Two teams, each comprising of eight people, will take on this epic 13 stage adventure. Each stage is a solo endurance effort or a team relay in which members of the team will take it in turns to cycle sections with the aim to achieve the quickest overall time. The team relay stages are where team tactics will come into play and the competition steps it up a gear. There must be a minimum of three riders on the road at all times from each team but no maximum.
The shortest day is 60km and the longest 314km. Teams will race against the clock and the team with the lowest accumulative time wins.
We'll cycle through California, Arizona, New Mexico, Texas, Louisiana, Alabama and Florida. The route takes us off-road to see some of the most beautiful parts of the USA, so we'll be racing on cross bikes from Wilier Bikes. It's a pretty rad bike!
I am so excited to share that I will be Team Captain for one of the teams. Rab Wardell will be the other team captain, read more about him here.
The values we want to uphold throughout this race are; inspiration, competition, respect and teamwork. To me that sounds like an awesome set of values to shine through in everything we do.
Outside of the team and myself, each team has a manager, a mechanic and our own bus to transfer from the finish of one stage to the start of the next. We also have a crew onboard to look after our every need so the competitors can focus on delivering outstanding performances and having an incredible adventure whilst not having to worry about logistics!
Each evening camp will be set up and a race village, sometimes in the middle of nowhere. An important aim for this event is to explore the wilderness and race through areas in unchartered terrain. Each night we will debrief and put a strategy in place for the following day, eat and share stories around the campfire before settling into | 414 |
ENGLEWOOD, Colo.<|fim_middle|>: "Thanks to this international collaboration, Western Union customers in the United States can send money directly into Banorte accounts and soon to other Mexican banks giving customers new choice based on their use, need and convenience.
"We are excited to offer our customers in Mexico a new way to conveniently receive money. Although receivers in Mexico continue to have a strong preference for cash and our retail growth has been solid, we believe the direct to bank services will bring in new types of consumers who prefer to receive funds in accounts.
"Expanding into the banking channels of Mexico in collaboration with UniTeller is a significant development; we are proud to uphold our promise to continually enhance convenience and choice for our customers," said Almeida.
Western Union's direct-to-bank product cements the company's advancement into the bank remittance segment. More than $528 billion was moved across the world in 2013 in remittances according to the World Bank2. Western Union offers direct-to-bank services in 50 countries including seven of the world's top 10 remittance receiving developing countries2—India, China, Philippines, Egypt, Pakistan, Bangladesh, Vietnam and soon to be Mexico. | & MEXICO CITY–(BUSINESS WIRE)– The Western Union Company (NYSE: WU), a leader in global payment services, today announced it will launch international direct to bank money transfers to Mexico from the United States via the Grupo Financiero Banorte's UniTeller network.
An agreement recently signed between Western Union and UniTeller, will allow Western Union customers in the US to send cash directly into qualifying bank accounts – totaling more than 60 million individual bank accounts1. The UniTeller network currently covers top banks in Mexico.
Planned for launch in the first quarter of 2015, customers will be able to send international money transfers direct-to-bank from participating retail Agent locations, www.westernunion.com and directly from Western Union smart phone mobile applications from the US.
"This agreement is a result of the competitiveness of our Remittance Platform and will enhance the international payment services for our customers in Mexico. As a leader of remittance processing services, UniTeller continues to support the end to end services for our customers in Mexico and abroad," added Alberto Guerra, CEO of UniTeller Financial Services at Grupo Financiero Banorte.
Odilon Almeida, President Americas and European Union of Western Union, said | 257 |
Have you ever thought about blogging for your college or university?
First of all, if you haven't read our awesome post about blogging yet, you should. And if you have, you'd know that blogging is still a pretty solid way to attract visitors—or in this case, students, to your school, as long as you're using it as a way to showcase your school's identity.
We know that the upcoming generation of college students is pretty skeptical—it's going to take a lot of convincing to get them to pick your university, let alone decide if they're going to a university in the first place.
Growing up with Google, it makes sense that the internet is where they'd go to start their search. When Junior Jessica types into the search engine: What college should I go to? Think about where you want to rank in the SEO. It's a competitive world. But, if you approach your blog as a resource and strategically use those keywords, topical information, and CTAs that feed the SEO on Google, your school will be more likely to stand out to Junior Jessica as it lands higher on the top-ranking pages—so long as you share the relevant and valuable information that she, and Google, are looking for.
To stand out, HIGH QUALITY CONTENT IS A MUST. Be the resource that provides the answers she's looking for.
Speak to students in a way that resonates with them and center your blog around the content they want to see. Highlight success stories, student life, programs, getting to know the faculty and staff, and whatever else your student personas<|fim_middle|> potential students and make sure it's mobile-friendly. Remember, blogging is still the best way an organization can boost its organic search engine rankings.
Use blogging as an opportunity for you to guide potential students in the direction you want them to go—while on their terms. Develop multiple channels where you can share your content that will be found by prospective students on their turf.
Are you staying on their radar when it comes to the apps they visit most? Facebook, Twitter, Instagram, YouTube, and Snapchat? Is the content you've made motivating? Informative? Simple? Consumable? Who says your blog has to be all writing? Vlogging attracts a huge number of views and subscribers and video is great for breaking content up and sharing to YouTube, Facebook, and Instagram; where a viewer can be directed to your university's page.
What do your prospective students really care about? Prove that you have the answers, and show that you are available to help them along the way. What better way to show your expertise and personality than through a blog? You have an opportunity to speak their language and take them through the stages of their buyer's journey.
And it all starts with creating the relevant and compelling content they are searching for. Do your students want to know what their life will be like as a freshman? Do they want to know what life is like as a student-athlete? Do they want to know what will help them as they save for school?
Blogging for the sake of blogging won't get you anywhere. You have to have a clear goal in mind and keep tying it back to your own strategic goals or it won't be worth your time.
Blogging isn't just a tool, it's an opportunity to tell your university's story while engaging with who matters most: your students. It increases your credibility and gives you a chance to share quality information, opinions, and news with prospective students; allowing them to see what life is really like at your university. | are interested in. Center it back to your current and | 11 |
We're Now Accredited by A2LA!
As the food safety landscape shifts from reactive to preventive, our internal labs are leveraging high-quality data and analytics to help ensure brands are getting the most accurate and insightful information about their products.
We believe in the power of rigorous and continuous testing to make sure<|fim_middle|> the veracity of results and the discussions around the implementation of The Food Safety and Modernization Act (FSMA) also build an expectation of these food labs to achieve universal lab accreditation.
At Clear Labs, we are pioneering a new standard in food as we look to the future of food safety. The food industry is demanding a new level of accountability from the players in the supply chain, and we are committed to helping food companies protect their brands through consistent, quality, and accurate food testing. | our customers can stand behind our brand as we help them stand behind theirs.
That's why we're proud to announce that we have achieved lab accreditation by A2LA for technical competence in the field of biological testing, in accordance with the recognized International Standard ISO/IEC 17025:2005. We have also met additional program requirements in the Biological field, including AOAC 2005 accreditation.
The marriage of food and genomics is at the forefront of an upheaval of the food industry business model. Next-generation sequencing (NGS) and big data analytics are helping realize the vision of food testing throughout the supply chain to help detect problems and de-risk the supply chain. As the industry adapts to these new testing capabilities and consumer demands for transparency, there will be a radical shift in accountability of food labs and standards.
Lab accreditations like the one provided by A2LA help the industry ensure that testing is held to a quality and consistent standard. Through this accreditation, Clear Labs is given the tools to maintain our ability to consistently produce valid and accurate results throughout the food testing process.
While different facets of the industry – poultry, spices, seafood, beef, packaged goods – all fall under varied regulations, consistent testing across the board is imperative to ensure that products are held accountable to the same standard at every step of the food supply chain. Independent assessments of food testing systems help verify | 287 |
The TAG 2016 Annual Conference will be held at the Loews Don CeSar Hotel in St. Pete Beach, FL November<|fim_middle|>6 Information page for ongoing updates and preview the exciting agenda.
99 foundations completed TAG's recent mini-survey about technology management. Survey results have been emailed to survey participants. If you participated and didn't receive the results, please contact Lisa Pool.
Each year the TAG Board elects a new 'class' of board members to guide TAG and represent the interests and needs of its members. We are seeking members to serve for 2017-2019.
Are you interested in the challenge, or do you know a TAG colleague who would be interested in serving on the TAG Board?
Candidates will be reviewed by the Board Nominating Committee, who will make a recommendation to the Board. The full Board will elect new members prior to the Annual Board meeting in November.
Please send nominations to Lisa Pool by July 29, 2016.
Online grant applications just got simpler with Foundant Technologies' integration with GuideStar for Grant Applications. Read Foundant President, Daren Nordhagen's take on it here. | 14th-17th. This year's theme is Impact: Collectively Changing Communities.
Start making your travel plans! Registration will open July 15th.
Visit the TAG 201 | 43 |
Eine Kuppe ist ein Berg oder Hügel mit Rundgipfel, der keine felsige Gipfelformation aufweist. Eine Gebir<|fim_middle|>and häufig. In diesem Zusammenhang werden beispielsweise auch Teile der Rhön als Kuppenrhön bezeichnet und Kuppe, Koppe findet sich als Wortbestandteil in Namen von Bergen, z. B. Schneekoppe.
Auch Stellen in aufgewölbten Sedimentschichten, an denen sich aufsteigendes Erdöl oder Erdgas gesammelt hat, werden als Kuppen bezeichnet.
Weblinks
Einzelnachweise
Geographischer Begriff | gsformation aus Kuppen nennt man Kuppengebirge (siehe unten). In der Geologie umfasst der Begriff auch entsprechende Formen der Stratigraphie.
Die Kartografie fasst den Begriff weiter, und bezeichnet als Kuppe allgemein alle Erhebungen (zweiachsig konvexe Geländeformen), also auch solche mit spitzerer Ausprägung.
Eine im Hang eines Berges liegende Kuppe wird als Rückfallkuppe bezeichnet. Häufig wurden mittelalterliche Burgen an solchen Standorten errichtet.
Etymologie
Kuppe stammt aus der mitteldeutschen Volkssprache des 18. Jahrhunderts, vermutlich stammt es vom spätlat.-gemeinroman. cuppa "Becher" ab, das dann übertragen im Sinn von "Haube" für einen Gipfel verwandt wurde.
In Flurnamen werden Kuppen auch mit Wörtern wie Stauf, Kogel, Kopf, Nock, Gupf oder Kulm bezeichnet.
Das Wort Kuppe bezeichnet daneben andere höchstgelegene Punkte, beispielsweise im Straßenbau und Straßenverkehr das Überqueren eines Höhenrückens. Kuppe findet sich aber auch als Wortbestandteil in Dingen, die eine Erhebung bilden (Fingerkuppe).
Geomorphologie und Geologie
Kuppengebirge ist ein Begriff der Geomorphologie. Typisch sind Kuppengebirge für die Mittelgebirge und die Voralpen. Ihre Entstehung hängt mit dem Gesteinstyp und einer meist regelmäßig ansetzenden Erosion zusammen.
Beispielsweise bezeichnet man die vielen Rundgipfel des Fichtelgebirges oder des Bachergebirges so, doch sind gleichmäßige Kuppen auch im Hügell | 423 |
How can I find professional private tutors in Kaneohe, Hawaii?
<|fim_middle|> connect you with somebody who can meet your child in person whenever and wherever you would like, so contact us today to get the process started! | Connecting with a gifted tutor in Kaneohe, HI, is a lot simpler than you might think. We'll ask questions to understand your needs. Then, we'll give you a quote for tutoring services and a custom learning plan that's designed to help you reach for success. Next, we perform a query to find a tutor who has the proper skills to fulfill your needs from our database.
How can one on one tutoring in Kaneohe, Hawaii, help students realize their full academic potential?
Hawaii is known more for fun in the sun than education, but academics are just as important for Hawaiian students as for those anywhere else. If your child is showing signs of falling behind in one or more of their classes, professional tutoring in Kaneohe may be able to help them get back on track.
An experienced Kaneohe tutor can provide their pupil with a one-on-one learning environment without the distractions found in a typical classroom. For example, many students end up fooling around with their friends instead of listening to the teacher in school. That temptation does not exist in a one-on-one setting, helping students concentrate on their work.
Private tutoring in Kaneohe also enables students to work at their own pace. If your child is a vocabulary expert but isn't as comfortable around numbers, their study sessions can focus on the latter exclusively. A Kaneohe tutor can also take the time to know your child, potentially incorporating their interests into more engaging study sessions.
If your child has a major exam coming up, such as Hawaii's Smarter Balanced Assessment (SBA) that measures mathematics and English Language Arts skills in grades 3-8 and 11, a tutor can help them prepare for it. Past exams may be provided as practice, helping your child learn exactly what the test expects of them. Their tutor can also break down where they performed well and what topics could use additional work, guiding future study sessions.
The SBA is administered online, so a tutor may help your child develop computer skills in preparation to take it. We can help you find an excellent Kaneohe tutor who can use a live learning platform to bring tutoring sessions online! We can also | 438 |
The Many Challenges Of Storytelling In Virtual Reality
Cine Virtual in Amsterdam | © Eliaboqueras/WikiCommons
Tech Editor
Virtual reality can put you on the edge of a cliff, in the middle of a jungle, or deep into space, but telling a story through the medium can be much more difficult than you might think.
The difference between virtual reality and other storytelling mediums is interactivity. In all forms of virtual reality, the user's experience is interactive. That can be as simple as moving their head to decide where they want to look, and as complicated as manipulating virtual environments with haptic gloves.
This makes it hard to include a narrative. If the user can do what they want, they may not follow a story in the same way as people do when they sit down to watch a film. As the technology is still in its early stages, there are no clear rules on how to make a story work in VR.
"We've come so far in the last year, but the tech is still changing every day," Kim Adams, head of production at Oculus Story Studio said at CES in Las Vegas. "There are no tried and tested systems and its very much in flux. At Story Studio<|fim_middle|> winner for a studio," said Jake Zim, Senior Vice President Virtual Reality at Sony Pictures Entertainment. He adds that studios should be asking what other value a VR project would bring, and what can be learned for future projects.
Attendees of CES try VR headsets.
Courtesy CES
Zim says that the major benefit of VR is that it can make the viewer feel something. In a standup comedy show, for example, a user is able to sit in the front row and squirm as the comedian makes them feel uncomfortable. If that capability of provoking emotion could be effectively translated to storytelling, the results would be extremely powerful.
Virtual reality storytelling requires a completely different form of scriptwriting, and a lot of expertise can be drawn from theater rather than traditional filmmaking. Oculus Story Studio is using a lot of theater professionals to help tell stories in VR, according to Adams.
It seems VR is yet to make the big breakthrough it needs in storytelling, but as the technology is constantly improving, it's surely only a matter of time before someone figures it out. "We're in the early days," Heller says. "We haven't made our version of the Great Train Robbery yet." | our first project was called 'Lost,' and our goal was just to prove narrative works in the medium. We're trying with each project to define something new."
The Oculus home landing page is mostly populated with games right now.
Courtesy Oculus.
So far, the real successes of VR have been straight forward experiences, rather than complex story telling. "Things that are performing for us are things where the experience for the user is very direct," Noah Heller, VP of Partnership and VR at streaming service Hulu, said at CES. He added that a helicopter ride in Vegas and being stalked by a jaguar in the jungle are two of the highest performing pieces of VR content on Hulu.
That might be disheartening for a director or filmmaker looking to move into VR, but Adams says there needs to be a change of attitude from current filmmakers if they are really going to take advantage of the medium. "As soon as traditional filmmakers can put what they know aside, they can get out of their own way."
Storytelling in VR may be one area where the worlds of Hollywood and video games collide, hopefully in a much more pleasing way than the recent movies made from video games. But despite VR games grabbing more attention, those in the industry believe neither game developers or filmmakers have an early advantage. "This is a medium that is drawing interest from both sides of the fence," Peter Akemann, CEO of Skydance Interactive said. "Neither side of the equation can come in and school the other side."
One of the drawbacks of virtual reality for major studios is there is a lack of audience, and it can be hard to make money. As headsets become cheaper and more popular, that is expected to change, but for now the audience is limited. "At this moment VR is not going to be a bread | 363 |
In loving memory of Joyce Dalton who tragically passed away 9/5/11 from a kayaking accident on the American River. An inspirational teacher, talented artist, and loving Mother – she will be dearly missed.
This was the hardest thing I've ever had to say, and it's even harder to write at this moment.
I'm wounded, not only because it was something I so dearly wish didn't happen, but because I'm beyond devastated for my best friend and her brother. I can hardly bear to imagine what they must have been experiencing when I had to say this to them, and what they now feel in the aftermath of it all.
That night I watched my best friend, my soul sister, who I jokingly call "my wife," straddle the line between life and death. She stood next to her dying mother while being pregnant with the life of her daughter — stretched between two generations, unable to bridge the gap between life and death and bring the two of them together. What a cruel contrast; a dichotomy in the circle of life.
Her pain is something unimaginable to me, and yet I've been watching it all week.
I imagine Sarah feels like Goldie Hawn's character in "Death Becomes Her," with a giant hole in her stomach, like she's missing her core. But physically she's the complete opposite of that picture with a wildly gorgeous pregnant belly. Empty yet full at the same time.
Devastating, sudden, traumatic, cruel loss combined with new life, new beginnings,<|fim_middle|>. Mostly I draw strength, inspiration and peace in her strength. It's a strength she learned from her mother. It's a strength she will teach her daughter. It's a strength that inspires me.
These are the lessons which spring all of us forward from this tragedy.
From the cruelty of life, we search for the glory. Embrace the glass as half full while recognizing its emptiness.
The finality of death is a reality to all of us, whether it is our own or our loved ones — the secret is to find a way to gulp life up in the meantime.
Toys, wealth, power, status, competition, even politics – all of this means nothing. What matters most in life is how you savor it, cherish it, and who you share it with.
I watch my friend take one step forward because her mom taught her how to LIVE.
Give life and live life, she will.
Such a beautiful column, Christy. Having lost my mother suddenly at age 27, I can tell you that the love and support of friends is the best healing power of all. Be there for your friend. Even if it's just in silence. You'll help her heal.
So sorry for the loss of your friends mother. It is hard to see someone you love go through a death of a loved one. Beautifully written.
Mary's comment: "When people wonder what to say, they can read this!" captures what I was TRYING to say about all of this — the event AND your column.
Sorry for your loss. This is a beautiful column that really captures the hopelessness, the pain and the reality of moving on. Having just lost a friend myself, I needed this column. Thank you.
Oleta Adams sings a song that says, "Life keeps moving on." So hard, but true, and necessary. Please give my condolences to Sarah and her family.
Thank you for a beautiful column.
Amazing Christy. Amazing Sarah. I am blessed to know you both and now have a different appreciation in my heart because of you.
Christy, thank you for sharing. Your strength through all of this has been more than inspirational (that is directed to both of you).
Beautifully said. It happens when we least expect it. I lost my best friend of 43 years in 1998. I was lucky to spend the last 5 months of her life with her everyday. We laughed, lived and loved. There is not a day that doesn't go by that I don't think of her. She is in my heart always. I am so sorry for your friend but I am sure she knows you are right beside her, behind her, next to her and in front of her as she navigates this loss.
Beautiful Christy.Your words are healing and full of love and the most sincere compassion.
2.Please place my name at the end of your list of men that adore you.
Really amazing column, Christy. Very heavy, but you guys appear to have a strong foundation upon which to built a future. Terribly sorry for your loss.
I'm so proud of you sweetheart, and I know that Sarah will be okay with you by her side. Life is so short compared to eternity, and no one but God knows when each of us will pass over to the other side. The most important thing is to be ready at all times, and value your true treasures in life- family, friends, and love.
This is very powerful, Christy. I loved what you said to the family about sharing the last moments.
This is an amazing column. Joyce will be deeply missed at Vanden. I miss her every morning when I pull around the corner and she isn't there walking with Jorge or joking with me about life. I miss her, and have learned from her. I am still learning to be a little nicer. To embrace whimsey and to love freely. These are Joyce's gifts. Thank you for saying so much in this space.
Christy, what a beautiful post; Sarah is lucky to have a friend as like you. You are all in my prayers. | and a new definition of self. I've meditated, I've prayed and I feel at loss as how to help her begin to go forward. And yet, I'm watching her take one step forward at a time. I'm a bystander to her grace, beauty and strength.
I realize that she won't "heal" from this pain — she's going to learn to live with the pain and she's going to be different because of it. She's redefining her life and finding her foothold in the roots of her mother's love.
I grieve for her grief. I find sorrow in her sorrow | 127 |
'...But the Whole Truth' (9 replica paintings by anonymous Chinese painters in Chinese faux gilded frames): Oil on canvas.
The limitation or advantage of a work of art is that, once created, it remains static. However, its meaning and interpretation keeps changing. This indicates that an art work continues to generate interest though it is never fully approachable.
In our milieu, installation is perhaps a genre that provides the most options to multiple decoding. On many occasions, what is presented as installation is required to be acknowledged, accepted and appreciated as<|fim_middle|> markets and militancy (since blackbirding is the coercion of people through trickery and kidnapping to work as labourers).
Her new body of work affirms how an artist deals with multiple sides of work — material, pictorial, political, conceptual —keeping the poetics of painting intact. She does extend the notion of poetics, painting and politics. Much like the genre of installation where it is difficult to detect the difference between life and art, in the art of Risham Syed the distance between content and form is diminishing. | art, as something separate from life. Thus the arrangement of fruits on a road stall, or heap of junk material and furniture in a room, or a table set for breakfast are not regarded as examples of installations, even though these ordinary settings may look not too dissimilar from some installations displayed at art galleries and museums.
One of the major differences between art installation and real life situation is the distinction between 'meaning' and 'function'. Accumulated stuff on a roadside, in an attic or in the dining room does not have a meaning in the real sense of the word but it does have a function. Although nothing in this world is devoid of meaning, the element of content in these arrangements is overpowered by their utility. On the other hand, installations do have a function and not just as works to be collected and to earn a living or fame; more than that they embody a subtext that is meant to be understood and deciphered by the viewer.
The aspect of meaning seems to be the most important component of Risham Syed's installations in her solo exhibition (Kaal Pakhan — Blackbirding) being held at the Canvas Gallery, Karachi from Dec 2-11, 2014. The most striking work in the show is "….But the Whole Truth", the room painted in yellow with nine canvases in elaborate gilded Chinese frames. These paintings have views of 19th century Paris with Eiffel Tower, historical buildings and avenues with carriages and pedestrians. The manner of making these pictures is commercial and hasty, accentuated with the gaudy and heavy frames.
Of course, the pictures are not painted by Risham Syed; she bought and hung these almost similar-looking urban views in a salon-like room. Once a visitor enters the space, he presumes that all frames contain identical imagery, only to discover later how each canvas is slightly different from the other.
Installation: History as Re-Present-Ation II'.
These are manufactured in China and exported to local markets in Lahore. The artist's decision to pick and place them at her solo exhibition is a comment on the debate of manual versus mechanical in art as well as on the industrialisation and commercialisation in the present age. Created with brush and oil paint, these almost uniform sceneries convey a sense of mechanical production for a market that yearns to own 'authentically hand painted'. These canvases show the view of Paris before it was invaded with industrially-manufactured items such as motorcars etc.
So the Chinese paintings, in a way, are suspended between hand-made crafts and industrial products. Both the manner of execution and the selection of period for the city allude to romanticism with pre-industrialisation age and the tradition of handmade, but their being created in such large numbers refers to mechanical manufacturing.
Another layer of meanings in this installation is about Orientalism. The term is understood, especially after Edward Said's seminal book, about European supremacy in/through viewing, interpreting and re-presenting the 'under-developed' Eastern societies. But Syed's work signifies the shift in this order of things. Now with China's triumph in the world economy, the balance of power has tilted; hence a Chinese painter's depiction of Paris is also an act of Orientalism, or Occidentalism, since he undertook the task of representing the cultural capital of Europe as an exotic visual to sell it to large and far reaching markets.
The idea of Orientalism is approached in another installation 'History as Past' in which Syed has copied a small canvas showing the detail of a Turkish bath, with white women being led by a dark female attendant inside a historical building. The manner of rendering the marble floor, pink flesh and stones in the vault is so convincing that one assumes that instead of painting, Risham may have framed a printed poster of 'Great Bath at Bursa'. A big towel is put under the framed canvas, thus creating a connection between the bare bum of the white woman and the soft white towel rolled towards the gallery floor. The artist's choice of linking the painting with another object in our times alludes to invisible politics — in the act of making and marketing images.
'Untitled2': ix media on paper.
Syed's works at Canvas Gallery affirm her views on socio-economic systems and division of world based upon colonial designs. In another work, 'History as Re-Present -Ation I' a chair is combined with a stand holding a small painting depicting a long vehicle on fire, witnessed by a small family riding on a motorcycle.
Or in another work ('History as Re-Present-Ation II') one comes across an old Victorian tripod covered with dark fur, two hands cast in metal and holding a small painting. The picture portrays people against a dark background with some white areas. Sensitive application of paint makes a viewer believe that he is looking at a photograph.
Like the installations, her collages on paper are also efforts to join diverse sources and visuals to create narratives connected to history as well as to investigate the hidden politics in image-making. In her work, a viewer is aware of the presence of political substance, but these critiques are made through a range of metaphors and aesthetic strategies.
The small postcard-like panels which serve as a key are meticulously painted with scenes of violence and disturbances, but along with these one comes across the form of a bird in two works. For Risham Syed, the bird refers to the colonial history of slave trade, hence the title of one work and whole exhibition Kaal Pakhan — Blackbirding. Through this sign of tyrannical practice of the past, she hints at the exploitation of modern day | 1,157 |
Seychelles: Insider's Guide
by Wendyperrin.com | March 26, 2016
Chez Batista Villas, Seychelles. Image courtesy of Torsten Dickmann - STB
The insider advice on this page is from one of Wendy's Trusted Travel Experts for the Seychelles: Justin Parkinson of Linara Travel.
Justin Parkinson
Justin's frequent trips to the Indian Ocean over the past 14 years make him uniquely qualified to match you with the specific island, resort<|fim_middle|>about $250–$300). Smaller wooden versions are just a few dollars. You'll find both options at the Seychelles Island Foundation Gift Shop, on Praslin. The foundation manages the Vallée de Mai Nature Reserve, a UNESCO World Heritage site, which your shopping dollars will help protect.
If you're interested in a coco de mer, don't take one from the island or buy a discounted one from a local; the government regulates their sales, so you'll have to show the proper tags and documentation from a souvenir shop when you leave.
Airport Intel
It is slow moving in the small Seychelles airport, as employees work on island time. Relax, remember you are on holiday, and you'll get through passport control eventually.
Tipping Tip
Many resorts and restaurants include a 10 percent service charge; a little extra is appropriate—though not at all necessary—if you've had good service. If no service charge is listed on the bill, add 10 percent.
Justin was wonderful...
Katie Hausfeld | July 25, 2021
Whale sharks and manta rays...
Kim Prater | May 24, 2021
Saw way more...
Priscilla Eakeley | January 13, 2020 | , and overwater bungalow—even with the specific dive instructor or massage therapist—that best suit your needs. This is especially crucial in the Maldives, where you're likely to spend all of your time at a single, private-island resort, and there are new properties opening every few months. In the Seychelles, Justin can help you rent a car to go exploring and point you to the best beaches and hiking trails. Given how many people fly to the Indian Ocean via Dubai, he has become an expert on the United Arab Emirates too (see Dubai and Abu Dhabi) and can help you save money there so that you can splurge in the islands. When he's not exploring these exotic locales, you'll find Justin at home in either Australia or L.A.
Trips have a three-night minimum and start at $800 per day for two travelers.
Grande Soeur Island Seychelles. Image courtesy of Torsten Dickmann – STB
Best bang-for-your-buck resort
The most luxurious resort on Praslin Island, the Raffles Praslin Seychelles, often has special offers that make it less expensive than a few resorts that aren't as fancy. The Panoramic Pool Villas have unobstructed views out over the ocean.
Best resort for couples
Maia Luxury Resort & Spa on Mahe has huge secluded villas with great views and 24-hour butler service—so you'll never have to leave your room if you don't want to. Book dual treatments in one of the spa's private open-air pavilions.
Sainte Anne Island Resort has spacious rooms with sleeping areas for children; for much of the year, two kids up to 17 years old can stay for free. This resort has a larger kid-dedicated staff than most others, and it's near the Sainte Anne Marine Park, one of the best places for snorkeling.
The less expensive Constance Ephelia has two- and three-bedroom villas that were built specifically for families, plus a kids' club with its own pool, arts and crafts projects, cooking classes, and such. This resort also has one of the largest and best water-sports centers, multiple beaches, a climbing wall, a zip line, tennis courts, and squash courts—in short, more things to do than anywhere else in the Seychelles.
Restaurant the locals love
The Marie Antoinette Restaurant in Victoria has been the most popular spot for local Seychellois Creole food since 1972, serving unique dishes such as fruit bat curry and octopus curry, plus freshly grilled fish.
Meal worth the splurge
Have lunch among rare birds in the canopy of a huge banyan tree at Fregate Island Private; it's like a picnic with Michelin star–quality food.
Fregate Island in Seychelles. Photo: Fregate Island
Anse Georgette on Praslin Island is one of the prettiest beaches in the Seychelles. It is hidden and hard to reach; access is easiest through Lemuria Resort (you can call to set it up even if you aren't a guest), or via a rugged trail from Anse Lazio. The beach has stunning granite boulders and often nobody is on it. It's a perfect spot for a romantic, private picnic.
Aride Island Nature Reserve. This is one of the most important avian sanctuaries in the Indian Ocean; hundreds of thousands of birds breed here, including five species found only in the Seychelles. You can visit for the day by boat or helicopter, spending the afternoon checking out the rare birdlife and plants and snorkeling in the pristine waters.
Don't bother
Oxcart rides on La Digue Island. It is the traditional way of getting around La Digue, but the ride is just a few hundred yards long and very slow. Instead, rent a bicycle and explore La Digue at your own pace.
Best beach for families
Anse Lazio on Praslin Island has lifeguards, calm water, good snorkeling, and a couple of restaurants overlooking the white-sand beach. There are also some Aldabran tortoises living nearby, which kids get a big kick out of seeing.
Anyone can go to Aride Island for the day, but Justin can set up an overnight visit. You'll sleep in one of the few cabins on the island, which are normally reserved for researchers, and get a much more in-depth experience watching the rare birds and tortoises and snorkeling in spots few people have visited before. It's truly special to be there in the early morning during breeding season (May through August), when tens of thousands of birds fill the air with their songs.
If you're staying on Praslin or Mahe, rent a car and explore the island on your own. There are lots of pretty beaches waiting to be explored. Have your resort pack you a lunch or stop off at a local grocery store and make your own. Explore the island and find a deserted beach to snorkel and swim at your leisure. Finish with a crisp and refreshing local Seybrew, a Seychelles-made beer.
Contact Justin
Maldives: Insider's Guide
by Wendyperrin.com | September 6, 2014
Abu Dhabi: Insider's Guide
by Wendyperrin.com | October 28, 2014
Dubai: Insider's Guide
by wendyperrin.com | July 20, 2017
While the Seychelles are warm year-round, February to October see the most sunny days. Rain can occur at any time of the year, but storms are typically short and isolated. Bear in mind that seas can be a little rougher from May to September. October is the best month for spotting whale sharks.
Worst Time to Go
Rainfall is highest in January; December also gets a fair bit of rain.
Biggest Rookie Mistake
The boat ride between Mahe and Praslin can be really rough from May to September. Take the 15-minute scenic flight instead; it's only a few dollars more and has lovely views.
Instagram Moment
Anse Source d'Argent on La Digue Island is the most photographed beach in the Seychelles. Go early when the colors of the water and sand are best, and you'll have the beach to yourself. Coming from Praslin Island, take an early ferry, rent a bicycle, and head straight to Anse Source d'Argent. In the afternoon, bike across the island to Grand Anse (there's a café that's a good option for lunch) and lovely Petit Anse, which you may well have all to yourself; there's a hill, but the effort is worth it.
A coco de mer, the famous double coconut or sea coconut, is the most well known souvenir in the Seychelles. An actual coco de mer that is perfectly proportioned is a bit expensive ( | 1,439 |
I've ordered these a few times now and quality and delivery always very good.
If you are looking for a fast, flexible and affordable printing service then you need look no further than Need A Print - Ireland's premier printing service.
Whether you want leaflets printing or professional business cards produced, Need A Print guarantees the highest quality products at the best possible prices. We understand that your printing is a reflection of you or<|fim_middle|> to make high quality prints just a few clicks away. Browse the store today and your order could be with you in just 48 hours. | your business and the quality of our results is a reflection of ours.
No job is too big or too small. Need A Print puts every customer at the centre of our business, whether it is a big company order or an individual project.
Everything from flyers to invoice books can be printed in full colour and to the highest standards. The shape, design, size and product is entirely up to you, although the Need A Print professionals are always on hand to offer expert advice if needed.
Every order can be placed online | 103 |
Hubble reveals Mars-sized plasma balls shooting from a dying star
David Szondy
Artist's concept of a plasma ball flying<|fim_middle|> comes to the closest point in its orbit, it plunges into the vacuous outer atmosphere of V Hydrae and starts to rapidly absorb gases.
These form an accretion disk around the companion as the gases circle in. As the mass of captured matter builds up, it eventually becomes too great and balls of plasma blast away at high speed. Because the disk wobbles, the direction of the balls flip flops occasionally. As the blobs move away from V Hydrae, they cool until they can only be seen by the Submillimeter Array in Hawaii.
"This accretion disk engine is stable because it's been able to launch these structures for hundreds of years without falling apart," says Sahai. "In many of these systems, the gravitational attraction can cause the companion to actually spiral into the core of the red giant star. Eventually, though, the orbit of V Hydrae's companion will continue to decay because it's losing energy in this frictional interaction. However, we do not know the ultimate fate of this companion."
The team believes the mechanism that produced the plasma balls flying away from V Hydrae could help explain the complex nebulae that surround dying stars. Similar knots have been seen in such structures and could have been made by companion stars and accretion dishes.
The team plans to continue using the Hubble to observe V Hydrae in conjunction with the Atacama Large Millimeter/Submillimeter Array (ALMA) in Chile, which will seek much older plasma balls that can only be seen in the infrared range.
The research was published in The Astrophysical Journal.
Panels showing the theoretical companion star orbiting V Hydrae, the companion going through the star's atmosphere, a plasma ball blasting from the accretion disk, and a series of plasma balls (Credit: NASA)
Artist's concept of a plasma ball flying away from V Hydrae (Credit: NASA)
#Hubble
#JPL | away from V Hydrae(Credit: NASA)
Data from the Hubble Space Telescope has helped solve the mystery of a seemingly impossible star. The red giant V Hydrae is the wrong type of star to be shedding gigantic "cannonballs" of energetic plasma, but that's exactly what it has been doing once every 8.5 years over the past 400 years. Now on closer examination it appears the culprit is its invisible companion.
V Hydrae is an unremarkable star – or should be. Some 1,200 light years from Earth, it's an ancient red giant that long ago burned up most of its nuclear fuel and as it cooled, it shed at least half its mass to form a gigantic envelope.
Such a dying star isn't supposed to do anything particularly energetic, but over the past 400 years V Hydrae has been blasting plasma balls every 8.5 years. These balls are twice the mass of Mars and travel at speeds of about 500,000 mph (800,000 km). The question is, how does it do this? It's like finding a glacier that spontaneously bursts into flame.
In 2002 and again in 2011, a team led by Raghvendra Sahai of the Jet Propulsion Laboratory (JPL) in Pasadena, California turned the Hubble's Space Telescope Imaging Spectrograph (STIS) on V Hydrae for two-year periods. According to the spectral data, a string of balls of plasma heated to over 17,000º F (9,400º C) and dating back to 1986 were seen moving away from the star. These formed structures that are 37 billion miles (60 billion km) from V Hydrae, or eight times the distance of the Kuiper belt from the Sun.
The team says that these plasma balls were most likely due to a superdense companion star, like a white dwarf or neutron star. Too small to be seen, the star circles V Hydrae in a highly elliptical orbit with a period of 8.5 years. As it | 447 |
Home Columns A MIXED BAG
A MIXED BAG
I was hardly prepared for the visceral punch of this brutal, involving, shocking, bloody, tortuous, disturbing, slick, tense, challenging, twisty, taunting, unpredictable, thrilling, horrific, rewarding and violent revenge story from Israel about the hunt and torture of a religious studies teacher assumed to be a serial child killer as carried out by the by the father of a murdered child.
Numerous and unsettling moral questions arise as the story unfolds, mainly<|fim_middle|>ighting, infection and a Martian zombification scenario. Such a wasted opportunity here with a storyline that does not engage, provoke or entertain. Blu-ray. Magnet.
Previous articleA Southern California Tale
Next articleAlicante Spanish Mediterranean Cuisine | about the law, grace, mercy, guilt, justice, evil and the very recognizable extremes of human behavior. But you will be hard pressed to consider them for any length of time because you will be pressed against the back of your seat trying hard to just breathe. One question that did stay in the forefront for me: Is there ever a situation or case that justifies inflicting pain on another? Maybe. Is this film from Israel elevated torture porn? Not quite. Unless extended by demand, this film is only showing through March 20 at Cinemas Palme d'Or.
ERNEST AND CELESTINE
From the makers of TRIPLETS OF BELLEVILE, comes this utterly engaging and charming old-fashioned animation about Celestine, who happens to be an artist mouse, and Ernest, a singing bear. This unlikely relationship, really a bond, between above and underground dwellers has earned numerous awards and even standing ovations. The water color-like animation has a human touch that jumps off the screen and gives the emotional story an authenticity that works. Based on the classic Belgian series of children's books by Gabrielle Vincent, this heartwarming story touches on how a friendship between two individuals from opposite communities is tested — in this case between bear-fearing and mouse-eating communities. The comic timing is classic as is the surprising chemistry between the leads. Highest recommendation. Now playing at Cinemas Palme d'Or.
Also still showing and worth seeing: BETHLEHEM and AFTERMATH.
NEW FOR THE HOME THEATER:
Disney's great looking but conservative and predictable adaptation of a Hans Christian Anderson story has already earned over a billion dollars worldwide, so nothing I say here will impact it one way or another. Released theatrically in a striking 3D version, the Blu-ray disc is state-of-the-art in picture and sound but there's no extra dimension on the disc. No, that's likely saved for Christmas when Disney hopes to double-dip on this tile. The movie is probably not aimed at my demographic and frankly, its success left me a little baffled and emotionally unmoved. The music struck me as nothing special, including the Oscar winning "Let It Go."
However, that said, there is a great reason to see this title and that's because of the animated short, "GET A HORSE" that's included in the bonus material.
What at first looks like a very early, hand-drawn, black and white Mickey Mouse cartoon from the Disney vault suddenly becomes colorfully wild and crazy when the characters literally step out of the screen and onto the stage of the "theater" in which the "old" cartoon is being projected.
The story involves a vintage skinny legged Mickey (vintage recordings of Walt Disney are used for Mickey's voice) and his girl friend (?) Minnie and their barnyard pals Horace Horsecollar and Clarabell Cow as they enjoy a musical wagon ride. That is, until Peg-Leg Pete shows up and runs them off the road.
The hallucinogenic mayhem borders on a dangerous acid trip. This is the best piece of animation to come from the Disney's cartoon factory in decades and bodes well for a core group that still reveres innovation and imagination. Many people still insist the old looking cartoon elements are authentic and have been manipulated by contemporary animators. Not so. It's all new! In 3D, this short is unhinged in the best way and is a must see for animation buffs –- too bad home viewers can't see this until they buy the next "Special Edition" of FROZEN. Blu-ray. Disney.
LAST DAYS ON MARS
What starts out with great promise on wonderful Jordanian locations and with terrific full-scale rover, quickly spirals into a B-movie devoid of freshness and intelligence. The plot about finding evidence of bacterial life on the Red Planet soon deflates into inf | 796 |
Marketplace Mechanics is BACK! After an unintentional one-year hiatus due to being busy building my own marketplace, I'm delighted to be recording MM again and to be releasing Episode 2<|fim_middle|> give to someone thinking about starting their own marketplace? | today.
In this episode, I speak to Jean-Michel Chalayer, the CEO & Co-Founder of LeSalon. I've known JM for several years now and our marketplaces are at similar stages (between Seed and Series A), so it's always a pleasure to sit down and discuss strategy and tactics with him.
Were my questions good and interesting?
Did you think the episode was too long, too short, or just right?
How was the audio quality?
I'm particularly interested in feedback on audio quality as I edited and mixed this episode myself. Episode 1 was done professionally, so let me know whether you think I should continue editing myself, or getting someone more knowledgeable to do it!
Don't forget to subscribe to the mailing list using the sidebar on the right, and to follow us on Twitter @marketplacepod if you haven't already.
And if you enjoyed this episode, please do leave a rating on your favourite platform.
4:50 Is LeSalon the Uber for therapists?
5:32 What did the first few months look like? How did you get started?
6:44 How did you know when you had found the right co-founder? Were there any real signs you were a good match when you met?
8:20 You've found your co-founder – what next? What does a typical day at early-stage LeSalon look like?
13:25 What are the criteria for therapists (suppliers) joining LeSalon? What makes a good therapist?
15:31 Do you reject a lot of therapists?
17:02 How do you approach trust? How do you help your customers get comfortable with a stranger entering their home to carry out beauty treatments?
18:11 How do foster a sense of community on your marketplace?
22:55 How is LeSalon better than the competition?
24:35 How did you arrive at the business model? Has it changed since you started? And is it a similar model to competitors, or have you done something unique?
25:55 Do you control the pricing on your platform?
32:37 What's your favourite part of building a two-sided marketplace?
34:30 Biggest piece of advice you'd | 463 |
Unless you're a brand new business, you'll need to consider how to move from your existing record-keeping system to your new online system. No matter whether you currently keep track of everything on paper, use spreadsheets or have some existing accounting software, you need to load up-to-date figures into the new system.
"Most providers don't upload previous data for you<|fim_middle|> a date in mind when you'll move to your new accounting system. There's no right or wrong time to do it and you can switch at any point, but the best time largely depends on your company's particular situation.
Assuming your business is VAT-registered, the best time to make the switch is at the end of your VAT quarter.
If you choose to wait until the end of your financial year, remember that you can start using your accounting system from day one of the new year. Your accountant should remain responsible for completing the previous year-end accounts and supplying new opening balances.
However, don't worry if you decide to make the switch in the middle of your financial year. The important thing is to get the correct opening balances for your profit and loss account and balance sheet into the new system. Your accountant should be able to supply these at any point.
Your accountant's advice can be invaluable in picking a good time to switch. Many online accounting systems also include consultancy. If yours does, use it!
"Your accounting system should automate the 'grunt work' that many businesses use an accountant or bookkeeper for," explains Darren.
However, you should still involve your accountant as you implement your new accounting system. A good system should reduce reliance on your accountant, but you'll still need their help at times.
"It's hard to completely automate everything," confirms Darren. "You still need an accountant. Lots of things have to be tuned for individual businesses and people always have lots of questions. Should they buy a company car? How do they claim back tax on their home office?"
There's no getting away from it: many businesses find that managing their accounts isn't that much fun.
"People have suffered a lot of pain with accountancy," continues Darren. "Accountants speak gobbledygook to them, so people do anything to avoid it. It doesn't have to be that way though. Getting on the ball isn't that difficult."
A new accounting system should make your accounting procedures more efficient. But the secret to taking the pain out of your accounts is to do them little and often.
"The best advice I can give is that the second a customer signs something off, go into your system and send out the invoice," says Darren. "With the right system you'll be able to do that in two minutes. Input details of your expenses regularly too and log in to your system regularly.
"I'd recommend you set some time aside each week to check your bank account and books. Don't forget that bank reconciliation can often be made so much easier with the best software by exporting bank statements.
"Some online systems can quickly crosscheck the statements with your sales data and transfer the bank statement detail onto your books.
"In any case, make time each week to crosscheck your company bank account with the figures in your accounting software. And stay in regular touch with your accountant. That way you can spot problems miles off," concludes Darren. | ," explains Darren Fell, managing director at Crunch, an online accountancy firm that provides small businesses with an easy-to-use accounting system supported by a team of accountants to answer bookkeeping and tax queries.
"If you haven't been in business long you can usually load your figures for the last few months fairly easily," he confirms. "But you may have to spend some time getting the system up to date.
"If you don't have the time to do that, look for a virtual bookkeeping service that can do it for you. At Crunch, we offer invoice and expenses import tools to make it easier to transfer data from other accounting systems."
It's important to have | 134 |
A beautiful afternoon yesterday. Blue skies, white puffy clouds, 50 degrees kind of lovely afternoon.
I had some errands to run, which included an animated conversation with a locavore chef, my favorite kind of person, a lover of good food and one who understands cause and effect of every step of growing.
Back on the farm straightening up and I see birds running. At first it looks like crows but then...there are birds of different colors...it's our baby hen flock! Jump into boots<|fim_middle|> are just like the day: clean, dry, warm and I can't carry so many in my hands.
Coat off, jacket improvised as an egg basket. A beautiful 5 dozen eggs. I return to the house as the sun is gone and the sky goes black. A bit of time like this makes up for the ugliness of the last few, freezing/sleety days. | and a heavier coat, run through the mud, coax them all back into the pen with a bit of corn. The sun is setting, at an amazingly quick pace, run some more to check if there are any more eggs.
Tons! These girls are happy and healthy and producing like crazy. It has only been a few hours since the last egg collection so it is astonishing to find so many more! In haste to get the pullets back in their pen I forgot to grab a basket. There are only funky buckets and these eggs | 108 |
In his mind, nothing more need be said. "Suits" are<|fim_middle|> when he held up an iPad and said, in effect, "Just imagine what you can do with this." Next month, the talk will be of form factors, screen sizes, thin bezels, deals with wireless carriers, price points. All well and good, but not compelling.
Now, I read that the suits at Progressive are thinking Flo must go. She smiles too much. As Mozzie might say, "suits" never quite get it. | bureaucrats, freedom-stiflers, order-keepers, creativity-squelchers. To free-thinkers like Mozzie, "suits" are the enemy.
I don't share Mozzie's disdain for people who wear suits, but I understand his passion for freedom, self-determination, creativity and the joy of being off-center.
Suits are in the news right now. Going public as a multi-billion-dollar company has forced Facebook to deal with "suit-ness." Investors want their payoff. Employees owning stock are frustrated with a 50% dive in the stock price since the IPO.
Facebook's irreverent public face is giving way to concern for revenue growth, pushing more ads at users, making deals, lobbying in Washington, and, yes, criticism of founder Mark Zuckerberg for not wearing suits.
All understandable, but it does take the fun out of using Facebook.
Same at Apple. With the wildly-off-center genius of Steve Jobs gone, suits are in charge. Now the talk is of controlling the supply chain, waging patent battles, making side deals with Microsoft, and, in a quickly-rescinded burst of utter suit-ness, a plan to maximize store revenues by cutting store staff.
Again, perfectly understandable. This is a huge corporation, and much depends on suits making wise decisions. But where's the fun? Where's the zing? No one doubts that Apple products announced next month will be as great as ever. But will they be compelling?
Compelling, you see, isn't suit-ness. Compelling is romance, surprise, creative spark. Steve Jobs did it | 327 |
Taylor Swift Says<|fim_middle|> now I'm at a point where I'm just having fun." | Ed Sheeran Collab LP Is 'Full Of Bops & Instant Classics'
Ed Sheeran and Taylor Swift go way back, so it was no surprise to see the pop titan support her longtime friend ahead of the release of his new album, No. 6 Collaborations Project, which dropped on Friday (July 12).
On Thursday, the 29-year-old superstar, who was recently announced as the highest-paid celebrity of the past year, took to her Instagram Stories to show some love to Sheeran. "As you get ready to release this new album full of BOPS and INSTANT CLASSICS," she captioned an old photo of her doing his makeup. "Just know how proud I am to be your friend and am wishing you the best release week!!" Swift doesn't appear on the just-released LP, which boasts some A-list stars like Justin Bieber, Bruno Mars, Chris Stapleton and Cardi B, but she has collaborated with her longtime confidant in the past on "Everything Has Changed" on 2012's Red and "End Game" on 2017's reputation.
In Sheeran's new interview with iHeartRadio's Charlamagne tha God, the singer/songwriter explained that the reason he made the LP fell on his agenda to have fun with his future ventures. "I made this because it was so much fun to make and it was all the artists I wanted to work with, and I made these songs that I was just so proud to play to my friends," Ed told The Breakfast Club host. "The fact is, I've already achieved more than I thought I could, so | 342 |
\section*{Introduction}
Let $G$ be a Poisson Lie group and $\mathfrak g$ the Lie algebra of $G$. Let
$\Ugh$ be the quantization of the universal enveloping algebra ${\U}(\g)$
along the corresponding Lie bialgebra structure on $\mathfrak g$. Consider
two Poisson homogeneous $G$-manifolds, $M:=G/G_M$ and $N:=G/G_N$
such that the stabilizer $G_M$ is a subgroup in $G_N$. Then there
exists a natural projection $M \to N$ of $G$-spaces, and it makes
$M$ into a $G$-bundle over $N$ with the fiber $G_N/G_M$. Suppose
this projection is a Poisson map. It is natural to consider the
problem of equivariant quantization of such a bundle. By this we
understand a $\Ugh$-equivariant quantization of the function algebras
together with the co-projection $F(M)\hookleftarrow F(N)$, to a
morphism $F_\ensuremath{\hbar} (M)\hookleftarrow F_\ensuremath{\hbar} (N)$ of $\Ugh$-algebras.
In the present paper, we quantize orbit bundles for the case when
$G=GL_n(\mathbb{C})$, and $\mathfrak g$ is equipped with a factorizable Lie
bialgebra structure. We assume the stabilizers $G_M$
and $G_N$ to be Levi subgroups of $G$.
Specifically for the $GL_n(\mathbb{C})$-case, those are precisely
reductive subgroups of maximal rank.
Then the $G$-varieties $M$ and $N$ can be
realized as semisimple coadjoint orbits $O_1,O_2\subset{\mathfrak{g}}^*$.
The Poisson structure on $\mathcal{O}_i$ is obtained by restriction
from a Poisson structure on ${\mathfrak{g}}^*$. The latter is a linear combination of
the $G$-invariant
Kostant-Kirillov-Lie-Souriau bracket (KKLS) and the
Semenov-Tian-Shansky bracket (STS).
In our case, $G=GL_n(\mathbb{C})$, they
are compatible, i.e. the Schouten bracket
between the two is equal to zero.
The Poisson bracket on $\mathcal{O}_i$ is not $G$-invariant, however, it makes
$\mathcal{O}_i$ Poisson-Lie manifolds over the Poisson-Lie group $G$.
Moreover, it is the only such bracket on $\mathcal{O}_i$ obtained by restriction from ${\mathfrak{g}}^*$.
Explicit quantization of semisimple orbits has been constructed in
\cite{DoninJMudrovAI:ExplicitQuantiz} for the special case of the
standard, or Drinfeld-Jimbo, quantum group $\Ugh$.
In the present paper, we extend that quantization to the case of any
factorizable Lie bialgebra structure on $\mathfrak g$ and the
corresponding quantum group.
We also describe all semisimple Poisson-Lie orbit bundles
$O_1\toO_2$ in ${\mathfrak{g}}^*$.
In particualar, we show that $O_2$ is necessarily
symmetric.
We explicitly construct a $\Ugh$-equivariant quantization
of the projection map $\prj$ for all orbit bundles.
The paper is organized as follows.
\noindent
In Section~1 we recall some
definitions concerning equivariant quantization.
\noindent
In Section~2 we establish necessary and sufficient conditions for
an orbit bundle to be Poisson.
\noindent
In Section~\ref{sect:REAlgebras} we study the behavior of algebras
defined by a modified (quadratic-linear) Reflection Equation
under twist of quantum groups.
\noindent
In Section~\ref{sect:DMQuantization} we use results of the previous
section to extend the double quantization of orbits
\cite{DoninJMudrovAI:ExplicitQuantiz} to the case of the quantum
group defined by an arbitrary factorizable classical r-matrix.
\noindent
In Section~\ref{sect:QnOfBundles} we prove that any Poisson orbit
bundle admits a $\Ugh$-equivariant quantization, so the conditions
of Section \ref{sect:Poisson-LieOrB} are also sufficient.
We give an explicit formula for the quantized bundle map.
\noindent
There is an Appendix at
the end of the paper where we study certain properties of the q-trace functions.
\subsubsection*{Acknowledgements}
We thank Steven Shnider whose valuable remarks led to a
substantial improvement of the text.
This work was supported by the EPSRC grant C511166
and by the RFBR grant 06-01-00451.
\section{Generalities on equivariant quantization}
\subsection{Deformation quantization of Poisson varieties}
Let $M$ be a variety with a Poisson bracket $\pb$ and $A=\fun[M]$ be the
algebra of polynomial functions $M\to\mathbb{C}$.
Recall the following definition (see e.g. \cite{DrinfeldW:Doklad}):
\begin{defin}
\label{def:QnOfPoissManifs} An algebra $(A_\ensuremath{\hbar},\star)$ over the ring
${\mathbb{C}[\![\ensuremath{\hbar}]\!]}$ of formal power series is called {\em quantization} of
$(A,\pb)$ if:
\begin{enumerate}
\item[ (i)]
$A_\ensuremath{\hbar}$ is a free ${\mathbb{C}[\![\ensuremath{\hbar}]\!]}$-module;
\item[ (ii)]
As a $\mathbb{C}$-algebra, the quotient $A_\ensuremath{\hbar}/\ensuremath{\hbar} A_\ensuremath{\hbar}$ is isomorphic to
$A$;
\item[ (iii)]
If $a,b\in A$ then $\displaystyle\frac{a\star b-b\star
a}{\ensuremath{\hbar}}\equiv\pb(a,b)$ modulo $\ensuremath{\hbar}$.
\end{enumerate}
The Poisson bracket $\pb$ is called {\em the infinitesimal} of
$(A_\ensuremath{\hbar},\star)$.
\end{defin}
\begin{rem}\label{nb:Pb}
The deformed multiplication is expanded as an $\hbar$-series:
$\displaystyle a\star b=\sum_{k=0}^\infty m_k(a\otimes b)\ensuremath{\hbar}^k$
for $a,b\in A\subset A_\hbar$.
Therefore one has $\pb(a,b)=m_1(a\otimes b) - m_1(b\otimes a)$.
\end{rem}
Let $(M,\pb_M)$ and $(N,\pb_N)$ be two Poisson varieties, $A_\ensuremath{\hbar}$
and $B_\ensuremath{\hbar}$ some quantizations of the function algebras $A=\fun[M]$
and $B=\fun[N]$ respectively, $f\colon B\to A$ a morphism of Poisson
algebras.
\begin{defin}
\label{def:QnOfPoissMorphs}
A homomorphism $f_\ensuremath{\hbar}\colon B_\ensuremath{\hbar}\to A_\ensuremath{\hbar}$ of
${\mathbb{C}[\![\ensuremath{\hbar}]\!]}$-algebras is called a {\em quantization of the map} $f$ if the
induced morphism $f_0\colon B_\ensuremath{\hbar}/\ensuremath{\hbar} B_\ensuremath{\hbar}\to A_\ensuremath{\hbar}/\ensuremath{\hbar}
A_\ensuremath{\hbar}$ of $\mathbb{C}$-algebras coincides with $f$.
\end{defin}
\begin{prop}
Suppose there exists a quantization of $f\colon B\to A$.
Then $f$ is a Poisson map.
\end{prop}
\begin{proof}
Denote by $m_{A_\ensuremath{\hbar}}$ the multiplication in $A_\ensuremath{\hbar}$ and by $m_A$ the
undeformed multiplication in $A$. The map $f_\ensuremath{\hbar}$ is supposed to
be an algebra homomorphism, i.e. $f_\ensuremath{\hbar}\comp
m_{B_\ensuremath{\hbar}}=m_{A_\ensuremath{\hbar}}\comp\left(f_\ensuremath{\hbar}\otimes f_\ensuremath{\hbar}\right)$. Consider the
infinitesimal part of this equality:
\begin{equation*}
f\comp m_{B_\ensuremath{\hbar},1}+f_1\comp m_B= m_A\comp\left(f_1\otimes f\right)+
m_A\comp\left(f\otimes f_1\right)+ m_{A_\ensuremath{\hbar},1}\comp\left(f\otimes f\right).
\end{equation*}
Applying this equality first to $a\otimes b\in A\otimes A$, then to $b\otimes a$
and taking the difference, one obtains $f\bigl(\pb_M(a,b) \bigr) =
\pb_N\bigl(f(a),f(b)\bigr)$ where $\pb_M(a,b)=m_{A_\ensuremath{\hbar},1}(a,b)-m_{A_\ensuremath{\hbar},1}(b,a)$ and
$\pb_N(a,b)=m_{B_\ensuremath{\hbar},1}(a,b)-m_{B_\ensuremath{\hbar},1}(b,a)$.
\end{proof}
\subsection{Quantization of $G$-varieties}
Consider a simple complex algebraic group $G$ and its Lie algebra $\mathfrak g$.
Suppose $G$ is a Poisson group; then $\mathfrak g$ is equipped with a quasitriangular
Lie bialgebra structure. Denote by $r\in \wedge^2\mathfrak g$
the corresponding classical r-matrix.
We consider only the factorizable case, when $r$ satisfies the {\em modified} classical Yang-Baxter equation.
By $\Ughr$ we denote the quantization of the universal enveloping algebra ${\U}(\g)$ along
$r$.
Consider the variety $M=K\backslash G$ where $K\subset G$ is a reductive subgroup in $G$ of maximal rank;
let $\mathfrak{k}$ denote its Lie algebra (we prefer to work with right coset spaces, so that the right $G$-action induces
a left action on functions).
Suppose $M$ is a Poisson $G$-variety, that is to say,
the action $G\times M\to M$ is Poisson. Set $A=\mathbb{C}[M]$ and let $A_\ensuremath{\hbar}$ be its quantization.
We expect the deformed
multiplication in $A_\ensuremath{\hbar}$ to be equivariant with respect to an
action of $\Ughr$. In other words, this multiplication should obey the
"Leibniz rule"
$$
x.(a\star b)=(x^{(1)}.a)\star (x^{(2)}.b)
$$
for all $a,b\in A$ and $x\in\Ughr$.
We use the standard Sweedler notation $x^{(1)}\otimes x^{(2)}$
for the coproduct $\Delta(x)$.
The infinitesimal of a
$\Ughr$-equivariant quantization $A_\ensuremath{\hbar}$
is always of the form (see \cite{DoninGurevicShnider:DoubleQuantiz})
\begin{equation}\label{eq:UhEquivariantPb}
\pb=\overleftarrow{r}+\overrightarrow{s}.
\end{equation}
Here $\overleftarrow{r}$ denotes the bivector field on
$M$ generated by $r\in \wedge^2\mathfrak g$ via the action of $G$,
and $\overrightarrow{s}$ denotes the invariant bivector field on
$M$ generated by an element $s\in\left(\wedge^2\mathfrak g/\mathfrak{k}\right)^\mathfrak{k}$.
The latter
should satisfy certain conditions, and the bivector field
$\overrightarrow{s}$ is called {\em quasi-Poisson structure} on $M$.
For simplicity, we call the generator $s$ a quasi-Poisson structure as well.
Recall the constructions of the bivector fields $\overleftarrow{r}$
and $\overrightarrow{s}$.
For $r\in\wedge^2\mathfrak g$ and $g\in G$, consider the bivector field $(R_g)_*r$
on $G$,
where $R_g:G\to G$ is the right translation $x\mapsto xg$.
This bivector field is left $G$-invariant, so it is left $K$-invariant.
Hence it is projectable to $M=K\backslash G$, and we denote the projection by
$\overleftarrow{r}$.
Note that $\overleftarrow{r}$ is not $G$-invariant.
To describe the bivector field $\overrightarrow{s}$,
lift $s$ from $\wedge^2\left(\mathfrak g/\mathfrak{k}\right)^\mathfrak{k}$
to $\left(\wedge^2\mathfrak g\right)^\mathfrak{k}$ and consider
a left $G$ invariant bivector field $(L_g)_*s$,
where $L_g:G\to G$ is the left translation $x\mapsto gx$.
It is also left $K$-invariant, hence it is projectable to $M=K\backslash G$.
We denote the projection by $\overrightarrow{s}$.
Any $G$ invariant bivector field on $M$ is obtained in this way.
Left and right invariant vector
fields on $G$ commute with each other, hence the Schouten bracket
$[\overleftarrow{r},\overrightarrow{s}]$ vanishes.
This implies that $p=\overleftarrow{r}+\overrightarrow{s}$ is
a Poisson bracket if and only if $[\overleftarrow{r},\overleftarrow{r}]=-[\overrightarrow{s},\overrightarrow{s}]$.
Recall that two Poisson brackets are called compatible if their any linear combination
is again a Poisson bracket. Suppose that the new bracket makes the variety $M$ Poisson over the Poisson
group $G$. Then the formula (\ref{eq:UhEquivariantPb}) suggests that
a Poisson bracket $\ensuremath{\varkappa}$ on $M$ is compatible with $p$ if and only if it is
$G$-invariant and $[\overrightarrow{s},\ensuremath{\varkappa}]=0$.
Next we recall the notion of 2-parameter, or double quantization (see,
for example, \cite{DoninJ:DoubleQuantizationOfLieGroups}).
\begin{defin}
\label{def:DoubleQnOfPoissManifs} Suppose that the commutative
algebra $A$ is endowed with two compatible Poisson brackets, $\pb$
and $\ensuremath{\varkappa}$, such that $\ensuremath{\varkappa}$ is $G$-invariant. An algebra
$(A_{\ensuremath{\hbar},t},\star)$ over the ring $\mathbb{C}{[\![}\ensuremath{\hbar},t{]\!]}$ of formal power
series in two variables is called {\em equivariant quantization} of
$(A,\pb,\ensuremath{\varkappa})$ if
\begin{enumerate}
\item[ (i)]
$A_{\ensuremath{\hbar},t}$ is a free module over $\mathbb{C}{[\![}\ensuremath{\hbar},t{]\!]}$;
\item[ (ii)]
The first order term of the deformed multiplication $\star$ is
$\ensuremath{\hbar}\pb+t\ensuremath{\varkappa}$;
\item[ (iii)]
The algebra $A_{\ensuremath{\hbar},t}$ is $\Ughr$-equivariant;
\item[ (iv)]
The quotient $A_{\ensuremath{\hbar},t}/\ensuremath{\hbar} A_{\ensuremath{\hbar},t}$ is a $G$-equivariant
(one-parameter) quantization of $(A,\ensuremath{\varkappa})$.
\end{enumerate}
\end{defin}
\section{Poisson-Lie orbit bundles}
\label{sect:Poisson-LieOrB}
\subsection{General remarks on coadjoint orbits in $\mathfrak{gl}_n^*(\mathbb{C})$}
\label{sect:GenRemarks}
Fix $G=GL_n(\mathbb{C})$ and put $\mathfrak g=\mathfrak{gl}_n(\mathbb{C})$. Choose the
algebra of diagonal matrices as a Cartan subalgebra
$\Cart\subset \mathfrak g$.
The non-degenerate $G$-invariant bilinear
form $\tr(XY)$ on $\mathfrak g$ allows us to think of $\Cart^*$
as a subset in $\mathfrak g^*$, the dual vector space for $\mathfrak g$.
Denote by $\ola$ the coadjoint orbit of a
semisimple element $\ensuremath{\lambda}\in\Cart^*\subset{\mathfrak{g}}^*$.
As a $G$-variety,
$\ola$ is isomorphic to $G^\ensuremath{\lambda}\backslash G$ where $G^\ensuremath{\lambda}$ is a Levi
subgroup of $G$. That is, the Lie algebra $\mathfrak g^\ensuremath{\lambda}$ of $G^\ensuremath{\lambda}$
is a Levi subalgebra of $\mathfrak g$ containing
$\Cart$.
The trace bilinear form on $\mathfrak g$ establishes a canonical
isomorphism between coadjoint orbits in ${\mathfrak{g}}^*$ and adjoint orbits
in $\mathfrak g$.
We will use this isomorphism without further noticing.
In the same way, we identify an element $\ensuremath{\lambda}\in\Cart^*$
with the corresponding diagonal matrix in $\Cart$.
Two diagonal matrices with different order of the entries belong
to the same $G$-orbit.
Hence we can
choose a representative of the orbit in which all equal entries are
grouped up together. In other words, we can think that
$\ensuremath{\lambda}=\diag(\ensuremath{\Lambda}_1,\ldots,\ensuremath{\Lambda}_l)$ where $\ensuremath{\Lambda}_i$ is the scalar
$n_i\times n_i$ matrix with $\ensuremath{\lambda}_i$ on its diagonal.
In particular, the orbit $\ola$ is determined by a pair
$(\mbox{\boldmath$\lambda$},\mathbf{n})$ where $\mbox{\boldmath$\lambda$}=(\ensuremath{\lambda}_1,\ldots,\ensuremath{\lambda}_l)$ is the row of pairwise
distinct eigenvalues of $\ensuremath{\lambda}$, and
$\mathbf{n}=(n_1,\ldots,n_l)$ and $\ensuremath{\lambda}_1,\dots,\ensuremath{\lambda}_l$ is the row of their
multiplicities.
Note that the orbit $\ola$ does not depend on
simultaneous permutations of the entries of $\mbox{\boldmath$\lambda$}$ and $\mathbf{n}$.
\subsection{The related Poisson structures on $\ola$}
The admissible quasi-Poisson bracket on a semisimple orbit has the form
(see \cite{DoninJ:QuanGMans},
\cite{DoninJOstapenkoV:EquivQn},
\cite{DoninGurevicShnider:DoubleQuantiz} and
\cite{KarolinskijE:ClassPoissHomSpace} for details):
$$
\sum_{1\leqslant i<j\leqslant l}c_{ij}\xi_{ij},
$$
where $c_{ij}$ are some coefficients depending on the eigenvalues of
$\ensuremath{\lambda}$ (see below for explicit formulas),
and $\xi_{ij}$ are defined as follows:
\begin{equation}\label{eq:BasisBivector}
\xi_{ij}=\sum_{s,t} E_{st}\wedge E_{ts} \mod \mathfrak g\wedge\mathfrak g^\ensuremath{\lambda}.
\end{equation}
Here $E_{st}$ is the $(s,t)$-th matrix unit, $l$ is the number of
different eigenvalues of $\ensuremath{\lambda}$, and the sum is taken over
$n_1+n_2+\dots+n_{i-1}< s \leqslant n_1+n_2+\dots+n_i$,
$n_1+n_2+\dots+n_{j-1}< t \leqslant n_1+n_2+\dots+n_j$, where $n_i$
denotes the multiplicity of the eigenvalue $\ensuremath{\lambda}_i$.
\subsubsection*{The KKSL Poisson bracket $\ensuremath{\varkappa}_\ensuremath{\lambda}$}
The Kirillov-Kostant-Lie-Souriau bra\-cket $\ensuremath{\varkappa}_\ensuremath{\lambda}$ is induced on
$\ola$ from the Lie structure on $\mathfrak g$.
For a semisimple (co)adjoint $GL_n(\mathbb{C})$-orbit $\ola$ it is given
by the following expression:
\begin{equation*}
\ensuremath{\varkappa}_\ensuremath{\lambda}=\sum_{1\leqslant i<j\leqslant l}\frac{1}{\ensuremath{\lambda}_i-\ensuremath{\lambda}_j}\ \xi_{ij}.
\end{equation*}
This is a $G$-invariant non-degenerate Poisson bracket.
\subsubsection*{The quasi-Poisson bracket $s^0_\ensuremath{\lambda}$.}
Consider the bivector field on $\ola$ restricted
from the Semenov-Tian-Shansky (STS)
bracket on $\End(\mathbb{C}^n)$, see \cite{STS:QDualityQDouble}.
Its quasi-Poisson part is generated by an element $s_\ensuremath{\lambda}^0\in\wedge^2(\mathfrak g/\mathfrak g^\ensuremath{\lambda})^{\mathfrak g^\ensuremath{\lambda}}$.
Specifically for the
case $G=GL_n(\mathbb{C})$, it takes the form:
$$
s_\ensuremath{\lambda}^0=\sum_{1\leqslant i<j\leqslant l} \frac{\ensuremath{\lambda}_i+\ensuremath{\lambda}_j}{\ensuremath{\lambda}_i-\ensuremath{\lambda}_j}\
\xi_{ij},
$$
see \cite{DoninJMudrovAI:MethodQuantChar}.
\subsubsection*{The brackets admitting $\Ughr$-equivariant
quantization}
In our case $G=GL_n(\mathbb{C})$, the Schouten bracket between $s_\ensuremath{\lambda}^0$
and $\ensuremath{\varkappa}_\ensuremath{\lambda}$ vanishes.
Thus, by adding a multiple of the KKLS
bracket to that generated by $s_\ensuremath{\lambda}^0$, one obtains the general form
for a quasi-Poisson bracket on $\ola$ admitting a $\Ughr$-equivariant
quantization:
\begin{equation}\label{eq:sla}
s_\ensuremath{\lambda}=s_\ensuremath{\lambda}^0+a \ensuremath{\varkappa}_\ensuremath{\lambda}= \sum_{1\leqslant i<j\leqslant
l}\frac{\ensuremath{\lambda}_i+\ensuremath{\lambda}_j+a}{\ensuremath{\lambda}_i-\ensuremath{\lambda}_j}\ \xi_{ij}, \mbox{ where }
a\in\mathbb{C}.
\end{equation}
Recall once again that we consider only those Poisson structures
that are restricted from ${\mathfrak{g}}^*$.
\subsection{The structure of Poisson orbit bundles}
Here we give the necessary and sufficient conditions for
an orbit map $\prj\colon \left(\ola,s_\ensuremath{\lambda}\right)\to\left(\omu,s_\mu\right)$
to be Poisson.
Recall that we do not distinguish between an element $\ensuremath{\lambda}\in{\mathfrak{g}}^*$ and
the corresponding diagonal matrix $\diag(\ensuremath{\Lambda}_1,\ldots,\ensuremath{\Lambda}_l)$.
\begin{prop}\label{prop:P}
Any semisimple orbit bundle $\ola\to\omu$ is of the form
$X\mapsto\Prj(X)$ where
$\Prj$ is a polynomial in one variable with complex coefficients.
\end{prop}
\begin{proof}
If an equivariant map $\left(\ola,s_\ensuremath{\lambda}\right)\to\left(\omu,s_\mu\right)$
brings $\ensuremath{\lambda}$ to $\mu$, then the isotropy group $G^\ensuremath{\lambda}$ is
a subgroup in $G^\mu$; this gives an inclusion $\mathfrak g^\ensuremath{\lambda}\subset \mathfrak g^\mu$ of their Lie algebras.
Consider $\mathfrak g=\mathfrak{gl}_n(\mathbb{C})$ as an associative algebra, $\mathfrak g\cong\End(\mathbb{C}^n)$,
and denote by $\Z(\mathfrak g^\ensuremath{\lambda})\subset\mathfrak g$ the centralizer of
$\mathfrak g^\ensuremath{\lambda}$.
Since $\mathfrak g^\ensuremath{\lambda}$ is a Levi subalgebra,
$\Z(\mathfrak g^\ensuremath{\lambda})$ is a semisimple commutative associative
algebra generated by $\ensuremath{\lambda}$ and by the unit matrix.
For any polynomial
$P$ in one variable the mapping $X\mapsto P(X)$, $X\in \mathfrak g$, is
$G$-equivariant.
Hence it suffices to check that $\mu = \Prj(\ensuremath{\lambda})$
for some polynomial $\Prj$.
The inclusion $\mathfrak g^\ensuremath{\lambda}\subset \mathfrak g^\mu$ implies the inclusion $Z(\mathfrak g^\mu)\subset Z(\mathfrak g^\ensuremath{\lambda})$.
Therefore the matrix $\mu$ is a polynomial in
$\ensuremath{\lambda}$.
\end{proof}
\begin{rem}
We will use the same symbol $\Prj$ for both the orbit map
$\ola\to\omu$ and for the corresponding polynomial.
\end{rem}
\subsubsection*{The graph of an orbit bundle}
It is convenient to use
the following graphical presentation of an orbit bundle $\Prj\colon\omu\to\ola$.
The orbit $\ola$ has a representative in the form of diagonal matrix
$\ensuremath{\lambda}=\diag(\ensuremath{\Lambda}_1,\ldots,\ensuremath{\Lambda}_l)$.
Set $\mu=\Prj(\ensuremath{\lambda})$, then $\mu$ also has the form
$\mu=\diag(\mathrm{M}_1,\ldots,\mathrm{M}_m)$, where $\mathrm{M}_j$ denotes the scalar
block corresponding to the eigenvalue $\mu_j$ of $\mu$.
Using this, denote by $\Gamma_\Prj$ the bipart type
graph whose upper nodes have labels $1,\dots,l$ corresponding to the
blocks $\ensuremath{\Lambda}_1,\dots,\ensuremath{\Lambda}_l$, and the lower nodes are labeled by
$1,\dots,m$ corresponding to the blocks $\mathrm{M}_1,\dots,\mathrm{M}_m$.
The $i$-th node of the upper part of $\Gamma_\Prj$ is connected to the
$\alpha$-th node of the lower part if and only if
$\Prj(\ensuremath{\lambda}_i)=\mu_\alpha$.
Note that each upper node has exactly one edge.
Since the map $\Prj$ is surjective, each
lower node is connected to some upper node.
Therefore the graph $\Gamma_\Prj$ is a disjoint union of trees of
the form:
\begin{center}\setlength{\unitlength}{.7in}
\begin{picture}(0,-1)
\multiput(-.9,0)(.3,0){3}{\circle{.08}}
\put(.45,0){\circle{.08}}
\put(0,-.9){\circle{.08}}
\put(-.88,-.03){\line(1,-1){.863}}
\put(-.59,-.03){\line(2,-3){.565}}
\put(-.3,-.03){\line(1,-3){.279}}
\put(.445,-.03){\line(-1,-2){.423}}
\put(-.03,-1.2){$\alpha$}
\multiput(-.06,-.05)(.12,0){3}{$\cdot$}
\end{picture}
\end{center}\vspace{1.0in}
Each tree is a connected component of $\Gamma_\Prj$
and it is labeled by the blocks of $\mu$.
The graph $\Gamma_\Prj$ gives a complete description of
the map $\Prj$.
\subsubsection*{The graph $\Gamma_\Prj$ for $\Prj$ Poisson}
Both $\ola$ and $\omu$ are endowed with Poisson
structures (\ref{eq:sla}).
The tangent space of $\ola$ at the point $\ensuremath{\lambda}$ is isomorphic as
a vector space to the quotient $\mathfrak g/\mathfrak g^\ensuremath{\lambda}$.
Recall that $\mathfrak g^\ensuremath{\lambda}\subset \mathfrak g^\mu$.
The tangent map $\prj_*:\mathfrak g/\mathfrak g^\ensuremath{\lambda}\to\mathfrak g/\mathfrak g^\mu$ of $\prj$ is given by
the formula:
$$
\prj_*(X)=\left\{
\begin{array}{l}
0, \mathrm{\ if\ } X\in\mathfrak g^\mu/\mathfrak g^\ensuremath{\lambda},\\
\ \\
X \mathrm{\ otherwise.}
\end{array}
\right.
$$
An element $X\in\mathfrak g\setminus\Cart$ cannot generate a vector field on
$\omu$ since it is not even $\Cart$-invariant.
However, the element like $\xi_{ij}$ (see formula
(\ref{eq:BasisBivector})) does generate a bivector field on $\omu$.
The map $\prj$ is Poisson if and only if
$\prj_*(s_\ensuremath{\lambda})=s_\mu$.
The tangent map $\prj_*$ is determined by
its values $\prj_*(\xi_{ij})=\xi_{\alpha\beta}$ where $i,j$ run over
the upper nodes of the graph $\Gamma_\Prj$ while $\alpha,\beta$ run
over the lower nodes of $\Gamma_\Prj$.
\begin{lm}\label{lm:GraphOfPoissBundle}
Let $\Prj\colon \ola\to\omu$ be a Poisson orbit bundle w.r.t.
the Poisson structure on $\ola$ determined by $s_\ensuremath{\lambda}=\sum
c_{ij}\xi_{ij}$ and some Poisson structure on $\omu$.
Suppose that $i\leqslant j<p\leqslant s$ are such {\em upper} nodes that $i$
and $j$ belong to the same connected component $\alpha$, and $p$, $s$ also
belong to the same connected component $\beta$ of $\Gamma_\Prj$.
Then $c_{ip}=c_{js}$.
\end{lm}
\begin{proof}
If $\Prj$ is Poisson then $s_\ensuremath{\lambda}$ is projectable under $\prj_*$.
Thus if $\prj_*(\xi_{ip})$ and $\prj_*(\xi_{js})$
enter the same basis bivector $\xi_{\alpha\beta}$, then $c_{ip}=c_{js}$.
\end{proof}
\subsubsection*{Classification of Poisson bundles}
We call a coadjoint orbit $\omu$ {\em symmetric} if the
corresponding matrix $\mathrm{M}$ has exactly two different eigenvalues.
\begin{thm}\label{th:MainPoiss}
A $GL_n(\mathbb{C})$-equivariant map $\pr<|fim_middle|> algebras induces a transformation of module
algebras, which we also call twist.
Given a $\Ugh$-algebra $\mathcal{A}$
one gets an algebra over $\Ughr$ with the new multiplication
$a\otimes b\mapsto(\mathcal{F}_{1} a)(\mathcal{F}_{2} b)$ for $a,b\in \mathcal{A}$.
Applying $\mathcal{F}$ to the mRE
algebra, one apparently destroys the form of relations (\ref{eq:mRE}).
Nevertheless, the mRE algebras corresponding to
$\Ughr$ and $\Ugh$
are still related by $\mathcal{F}$, as we now demonstrate.
Let $\mathcal{A}$ and $\widetilde \mathcal{A}$ denote the quadratic RE algebras
corresponding to quantum groups $\Ugh$ and $\Ughr$ respectively.
We assume that they are extended trivially to $\mathbb{C}[t]$-algebras.
Let $\widetilde \mathcal{A}'$ be the twist of the algebra $\mathcal{A}$ by
the cocycle $\mathcal{F}$.
Denote by $\{Q_{ij}\}\subset \mathcal{A}$ and $\{\widetilde Q_{ij}\}\subset \widetilde\mathcal{A}$
the generators satisfying the quadratic RE, i.e. the equation similar to
(\ref{eq:mRE}) but with zero in the r.h.s. These algebras
are quantizations of $\mathbb{C}[\End(\mathbb{C}^n)]$ along the STS brackets. As was shown in
\cite{KulishPMudrovA:dRE}, $\widetilde\mathcal{A}'$ is isomorphic to $\widetilde\mathcal{A}$
as $\Ughr$-module algebras,
and the isomorphism $\phi\colon \widetilde\mathcal{A}\to\widetilde\mathcal{A}'$ is given by the
formula
\begin{equation}\label{eq:RETwist}
\widetilde{Q}\mapsto (\rho\circ\gamma)(\mathcal{F}_{1} \zeta)Q\rho(\mathcal{F}_{2}).
\end{equation}
Here $\zeta:=\mathcal{F}^{-1}_{2}\gamma^{-1}(\mathcal{F}^{-1}_{1})\in \Ugh$ is the
element which participates in definition of the antipode $\tilde{\gamma}$ of $\Ughr$,
namely $\tilde \gamma(x)=\gamma(\zeta^{-1} x\zeta)$
for all $x\in \Ughr$.
Choose the new generators $\{K_{ij}\}\subset \widetilde\mathcal{A}'$ by setting
$K_{ij}:=Q_{ij}-t\ensuremath{\delta}_{ij}$ and similarly for $\{\widetilde K_{ij}\}\subset \widetilde\mathcal{A}$.
Note that $K_{ij}$ are also generators of $\mathcal{A}$.
\begin{lm}\label{lm:LinGen}
The isomorphism $\phi$ given by the formula (\ref{eq:RETwist}) defines a linear map
$\Span\bigl(\widetilde K_{ij}\bigr)\to \Span(K_{ij})$ through the formula
\begin{equation}
\label{Phi}
(\id\otimes \phi)(\widetilde K)= (\Phi\otimes \id)(K),
\end{equation}
where $\Phi$ is an invertible linear operator $\End(V)\to \End(V)$ acting by the rule
$\Phi(X)=(\rho\circ\gamma)(\mathcal{F}_{1}\zeta)X\rho(\mathcal{F}_{2})$
\end{lm}
\begin{proof}
Evaluating $\phi$ on the generators we find
$$
\phi(\widetilde K)=\rho\big(\gamma(\mathcal{F}_{1}\zeta)\big)Q\rho(\mathcal{F}_{2})-t=
\rho\big(\gamma(\mathcal{F}_{1}\zeta)\big)K\rho\big(\mathcal{F}_{2}\big)
+t\rho\big(\gamma(\mathcal{F}_{1}\zeta)\mathcal{F}_{2}\big)-t.
$$
The assertion will be proved if we show that $\gamma(\zeta)\gamma(\mathcal{F}_1)\mathcal{F}_2=1$.
But this is a well known fact from the twist theory, see \cite{DrinfeldW:AlmostCocomHopfAlgs}.
\end{proof}
Denote by $\mathcal{L}$ and by $\widetilde \mathcal{L}$ the mRE algebras corresponding to
$\Ugh$ and $\Ughr$, respectively.
\begin{prop}\label{prop:REtwisted}
The algebra $\widetilde \mathcal{L}$ is isomorphic to the twist of
$\mathcal{L}$ by the cocycle $\mathcal{F}$.
\end{prop}
\begin{proof}
Let $\widetilde\mathcal{A}'$ and $\widetilde \mathcal{L}'$ be respectively the twists of the
algebras $\mathcal{A}$ and $\mathcal{L}$ by the cocycle $\mathcal{F}$.
The algebra $\mathcal{A}$
admits an embedding in $\mathcal{L}$ through the assignment
\begin{equation}
\label{embed}
K\mapsto (1-q^{-2}) L.
\end{equation}
This embedding induces an embedding $\widetilde\mathcal{A}'\hookrightarrow
\widetilde\mathcal{L}'$ of the twisted algebras. Let us prove that the isomorphism
(\ref{eq:RETwist}) extends to an isomorphism $\widetilde \mathcal{L}\to\widetilde \mathcal{L}'$.
Denote by $\mathbb{C}(\!(\hbar)\!)$ the field of Laurent formal series in
$\hbar$. First of all notice that the mapping (\ref{embed}) is
invertible over $\mathbb{C}(\!(\hbar)\!)$.
Further, the mapping (\ref{eq:RETwist}) induces the isomorphism
$$
\widetilde \mathcal{L}\otimes_{{\mathbb{C}[\![\ensuremath{\hbar}]\!]}}\mathbb{C}(\!(\hbar)\!)\simeq
\widetilde\mathcal{A}\otimes_{{\mathbb{C}[\![\ensuremath{\hbar}]\!]}}\mathbb{C}(\!(\hbar)\!) \longrightarrow
\widetilde\mathcal{A}'\otimes_{{\mathbb{C}[\![\ensuremath{\hbar}]\!]}}\mathbb{C}(\!(\hbar)\!)\simeq
\widetilde\mathcal{L}'\otimes_{{\mathbb{C}[\![\ensuremath{\hbar}]\!]}}\mathbb{C}(\!(\hbar)\!).$$ of $\mathbb{C}(\!(\hbar)\!)$-algebras,
which we denote by $\hat \phi$.
Since $\widetilde\mathcal{L}$ and $\widetilde\mathcal{L}'$ are
free over $\mathbb{C}{[\![}\ensuremath{\hbar}{]\!]}$, we have the inclusions
$\widetilde \mathcal{L}\subset \widetilde \mathcal{L}\otimes_{{\mathbb{C}[\![\ensuremath{\hbar}]\!]}}\mathbb{C}(\!(\hbar)\!)$
and $ \widetilde\mathcal{L}'\subset \widetilde\mathcal{L}'\otimes_{{\mathbb{C}[\![\ensuremath{\hbar}]\!]}}\mathbb{C}(\!(\hbar)\!)$.
It is therefore sufficient to check that the
image of $\widetilde \mathcal{L}$ under
$\hat \phi$ lies in $ \widetilde\mathcal{L}'$ and similarly for the inverse of $\hat \phi$.
Introduce the linear operator $\Phi^*\colon\Span(K_{ij})\to \Span(K_{ij})$
through the equality $(\Phi\otimes \id)(K)=(\id\otimes \Phi^*)(K)$
(the dual conjugate of $\Phi$).
Evaluate $\hat \phi$ on a monomial in the generators $\widetilde L_{ij}$:
$$
\hat\phi (\widetilde L_{i_1 j_1}\ldots \widetilde L_{i_k j_k})
=
\hat\phi \left(\frac{1}{\omega}\widetilde K_{i_1 j_1}\ldots \frac{1}{\omega}\widetilde K_{i_k j_k}\right)
=
\frac{1}{\omega}\Phi^*(K_{i_1 j_1})\ldots \frac{1}{\omega}\Phi^*(K_{i_k j_k}),
$$
where $\omega=1-q^{-2}$.
The last equality is obtained using Lemma~\ref{lm:LinGen}.
But the rightmost expression is
$\Phi^*(L_{i_1 j_1})\ldots \Phi^*(L_{i_k j_k})\in \widetilde \mathcal{L}'$.
In the same fashion, one can check that ${\hat \phi}^{-1}(\widetilde \mathcal{L}') \subset \widetilde \mathcal{L}$.
\end{proof}
\begin{cor}\label{cor:twist}
Let $\ola$ be a semisimple coadjoint orbit. For any quantum group $\Ughr$ there
exists a $\Ughr$-equivariant quantization of $\fun$ which is a
quotient of the mRE algebra associated with $\Ughr$.
\end{cor}
\begin{proof}
Let $\mathcal{B}$ be the quantization of $\fun$ corresponding to the
standard quantum group $\Ugh$.
It is a quotient of the mRE algebra
$\mathcal{L}$. The twisted module algebra $\widetilde{\mathcal{B}'}$ is a
$\Ughr$-quantization of $\fun$.
It is a quotient of the algebra
$\widetilde\mathcal{L}'$, which is isomorphic to $\widetilde\mathcal{L}$ by
Proposition~\ref{prop:REtwisted}.
\end{proof}
\subsection{More on RE algebras and twists}
\label{subsect:Twist&REA}
We are going to derive a description of quantum orbits for
an arbitrary quantum group from that corresponding to
the Drinfeld-Jimbo quantum group.
To this end, we need
some facts about Hopf algebras.
As we argued in the previous section (see Proposition~\ref{prop:REtwisted}),
the twist of the (modified) reflection
equation algebra associated with a quantum group
is isomorphic to the (modified) reflection equation algebra
associated with the twisted quantum group.
In this section we obtain a more detailed information about
that isomorphism.
We start with the following auxiliary algebraic assertion.
\begin{lm}\label{4-3}
Let $\mathcal{H}$ be a Hopf algebra with multiplication $m$, comultiplication $\Delta$,
and invertible antipode $\gamma$. Suppose $\mathcal{F}\in \mathcal{H}\otimes \mathcal{H}$ is a twisting cocycle.
Then
$$
m_{23}\circ\gamma_3\Bigl((\Delta\otimes \Delta)(\mathcal{F})(\mathcal{F}\otimes\mathcal{F})(\zeta\otimes 1\otimes \zeta\otimes 1)\Bigr)=
\mathcal{F}_{1}\zeta\otimes 1\otimes \mathcal{F}_{2},
$$
where the argument in the left-hand-side belongs to $\mathcal{H}^{\otimes 4}$.
\end{lm}
\begin{proof}
Applying the cocycle equation (\ref{eq:cocycle}) to
$(\Delta\otimes \Delta)(\mathcal{F})\mathcal{F}_{34}$, we obtain for the left-hand side
the expression
$$
\mathcal{F}_1^{(1)}\mathcal{F}_{1'}^{(1)}\mathcal{F}_{1''}\zeta\otimes \mathcal{F}_1^{(2)}\mathcal{F}_{1'}^{(2)}\mathcal{F}_{2''}\gamma(\mathcal{F}_1^{(3)}\mathcal{F}_{2'}\zeta)\otimes \mathcal{F}_2.
$$
In order to distinguish between different copies of $\mathcal{F}$, the subscripts are marked with dashes.
We apply the cocycle equation to $\mathcal{F}_{1'}^{(1)}\mathcal{F}_{1''}\otimes \mathcal{F}_{1'}^{(2)}\mathcal{F}_{2''}\otimes \mathcal{F}_{2'}$
and obtain
$$
\mathcal{F}_1^{(1)}\mathcal{F}_{1'}\zeta\otimes \mathcal{F}_1^{(2)}\mathcal{F}_{2'}^{(1)}\mathcal{F}_{1''}\gamma(\mathcal{F}_1^{(3)}\mathcal{F}_{2'}^{(2)}\mathcal{F}_{2''}\zeta)\otimes \mathcal{F}_2.
$$
Now the statement immediately follows from the equalities
$
\mathcal{F}_{1}\gamma(\zeta)\gamma(\mathcal{F}_{2})=1
$
and (\ref{eq:cocycle_norm}).
\end{proof}
Suppose that $\mathcal{H}$ is a quasitriangular Hopf algebra and
let $(V,\rho)$ be a finite dimensional representation of $\mathcal{H}$.
We say that a matrix $A\in \End(V)\otimes \mathcal{A}$ is {\em invariant}, if
$h\triangleright A=\rho\bigl(\gamma(h^{(1)})\bigr)A \rho(h^{(2)})$ for
all $h\in \mathcal{H}$, where $h\triangleright A$ denotes the action (\ref{eq:action}).
Let $\mathcal{A}$ and $\widetilde \mathcal{A}$ be the (quadratic) RE algebras
corresponding to
the Hopf algebras $\mathcal{H}$ and $\widetilde \mathcal{H}$, where $\widetilde \mathcal{H}$
is the twist of $\mathcal{H}$ by the cocycle $\mathcal{F}$.
The map (\ref{eq:RETwist}) implements an equivariant isomorphism
of $\widetilde\mathcal{H}$-module algebras $\widetilde \mathcal{A}\to \widetilde \mathcal{A}'$ where $\widetilde \mathcal{A}'$
is the twist of $\mathcal{A}$ by $\mathcal{F}$.
We can also consider $\phi$ as an isomorphism $\widetilde \mathcal{A}\to \mathcal{A}$ of $\mathcal{H}$-modules.
For an invariant matrix $\widetilde A\in \End(V)\otimes\widetilde \mathcal{A}$
we have
\begin{equation}\label{eq:AtA}
(\id \otimes \phi)(\widetilde A)=(\Phi\otimes \id)(A),
\end{equation}
where
$A$ is an
invariant matrix in $\End(V)\otimes\mathcal{A}$.
(For the definition of the operator $\Phi$, see Lemma \ref{lm:LinGen}).
\begin{prop}\label{A*B}
Suppose that $\widetilde A$ and $\widetilde B$ are invariant matrices from $\End(V)\otimes\widetilde \mathcal{A}$.
Then
$(\id\otimes \phi)(\widetilde A\widetilde B)=(\Phi\otimes\id) (AB)$,
where $A$ and $B$ are invariant matrices from $\End(V)\otimes\mathcal{A}$ defined by
(\ref{eq:AtA}).
\end {prop}
\begin{proof}
Follows from Lemma~\ref{4-3}.
\end{proof}
For any invariant matrix $A\in \End(V)\otimes\mathcal{A}$
we define an invariant (hence central) element
$\tr_q(A):=\tr_V\bigl(\mathcal{R}_1\gamma(\mathcal{R}_2)A\bigr)\in \mathcal{A}$.
Note that here we suppress
the representation symbol and we do not care
about the normalizing scalar, contrary to Section~\ref{subsection:mREA}.
\begin{prop}\label{tr-tr0}
Suppose that $\widetilde A$ and $A$ are invariant matrices with coefficients
in $\widetilde\mathcal{A}$ and $\mathcal{A}$, respectively, related by (\ref{eq:AtA}). Then
$$
(\tr_q\otimes \phi)(\widetilde A)=\tr_q(A).$$
\end{prop}
\begin{proof}
Suppressing the representation symbol $\rho$, we find
$$
(\tr_q\otimes \phi)(\widetilde A)=\tr\Bigl(\widetilde \mathcal{R}_1\widetilde\gamma(\widetilde \mathcal{R}_2)\gamma(\mathcal{F}_1\zeta)A\mathcal{F}_2\Bigr),
$$
where $\widetilde \gamma$ is the antipode in $\widetilde \mathcal{H}$, $\widetilde \gamma(x)=\gamma(\zeta^{-1}x\zeta)$.
But
$$
\mathcal{F}_2 \widetilde\mathcal{R}_1\widetilde \gamma(\widetilde \mathcal{R}_2)\gamma(\mathcal{F}_1\zeta)=
\mathcal{F}_2\widetilde\mathcal{R}_1\gamma(\mathcal{F}_1\widetilde \mathcal{R}_2\zeta)
=\mathcal{R}_1\mathcal{F}_1\gamma(\mathcal{R}_2\mathcal{F}_2\zeta)
=\mathcal{R}_1\gamma(\mathcal{R}_2)
$$
because of the equality $\mathcal{F}_1\gamma(\zeta)\gamma(\mathcal{F}_2)=1$.
This proves the assertion.
\end{proof}
Denote by $\{Q_{ij}\}\subset \mathcal{A}$ the RE generators
considered simultaneously as generators for $\widetilde \mathcal{A}'$
(the latter coincides with $\mathcal{A}$ as an $\mathcal{H}$-module
and has the same system of generators as an algebra).
Let $\{\widetilde Q_{ij}\}$ denote the RE generators of $ \widetilde \mathcal{A}$.
The matrices $Q$ and $\widetilde Q$ are invariant and so are
their powers relative to the multiplications in
$\mathcal{A}$ and $\widetilde \mathcal{A}$, respectively.
The isomorphism $\phi$ relates $\widetilde Q$ and $Q$
by the formula (\ref{eq:AtA}).
The following result is an immediate corollary of Propositions~\ref{A*B} and \ref{tr-tr0}.
\begin{prop}\label{tr-tr}
Regard the algebra isomorphism $\phi\colon \widetilde\mathcal{A}\to \widetilde\mathcal{A}'$ as an isomorphism $\widetilde \mathcal{A}\to \mathcal{A}$
of vector spaces. Then
$
(\tr_q\otimes \phi)(\widetilde Q^m)=\tr_q(Q^m).$
\end{prop}
Now let $\widetilde \mathcal{L}$ and $\mathcal{L}$ be the mRE algebras corresponding
to $\widetilde \mathcal{H}$ and $\mathcal{H}$.
Let $\{\widetilde L_{ij}\}\subset \widetilde \mathcal{L}$ and $\{L_{ij}\}\subset \mathcal{L}$
be their mRE generators. Put $\widetilde \mathcal{L}'$ to be the twist of $\mathcal{L}$ by $\mathcal{F}$.
Regard the algebra isomorphism $\phi\colon\widetilde \mathcal{L}\to \widetilde \mathcal{L}'$
extending the isomorphism $\phi\colon\widetilde \mathcal{A}\to \widetilde \mathcal{A}'$
as an isomorphism $\widetilde \mathcal{L}\to \mathcal{L}$ of vector spaces.
\begin{prop}\label{phi_preserves_submodules}
\begin{enumerate}
\item[{\em (a)}]
The map $\phi$ preserves q-traces:
$
(\tr_q\otimes \phi)(\widetilde L^m)=\tr_q(L^m).
$
\item[{\em (b)}]
For any polynomial $P$ in one variable,
$(\id \otimes \phi)\bigl(P(\widetilde L)\bigr)=(\Phi \otimes \id)\bigl(P(L)\bigr)$.
\end{enumerate}
\end{prop}
\begin{proof}
The proof readily follows from
Propositions \ref{A*B} and \ref{tr-tr} and
the fact that the twist extends from the quadratic RE algebras to
the modified RE algebras, by Proposition \ref{prop:REtwisted}.
\end{proof}
\section{$\Ughr$-equivariant quantization of orbits}
\label{sect:DMQuantization}
In this section we give a description of a 2-parameter
quantization of the function algebra $\fun$ starting from an
arbitrary (factorizable) classical r-matrix.
This generalizes the construction
given in \cite{DoninJMudrovAI:ExplicitQuantiz}.
The linear term of
this quantization (or, more precisely, the "quasi-Poisson part" of
it (see formula (\ref{eq:UhEquivariantPb})) is
$\ensuremath{\hbar} s^0_\ensuremath{\lambda}+t\ensuremath{\varkappa}_\ensuremath{\lambda}$ where $\ensuremath{\hbar}$ and $t$ are formal parameters.
Reducing this to a one-parameter quantization corresponding to the
curve $t=\ensuremath{\lambda}_1\left(e^{-2\ensuremath{\hbar}}-1\right)$ on the plane $(\ensuremath{\hbar},t)$, we
get a quantization $\funh$ with the linear term
$\ensuremath{\hbar}\left(s^0_\ensuremath{\lambda}-2\ensuremath{\lambda}_1\ensuremath{\varkappa}_\ensuremath{\lambda}\right)$.
\subsection{Algebraic description of coadjoint orbits}
Organize the generators of the symmetric algebra $\Sg$ in an
$n\times n$ matrix $L=(L_{ij})$, then $\Sg=\mathbb{C}[L_{ij}]$.
The algebra $\fun$ of polynomial functions on $\ola$ is a quotient
of $\mathbb{C}[L_{ij}]$ by two sets of relations. The first set of $n^2$
relations can be written in the matrix form as
\begin{equation}\label{eq:CH}
\left(L-\ensuremath{\lambda}_1\right)\dots\left(L-\ensuremath{\lambda}_l\right)=0,
\end{equation}
where $(x-\ensuremath{\lambda}_1)\dots(x-\ensuremath{\lambda}_l)$ is the minimal polynomial for $\ensuremath{\lambda}$.
To distinguish the orbits corresponding to the same eigenvalues with
different multiplicities, one should impose the following {\em trace
conditions}:
\begin{equation}\label{eq:mults}
\tr\left(L^r\right)=\sum_{j=1}^l n_j\ensuremath{\lambda}_j^r,\quad r=1,\dots,l-1,
\end{equation}
where $\displaystyle\sum_{j=1}^l n_j=n$. It is known that the ideal generated
by (\ref{eq:CH}) and (\ref{eq:mults}) is radical, hence it is
precisely the ideal of functions vanishing on $\ola$.
\subsection{On central characters of the mRE algebra}
\label{sec:DMquantization}
To describe quantum orbits explicitly, we need $q$-analogs of the
polynomials in the right-hand side of (\ref{eq:mults}), i.e. quantum
trace functions. For every $m\in \mathbb{N}$ put
$\displaystyle\hat m:=\frac{1-q^{-2n}}{1-q^{-2}}$.
Fix
$\mbox{\boldmath$\lambda$}:=(\ensuremath{\lambda}_1,\ldots,\ensuremath{\lambda}_l)$ and $\hat{\mathbf{n}}:= (\hat n_1,\ldots,\hat n_l)$
assuming $\ensuremath{\lambda}_i$ pairwise distinct; put also
$\tilde\mbox{\boldmath$\lambda$}=(\tilde\ensuremath{\lambda}_1,\ldots,\tilde\ensuremath{\lambda}_l)$, where
$\displaystyle\widetilde\ensuremath{\lambda}_i=\ensuremath{\lambda}_i-\frac{t}{\omega}$.
Consider the family of
functions $\vartheta_r(\mbox{\boldmath$\lambda$},\hat{\mathbf{n}},q^{-2},t)$, $r=0,\ldots,\infty$, defined
by
\begin{equation}\label{eq:qmults}
\vartheta_r(\mbox{\boldmath$\lambda$}, \hat{\mathbf{n}},q^{-2},t):=\sum_{i=1}^l C_i(\widetilde\mbox{\boldmath$\lambda$} ,
\hat{\mathbf{n}},\omega)\ensuremath{\lambda}_i^r,
\end{equation}
where
\begin{equation}
C_i(\mbox{\boldmath$\lambda$} , \hat{\mathbf{n}},\omega):=\hat n_i\prod_{j\not =i}
\Bigl(1+\omega\frac{\hat n_j \ensuremath{\lambda}_j}{\ensuremath{\lambda}_i-\ensuremath{\lambda}_j}\Bigr).
\end{equation}
(Recall that we use the notation $\omega=1-q^{-2}$).
Although manifestly rational, the functions $\vartheta_r$ are in fact
polynomials in all arguments, see
\cite{DoninJMudrovAI:ExplicitQuantiz}.
In the classical limit $\omega\to 0$, the
function $\vartheta_r$ turns into the classical trace function
$\displaystyle\sum_{i=1}^l n_i\ensuremath{\lambda}_i^r$.
Fix a polynomial $\Prj$ in one variable with coefficients in $\mathbb{C}$.
Consider the quotient of $\mathcal{L}$ by the
$\Ughr$-invariant ideal of relations $\Prj(L)=0$.
Denote by $Z_\Prj$ its subalgebra of invariants.
We call a homomorphism $Z_\Prj\to\mathbb{C}{[\![}\ensuremath{\hbar}{]\!]}[t]$
{\em a character} of $Z_\Prj$.
The meaning of the functions $\vartheta_r(\mbox{\boldmath$\lambda$}, \hat{\mathbf{n}},q^{-2},t)$
is explained by the following proposition.
\begin{prop}\label{center_in_M_p}
The algebra $Z_P$ is a free module over $\mathbb{C}{[\![}\ensuremath{\hbar}{]\!]}[t]$.
The characters of $Z_\Prj$ are given by the formulas
\begin{equation}\label{eq:char}
\chi_{\hat \mathbf{n}}\colon\tau_r\mapsto\vartheta_r(\mbox{\boldmath$\lambda$}, \hat{\mathbf{n}},q^{-2},t),
\quad r=1,\ldots, \infty,
\end{equation}
and define an embedding of $Z_\Prj$ in the direct sum
$\bigoplus_{\hat{\mathbf{n}}}\mathbb{C}{[\![}\ensuremath{\hbar}{]\!]}[t]$.
This embedding becomes an isomorphism
over $\mathbb{C}{[\![} \hbar,t{]\!]}$.
\end{prop}
This proposition is proved in \cite{DoninJMudrovAI:ExplicitQuantiz}
for the case of standard quantum group.
One can prove it for
the general quantum group $\Ughr$ using similar arguments.
\subsection{The DM quantization of coadjoint orbits}
Now we are in possession of all ingredients for construction of
quantum orbits. We will work over the ring of scalars being $\mathbb{C}{[\![} \hbar,t{]\!]}$.
\begin{thm}\label{th:DMQuantization}
Let $\Ughr$ be {\em any} quasitriangular quantization of ${\U}(\g)$ along
a factorizable Lie bialgebra $\mathfrak g$. Let
let $\mathbb{C}_{\hbar,t}[{\mathfrak{g}}^*]$ be the corresponding mRE algebra generated
by $n^2$ entries of the matrix $L$. Then the quotient of
$\mathbb{C}_{\hbar,t}[{\mathfrak{g}}^*]$ by the ideal of relations
\begin{equation}\label{eq:MinPolynomCondition}
(L-\ensuremath{\lambda}_1)\ldots(L-\ensuremath{\lambda}_l)=0,
\end{equation}
\begin{equation}\label{eq:qTraceCondition}
\tr_q(L^r)=\vartheta_r(\mbox{\boldmath$\lambda$}, \hat{\mathbf{n}}, q^{-2},t,), \quad
m=1,\ldots,l-1,
\end{equation}
is a $\Ughr$-equivariant quantization of the orbit of matrices with
eigenvalues $\mbox{\boldmath$\lambda$}$ of multiplicities $\mathbf{n}$.
\end{thm}
\begin{proof}
The description of the quantized ideal of the orbit can be deduced
from Corollary \ref{cor:twist} and Proposition \ref{center_in_M_p} using
deformation arguments.
We will give an alternative proof based on the results
of Section~\ref{subsect:Twist&REA}, deriving the quantized ideal
of the orbit from the Drinfeld-Jimbo case.
Let $\widetilde \mathcal{L}$ and $\mathcal{L}$ denote the mRE algebras corresponding
to $\Ughr$ and $\Ugh$, respectively. The quantum group
$\Ughr$ is the twist of $\Ugh$ by a cocycle $\mathcal{F}$. Denote by $\widetilde \mathcal{L}'$
the corresponding twist of $\mathcal{L}$; that is a module algebra over $\Ughr$.
By Proposition \ref{prop:REtwisted}, there is an equivariant
isomorphism of algebras $\phi\colon \widetilde \mathcal{L}\to \widetilde \mathcal{L}'$.
The map $\phi$ is determined by formula (\ref{Phi}), where
the matrices $\widetilde K$ and $K$ should be replaced by
$\widetilde L$ and $L$, respectively.
Denote by $\mathcal{B}$ the quantization of the orbit $O_\ensuremath{\lambda}$ which is
equivariant under $\Ugh$.
It is a quotient of $\mathcal{L}$ by the ideal $\mathcal{J}$ of relations
(\ref{eq:MinPolynomCondition})
and (\ref{eq:qTraceCondition}).
The twist $\widetilde \mathcal{B}'$ of the algebra $\mathcal{B}$ by $\mathcal{F}$ is a quantization
of $O_\ensuremath{\lambda}$ which is equivariant under $\Ughr$.
It is a quotient of $\widetilde \mathcal{L}'$ by the ideal $\widetilde \mathcal{J}'$ which
coincides with $\mathcal{J}$ as a vector space.
Moreover, $\widetilde \mathcal{J}'$ is generated by the same submodule as $\mathcal{J}$ in $\mathcal{L}$.
In our case that submodule is spanned by the elements
of the matrix $P(L)$ and the kernel of the central character of $\mathcal{L}$. Consider the
equivariant isomorphism $\phi^{-1}\colon \widetilde \mathcal{L}'\to \widetilde \mathcal{L}$.
By Proposition \ref{phi_preserves_submodules}, it sends $\Span \bigl(P(L)_{ij}\bigr)$
to $\Span \bigl(P(\widetilde L)_{ij}\bigr)$ and preserves the q-traces.
This proves the theorem.
\end{proof}
\begin{rem}
In \cite{MudrovA:QConjClasses}, a description similar to
Theorem \ref{th:DMQuantization} of semisimple quantum conjugacy classes
of the Drinfeld-Jimbo matrix quantum groups is given.
Using the same arguments as in the proof of Theorem \ref{th:DMQuantization}
and the results of Section \ref{subsect:Twist&REA},
the quantization of \cite{MudrovA:QConjClasses} extends to arbitrary
quantum groups of the classical series.
\end{rem}
\section{Quantization of orbit bundles in $\mathfrak{gl}_n^*(\mathbb{C})$}
\label{sect:QnOfBundles}
In this section we prove that all orbit bundles admit
$\Ughr$-equivariant quantization and give the explicit construction.
We start with the following
algebraic lemma \cite{DoninJMudrovAI:MethodQuantChar} which we prove
here for the sake of completeness.
\begin{lm}\label{lm:AlgLemma}
Let $Q(x)$ be a polynomial over a field $F$ of zero characteristic,
$\alpha, \beta$ some elements of $F$, and $L,S$ elements of an
associative algebra with unit over $F$ satisfying the following
conditions:
\begin{enumerate}
\item[\em (a)]
$[SLS,L]=0$,
\item[\em (b)]
$S^2=\alpha S+1$,
\item[\em (c)]
$LQ(L)=\beta L$.
\end{enumerate}
Then one has $[SQ(L)S,Q(L)]=0$.
\end{lm}
\begin{rem}
The algebra generated by $S$ and $L$ subject to conditions (a)--(c) is a special case of cyclotomic affine Hecke algebra of rank 1.
\end{rem}
\begin{proof}
Prove, using the induction on $m\geq 1$, that $[SL^mS,Q(L)]=0$. The
induction base, $m=1$, holds true for one checks readily that (a)
implies $[SLS,L^k]=0$ for any $k$. Now, suppose $[SL^mS,Q(L)]=0$,
then one has using (b):
\begin{gather}
[SL^{m+1}S,Q(L)]=[SL1L^mS,Q(L)]=[SL(S^2-\alpha S)L^mS,Q(L)]=\nonumber \\
=[SLS^2L^m S,Q(L)]-\alpha[SLSL^mS,Q(L)].\label{eq:One}
\end{gather}
According to the induction assumption, both $SLS$ and $SL^mS$ commute
with $Q(L)$, thus
$$
[SLS^2L^mS,Q(L)]=[(SLS)(SL^mS),Q(L)]=0.
$$
The last term in (\ref{eq:One}) is treated as follows:
\begin{eqnarray*}
[SLSL^mS,Q(L)]&=&
SL\bigl(SL^mSQ(L)\bigr)-\bigl(Q(L)SLS\bigr)L^mS\\
&=&SLQ(L)SL^mS-SLSL^mQ(L)S \\
&=&\beta SLSL^mS-\beta SLSL^mS=0,
\end{eqnarray*}
where the induction assumption and (c) were used.
\end{proof}
Recall from see Proposition~\ref{prop:P} that any orbit map is determined
by a polynomial $\Prj$ in one variable.
\begin{thm}\label{th:Main}
Fix a factorizable quantum group $\Ughr$, where $\mathfrak g=\mathfrak{gl}_n(\mathbb{C})$.
Let $\ola$
and $\omu$ be two orbits in $\mathfrak g$ satisfying the condintions of
Theorem~\ref{th:MainPoiss}, and denote by
$\mathbb{C}_\ensuremath{\hbar}[\ola]=\mathbb{C}_\ensuremath{\hbar}[L_{\ensuremath{\lambda},ij}]$ and
$\funh[\omu]=\mathbb{C}_\ensuremath{\hbar}[L_{\mu,ij}]$ their quantizations from
Theorem~\ref{th:DMQuantization} with
$t=\ensuremath{\lambda}_1\left(e^{-2\ensuremath{\hbar}}-1\right)$.
Then the assignment
$L_\mu\mapsto \Prj(L_\ensuremath{\lambda})$, where the polynomial $\Prj$ is
given by (\ref{eq:DefOfP}), is a $\Ughr$-equivariant quantization of
the orbit bundle $\ola\to\omu$ determined by $P$.
\end{thm}
\begin{proof}
Denote by $\prj^*$ the algebra monomorphism $\fun[\omu]\to\fun$
corresponding to the map $\prj$.
Both $L_\ensuremath{\lambda}$ and $L_\mu$ are
subject to the relations (\ref{eq:CH}) and (\ref{eq:mults}).
The algebra homomorphism $\prj^*\colon \fun[\omu]\to\fun$ is determined
by the correspondence $L_\mu\mapsto P(L_\ensuremath{\lambda})$.
We need to prove that
the same correspondence defines a $\mathbb{C}{[\![}\ensuremath{\hbar}{]\!]}$-algebra monomorphism
$\funh[\omu]\to\funh$, i.e. that the matrix $\prj(L_\ensuremath{\lambda})$
satisfies the same relations as the matrix $L_\mu$.
1. Check the relation: $[SP(L_\ensuremath{\lambda})
S,P(L_\ensuremath{\lambda})]=\mu_1(q-q^{-1})[S,P(L_\ensuremath{\lambda})]$.
It can be written in the form:
\begin{equation}\label{eq:REforP}
[S\left(P(L_\ensuremath{\lambda})-\mu_1\right) S,P(L_\ensuremath{\lambda})-\mu_1]=0,
\end{equation}
as $S$ is a Hecke matrix.
It is easy to check that $(L_\ensuremath{\lambda}-\ensuremath{\lambda}_1)\left( P(L_\ensuremath{\lambda})-\mu_1
\right)=(\mu_2-\mu_1)(L_\ensuremath{\lambda}-\ensuremath{\lambda}_1)$. Now set $\beta:=\mu_2-\mu_1$,
$L:=L_\ensuremath{\lambda}-\ensuremath{\lambda}_1$, $Q(x):=P(x+\ensuremath{\lambda}_1)-\mu_1$, then
(\ref{eq:REforP}) follows from Lemma~\ref{lm:AlgLemma}.
2. Check the relation:
\begin{equation}\label{eq:CHforP}
(P(L_\ensuremath{\lambda})-\mu_1)(P(L_\ensuremath{\lambda})-\mu_2)=0.
\end{equation}
Substituting (\ref{eq:DefOfP}) into the l.h.s. of (\ref{eq:CHforP}),
one gets
\begin{equation}\label{eq:CheckingHC}
\prod_{i=2}^l(L_\ensuremath{\lambda}-\ensuremath{\lambda}_i) \left(
\prod_{i=2}^l(L_\ensuremath{\lambda}-\ensuremath{\lambda}_i)-\prod_{i=2}^l(\ensuremath{\lambda}_1-\ensuremath{\lambda}_i) \right)
\end{equation}
up to a constant multiple. The expression in the big brackets is
divisible by $L_\ensuremath{\lambda}-\ensuremath{\lambda}_1$.
Indeed, for any polynomial $f(x)$,
the polynomial in two variables $F(x,y):=f(x)-f(y)$ is divisible by
$x-y$.
This implies that (\ref{eq:CheckingHC}) is divisible by the
minimal polynomial of $\ensuremath{\lambda}$, so it is equal to zero.
3. In order to check the q-Trace Condition,
\begin{equation}\label{eq:TraceCondForP}
\tr_q P(L_\ensuremath{\lambda})=\tr_q(L_\mu),
\end{equation}
we put $\mbox{\boldmath$\nu$}=\hat{\mathbf{n}}=(\hat n_1,\ldots,\hat n_l)$ and $\omega:=1-q^{-2}$
in the functions $C_i(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)$, see Appendix, formula
(\ref{eq:Cs}). (As above, $\hat n_i =
\frac{1-q^{-2n_i}}{1-q^{-2}}$).
Replacing $\mbox{\boldmath$\lambda$}$, $\mbox{\boldmath$\mu$}$, $L_\ensuremath{\lambda}$, $L_\mu$ and $\Prj(x)$
by $(0, \ensuremath{\lambda}_2-\ensuremath{\lambda}_1,\ldots,\ensuremath{\lambda}_l-\ensuremath{\lambda}_1)$, $(0,\mu_2-\mu_1)$,
$L_\ensuremath{\lambda}-\ensuremath{\lambda}_1$, $L_\mu-\mu_1$ and $\Prj(x+\ensuremath{\lambda}_1)-\mu_1$
respectively, one reduces the problem to the case $\ensuremath{\lambda}_1=\mu_1=0$.
So, it suffices to prove that the condition (\ref{eq:TraceCondForP})
is satisfied when $\ensuremath{\lambda}_1=0$ and $\Prj(0)=0$.
By assumption, $\mu_1=\Prj(0)=0$, therefore one has:
\begin{equation}\label{eq:TrMu}
\qtr L_\mu=C_2(\mbox{\boldmath$\mu$},\hat{\mathbf{m}},q)\mu_2=\hat n'\mu_2,
\end{equation}
where $\mathbf{m}=(n_1,n')$ and $\displaystyle n':=\sum_{i=2}^l n_i$. On the other
hand,
\begin{equation}\label{eq:TrLa}
\qtr\bigl(P(L_\ensuremath{\lambda})\bigr)= \sum_{i=1}^l P(\ensuremath{\lambda}_i)C_i(\mbox{\boldmath$\lambda$},\hat{\mathbf{n}},q)=
\mu_2\sum_{i=2}^l C_j(\mbox{\boldmath$\lambda$},\hat{\mathbf{n}},q),
\end{equation}
because $\Prj(\ensuremath{\lambda}_1)=\Prj(0)=0$. By Corollary~\ref{prop:Reductio}
(see Appendix),
\begin{equation}\label{eq:SumOfCs}
\displaystyle\sum_{i=2}^l C_i(\mbox{\boldmath$\lambda$}, \hat{\mathbf{n}}, \omega)=\hat n',
\end{equation}
since $1-\omega\hat n_i=q^{-2n_i}$. Substituting (\ref{eq:SumOfCs})
into (\ref{eq:TrLa}), one concludes that the latter is equal to
(\ref{eq:TrMu}).
\end{proof}
\section*{Appendix}
In this section, we study some properties of the coefficients $C_i$
in (\ref{eq:qmults}), which were announced without proof in
\cite{DoninJMudrovAI:GeneralizedVermaMod}.
For $1\leqslant i\leqslant l$,
define a function of $2l+1$ variables $\mbox{\boldmath$\lambda$}=(\ensuremath{\lambda}_1,\ldots,\ensuremath{\lambda}_l)$,
$\mbox{\boldmath$\nu$}=(\nu_1,\ldots,\nu_l)$ and $\omega$:
\begin{equation}\label{eq:Cs}
C_i(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega):= \nu_i\prod_{\substack{1\leqslant j\leqslant l\\j\not
=i}} \left(1+\omega\frac{\nu_{j}\ensuremath{\lambda}_{j}}{\ensuremath{\lambda}_i-\ensuremath{\lambda}_j}\right),
\end{equation}
and also another function of the same variables:
\begin{equation*}
S(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)=\sum_{i=1}^l C_i(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega).
\end{equation*}
These functions were introduced in
\cite{DoninJMudrovAI:ExplicitQuantiz} and
\cite{DoninJMudrovAI:GeneralizedVermaMod}. Our goal is to prove
Proposition~\ref{prop:MainLemmaOnC} below.
Obviously, $S(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)$ is stable under simultaneous
permutations of the entries of $\mbox{\boldmath$\lambda$}$ and the entries of $\mbox{\boldmath$\nu$}$.
In fact, a stronger statement is true:
\begin{lm}
$S(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)$ is a symmetric function of $\mbox{\boldmath$\lambda$}$.
\end{lm}
\begin{proof}
It suffices to show that $S(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)$ is stable under the
transposition $\ensuremath{\lambda}_1\leftrightarrow \ensuremath{\lambda}_2$.
First, opening the
brackets in (\ref{eq:Cs}) one gets
\begin{equation}\label{eq:CsExpanded}
C_i(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)= \nu_i+\nu_i\sum_{k=1}^{l-1}\omega^ k
\sum_{j_1<\ldots<j_ k} \frac{\nu_{j_1}\ensuremath{\lambda}_{j_1}}{\ensuremath{\lambda}_i-\ensuremath{\lambda}_{j_1}}
\ldots \frac{\nu_{j_ k}\ensuremath{\lambda}_{j_ k}}{\ensuremath{\lambda}_i-\ensuremath{\lambda}_{j_ k}}.
\end{equation}
In this form, the functions $C_i$ were introduced in \cite{DoninJMudrovAI:ExplicitQuantiz}.
The multiplicative form (\ref{eq:Cs}) appeared in
\cite{GurewitzSaponov:GeomNCOrbits}.
All the terms in (\ref{eq:CsExpanded}) containing $\ensuremath{\lambda}_1$ and
$\ensuremath{\lambda}_2$ can be arranged into sums of the following three forms:
\begin{gather*}
\nu_j\frac{\nu_1\ensuremath{\lambda}_1}{\ensuremath{\lambda}_j-\ensuremath{\lambda}_1} \frac{\nu_2\ensuremath{\lambda}_2}{\ensuremath{\lambda}_j-\ensuremath{\lambda}_2}f
=\nu_j\nu_1\nu_2\frac{\ensuremath{\lambda}_1}{\ensuremath{\lambda}_j-\ensuremath{\lambda}_1}
\frac{\ensuremath{\lambda}_2}{\ensuremath{\lambda}_j-\ensuremath{\lambda}_2}f, \\
\ \\
\nu_1\frac{\nu_2\ensuremath{\lambda}_2}{\ensuremath{\lambda}_2-\ensuremath{\lambda}_1}f+
\nu_2\frac{\nu_1\ensuremath{\lambda}_1}{\ensuremath{\lambda}_1-\ensuremath{\lambda}_2}f=
\nu_1\nu_2f, \\
\ \\
\nu_j\frac{\nu_1\ensuremath{\lambda}_1}{\ensuremath{\lambda}_j-\ensuremath{\lambda}_1}f+
\nu_j\frac{\nu_2\ensuremath{\lambda}_2}{\ensuremath{\lambda}_j-\ensuremath{\lambda}_2}f+
\nu_1\frac{\nu_j\ensuremath{\lambda}_j}{\ensuremath{\lambda}_1-\ensuremath{\lambda}_j}f+
\nu_2\frac{\nu_j\ensuremath{\lambda}_j}{\ensuremath{\lambda}_2-\ensuremath{\lambda}_j}f
=-(\nu_j\nu_1+\nu_j\nu_2)f,
\end{gather*}
with $j\not=1,2$, and $f$ being independent on $\ensuremath{\lambda}_1$ and $\ensuremath{\lambda}_2$.
It is seen that the expressions in the right hand sides are stable
under the transposition $\ensuremath{\lambda}_1\leftrightarrow \ensuremath{\lambda}_2$.
\end{proof}
\begin{prop}\label{prop:MainLemmaOnC}
$\displaystyle\omega S(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)=1-\prod_{i=1}^l(1-\omega\nu_i)$.
\end{prop}
\begin{proof}
Prove first that $S(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)$ does not actually depend on
$\mbox{\boldmath$\lambda$}$. Fix $\mbox{\boldmath$\nu$}$ and $\omega$, and consider $S(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)$ as a
rational function of $\mbox{\boldmath$\lambda$}$ only. This function is homogeneous of
degree zero.
Reducing $S(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)$ to the common denominator
$\prod_{i<j}(\ensuremath{\lambda}_i-\ensuremath{\lambda}_j)$ we obtain a ratio of two homogeneous
polynomials of the same degree.
Since $S(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)$ is a
symmetric function of $\mbox{\boldmath$\lambda$}$, the numerator is divisible by
$\prod_{i<j}(\ensuremath{\lambda}_i-\ensuremath{\lambda}_j)$ because the ring of polynomials is a
unique factorization domain.
Since the numerator of
$S(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)$ has the same degree as the denominator,
$S(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)$ is independent on $\mbox{\boldmath$\lambda$}$.
Now put $\ensuremath{\lambda}_l=0$, then it follows from (\ref{eq:Cs}) that
$S(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)=S(\mbox{\boldmath$\lambda$}',\mbox{\boldmath$\nu$}',\omega)+
\nu_l\prod_{i=1}^{l-1}(1-\omega\nu_i)$, where
$\mbox{\boldmath$\lambda$}'=(\ensuremath{\lambda}_1,\ldots,\ensuremath{\lambda}_{l-1})$ and
$\mbox{\boldmath$\nu$}'=(\nu_1,\ldots,\nu_{l-1})$. Finally, one applies the induction
on $l$.
\end{proof}
\begin{cor}\label{prop:Reductio}
\begin{enumerate}
\item[{\em (a)}]
If $\ensuremath{\lambda}_1=0$ then $\displaystyle\omega\sum_{i=2}^l C_i(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)
=1-\prod_{i=2}^l (1-\omega\nu_i)$.
\item[{\em (b)}]
Denote $\mbox{\boldmath$\lambda$}'=(\ensuremath{\lambda}_2,\ldots,\ensuremath{\lambda}_l)$,
$\mbox{\boldmath$\nu$}'=(\nu_2,\ldots,\nu_l)\in\mathbb{C}^{l-1}$, and suppose that
$\ensuremath{\lambda}_1=0$.
Then $\displaystyle\sum_{i=2}^l C_i(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)
=\sum_{i=2}^l C_i(\mbox{\boldmath$\lambda$}',\mbox{\boldmath$\nu$}',\omega)$.
\item[{\em (c)}]
One has $\displaystyle\sum_{i=1}^l C_i(\mbox{\boldmath$\lambda$}, \hat{\mathbf{n}}, \omega)=\hat n$.
\end{enumerate}
\end{cor}
\begin{proof}
(a) Denote $S'(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)=\displaystyle\omega\sum_{i=2}^l
C_i(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)$.
Then
\begin{gather*}
\omega S'(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)=
\omega\bigl(S(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)-C_1(\mbox{\boldmath$\lambda$},\mbox{\boldmath$\nu$},\omega)\bigr)=\\
=1-\prod_{i=1}^l(1-\omega\nu_i)-\omega\nu_1\prod_{i=2}^l
(1-\omega\nu_i)=1-\prod_{i=2}^l (1-\omega\nu_i).
\end{gather*}
(b) Obvious.
(c) Note that $1-\omega\hat n_i=q^{-2n_i}=e^{-2n_i\ensuremath{\hbar}}$, recall that
$\displaystyle n=\sum_{i=1}^l n_i$ and use
Proposition~\ref{prop:MainLemmaOnC}.
\end{proof}
| j\colon O_1\toO_2$ is Poisson if and
only if the following three conditions are satisfied:
\begin{enumerate}
\item[{\em (a)}]
The orbit $O_2$ is symmetric;
\item[{\em (b)}]
There exist $\ensuremath{\lambda}\inO_1$ and $\mu\inO_2$ such that
$\prj(\ensuremath{\lambda})=\mu$ and the multiplicity $n_1$ of the eigenvalue $\ensuremath{\lambda}_1$
is equal to the multiplicity $m_1$ of the eigenvalue $\mu_1$;
\item[{\em (c)}]
The Poisson structures on $O_1$ and $O_2$ are defined by $s_\ensuremath{\lambda}
= s_\ensuremath{\lambda}^0 - 2\ensuremath{\lambda}_1 \ensuremath{\varkappa}_\ensuremath{\lambda}$ and $s_\mu = s_\mu^0 - 2\mu_1 \ensuremath{\varkappa}_\mu$
respectively.
\end{enumerate}
\end{thm}
\begin{proof}
Show first that if $\Prj\colon O_1\toO_2$ is a Poisson map,
then the orbit $O_2$ is symmetric, i.e. the graph $\Gamma_\Prj$
consists of exactly two connected components.
Indeed, suppose that $\Gamma_\Prj$ has the
form \vspace{.3in}
\begin{center}\setlength{\unitlength}{.7in}
\begin{picture}(0,-2)
\put(-1.6,0){\circle{.08}}
\put(-1.2,0){\circle{.08}}
\put(-.4,0){\circle{.08}}
\put(0,0){\circle{.08}}
\put(-2.0,-1){\circle{.08}}
\put(-.8,-1){\circle{.08}}
\put(.4,-1){\circle{.08}}
\put(-1.6,-.04){\line(-2,-5){.37}}
\put(-1.2,-.04){\line(2,-5){.37}}
\put(-.4,-.04){\line(-2,-5){.37}}
\put(0,-.04){\line(2,-5){.37}}
\put(-1.7,.2){$i$}
\put(-1.4,.2){$i+1$}
\put(-.5,.2){$j$}
\put(-.2,.2){$j+1$}
\put(-2.05,-1.4){$1$}
\put(-0.85,-1.4){$2$}
\put(.35,-1.4){$3$}
\multiput(-2.05,-.05)(.12,0){3}{$\cdot$}
\multiput(-.99,-.05)(.12,0){4}{$\cdot$}
\multiput(.15,-.05)(.12,0){3}{$\cdot$}
\put(1.5,-.1){$\ola$}
\put(1.5,-1.1){$\omu$}
\put(1.6,-.3){\vector(0,-1){.5}}
\put(1.72,-.6){$\Prj$}
\end{picture}
\end{center}\vspace{.3in}\vs\vspace{.3in}
Since $\Prj$ is Poisson, Lemma~\ref{th:MainPoiss} leads to the
following system of conditions:
$$
\left\{
\begin{array}{l}
c_{i,i+1}=c_{i,j}\\
c_{i+1,j+1}=c_{j,j+1},
\end{array}
\right.
$$
where $\displaystyle c_{ij}=\frac{\ensuremath{\lambda}_i+\ensuremath{\lambda}_j+a}{\ensuremath{\lambda}_i-\ensuremath{\lambda}_j}$, see formula
(\ref{eq:sla}). Thus we should solve the following overdefined
system of linear equations in $a$:
$$
\left\{
\begin{array}{l}
\displaystyle \frac{\ensuremath{\lambda}_i+\ensuremath{\lambda}_{i+1}+a}{\ensuremath{\lambda}_i-\ensuremath{\lambda}_{i+1}}=
\frac{\ensuremath{\lambda}_{i}+\ensuremath{\lambda}_{j}+a}{\ensuremath{\lambda}_{i}-\ensuremath{\lambda}_{j}} \\
\ \\
\displaystyle \frac{\ensuremath{\lambda}_{i+1}+\ensuremath{\lambda}_{j+1}+a}{\ensuremath{\lambda}_{i+1}-\ensuremath{\lambda}_{j+1}}=
\frac{\ensuremath{\lambda}_{j}+\ensuremath{\lambda}_{j+1}+a}{\ensuremath{\lambda}_{j}-\ensuremath{\lambda}_{j+1}}
\end{array}
\right.
$$
This system is inconsistent, thus our hypothesis is wrong, and
$\Gamma_\Prj$ consists of exactly two connected trees.
This means that
$\mu$ has exactly two different eigenvalues:
$\mu=\diag(\mathrm{M}_1,\mathrm{M}_2)$, i.e. it is symmetric.
We now show that if $\Prj$ is Poisson, then either
$\mathrm{mult}\>\ensuremath{\lambda}_1=\mathrm{mult}\>\mu_1$ or $\mathrm{mult}\>\ensuremath{\lambda}_l=\mathrm{mult}\>\mu_2$,
where $\mathrm{mult}$ means the multiplicity of the corresponding eigenvalue.
In other words, we need to prove that
if $\Prj$ is Poisson, then one of the two connected components of
the graph $\Gamma_\Prj$ contains precisely one edge.
Suppose, to the contrary, that $\Gamma_\Prj$ is of the form:
\vspace{.3in}
\begin{center}\setlength{\unitlength}{.7in}
\begin{picture}(0,-1)
\put(-1.2,0){\circle{.08}}
\put(-.6,0){\circle{.08}}
\put(0,0){\circle{.08}}
\put(.6,0){\circle{.08}}
\put(-.6,-1){\circle{.08}}
\put(0,-1){\circle{.08}}
\put(-1.2,-.04){\line(3,-5){.57}}
\put(-.6,-.04){\line(0,-1){.93}}
\put(0,-.04){\line(0,-1){.93}}
\put(.6,-.04){\line(-3,-5){.57}}
\put(-1.3,.2){$1$}
\put(-.65,.2){$i$}
\put(-.25,.2){$i+1$}
\put(.6,.2){$l$}
\put(-.65,-1.4){$1$}
\put(-.03,-1.4){$2$}
\multiput(-1.05,-.05)(.12,0){3}{$\cdot$}
\multiput(.15,-.05)(.12,0){3}{$\cdot$}
\put(1.5,-.1){$\ola$}
\put(1.5,-1.1){$\omu$}
\put(1.6,-.3){\vector(0,-1){.5}}
\put(1.72,-.6){$\Prj$}
\end{picture}
\end{center}\vspace{.3in}\vs\vspace{.3in}
Again, by Lemma~\ref{th:MainPoiss} the following system of
conditions should be satisfied: $c_{1,i+1}=c_{i,i+1}=c_{i,l}$.
This is a system of equations in $a$:
$$
\frac{\ensuremath{\lambda}_{1}+\ensuremath{\lambda}_{i+1}+a}{\ensuremath{\lambda}_{1}-\ensuremath{\lambda}_{i+1}}=
\frac{\ensuremath{\lambda}_i+\ensuremath{\lambda}_{i+1}+a}{\ensuremath{\lambda}_i-\ensuremath{\lambda}_{i+1}}=
\frac{\ensuremath{\lambda}_{i}+\ensuremath{\lambda}_{l}+a}{\ensuremath{\lambda}_{i}-\ensuremath{\lambda}_{l}},
$$
which obviously has no solution.
Thus one of the two connected
components of $\Gamma_\Prj$ contains one edge.
By appropriate choice of
the representatives $\ensuremath{\lambda}\in\ola$ and $\mu\in\omu$, one can assume
that to be the left component:
\vspace{.3in}
\begin{center}\setlength{\unitlength}{.7in}
\begin{picture}(0,-1)
\put(-.6,0){\circle{.08}}
\put(0,0){\circle{.08}}
\put(.6,0){\circle{.08}}
\put(-.6,-1){\circle{.08}}
\put(0,-1){\circle{.08}}
\put(-.6,-.04){\line(0,-1){.93}}
\put(0,-.04){\line(0,-1){.93}}
\put(.6,-.04){\line(-3,-5){.57}}
\put(-.7,.2){$1$}
\put(-.1,.2){$2$}
\put(.6,.2){$l$}
\put(-.65,-1.4){$1$}
\put(-.03,-1.4){$2$}
\multiput(.15,-.05)(.12,0){3}{$\cdot$}
\put(1.5,-.1){$\ola$}
\put(1.5,-1.1){$\omu$}
\put(1.6,-.3){\vector(0,-1){.5}}
\put(1.72,-.6){$\Prj$}
\end{picture}
\end{center}\vspace{.3in}\vs\vspace{.3in}
i.e. that the multiplicities of $\ensuremath{\lambda}_1$ and $\mu_1$
coincide.
Lemma \ref{lm:GraphOfPoissBundle} applied to the above graph gives rise
to the overdefined system of $l-1$ linear equations
$c_{12}=c_{13}=\ldots=c_{1l}$. This system is
consistent, and the solution is $a=-2\ensuremath{\lambda}_1$. Hence the
quasi-Poisson brackets on $O_i$ are as in (c).
Now we prove the sufficiency of the conditions (a)--(c).
Indeed, consider an invariant mapping $\Prj\colon O_1\toO_2$
corresponding to the above graph.
Suppose that $\Prj(\ensuremath{\lambda})=\mu$. Then for $s_\ensuremath{\lambda} =
s_\ensuremath{\lambda}^0 - 2\ensuremath{\lambda}_1 \ensuremath{\varkappa}_\ensuremath{\lambda}$ and $s_\mu = s_\mu^0 - 2\mu_1 \ensuremath{\varkappa}_\mu$ one
has $\Prj_*(s_\ensuremath{\lambda})=s_\mu$, i.e. $\Prj$ is a Poisson map with respect
to those brackets.
\end{proof}
\subsection{Explicit formula for the map $\prj$}
Denote by $\ensuremath{\lambda}$ and $\mu$ elements of
$\Cart$ satisfying the conditions of Theorem~\ref{th:MainPoiss} and by
$\ola$ and $\omu$ their adjoint orbits.
For the purpose of quantization, we need an explicit expression for
$\prj$.
Recall that $\ensuremath{\lambda}_1,\ensuremath{\lambda}_2,\dots,\ensuremath{\lambda}_l$ denote all the distinct
eigenvalues of $\ensuremath{\lambda}\in\mathfrak g$, so we need to find a polynomial
$\Prj(x)$ of degree $l-1$ in one variable with complex coefficients
such that
$\Prj(\ensuremath{\lambda}_1)=\mu_1$ and $\Prj(\ensuremath{\lambda}_2)=\ldots=\Prj(\ensuremath{\lambda}_l)=\mu_2$.
These $l$ equations determine $\Prj$ uniquely:
\begin{equation}\label{eq:DefOfP}
\Prj(x)=(\mu_1-\mu_2)\prod_{i=2}^l\frac{x-\ensuremath{\lambda}_i}{\ensuremath{\lambda}_1-\ensuremath{\lambda}_i} +
\mu_2.
\end{equation}
\section{Reflection equation algebras}
\label{sect:REAlgebras}
An equivariant two-parameter quantization of coadjoint orbits is
constructed in \cite{DoninJMudrovAI:ExplicitQuantiz} for the
special case of the standard, or Drinfeld-Jimbo, quantum group
$\Ugh$.
In this section we extend the quantization of \cite{DoninJMudrovAI:ExplicitQuantiz} for an arbitrary
quantum group $\Ughr$, not necessarily the standard.
Note that
possible factorizable Lie bialgebra structures on $\mathfrak g$ are
parameterized by Belavin-Drinfeld triples and a subspace in $\mathfrak h$,
\cite{BelawinDrinfeld:CYBE}.
Quantization of the universal enveloping algebra along any Lie
bialgebra structure has been constructed in
\cite{EtinhoffKazdan:QuantBialg}.
To describe quantized coadjoint orbits explicitly, we need some
facts about the so called {\em modified reflection equation} (mRE)
algebra.
It is a two parameter quantization of the polynomial ring
on the vector space of $n\times n$-matrices.
The quantized orbits will be
presented as quotients of the mRE algebra by certain ideals which
are deformations of the classical ideals of the orbits.
In the present section we study how mRE algebras transform under
twist of quantum groups.
\subsection{The definition and basic facts}
\label{subsection:mREA}
Let $\Ughr$ be a quantization of the universal enveloping algebra of
$\mathfrak g=\mathfrak{gl}_n(\mathbb{C})$ along a classical r-matrix $r$.
Let $R\in \End(\mathbb{C}^n\otimes
\mathbb{C}^n){[\![}\ensuremath{\hbar}{]\!]}$ be the image of its universal R-matrix in the basic
representation in $\mathbb{C}^n{[\![}\ensuremath{\hbar}{]\!]}$.
Denote by $S:=\sigma R\in
\End(\mathbb{C}^n\otimes\mathbb{C}^n){[\![}\hbar{]\!]}$ the quantum permutation, where $\sigma$
designates the usual flip $\mathbb{C}^n\otimes\mathbb{C}^n\to \mathbb{C}^n\otimes\mathbb{C}^n$, $u\otimes
v\mapsto v\otimes u$.
\begin{defin}
The mRE algebra $\mathcal{L}$ is an associative unital
algebra over the ring $\mathbb{C}{[\![}\hbar{]\!]}[t]$ generated by the entries of
the matrix $L=\left(L_{ij}\right)_{i,j=1}^n$
modulo the relations
\begin{equation}\label{eq:mRE}
[SL_2S,L_2]=-qt[S,L_2] \in \End(\mathbb{C}^n\otimes
\mathbb{C}^n)\otimes\mathcal{L},
\end{equation}
where $L_2:=1\otimes L$ and $q:=e^\hbar$.
\end{defin}
The action of $\Ughr$ on the algebra $\mathcal{L}$ is given by the formula
\begin{equation}\label{eq:action}
x\triangleright L= \rho\bigl(\gamma(x^{(1)})\bigr)L\rho(x^{(2)}),
\end{equation}
where $\gamma$ is the antipode of $\Ughr$ and $\rho$ is the representation
$\Ughr\to\End(\mathbb{C}^n){[\![}\ensuremath{\hbar}{]\!]}$.
The algebra $\mathcal{L}$ is a $\Ughr$-equivariant
quantization of the polynomial ring $\mathbb{C}[\End(\mathbb{C}^n)]$
with $\ensuremath{\hbar} s^0_\ensuremath{\lambda}-t\kappa_\ensuremath{\lambda}$
being the linear term of the deformed multiplication,
\cite{DoninJMudrovAI:ExplicitQuantiz}.
\begin{rem}
The relations (\ref{eq:mRE}) are called the
{\em modified reflection equation} (mRE).
These relations become quadratic when $t=0$.
The corresponding quotient $\mathcal{L}/t\mathcal{L}$ is called
{\em quadratic} or simply {\em reflection equation} (RE) algebra.
This algebra can be defined
for any quasitriangular Hopf algebra $\mathcal{H}$ and its
representation.
When $\mathcal{H}$ is a quantized
universal enveloping algebra of an algebraic matrix group $G$,
then a certain quotient of the quadratic RE algebra yields a
(one-parameter) quantization of $\mathbb{C}[G]$.
The mRE algebra $\mathcal{L}$ as a two-parameter quantization of the
coordinate ring on the matrix space is special for the case $\mathfrak g=\mathfrak{gl}_n(\mathbb{C})$.
\end{rem}
Let us describe the center $Z(\mathcal{L})$ of the algebra $\mathcal{L}$.
First of all, $Z(\mathcal{L})$ coincides with
the subalgebra of $\Ughr$-invariants and it is isomorphic to
$Z_0\otimes \mathbb{C}{[\![}\ensuremath{\hbar}{]\!]}[t]$, where $Z_0\subset\mathbb{C}[\End(\mathbb{C}^n)]$ is the
subalgebra of classical invariants.
To describe $Z(\mathcal{L})$, consider the
matrix $R^*:=\bigl((R^{t_1})^{-1}\bigr)^{t_1}=R^*_1\otimes R^*_2$,
where $t_1$ means transposition of the first tensor
component. This matrix is equal to $\mathcal{R}_1\otimes\gamma(\mathcal{R}_2)$ evaluated
in the basic representation.
Define the matrix
$D:=\nu(R_1^*R_2^*)\in \End(\mathbb{C}^n){[\![}\ensuremath{\hbar}{]\!]}$,
where $\nu$ is a scalar.
It is convenient to choose $\nu$ such that
$\displaystyle\tr(D)=\frac{1-q^{-2n}}{1-q^{-2}}$.
Put $\tau_m=\tr_q(L^m):=\tr(DL^m)\in Z(\mathcal{L})$ for $m=1,2,\dots$.
Then the $Z(\mathcal{L})$ is a polynomial ${\mathbb{C}[\![\ensuremath{\hbar}]\!]}$-algebra
generated by $\tau_1,\dots,\tau_{n-1}$.
\subsection{mRE algebras and twist}
The quantum group $\Ughr$ is a twist of the standard quantization
$\Ugh$.
Let $\mathcal{F}\in \Ugh^{\otimes 2}$ be the corresponding twisting cocycle.
It is an invertible element satisfying the identities
\begin{equation}\label{eq:cocycle}
(\Delta\otimes \id)(\mathcal{F})\mathcal{F}_{12}=(\id \otimes \Delta)(\mathcal{F})\mathcal{F}_{23},
\end{equation}
\begin{equation}
\label{eq:cocycle_norm}
(\varepsilon\otimes \id)(\mathcal{F})=1\otimes 1=(\id \otimes \varepsilon)(\mathcal{F}),
\end{equation}
where $\varepsilon$ is the counit in $\Ugh$.
As an associative algebra, $\Ughr$ coincides with $\Ugh$
but has a different comultiplication, $x\mapsto\mathcal{F}^{-1} \Delta(x)\mathcal{F}$.
The antipode is transformed accordingly, see \cite{DrinfeldW:AlmostCocomHopfAlgs}.
Recall that
a twist of Hopf | 4,910 |
Trailing the Reds 9-3 starting the bottom of the ninth, Brooks Conrad's pinch-hit grand slam gives the Braves an amazing 10-9 walk-off victory at Turner Field. The seven-run frame's big blow by the 30 year-old journeyman barely<|fim_middle|>man barely clears the fence, with the ball deflecting off Laynce Nix's glove when the left fielder reaches over the top of the wall at the 380-foot sign.
National Pastime
Own this Day and Be Part of Baseball History
PreviousMets center fielder Angel Pagan initiates the tenth triple play in franchise history when he snags Cristian Guzman's sinking liner with first and second base occupied. After making the stunning catch that surprises both of Washington's baserunners, the outfielder overthrows the infield, but catcher Henry Blanco takes the errant toss and throws the ball to Jose Reyes at second base to double off Livan Hernandez, and then the shortstop relays the ball to first baseman Ike Davis to triple up Nyjer Morgan, making it the first 9-2-6-3 triple killing in major league history.
NextCardinals pitcher Brad Penny makes his mark with the bat, connecting for a grand slam in the 3rd inning, but then has to leave the game shortly afterwards with a back injury. The Cardinals beat the Angels, 9 – 5, as reliever Jason Motte picks up the win.
1889 – The Spalding Baseball Tourists play their final game in Australia, with the Chicagos winning, 5 – 0.
Pete Alexander pitches the Phils to a 1 – 0 win over Boston's 44-year-old Cy Young
At Shibe Park, the A's clinch their second straight American League pennant, defeating the Tigers, 11 – 5. Frank Baker leads the offense with a homer and two doubles. Detroit, which led the A's by 12 games in May, will finish 2nd, 13 1/2 games back.
Yankee P David Wells threatens to punch out owner George Steinbrenner during a clubhouse argument. | clears the fence, with the ball deflecting off Laynce Nix's glove when the left fielder reaches over the top of the wall at the 380-foot sign.
May 20, 2010 | This Day In Baseball |
On May 20, 2010 — Trailing the Reds 9-3 starting the bottom of the ninth, Brooks Conrad's pinch-hit grand slam gives the Braves an amazing 10-9 walk-off victory at Turner Field. The seven-run frame's big blow by the 30 year-old journey | 119 |
Skylight Community
The Poor People's Campaign
BK@24FPS
Academic Screening Packages
Matisse Bustos-Hawkes
Communications & Outreach Lead
Matisse Bustos-Hawkes is a strategic communications professional and founder of Otro Lado Communications with 20 years in the non-profit<|fim_middle|>ing it On: An Interview with Filmmaker Monica Wise Robles
Skylight Files Freedom of Information Act Request About Border Protection's Military-Style Raids on Humanitarian Aid Camps
Passing It On: An Interview with Andrea Ixchíu Hernández
THE DISAPPEARANCE OF CARLOS COY AND THE ASSASSINATIONS OF BENITO MARIA AND MISAEL LÓPEZ
about 5 days agoWatch now: LUPITA a documentary about a Tzotzil Maya woman at the forefront of a Mexican indigenous movement, ava… https://t.co/IohVzLvJmz | and social change sectors. She spent over a decade at WITNESS, the global organization founded by musician and activist Peter Gabriel that makes it possible for anyone to harness the power of video and technology, safely and effectively for human rights. She has amplified human rights campaigns with partners from Burma to Brazil, Congo to Cambodia, and beyond. Employing a holistic approach to communications, Matisse is experienced in organization-wide strategic planning, earned media, social media, event management, and team development. She has placed stories in outlets from Al Jazeera, The Guardian, PBS NewsHour, The New York Times, Vice, and Wired. Matisse is committed to building strategic partnerships and empowering diverse teams whose purpose is making the world a more just and equitable place to live.
A Letter from the Indigenous Women's Platform to Kamala Harris
Pass | 168 |
iDemand wins 1 MW storage deal in San Diego
iDemand Energy Storage (iDES3) has begun engineering and design work on a $4.1 million solar-plus-battery storage project for five buildings owned by San Diego County-based biotech company.
January 18, 2017 Charles W. Thurston
The contract to manufacture uninterrupted-energy-supply batteries capable of storing and discharging up to 1.078 MW of solar energy was awarded to iDES3 in early January by SunFusion Solar Inc. Both are San Diego companies. Work, including installation of the battery units and solar arrays, is expected to be completed in mid-October.
"One of the challenges of this project will be to customize solar awnings that will hang off the sides of the buildings," said Ray Trejo, co-founder and senior<|fim_middle|> kilowatt hours for the five buildings' load is the largest to date for the startup battery manufacturer.
The client's objective is to shave peak-load electricity demand during the middle of the day by using energy discharged from the battery units that was stored overnight. High time0f-use rates may run as high as $20 per KW between noon and 6 p.m. and $15 per kilowatt from 6 p.m. to 10 p.m.
Charles W. Thurston
Charles specializes in renewable energy, from finance to technological processes. Writing for pv magazine since 2010, he focuses on balance of systems, tracking, the EPC sector, and the Brazilian market.
More articles from Charles W. Thurston | vice president of six-month-old iDES3. "They will need to be specially engineered to ensure that they're not too heavy. There will also be solar arrays atop carports and rooftops."
"This is the first of potentially several projects for the biotech company, which in addition to its buildings in San Diego County, also has facilities in Baja, Mexico," said Sandy Ellard, president of SunFusion. The biotech contract, which calls for 900 | 97 |
Since beginning the Adamsdown Song project and first hearing of the soul singer Gill 'Tawny' Reed, of Diamond Street, Adamsdown, I've done my best to find out more about this largely forgotten star, tracking down musicians who played with her, meeting members of her family, and researching her sadly short life. As a result of this I wrote an article about her, first posted on my creative writing blog, but now moved to a more appropriate home on this site. Please read it and get in touch with me if you know any more about Gill.
The glorious days when Adamsdown Song topped a leading internet chart may be over, but our success is not forgotten: Soundclick, top site for people uploading their own music, records our best chart position on our page there: number one.
At the end of last term, Tredegarville Primary's Year Six performed the song live at a special school event and did a fantastic job of it. Well done. Hopefully this will not be the last time the song is performed, as all along it was planned as a Song for Adamsdown to be passed on as a celebration of the unique area in which we live.
The fans of Adamsdown Song group on Facebook is still growing and there have been steady sales of the CD on Clifton St at Hungry Planet. This website has had well over 2000 hits and we have received compliments from all over the world. Once again, well done to everyone involved. However, there are still plenty of people in Adamsdown who still aren't aware of the song, so keep spreading the word!
The Adamsdown Song CD is now on sale at Hungry Planet, Spar and Driscolls on Clifton Street<|fim_middle|>, we're hoping this project will be just the beginning and there will be a chance for many more of Adamsdown's residents to get their voices heard.
The launch of Adamsdown Song finally takes place this Thursday, 11 June, 4pm, at Adamsdown Primary School.
Everyone is welcome to the launch of our internet chart-topper, where we'll hear the song, watch the video, see pupils' artwork and poems and finally get our hands on the CDs!
Pupils who took part in the project are entitled to a free CD, as are staff from the three schools involved and others who've helped with the project. Everybody else can buy the CD for just £1.
After the launch the CD will be available at shops on Clifton Street and an exhibition of pupils' work and the historic photos of John Briggs will be on display at Roath Library.
Finally, an apology to one of our star singers, Emma Bishop, who's name is printed wrongly on the CD sleeve. If we reprint the CD that will be put right. | and through the three Adamsdown primary schools. If you can't get hold of a copy simply email us or visit the Adamsdown Community Project on Moira Terrace.
Thanks to everyone who made the launch event such a great success. Adamsdown Song has now featured on BBC News online, BBC Radio Wales (Good Evening Wales and the Adam Walton Show), Radio Cardiff, the South Wales Echo and a host of websites around the world – try googling 'Adamsdown Song' and see what comes up!
If funds are made available | 106 |
On behalf of the Town of Merrimack and the Merrimack Village District (MVD), EGGI oversaw a groundwater quality protection<|fim_middle|> available science and leading industry practice. To monitor the effectiveness of the blasting plan, EGGI developed and oversaw the execution of a comprehensive groundwater and surface water monitoring program involving monthly groundwater sample collection from a network of onsite wells and surface water bodies. Sampling began prior to the start of blasting to establish baseline chemistry of the local aquifer, and continued on a monthly basis throughout the construction period.
Hundreds of water quality samples were collected at the project site. Although elevated nitrate levels associated with the blasting activities did occur at a select few sites, blasting activities could be properly managed such that the nitrate did not cause diminishment in groundwater quality at, or near, the MVD Production Well. EGGI continues to monitor water quality collected by the developer on a regular basis.
As the Town's consultant, EGGI ensured that the developer had prepared and followed a detailed blasting plan that was based on the best available science and leading industry practice. | program for one of the largest blasting projects in the State of New Hampshire. Construction of the Merrimack Premium Outlet Mall required the blasting of nearly 1 million cubic yards of rock, which is equivalent to the largest rock quarry activity in the State of New Hampshire. A significant portion of the blast zone was located within the Wellhead Protection Area (WHPA) for one of the highest-yielding public water supply wells operated by the Merrimack Village Water District. (This well yields 1.2 MGD.) Protecting the quality and quantity of the groundwater resources produced from this well during blasting was imperative.
As the Town's consultant, EGGI ensured that the developer had prepared and followed a detailed blasting plan that was based on the best | 151 |
Sir Augustus Wall Callcott, 1779–1844, British, Windsor from Eton, between 1808 and 1809, Oil on canvas, Yale Center for British Art, Paul Mellon Collection, B2001.2.235
Sir Augustus Wall Callcott, 1779–18<|fim_middle|> his childhood on summer visits to Windsor: "From those distant summers I remember huge dark trees in rolling parks, herds of small friendly deer, flotillas of white swans on the Thames, dappled tan cows in soft green fields, the grey mass of Windsor Castle towering in the distance against a background of huge golden summer clouds; soldiers in scarlet and bright metal, drums and bugles, troops of grey horses; laughing ladies in white with gay parasols, men in impeccable white flannels and striped blazers, and always behind them and behind everything the grass was green, green, green...There seemed to be a tranquility in those days that was never again to be found, and a quietness as detached from life as the memory itself." He hung Callcott's painting in a place of high honor, over the fireplace in his study in New York.
Malcolm Warner
Warner, Malcolm and John Baskett. The Paul Mellon Bequest: Treasures of a Lifetime. New Haven : Yale Center for British Art, 2001, p. 10
The Paul Mellon Bequest : Treasures of a Lifetime (Yale Center for British Art, 2001-02-17 - 2001-04-29)
The British Castle : A Symbol in Stone, Yale Center for British Art, New Haven, 2017, p. 21, cat. 13, V2722
Malcolm Warner, The Paul Mellon Bequest : treasures of a lifetime, , Yale Center for British Art, New Haven, CT, 2001, p. 10, N5247 M385 P28 2001 (YCBA) | 44, British, Windsor from Eton, between 1808 and 1809
Sir Augustus Wall Callcott, 1779–1844, British
Windsor from Eton
Support (PTG): 29 1/2 x 44 1/4 inches (74.9 x 112.4 cm)
B2001.2.235FR
castle | cattle | clouds | landscape | light | meadow | pond | river | sky | skyline
Berkshire | England | Eton | Thames | United Kingdom | Windsor | Windsor Castle
Paul Mellon was christened in St George's Chapel, Windsor Castle, and spent some of the happiest days of | 160 |
The excitement and energy that Missoula's University of Montana brings, also comes with a tradeoff. As a community, we have far more renters than the national average, making the rental market even more competitive. According to the 2011 Missoula Housing Report, the split is about 50/50 renters versus owners. On a national level that rate hovers on the side of home ownership at about 65%.
Adding to the student factor is that housing prices that have been, for many<|fim_middle|>la Real Estatearchive.
Diane Beck has been selling real estate in Missoula for over 20 years. Her knowledge, experience and commitment to the community has placed her in the forefront of the real estate market. Diane is serving the Missoula Organization of REALTORS® as their 2011 President and she continues to strive for the best interests of their members, community and herclients. | years, out of reach for many individuals and families that live here. The high cost of housing has forced residents to rent when buying might have been their ultimate goal, further straining the rental market. According to the Housing Report, vacancy rates for rentals are perched around 3%.
What has happened since 2007? A decrease in the cost to purchase housing in Missoula. While I cannot report on that trend locally yet for 2011, on a national level, a survey found that 48% of respondents reported that they saw rental rates increase. For many, that means they can now carry a mortgage for the cost of what they had been paying in rent.
In addition, home ownership is still a priority for US citizens. A majority of renters aspire to home ownership as a long-term goal. According to the "2011 National Housing Pulse Survey" released by the National Association of Realtors, 72 percent of renters surveyed said owning a home is a top priority for their future, up from 63 percent in 2010.
Median Price of a Home: $200,500, down from $219,550 in 2007.
Housing Affordability Index for Four Person Household in 2011: 107, meaning they can afford 107% of a median priced home.
Mortgage Interest Rates: hovering around 4.25%.
Rents: increased in 2010 to an average of $740 per month from $710 in 2009.
At 4.25% interest, $740 per month carries an approximately $150,000 mortgage.
The average rent of a 3 bedroom house is $1,100 per month, which at 4.25% interest could carry a $225,000 mortgage.
While the decision to rent versus buy is not simple, nor has the same deciding factors for each family, we can tell several things. First, despite the burst of the housing bubble and a lot of bad press, home ownership is still a high priority for most renters. Second, as rental rates climb, and both housing prices and vacancy rates drop, we will begin to see individuals move back into the ownership market. Finally, it seems that Missoula is poised to see changes in the way individuals view renting versus home ownership, and it will be interesting to see what happens next.
Back to the Real Estate home blog page. Missoula Maps. Moving to Missoula.
Click here to see the Missou | 553 |
Musical Tables: Poems
by Billy Collins
From the former United States Poet Laureate and New York Times bestselling author of AIMLESS<|fim_middle|>Billy Collins
You can spot a Billy Collins poem immediately. The amiable voice, the light touch, the sudden turn at the end. In his own words, his poems tend to "begin in Kansas and end in Oz."
Now "America's favorite poet" (The Wall Street Journal) has found a new form for his unique poetic style: the small poem. Here Collins writes about his trademark themes of nature, animals, poetry, mortality, absurdity and love --- all in a handful of lines. Neither haiku nor limerick, the small poem pushes to an extreme poetry's famed power to condense emotional and conceptual meaning. Inspired by the small poetry of writers as diverse as William Carlos Williams, W.S. Merwin, Kay Ryan and Charles Simic, and written with Collins' recognizable wit and wisdom, the poems of MUSICAL TABLES show one of our greatest poets channeling his unique voice into a new phase of his exceptional career.
Genres: Poetry, Poetry Collection | LOVE, a collection of more than 125 small poems, all of them new, and each a thought or observation compressed to its emotional essence.
"Whenever I pick up a new book of poems, I flip through the pages looking for small ones. Just as I might have trust in an abstract painter more if I knew he or she could draw a credible chicken, I have faith in poets who can go short." — | 86 |
On New Year's Eve 2004 we were with friends and family discussing what we wanted to achieve in the next 12 months. We wanted to get civil partnershipped but we didn't hear until 21 Feb 2005 that the law would definitely change. We had already been together 15 years and didn't know whether to have something small or<|fim_middle|> cancellation at The Inn on the Lake in Cumbria for 29 December, so we took it.
I was so excited in the build-up to the day, I couldn't believe it was real or that we'd let ourselves in for so much work. There was a lot of planning and neither of us have family nearby who could help.
Many people I've spoken to say they enjoyed our day more than 'straight' weddings they'd been to. Maybe, as it's not so formulaic, what is said is really meant and felt.
I don't feel any different now but it was brilliant that we were able to do it. Fifteen years ago I fell in love with Jo, since then I have wanted to shout it from the rooftops, and now I can. That's what our wedding day was all about.
It's your day, make it the best you can but don't take responsibility for everyone's travel/sleeping/eating/breathing arrangements - it's too much!
Don't watch a movie or look at photos until you have your own memories stored away in your head - or they will be replaced by snaps. | large.
A priority guest was my sister in New Zealand. When we suddenly heard that she could make it at Christmas, so we had to have a big party! However, it wasn't easy finding a venue. There was a | 46 |
The best restaurants in Bordeaux
In a city where locals can<|fim_middle|>ache. | talk for hours about the subtle resonance of a 1974 first-growth, you'd expect them to be picky about their food. And you'd be right: Bordeaux has some pretty fancy restaurants, which flatter the wines with a dining ceremony that's almost excessive. But dining in Bordeaux doesn't necessarily have to be posh. The city is also steeped in traditions from southwestern France and its heartier dishes. We're talking Pauillac lamb or local Bazas beef, perhaps grilled over vine prunings. Wood pigeon in red wine sauce with garlic croutons is another one to look out for, as are foie gras and Arcachon Bay oysters. Locals are also keen on whatever they can haul out of the river, be it lampreys, eel, shad or sturgeon – and its caviar.
For further Bordeaux inspiration, see our guides to the city's best hotels, nightlife and things to do.
This restaurant has had its ups and downs since its establishment in the 19th century, but is generally the most celebrated table in town. It's the type of place where artists and visiting presidents dine. Painter Henri de Toulouse-Lautrec and stage icon Sarah Bernhardt helped set the trend – and presumably appreciated the extraordinary man-made rocks, which have been threatening to take over the dining room since about 1900. The rest of the restaurant has been significantly lightened up since then, but this remains a place for class food, say, scallops with peppered mandarins in a nutty butter and quinquina sauce – served with bow-tied pan | 335 |
CommunityYour News
community, your-news,
Relief is on its way for frustrated commuters at Wendouree Train Station. Over three years on from its initial announcement, Wendouree Train Station is set to receive an extra 200 car parks by the end of October. In 2014, then Premier Dennis Napthine promised the extra parking spaces would be added to the station if Liberals won the election. However, it was not actually funded until Jacinta Allan committed $2.5 million in August, 2015. At the time, it was announced it would be complete by late 2017. Commuters had been hard pressed to find a park at the station, forcing them to get creative when it comes to searching for a place to leave their cars, often forcing them to parking on footpaths and over pedestrian crossings. Daily commuter Steven Fry told The Courier in 2015 that the park is close to half-full by the time he boards the second train of the day, the 6.13am Wendouree to Southern Cross service. "It's not good," Mr Fry said. "This has been getting worse and worse for about the last three weeks." VicTrack blames the poor weather conditions for the delays, and is confident that works will be completed by the end of October. "We are building 200 new parking spaces at Wendouree Station to help the growing number of people using the station to<|fim_middle|> works will be completed by the end of October.
"We are building 200 new parking spaces at Wendouree Station to help the growing number of people using the station to access train services more easily." said a VicTrack spokesperson in a statement.
"There were changes to the design earlier this year to accommodate changes to the Station as required as part of the Ballarat Line Upgrade.
"Works on the project began in June this year, but heavy rain in July and August meant the site became waterlogged and works were unable to continue for safety reasons, and the risk of equipment becoming bogged.
"Following a delay because of wet weather, works will be back underway next week and are on track to be complete by the end of October."
These sentiments were echoed by the Minister for Public Transport, Jacinta Allen.
"As we're seeing more and more growth in people catching train services, of course we have to improve facilities around train stations and stations themselves." said Minister Allen
"But part of the challenge in delivering the Wendouree car parking project is that it's being done over winter, and as people in the local community know, particularly at the start of winter there was a lot of weather that slowed the progress down."
While this is sure to please commuters, Ben Lever from the Public Transport Users Association believes improving bus lines and making it safer to walk and cycle to the station are a much more sustainable option.
Have you signed up to The Courier's daily newsletter and breaking news emails? You can register below and make sure you are up to date with everything that's happening in Ballarat. | access train services more easily." said a VicTrack spokesperson in a statement. "There were changes to the design earlier this year to accommodate changes to the Station as required as part of the Ballarat Line Upgrade. "Works on the project began in June this year, but heavy rain in July and August meant the site became waterlogged and works were unable to continue for safety reasons, and the risk of equipment becoming bogged. "Following a delay because of wet weather, works will be back underway next week and are on track to be complete by the end of October." These sentiments were echoed by the Minister for Public Transport, Jacinta Allen. "As we're seeing more and more growth in people catching train services, of course we have to improve facilities around train stations and stations themselves." said Minister Allen "But part of the challenge in delivering the Wendouree car parking project is that it's being done over winter, and as people in the local community know, particularly at the start of winter there was a lot of weather that slowed the progress down." While this is sure to please commuters, Ben Lever from the Public Transport Users Association believes improving bus lines and making it safer to walk and cycle to the station are a much more sustainable option. Have you signed up to The Courier's daily newsletter and breaking news emails? You can register below and make sure you are up to date with everything that's happening in Ballarat.
https://nnimgt-a.akamaihd.net/transform/v1/crop/frm/ben.hopkins/faba0e19-d2b3-466c-ae96-82f9091bc4a3.jpg/r0_70_3013_1772_w1200_h678_fmax.jpg
Wendouree Train Station will be receiving a new car park after a three year wait
Ben Hopkins
Relief is on its way for frustrated commuters at Wendouree Train Station.
Over three years on from its initial announcement, Wendouree Train Station is set to receive an extra 200 car parks by the end of October.
LONG WAIT: After three years, commuters parking at Wendoure Train Station are set for some respite as the 200 car parks promised by Dennis Napthine approaches completion. PICTURE: LUKE PARKER Skyline Drone Imaging.
In 2014, then Premier Dennis Napthine promised the extra parking spaces would be added to the station if Liberals won the election.
However, it was not actually funded until Jacinta Allan committed $2.5 million in August, 2015.
At the time, it was announced it would be complete by late 2017.
Commuters had been hard pressed to find a park at the station, forcing them to get creative when it comes to searching for a place to leave their cars, often forcing them to parking on footpaths and over pedestrian crossings.
Daily commuter Steven Fry told The Courier in 2015 that the park is close to half-full by the time he boards the second train of the day, the 6.13am Wendouree to Southern Cross service.
"It's not good," Mr Fry said.
"This has been getting worse and worse for about the last three weeks."
VicTrack blames the poor weather conditions for the delays, and is confident that | 697 |
Tag Archives: Wilson
House – "Wilson"
You might be wondering why I stopped reviewing House after the season premiere. And, well, the answer is quite simple: I stopped watching House after the season premiere.
It wasn't an intentional decision: a few episodes piled up on the DVR, which proceeded to crash and lose all of its files, and then more episodes piled up alongside some frustrated critics who were growing tired of the show's ignorance of the rather great premiere, "Broken." And so my desire to catch up with House was limited, and until tonight I was kind of convinced that I may never return to the show again.
However, on the advice of those same critics, I returned to "Wilson" and discovered what role House will play in my television criticism future. It is a show where the only episodes that truly engage me, truly suck me in, are those which feel uniquely possible within the show's universe. Alan Sepinwall quite rightly observes in his review of the episode that the focus on Wilson in the episode would never work if not for the inherent juxtaposition of his methods to House's methods.
It's an episode that puts someone else in the driver's seat, and rather than feeling like an overly complicated, soap operatic version of the show's basic premise (which, based on what I've read of the season so far and parts of last season, is effectively what the show has boiled down to) the episode felt like a rumination on character, themes, and the inherent humanity or lack thereof at the show's core.
The result was a very compelling hour of television, one which is uniquely housed (I made a funny!)<|fim_middle|>-rationalizing, and Chase will always be a character without, well, a character.
But even if it wasn't a life-changing return to our former cottages, I'd say it was enjoyable enough.
Tagged as Agoraphobia, Cameron, Chase, Cuddy, Episode Seven, Hugh Laurie., Jennifer Morrison, Jesse Spencer, Lisa Edelstein, Robert Sean Leonard, Season Five, Stuart, The Itch, Wilson
RT @brianfauteux: I can't wait to get home and tell my toddler with a very serious peanut allergy that Mr. Peanut is dead. 10 hours ago | within this particular series but will do little to change its overall downward trajectory.
Filed under House
Tagged as Apartment, Cuddy, Dr. House, Entertainment, Episode 10, FOX, Joshua Malina, leukaemia, Review, Robert Sean Leonard, Season 6, Television, Tucker, TV, Wilson
Season Premiere: House – "Broken"
"You're not God."
There was a lot of response to "Broken," as there is to many House premieres and finales. House, like many other shows which on a week-to-week basis only seem to dabble in serialized storylines, likes to pile on the sudden tension in the late and early parts of each season. It's the time of year where Amber dies in a tragic accident, or when House begins hallucinating due to his use of Vicodin, or when House gets shot and goes into a dream-like state and regains some use of his leg. In all instances, the show presents us with a simple question: what if Dr. House changed? What if, after losing Amber or having his leg fixed or firing all of his fellows or the suicide of one of his fellows or (in the Season 5 finale) being institutionalized, he grows up in a way that changes his dynamic with the people around him and how he does his job?
Every year, however, the same thing happens: he and Wilson reconcile, he convinces himself his leg isn't better, he hires new fellows and everything effectively goes back to normal. House is, ultimately, like every other procedural in that there are parts of its identity which cannot change as fundamentally as the finales want us to believe, the premieres always designed as a first step to righting the character's universe. This is something that I've complained about in the past, but I think I've finally come to terms with it.
"Broken" is certainly, at the very least, the most impressive effort yet to make House's re-entry into his world both believable and not without consequence. Taking the form of "House: The Movie," ditching the entire cast save a cameo from Robert Sean Leonard in favour of a collection of doctors, patients and visitors from Mayfield Psychiatric Hospital, the two-hour episode takes the time to go through every stage of House's process. It allows us to see his usual behaviour, conniving and manipulative, and then to deconstruct it in a way which never feels preachy, and which in the end reveals a character who remains acerbic and charming but who does seem a lot closer to what one might consider happy.
And while only time will tell how far these changes go, I'm not really concerned: long-term change or no, this was an extremely compelling two hours of television.
Tagged as Alvy, Andre Braugher, Broken, Cello, Dr. House, Dr. Nolan, Emmy, Entertainment, Episode 1, Flying, Franka Potente, House: The Movie, Hugh Laurie., Lin-Manuel Miranda, Lydia, Mayfield Psychiatric Hospital, Piano, Premiere, Re-Birthday, Season 6, Season Premiere, Television, TV, Two-Hour, Ward 6, Wilson
Season Finale: House – "Both Sides Now"
You will notice that this is only one of a handful of times that I've blogged about House all season. The reasons for that are really quite simple: the show has done very little to compel me to watch it, yet alone write about it, and the longer the season wears on the more weary I become of some of its formula. I wrote about the biggest moment of the season, Kutner's suicide, but even then it was in an admittedly negative tone: the show is so averse to change, House always being House and the formula always being the same, that any chance to fundamentally change the series always feels like a missed opportunity once you're a few episodes out.
But the show loves doing season finales, as demonstrated in "Both Sides Now" where we make a 'shocking' discovery about the events in last week's penultimate episode, which featured the long-anticipated (by some) House/Cuddy hookup and more of the return of Anne Dudek as Amber. I love Anne Dudek, and I enjoy the tension between House and Cuddy, but the episode didn't really do much for me in the end, outside of providing Hugh Laurie with his Emmy reel.
Hopefully, the Emmy voters don't see the finale which, although containing perhaps the most interesting "case" of the season, felt like more manipulation for the sake of manipulation.
Tagged as 2009, Air Guitar, Alien Hand Syndrome, Amber, Anne Dudek, Both Sides Now, Cameron, Chase, Cuddy, Deodorant, Entertainment, Episode 24, Finale, FOX, Gregory House, Hallucinations, Hugh Laurie., Is House Crazy, Kal Penn, Kutner, Left Hand, Lipstick, Psychiatric Hospital, Season 5, Season Finale, Television, Vicodin, Wedding, Wilson
Yes, I'm Still Watching…FOX's House
Yes, I'm Still Watching…House
But BARELY.
I don't particularly know if I can put my finger on why I care so little about House's fifth season, considering that I was actually quite a big fan of the fourth one. Although oft criticized for eschewing the show's regular sidekicks for a new batch, the fourth season felt like things were being shaken up: that the producers realized that the show was in danger of becoming too formulaic, and that some changes were necessary. I like that level of self-awareness in my showrunners, personally, and it was healthy to see it here.
Unfortunately, House has fallen off the wagon for me this season, and I'll admit right now to having very little desire to even watch last night's episode, which is waiting for me on the DVR as soon as I get around to it. [I watched it – check for my thoughts in parenthesis throughout the post added after I sat down to watch the episode]. There just isn't anything about the show that I find engaging, which is because of two fundamental problems: one is the show focus on what is ultimately an uninteresting and worthless character, and the other is that the show's other drama must derive entirely from relationships, all of which are misguided and doomed to failure if only for the sake of the show's normal points of tension.
It all adds up to a show that I honestly don't care about anymore – and there will come a point where I might stop watching altogether in the very near future.
Tagged as Cuddy, Dr. House, Entertainment, Episode 16, Foreman, FOX, Heroin, Kutner, Season 5, Taub, Television, The Softer Side, Thirteen, Vicodin, Wilson
The 2008 Television Time Capsule: House – "Wilson's Heart"
"Wilson's Heart"
Season Four, Episode Sixteen
Airdate: May 18th, 2008
House's fourth season was a needed shakeup of its formula, and presented some of its strongest comedy ever in its opening reality show-esque hunt for a set of new fellows to play sounding board for House's eccentricities. But the emerging fellows also brought the introduction of Amber, also known as Cutthroat Bitch and, by season's end, the emotional lynchpin for one of the most powerful episodes in the series.
While some may prefer the loud and dangerous "House's Head," focused more on the doctor's internal struggle to remember the events of the bus crash through dangerous drugs and procedures, "Wilson's Heart" is where the storyline truly comes together. Learning that it was Amber on that bus raised the stakes considerably, and while the first part of the finale ("Head") gains greater meaning with this revelation I nonetheless cared less about House (who was tragically partly responsible) than I did about Wilson, who had to bear the brunt of the consequences of his friend's actions.
While Season Five's attempts at pairing House and Cuddy have felt similarly broad as something meaningful to the show's emotional core, like House's flashback to his injury in "Three Stories," this episode felt the most tapped into something bigger than the show's procedural construct. Robert Sean Leonard is often given too little to do on this show, with the focus being divided as it is, but he is fantastic here as a grieving boyfriend and, eventually, a friend who blames House for her death.
The episode is also a goodbye for Anne Dudek's "CTB," who may have been too much a female version of House to be his fellow but was too delightful a character to abandon entirely. While the winning fellows may have "won," added as series regulars and all, Dudek got the most material by far: she was robbed of an Emmy nomination for some great work in this episode (and others), but her emotional farewell was nonetheless one of the show's highlights through four seasons.
"Wilson's Heart" is somewhat tainted by the fact that the show has more or less abandoned its ramifications halfway into its fifth season, but let its inclusion in the Time Capsule serve as a reminder for the writers: this is how you craft a storyline where we care about the characters and their consequences, not through giving a boring bisexual doctor a terminal illness and having her flaunt it for everyone to see. That's not tragic, it's just surprisingly boring for such destructive behaviour, and at the end of the day the show needs to tap into what they had with Amber before Thirteen can feel like something we should care about.
Let's hope they listen.
Related Posts at Cultural Learnings
Review: "Wilson's Heart"
Cultural Learnings' Coverage of House
[For more details on the Cultural Learnings 2008 Television Time Capsule, click here!]
Filed under 2008 Television Time Capsule
Tagged as 2008, Amber, Anne Dudek, Entertainment, Episode, Episode Sixteen, Finale, House, Robert Sean Leonard, Season Finale, Season Four, Television, Time Capsule, Wilson, Wilson's Heart, Year in Review
House – "Emancipation"
A week after throwing the show's structure for a loop by reintroducing Chase and Cameron to the central narrative, House is at the kind of place where the show never really was last season. It's a sort of unstable normalcy, where everything on the surface is the same but underneath there is clearly unrest amongst the team. There's drama building everywhere, and it's the kind of drama that will eventually explode in some fashion.
It's a lot of moving parts, so I wonder how long they can make it last. "Emancipation" largely only works because of Omar Epps giving Foreman a very real sense of tarnished pride, a character who tried making it on his own last season only to find that he's too much like House for his own good but now finds himself unable to get himself out from his shadow. While the fragmented nature of the episode was problematic in a few ways, the dual cases gave Foreman his biggest showcase of the season to date, more Chase and Cameron than we've received on average, some Wilson and House interaction, and even some new ripples appearing in the world of the three newer cast members.
No individual part of the episode really got to stand out beyond Foreman, but it all felt like positive momentum at this stage in the game.
Tagged as 13, Cameron, Chase, Dr. House, Emancipation, Entertainment, Episode Eight, Foreman, Iron, Kutner, Omar Epps, Review, Robert Sean Leonard, Season Five, Taub, Television, Wilson
House – "The Itch"
"The Itch"
When David Shore and Co. decided to make the rather odd decision to "fire" the three fellows who worked for Dr. Gregory House at the end of the show's third season while still employing them as cast regulars, I think we all asked ourselves a question: how, precisely, do they plan on balancing new fellows with the old ones who are off in various corners of the hospital.
And while they pushed Foreman back into the diagnosis group fairly quickly, this has remained a problem, especially as it relates to developing the characters of Chase and Cameron, and the new fellows for that matter. There have been some rumblings about House beginning to fall into the medical procedural trap, designing cases which are "on the nose" for individual cast members as a shorthand version of character development. And for Chase and Cameron, who have had almost zero "showcases" since leaving House's team, this episode has been a long time coming.
"The Itch," at the end of the day, is an episode that walked a fine line between organic investigation into the lives of these characters and a convenient episode that dealt with how we scratch that itch, whether through imaginary mosquitoes, coveting every single drawer in your apartment, or giving in to your agoraphobia. What we learn most of all is that some things never change: House will always be manipulative but emotionally stunted, Cameron will always be woefully incapable of self | 2,717 |
Home»NHL»Marchenko's hat trick leads to smiles all around for Blue Jackets
Marchenko's hat trick leads to smiles all around for Blue Jackets
It would be a stretch to say Kirill Marchenko couldn't miss on Saturday in Nationwide Arena.
He had a team-high eight shots on goal, and they didn't all go in. But as he kept firing on the way to becoming just the sixth Blue Jackets rookie to post a hat trick in franchise history, Marchenko started to feel like anything he would put on net would go in.
Take his third goal, for example, which tied things in the third period and helped lead to the Jackets' eventual 4-3 victory against Carolina. After spinning away from a check by Russian countryman Andrei Svechnikov along the wall and cutting toward the left circle, Marchenko let go a shot that snuck underneath the stick of goalie Antti Raanta.
It wasn't a snipe by any stretch, but it was good enough to go in. And as Marchenko admitted after the game, after scoring twice on the<|fim_middle|>-game stretch.
He's not afraid to make a move or put pucks on net, and that was especially true in front of a sellout crowd Saturday.
"It's more confidence, but after two goals, (I'm) just shooting," Marchenko said. "I just close my eyes and keep shooting. To score three, wow, and to score in the shootout and win, wow. I don't have any words for this moment."
"It's a dream for me. Just enjoy the moment."
{ if (f.fbq) return; n = f.fbq = function() { n.callMethod ?
n.callMethod.apply(n, arguments) : n.queue.push(arguments) };
if (!f._fbq) f._fbq = n; n.push = n; n.loaded = !0; n.version = '2.0';
n.queue = []; t = b.createElement(e); t.async = !0;
t.src = v; s = b.getElementsByTagName(e)[0];
s.parentNode.insertBefore(t, s) }(window, document, 'script',
'https://connect.facebook.net/en_US/fbevents.js');
fbq('track', 'PageView');
Michael Pezzetta with a Goal vs. Detroit Red Wings – Yahoo Sports
Thursday fantasy hockey tips – NHL picks, matchups, more | power play in the second period, he wasn't afraid to fire from any angle.
Video: CAR@CBJ: Marchenko records first hat trick vs. Canes
"No, I was just shooting," he said when asked if he saw the hat trick goal go in. "Two goals, I just shoot. I'm like, is the net there? And just shoot. It's working. I don't know how, but it's great."
Savvy Blue Jackets fans have waited for the arrival of Marchenko for four years, as he was chosen in the second round of the 2018 draft with plenty of hype thanks to his goal-scoring ability. The Barnaul, Russia, native stayed in his home country the next four seasons to play for one of the top teams in the KHL, SKA St. Petersburg, before making the big decision to head to the Blue Jackets after last season.
Scoring goals has never been a question, as he had 27 in 80 games over his last two KHL seasons with SKA. While he thinks the game well and has an endless enthusiasm for being on the ice, Marchenko started the season with Cleveland of the AHL just to keep getting used to the fast-paced style of North America.
After filling up the net with the Monsters with eight tallies in 16 games, he came to Columbus, and his hat trick gives him eight goals in 15 games at the world's top level. It's not only the most among NHL rookies since his debut, it's tied for fourth in the league this season for first-year players.
"Special night for him, right?" head coach Brad Larsen said after his hat trick. "We have been talking about his pace; tonight he was flying. That is a hard team to find space, so that is the encouraging thing, because they check well and are good skaters, and he is strong on the puck. I think he ended up with eight shots on goal. I mean he almost did it again there and got his fourth. So that's a heck of a night for him, great to see."
As Larsen said, Marchenko had more scoring chances in addition to his goals, with the first tally coming on a wraparound on the power play in the second period and his second on a one-timer off a feed from Kent Johnson just 1:36 after his first tally. He had a shot that surprised Raanta in the first period that nearly beat the Carolina goalie and led to a juicy rebound chance, and he used his speed to create a breakaway chance in the dying moments of the third period that Raanta turned aside.
Marchenko did get one more chance to impact the game and made the most of it, as he scored the first shootout goal in the team's victory in the skills competition.
"I personally knew he was going to score," linemate Cole Sillinger said. "I mean, when it's going like that. I was hanging out beside Johnny and was like, 'In the net,' and then sure, it happens. He has the confidence to do a move, another move, and then lift it up over his pad. It was a big shootout goal for us to get us on the board, so it was good."
Marchenko said he doesn't usually prefer to lead off the shootout, but given how things were going, Larsen didn't have to think hard to put the 22-year-old over the boards.
Video: The Blue Jackets speak to the media.
"I didn't think I'd go first, but coach had me go first," Marchenko said. "Usually I look at the first guy in the shootout and how the goalie plays, and then I think about what I want to do. But now I go first, I think, 'Wow, OK.' I didn't know a great move, but I scored. It's working. It's good."
Whether it was because Marchenko was celebrating Russian Orthodox Christmas or because he's simply getting more and more confident at the NHL level, Saturday was a night to remember. Not only did he become the sixth CBJ rookie to notch a hat trick, he was the first rookie in the NHL to do so this year. In all, he's just the second Blue jackets rookie after Matt Calvert in 2011 to tally six times in a seven | 898 |
Working with our clients is a collaborative relationship.
Bringing Simplicity to Business Improvement isn't just a slogan, it is our mission. You will discover it encompasses the principles of how we will work with you.
There is no more proven way to win peoples hearts than<|fim_middle|> people solving key problems together; Increases Profit!
which enable you to meet your goals. We work hard to exceed your expectations with creative answers to old challenges. | to engage them in solving their problems. Leadership behaviors that support everyone implementing solutions which improve business performance reinforce that this approach creates success.
Unleash the capacity of people in your organization!
Developing and coaching leaders with the necessary skills, mindsets and behaviors at a more accelerated rate than traditionally accepted is a critical success factor in unleashing the talent in your organization.
Leading by empowering and engaging your people creates a culture where everyone identifies and solves problems. Capable | 92 |
One of my family's favorite treats is really quite simple. It's a homemade gelatin dessert that is just about the easiest sweet treat I can think of! And, with only two ingredients, you can pull together this refreshing summer dessert in just minutes!
Our favorite way to make this homemade gelatin recipe is to use RW Knudsen's® Just Tart Cherry Juice. RW Knudsen prides themselves on being a better for you option and each 8oz serving contains 100% undiluted juice and a full serving of fruit! I make all of my gelatin desserts with their organic juices because I believe it's a better option for myself and my family. And the best part is, I don't have to go far to find it — RW Knud<|fim_middle|> easy little dessert, especially if I can make it quickly!
1: Measure 1 cup of cherry juice into a large bowl.
2: Sprinkle 4 envelopes of unflavored gelatin onto the cold juice.
3: In a saucepan, bring 3 cups of cherry juice to a low boil.
4: Add the hot juice to the cold juice and gelatin.
5: Stir for 5 minutes or until the gelatin is completely dissolved.
6: Carefully pour hot mixture into ramekins.
7: Chill the gelatin dessert for 3 hours or until firm. Serve and enjoy!
Looking for more easy recipes? Try these! | sen can be found at my local Walmart!
The calendar hanging in my kitchen shows that the school year is coming to an end and my kids are beyond ecstatic. Each day, they arrive home from school and gleefully cross off another day with a thick, black marker. I have to admit, I am very happy for them. Even though they may not believe me, I still remember how exciting the last few days of school were when I was their age.
However, every year, I'm always caught off guard with how quickly summer gets here. For some reason, I always imagine a slow, lazy transition into the summer, but in reality, it is anything but slow and lazy! Instead, the last few remaining school days are always jam-packed with school trips, recitals, and field days. These past two weeks have flown by so fast, I have barely had a second to catch my breath!
So, whenever our schedules get a bit too crazy, I try to plan super simple dinners that can be made with little to no prep work. Things like easy-to-grill chicken or fish and lots of fresh vegetables fill our dinner menus. And, if my kids are really lucky, I'll even make them an | 245 |
Topics News and Events
Letter from President Paxson: Brown's commitment to Providence and Rhode Island
New food security and research funding initiatives will augment the many ways in which Brown students, faculty and staff are already supporting the University's home city and state during the COVID-19 pandemic.
Researchers from the Brown University School of Public Health, based at 121 South Main St. in Providence, have been among the many Brown community members partnering with city, state and health system colleagues to assist in the fight against COVID-19. Photo by Kenneth C. Zirkel.
PROVIDENCE, R.I. [Brown University] — From research collaborations with Rhode Island's health care leaders and donations of urgently needed medical supplies to enhanced food security for Providence residents and community grants for local artists, members of the Brown University community are finding ways to assist the city, state and local residents and organizations as COVID-19 continues its spread.
University President Christina H. Paxson outlined those initiatives and others in an April 3 letter to students, faculty and staff.
"The city and state we call home are confronting an unprecedented set of challenges," Paxson wrote. "We all feel the severe effects of this pandemic — in our jobs, our schools and our neighborhoods. The Brown community has come together in a wonderful way to support our local community on a multitude of fronts."
While many of the earliest efforts to support the local community, and health care workers in particular, emerged in the weeks immediately following COVID-19's arrival in Rhode Island, Paxson outlined a number of new and soon-to-launch initiatives. Among those:
Brown will partner with the city's Healthy Communities Office to purchase and distribute meals for residents of the city with food security needs. The initiative will begin on Tuesday, April 7, and is expected to produce 24,000 meals for over 1,600 people during the course of a two-month period.
A new Brown COVID-19 Research Seed Fund will provide funding to fast-track innovative proposals for research with the potential for significant and rapid impact on human health with respect to COVID-19 or that involves use of Brown facilities to produce products urgently needed by health providers.
Brown administrators are in regular communication with city and state leaders and continue to explore ways in which the University can support the fight against COVID-19, Paxson noted.
"I am inspired and moved by the many students and employees of Brown who continue to show tremendous commitment to supporting the Providence and Rhode Island community," she wrote. "I am deeply grateful for everyone's ongoing engagement and partnership with our local community during this public health crisis."
The full text of Paxson's letter is included below and on Brown's comprehensive COVID-19 response website.
Brown's commitment to Providence and Rhode Island
Dear Members of the Brown University Community,
For over two and a half centuries, the health and vitality of Brown and that of Providence and Rhode Island have been deeply intertwined. With the spread of COVID-19 across the country and the world, Brown and the city and state we call home are confronting an unprecedented set of challenges. We all feel the severe effects of this pandemic — in our jobs, our schools, and our neighborhoods.
The Brown community has come together in a wonderful way to support our local community on a multitude of fronts. An effort by Brown faculty and staff has gathered more than 4,000 N95 masks and other essential medical supplies for donation to Rhode Island health care agencies and providers. Over 150 Brown medical students have volunteered to provide direct assistance to health care providers and agencies. And researchers from the Department of Economics and the School of Public Health have partnered with the Rhode Island Department of Health to develop methods to better track the spread of COVID-19. These are only a few of the many examples in recent weeks.
In recognition of the rapidly evolving impact<|fim_middle|>00 Brown faculty and staff contributed $28,000 to 401Gives, an online fundraising campaign for local nonprofits. This is in addition to Brown's $100,000 contribution to the Rhode Island COVID-19 Response Fund, a joint effort by United Way of Rhode Island and the Rhode Island Foundation to support local nonprofit organizations affected by the pandemic.
There is a great deal of uncertainty around the COVID-19 pandemic, and the long-term financial consequences for Rhode Island, the country and the world are unclear. Brown administrators are in regular communication with city and state leaders and are exploring a multitude of ways in which the University can continue to support the fight against COVID-19. Brown also remains in discussions with the state and health system partners about using unoccupied dormitory spaces to meet needs identified by the state and others on the front lines of the pandemic. Over the coming weeks and months, it is imperative that we all work together to maintain our community.
I am inspired and moved by the many students and employees of Brown who continue to show tremendous commitment to supporting the Providence and Rhode Island community. I am deeply grateful for everyone's ongoing engagement and partnership with our local community during this public health crisis.
Christina H. Paxson
Tags COVID-19 President Research
Open details for Letter from President Paxson: Brown's commitment to Providence and Rhode Island | of COVID-19 on our local community, Brown will invest in three new initiatives that build on Brown's longstanding commitment to Providence and Rhode Island. These initial efforts will focus on addressing the immediate needs of local residents, businesses, and nonprofit organizations and providing urgent medical support.
Community Meal Service
To provide immediate local relief, Brown has partnered with the City of Providence and the Healthy Communities Office to purchase and distribute meals for residents of the city with food security needs. Brown Dining Services will purchase and prepare five-day food packs in on-campus dining facilities while following strict public health and safety protocols regarding social distancing and sanitation. This initiative will launch on Tuesday, April 7, and continue through the month of May. We anticipate this partnership will produce 24,000 meals for over 1,600 people during the course of a two-month period. With this support, we hope to help some of our most vulnerable neighbors in this challenging time.
Brown COVID-19 Research Seed Fund
The Brown COVID-19 Research Seed Fund is a one-time funding mechanism intended to fast track innovative research proposals that directly address the urgent needs of the COVID-19 pandemic. These awards will support research with the potential for significant and rapid impact on human health with respect to the disease (COVID-19) or the causal virus (SARS-CoV-2), and research that involves the use of Brown's facilities to produce products of immediate need for the health care system in Rhode Island and the nation. For example, Brown researchers have already manufactured and donated enough viral transport medium, a solution used for COVID-19 testing, for 2,100 tests, and we anticipate that these efforts will continue. Faculty members can direct inquiries and submit proposals to [email protected].
Support for Local Businesses and Nonprofit Organizations
In addition, Brown is undertaking an array of initiatives to support local businesses and nonprofit organizations during this time of need. The Real Estate & Auxiliary Housing Office granted rent deferrals for the month of April and May to retail tenants who have ceased normal operations due to state-mandated closures of non-essential businesses to stem the spread of the pandemic. The Brown Arts Initiative launched a Community Development Grant that will award $2,000 grants to 10 local artists in recognition of the severe impact of the pandemic on the arts community. And over 3 | 482 |
Release Complexity
Identifying & releasing unnecessary complexity in next generation infrastructure development
Bonnitta Roy
The ability to understand how complexity creeps into infrastructure development processes, enables leaders to identify, anticipate and avoid "solutions" that escalate systemic complexity and thereby increase systemic risk. Systemic risk in infrastructure development has local, regional and global impact that shows up as lack of accountability, skyrocketing costs, political instability, operational fragility, and developmental overshoot. Escalating systemic complexity severely limits our ability to achieve key targets of next generation infrastructure such as sensitivity to regional context and environmental health. Leaders who fall in over their heads fail to attract funding or catalyze political will if they cannot keep up with advancements in technology that fuel the cultural imagination and drive demand toward evermore innovative approaches to infrastructure development. This article examines the root causes of systemic complexity and where and how it can be released to avoid vicious cycles of increasing escalation. We propose a methodological approach that releases systemic complexity in three ways: 1) by refactoring organizational power, 2) by reducing operational path dependencies, and 3) by reformulating mental models to lower levels of abstraction.
Our approach is similar to code refactoring in programming which eliminates unnecessary levels of complexity by examining the underlying logic of the source code in order to remove unwarranted layers of interdependencies, and resolve hidden, dormant or undiscovered vulnerabilities. When applied to organizational or operational contexts, successful refactoring draws on principles such as universal access, transparency, distributed decision making, and open participation. It enables people across multiple domains and scales to make decisions that are responsive to local context and conditions while maintaining alignment with larger and larger strategic wholes. It creates peer networks of cross-functional teams, which are capable of autonomous action in proximate domains, giving a high degree of responsiveness and accountability at the local levels. Cross-functional teams in turn, are linked by operational functionality across the entire network, building both horizontal and vertical depth to the network. In infrastructure development, this means we are refactoring in order to get beyond endlessly building systems within systems within even larger systems, until the "whole system" is too big to know, ownership is progressively monopolized until it is too big to fail, while the system, that is already too big to fix,becomes increasingly vulnerable<|fim_middle|> much different process than reducing complexity. Organizational dynamics are rich and complex, and human relationships are deeply interdependent. Here we are talking about preserving a view of organizations as holistically complex. Think for example of Ptolemy's system of epicycles employed to explain and predict the relative motions of the planets as observed in the night sky from earth. His system was complex, but Copernicus' heliocentric view allowed for a simpler, more elegant view. Not only was the new system easier to understand, but it provided us with even more explanatory power. The complexity in the system was released, not reduced.
A useful way to think about complexity
COMPLEXITY = POWER (asymmetry) x PATH (dependencies) x SYSTEM LEVEL (abstraction)
The above equation helps us reduce complexity in our organizations, by reminding us where unwarranted complexity comes from, and how it escalates out of control. The three key drivers of complexity are power, path and system. Leaders can be vigilant about keeping these drivers "clean" — operating at the minimum level of complexity required. This means continuously refactoring, cleaning up, simplifying and minimizing
· power asymmetry between people
· path dependencies in operational frameworks
· level of abstraction needed to describe "the system"
These three factors tend to grow in an ad hoc manner as teams respond to everyday ordinary challenges. In the same way software developers had to learn to release complexity in their code in order to improve outcomes and increase the potential of innovation, next generation infrastructure developers must incorporate the principle of vigilance and continuous refactoring as priorities in their design-develop-decide phases, in order keep ahead of the challenges they face. Over the next series of articles these three are discussed in detail.
[Part II Here]
Our Future at Work
open participatory organizations at work
source code analyst .. APP AI | to local data and fluctuations that are too small to detect.
Releasing complexity is a | 17 |
How is Fault Determined in an Ohio Car Accident?
Determining Fault in Ohio Car Accidents
Emotions can run high after a car accident, with drivers pointing fingers at each other and making accusations about who was at fault in the collision. However, what the parties may say or admit in the chaotic aftermath of a car crash doesn't necessarily prove legal "fault." For purposes of a victim's lawsuit to recover losses for his or her injuries, fault is careless conduct that amounts to negligence.
The attorneys at Tittle & Perlmuter have extensive experience in investigating car accidents and gathering the proof necessary to establish negligence in a personal injury case. There are a number of different factors to consider in order to support a claim for compensation.
<|fim_middle|> lawyers of Tittle & Perlmuter. Our lawyers will consult with you and advise you on your options. | Official Police Reports
Usually, the primary factor in determining fault in the eyes of insurance companies will be the police report. Since the police are often first on the scene and are impartial witnesses, their account of the accident is incredibly valuable. In this paperwork, there may be a statement of an officer that the other driver was careless in operating the vehicle.
Ohio Motor Vehicle Code
Ohio sets the "rules of the road" in the Ohio Revised Code. It also includes judicial decisions interpreting the Ohio Revised Code in car accident cases. If a police officer issued a ticket for failure to adhere to traffic laws, this may indicate fault in a car accident. The rules ensure the safety of all motorists on the road. Not following them may result in one acting negligently. For cases of negligence, the responsible party breaches the duty of care that she owes to others using Ohio's roadways.
Damage to the Vehicles
It is possible to establish fault by assessing the damage to the respective vehicles. It can act as proof of the circumstances of the collision and conduct of the other driver.
Rear End Collisions:
A driver who strikes the rear-end of your vehicle is likely at fault most of the time.
A fundamental rule of the road is that motorists should leave enough space between their own car and the vehicle in front of them.
There should be at least enough room to be able to stop safely according to traffic patterns and weather conditions. If the other driver failed to do so, this is careless driving that may rise to the level of negligence.
Left Turn Collisions: A driver who makes a left turn across oncoming traffic is almost always at fault. The cars that approach from the other direction have the right-of-way in the absence of a green arrow, and the motorist who is turning left If a left turn must wait until it's safe to do so. If the turn cannot be made safely, the driver should not attempt it; if they do turn and cause a collision, this is considered negligence.
In both cases, the location of damage to the vehicles is evidence of the type of accident. This gives strong support to the argument of fault.
Consult with an Experienced Attorney About Fault in Car Accident Cases
Proving fault in an Ohio car accident case requires extensive knowledge of the law. Experience in personal injury cases is also helpful. The accusations of drivers don't carry as much weight as this type of evidence. This is true in court and during negotiations with insurance companies. It's critical to have a skilled car accident attorney fight for your rights. They will present all available proof of the other driver's negligence. If you've been injured in a car crash – regardless of who you think is at fault – please contact the Cleveland car accident | 548 |
Bay Real Estate Group - Your First and Forever Home
District Guide
Venetia Kate Saunders
Venetia Kate Saunders is a fourth-generation native of the San Francisco Peninsula, as well as a third-generation Bay Area real estate professional. Following in the footsteps of her paternal grandfather, she focuses on residential sales in and around the hilly enclaves of the mid-Peninsula and the city.
Launching her real estate career in New York City while apprenticing with one of Manhattan's top-producing veteran brokers, Venetia has a decade of industry experience and is grounded with a matter-of-fact approach to negotiation. She is data-driven, drawing upon strong comparative market analysis.
A former lifestyle journalist and marketing copywriter, she taps into her own brand of creative genius to effectively differentiate each property listing, letting the home shine via its own unique story. She harnesses her keen eye for aesthetics and design, solid project management skills, and the extraordinary resources available to her at Bay Real Estate Group to position each property for optimal success on behalf of her seller clients.
Venetia listens and advises carefully. Once she homes in on her<|fim_middle|>; its sublime offerings; its microclimates — from San Francisco and the Peninsula to Sausalito to Sonoma and Napa Valleys — to help her buyers find their special place and achieve their homeownership and investment goals.
On a personal note: Venetia has traveled and lived extensively throughout the world — once a U.S. expat in Asia, the Middle East, and the Caribbean. She is a foodie, an Alpine skier, an amateur (but enthusiastic) gardener, and an avid wine collector with a (mostly) Sonoma and Napa vineyard-designated cellar. She lives in the Emerald Hills enclave of Redwood City with her husband, Charles, and their two tuxedo kitties, Oliver and Bixby.
© 2022 Bay Real Estate Group, DRE# 02014153
We use cookies and tracking technology in connection with your activities on our website. By viewing and using our website, you consent to our use of cookies and tracking technology in accordance with our Privacy Policy. | buyer clients' preferences, she responds with a bespoke home search plan. She works diligently with the point of view of a passionate local who appreciates the area's majestic beauty. She knows its nooks, crannies, hidden gems | 46 |
Rosemary, sea salt & sesame popcorn is the perfect power snack. With a hint of fresh herby rosemary flavour, both my children loved the popcorn especially while we were enjoying our movie night. This is super tasty and flavoursome and I was surprised that both my children loved it as much as they did because of the herby flavour!
This recipe is from Natural: Wholesome recipes for pure nourishment cookbook. The book will be released on 15th March 2016 to buy on Amazon and is published by Parragon Books Ltd. The book is hardback containing about 320 pages. It comes with eight chapters: wake up, energy-fuelling lunches, super-charged snacks & sides, dressing, sauces & dips, a feast of vegetables, power-packed protein, the sweet stuff and healthy nectars. It is easy to navigate through the book for recipe ideas.
Each recipe comes with clear instructions and beautiful photos. The recipes drives towards eating a clean and health giving approach to everyday eating. It incorporates more nutrient-dense foods and less processed ones to help boost, balance and benefit your overall health. It has certainly enlightened me how to use more wholesome ingredients in my normal cooking and baking.
Out of so many recipes, I decided to make this popcorn dish as it is the simplest and I had the ingredients to hand! I really need to buy more wholesome ingredients and root vegetables! There are so many recipes using beetroot and avocado. They are one of the best superfoods!
To make this popcorn which serves 4 persons, you will need.
Add the sesame seeds to a large frying pan with 1 teaspoon of the olive oil. Cover and cook over a medium heat for 2 – 3 minutes, shaking the pan from time to time, until the seed are toasted golden brown and beginning to pop. Scoop out of the pan into a bowl<|fim_middle|> over a medium heat for 3 – 4 minutes, shaking the pan, until all the popcorn has popped.
Remove from the heat and sprinkle with the toasted sesame seeds and season with the salt and vinegar, then tip into a serving bowl, discarding the rosemary just before eating.
I omitted the vinegar as my children are not keen on it. The popcorn is very flavoursome and delicious!
Disclosure: I received this book from the publisher for free. However, they have not paid me for this review, and they do not exercise any editorial control over my review or anything else on this site. Contains Amazon affiliate link. | .
Add the remaining oil and the rosemary to the pan and heat gently, shaking the pan to release the rosemary's oil. Add the corn, cover with the lid and cook | 37 |
The Buc<|fim_middle|>Leave a legacy to Barry University Athletics by including us in your estate plans.
Please visit our planned giving webpage for details.
Many companies match dollar for dollar your charitable gifts to Barry University and some even double your donation to Barry.
Does your company participate in this program?
Check with your Human Resources Department or visit our matching gifts webpage to perform a company search. | Club operates under Intercollegiate Athletics Department at Barry University, which is part of the Division of Academic Affairs. Our membership drive is continuous, although we operate on the University fiscal calendar from July 1 through June 30. We need YOU to be a part of the exciting things happening here at Barry University.
Through contributions to the Buc Club, members provide support to Barry University student-athletes by funding scholarships, facility enhancements and individual team needs for all 12 sports, as well as operational needs for the Intercollegiate Athletics Department. Your charitable donations to the Buc Club help support more than 200 student-athletes as they strive towards achieving academic and athletic excellence.
"Be a Champion for our Champions today and give a gift that will last a lifetime."
Make a gift of $50 or more annually and you become a member of the Buc Club! All members enjoy the pride wearing the RED, SILVER, & BLACK because you are supporting Barry Athletics. Tax deductions are also a benefit as per 501 c-3 rules. The annual Athletics Viewbook and the Buccaneer E-newsletter help us keep you informed about achievements and upcoming events.
See our membership benefit chart below.
Joining the Buc Club and renewing your membership on an annual basis helps us meet our scholarship and operational needs.
Your yearly support is vital for the success of our programs and for the educational and athletic successes of our student-athletes.
Endowing a scholarship is one way to make a huge impact on our programs and help our student-athletes. Scholarship endowments start at $50,000.
Contact us for more information on how to endow a scholarship.
You can make your mark and help support Athletics programs by choosing one of our Naming Opportunities.
Contact us for information on current and future naming opportunities across campus.
| 380 |
We all know John Public is frugal, but just how frugal is he? Not only does the Jersey City buzzmaker rock a thrift-store wardrobe, but he forgoes pricey off-the-shelf time in favor of lightly-used Second-Hand Minutes. How is reusing a minute even possible? I have no clue – you'll have to ask him. Moving right along, the latest world premiere off the freestyle series alum's forthcoming street album sees Public hooking up with a familiar face from the DMV. Over Diamond District rapper<|fim_middle|> minute with sixty seconds' worth of distance hustled" (to paraphrase Rudyard Kipling). Rising R&B star Mike Maven delivers the coup de grace, summing it all up on the nose-to-the-grindstone hook: "Time is on your side, you know you got it – use it." Digging this motivational head-nodder? Then I have a feeling that Public's Booth-sponsoredRegifted: The Thrift Shop Experience (due out Dec. 13) will be well worth your time. | /producer Oddisee's street-ready piano-loop boardwork, the emcee delivers a lyrical snapshot of the city life; though the pace is ever-accelerating, he remains determined to "fill the unforgiving | 46 |
The last ITU<|fim_middle|> awareness and promote a common understanding and dialogue among stakeholders for enabling OTT environment and ecosystem within the remit of ITU'; (2) 'to continue fostering studies on OTT aspects'; (3) 'to foster capacity-building programmes among ITU members in order to share information related to best practices and technical guidance on OTTs, especially for developing countries'. It also instructed the Secretary-General to continue collaboration with other relevant organisations to further the objectives of the resolution; and to submit an annual report on the council on the activities undertaken under the resolution. | Plenipotentiary Conference, held in Dubai, managed to make Resolution WGPL/3 through adoption. It was recognised that emerging over-the-top (OTT) telecommunications technologies pose both opportunities and regulatory challenges for national telecommunication regulations. Specifically, the Resolution resolves (1) 'to raise | 59 |
These gorgeous looking mango muffins with crunchy walnuts are to die for. The mango frosting adds extra richness and creamy taste for this mango dessert. To make it bright orange I add mango pulp to the batter. You can try different variations like adding mango pieces instead of the pulp. I am sure<|fim_middle|>e, melted butter, and vanilla with spatula. In another large bowl combine the wheat flour, sugar, baking powder, baking soda and salt.
Now lightly pour the wet ingredients into the dry ingredients until they are combined and the batter is thick and chunky. (Do not to over-mix the batter. Over mixing the batter will yield tough, rubbery muffin.) Add milk as required if the batter becomes too thick.
Spoon the batter into the prepared muffin liners. Bake for about 25 minutes or until a toothpick inserted comes out clean.
Yields- 20 medium sized muffins.
← Holidays Are Here – Now What? | they will be delicious & full of flavour.
In a medium-sized bowl beat eggs until light and fluffy, combine the mango pure | 25 |
Does it Make Sense to Analyze BoP Firms from an Industry Lens?
This post tries to correct a missed opportunity in the BoP space: the analysis and categorization of firms in low-income markets from an industry basis. From a sociological standpoint, when we categorize firms as belonging to a specific industry we do it to make better sense of the diversity of firms in the real world. When we lump things together we carve "islands of meaning" (Zerubavel, 1996) that, in spite of not being logical, are useful to analyze and understand the reality that surrounds us.
These "islands of meaning" come at the cost of simplifying reality and can result in biased judgments of a firm working in more than one industry. For instance, it has been shown that security analysts regularly penalize in their valuations those firms which straddle industry boundaries (Zuckerman, 2000). Such penalization is independent of the firm economic performance or its strategy. It arises because straddling or diversified firms are more difficult to analyze and understand since they do not conform to this ready-made categorization. I believe we often make the same mistake in BoP markets and that this mistake is more serious than in developed markets.
To see why this is a mistake, forget for a second that a firm may belong to a particular industry. Consider instead that, first, at the firm level, many of the most successful business models in low-income markets (from economic and social perspectives) are hybrids and hence straddle different industries. Therefore, by focusing on developing business models that may squarely fit on one industry we are decreasing our chances of maximizing our impact in these markets. The best-known case of hybrid business models is probably mobile phone banking, although important developments have made in health services offered through IT platforms and multi-product selling using the same commercial platform to take advantage of the platform's capillarity and information.
Second, at the household level, potential consumers are extremely cash constrained. It is generally argued that as a result, if a customer increases her purchases in one product, she will have to decrease expenditures on other products. However, what is usually overlooked is that the purchase and consumption of a good can in fact result in additional expenditures one other types of goods which are traditionally within the scope of other industries. This positive domino effect has been shown in, for example, households buying mobile phones and as a result increasing their expenditures on other basic goods thanks to better information access (Jensen, 2007).
By approaching low-income firms using our "industry-glasses", we become blind to a portion of the true potential of the private sector in developing countries. Indeed, it is likely that we are becoming blind to the most promising aspect of private sector solutions. Take, for instance, the case of utility retailers. Utility retailers are usually not especially exciting for BoP entrepreneurs or investors because of the high-fixed costs required to set up these firms. Instead, decentralized energy services are often favored, such as setting up solar panels or pedal-powered water pumps. Moreover, these solutions avoid dependence on the state and, if households are connected to the grid, they may even make some money by selling unused energy.
The problem with this analysis is that it fails to consider the relationship between utility relaters and other industries. At the firm level, using a "multi-industry" approach can result in important findings. Utility retailers have developed extensive platforms to cater to particular areas and generate potentially useful billing information about their customers. For instance, witness, the case of Codensa. After improving its energy losses and its infrastructure management, it used its customer information and its privileged access to customers to offer credits for the acquisition of electrical appliances (for more information go here). Codensa is the story of a firm that developed a hybrid business model and jumped from being an "also-ran" utility retailer in the BoP arena, to a pioneering organization that has become a classic case study in many MBA programs.
At the customer level, access to electricity has the potential to significantly affect expenditures on other goods. The immediate benefit of electrification comes through improved lighting. Additionally, lighting promotes extended hours of study, thus leading to better educational achievement. Furthermore, electrification increases the use of electronic devices such as radio and television, which improves the access to information. Crop productivity can be increased by the application of electric irrigation pumps and businesses can be operated longer hours. As a result, electrification may also lead to higher incomes and increased expenditures in other industries. In rural Vietnam electrification among poor households jumped from 77% in 2001 to over 90% in 2008. As a result, school enrollment increased 17% for boys and 15% for girls between 2002 and 2005. Moreover electricity use has increased household's income by 7.4%. Such positive effects last for about 9.25 years after which they peter out (Khandker, Barnes, Samad and Minh, 2009). Similar results have been found in Bangladesh as well (Khandker, Barnes and Samad, 2009).
Therefore, the question of examining BoP firms through the lenses of industries is not a theoretical one – it has very practical<|fim_middle|> industry increase their economic and social impact if they adopted an alternative approach and, if so, which one? Would business model competitions stimulate more insightful entries if they did not restrict competitors to a particular industry? Although I suspect that there may not be any satisfactory solution to these questions, by breaking through the constraints of our current industry categorization, I am hopeful that we may be in track to at least increasing the power and applicability of private sector solutions in low-income markets. | implications. As the case of utility retailers exemplifies, if we fail to consider firms straddling industry boundaries we become blind to the economic and social potential of hybrid business models. This is especially important in low-income markets, as the case for mobile phone banking or IT health care has shown. In other words, it means that we may not be doing as well as we could by focusing on firms from an industry perspective.
Unfortunately, if we discard the industry categorization we require something else to substitute it and this is easier said than done. Which set of categories should we use to comprehend and analyze the BoP space? Would it be more useful to take a generalist approach and concentrate on a particular region or a population segment (women, children or disadvantaged groups)? Would it be more interesting to not abandon the industry nomenclature altogether and take the middle ground by focusing on clusters or binomies of industries? These clusters could involve industries with significant potential for hybrid solution, such as finance + mobile phones or IT services + health.
Take, for instance, the myriad of social investors or foundations in the BoP arena that focus on just one or two industries. Could their impact be increased by going beyond their industry classification and analysis of BoP firms? Would social investors or foundations specializing in one | 260 |
The spring 2013 Sign Magic Workshop is now behind us. We had a full workshop with a class of very eager students. We changed things up a little this time with the meals taken in the<|fim_middle|> the new house. Our guests enjoyed looking at every detail we had incorporated throughout it's construction.
With the workshop meals in the new house it freed up a whole lot of space in the shop. Once again we were able to seat everyone at a single table, making things easier and more enjoyable for all.
Jeff Hartman, one of the creators of EnRoute was our guest lecturer. He did a great job. We routed a lot more sample pieces during this workshop showing how the files were created how they routed and then how we finished them.
We also did hands-on demonstrations of our fiberglass-reinforced-concrete carving techniques.
The hands-on painting and sculpting was enjoyed by all.
And here's a shot of the entire class.
It was a fun workshop without a doubt. Thanks to all who participated! | new house. We were able to seat thirty people (students and our team of helpers) at one table comfortably. It worked out well and it was a great test drive of | 35 |
*EXCLUSIVE OFFER - Extraordinary days! Stay with us between 15 February – 12 April 2019 and benefit from a 20% Discount!
Escape to your very own tropical paradise at this<|fim_middle|>Estate Fitness Centre 5 Minutes Walk Away.
One airport transfer each way, live-in staff, a daily breakfast, a Thai chef with food costs on guests account, concierge service and English speaking villa manager. | beautiful 5-bedroom Koh Samui (sleeps 10), offering direct access to Maenam Beach on the island's north shore.
Relaxation here comes easy, with a sparkling infinity pool, beachfront sala for al fresco dining, a sprawling living space with vaulted ceilings, and gorgeous bedrooms with ocean views. An in-villa Thai chef, access to sea kayaks, and a year-round swimming beach add more delights to this blissful island getaway.
Start the day with a splash in your gorgeous L-shaped infinity pool. Just beyond, a white-sand beach and the dazzling blue ocean are laid before you. Or kick back in the poolside sala to your favourite tunes - piped through the sala's built-in speakers.
Beyond, a beachside lawn is perfect for morning yoga. And with access to the villa's kayaks, you can explore the local seafront whenever the mood takes you. If you've still got energy to burn, squeeze in a workout at the shared on-site gym.
Come together for group gatherings in an expansive living/dining pavilion with vaulted ceilings. Sip ice cold drinks while you unwind in the sitting area. A pair of cushioned sofas offer a comfy spot for chill-out time, and glass doors let you stroll straight back to the pool.
Discuss the day's adventures at the solid wooden dining table, or enjoy outdoor dining in the covered sala. Ask the chef to treat you to a seafood feast while the sun fizzles into the ocean.
Five tastefully furnished bedrooms each feature ocean views, vaulted ceilings, and Thai-inspired decor. And everyone gets their own en-suite bathroom with marble floors, and indoor and outdoor showers.
Three of the bedrooms have two twin beds, and a fourth bedroom comes with a double bed.
In the spacious master bedroom, you can step out of bed and straight onto your private beachfront veranda. Sip morning coffee from a sun lounger or an inviting double daybed.
Located on Koh Samui's north coast, this luxury villa is one of just 8 exclusive properties in a private tropical haven on Maenam Beach. Take a morning run along the pristine strip of sand waiting just steps from your door. Or drift along the coastline in one of the villa's kayaks. The sea here is also great for year-round swimming.
Just over a 10-minute drive away, Fisherman's Village offers local restaurants, shops, and a popular Friday Walking Street Market. While 20 minutes away, Chaweng (Samui's buzzing resort town) is packed with restaurants, shops, bars and nightlife. Golf lovers are under a 15-minute drive from the 18-hole championship Santiburi Golf Course.
We are a group of 7 friends who celebrated 50th birthdays of two of friends at this villa in a span of 2 years. In 2015 when we visited this villa for the first time we had a whale of time and had some awesome memories to cherish for life time. As one of our group member was hitting 50th this Sept, the search for party destination begun 6 months back, traversing around the globe with multiple location we could not but select Water Lilly Villa at Miskawaan because of couple of simple facts outlined here under: Serene and Beautiful villa located right on the beach. Excellent Staff!!! Always smiling and ready to help and serve at what ever hour!! All rooms, kitchen and over villa facility are avant-garde and cannot complain for anything. Neat, clean, spick and span villa. Before we get up in the morning after partying till late hours, Villa is picture perfect, neat and clean. Swimming pool is an simply amazing with a nice gazebo and bar over looking beach for sunset.
I have been world traveler and have visited several beach destinations round the globe. I can say Miskawan Water Lilly Villa is one of the best. The villa is so beautifully and tastefully designed, well equipped and the staff is so good that you can ask for anything and they will bring it for you probably moon also!! In particular Poi the head staff was excellent, very courteous and always smiling and ready to make your stay as comfortable as possible. Her subordinates were equally very cooperative and supportive, at no point of time you felt that privacy was being invaded. I would recommend every one , family, couples, bachelors or bachelorettes to consider this villa for their stay at Koh Samui.
We had an amazing time and wished we could have stayed at the villa a bit longer and have thought about returning at some point. Almost all of our guests commented on the villa and said we should have booked them all in to stay at the villas too. The staff were all wonderful especially Tim our villa manager and Sarah, our wedding planner. We has 35 guests and they all had a wonderful time at the cocktail night and enjoyed the food made by the villa chef. She cooked the meal for our wedding too and it was spectacular. Overall it was a brilliant experience and we would recommend it to all our family and friends. Would love to be able to go back there and spend some quality time as it was quite hectic for us in the run up to the wedding.
| 1,068 |
Did you know that it can cost $30,000 to<|fim_middle|> philosophy has led him to where he is today.
Next week, my guest will be Ian Clarke, former CFO of Maple Leaf Sports and Entertainment and current CFO of the Greater Toronto Airports Authority. | hire someone in the tech industry?
Let's say you have a company and you want to hire a data scientist or mobile developer. Maybe you'll pay them a $100,000 salary. Tech recruitment companies could charge you 30% of that first year's salary to find you the right person.
Why would you pay this much to hire someone? Well, hiring is complicated.
You want to find the right person, but you might not have the network or the resources to do that. You don't want to waste your time and end up having to settle for whoever's available, so that's why recruiters exist. They're specialists.
Plus, the best people are going to go to the Googles and Microsofts of the world and if you are a small company, they might not even know you exist.
But there's gotta be a better way than spending $30,000 to hire someone, right?
That's what Brian Daley thought when he started his new company SmartRefer, which is the first open-source employee referral platform to leverage blockchain technology.
Brian didn't start out in the recruiting business, or the tech business, but he always had this philosophy of keeping his options open, and constantly building skills and relationships.
Let's hear Brian's personal finance story and how his personal | 268 |
The Rio Grande Association was a Class D minor baseball league that lasted for less than one season, 1915.
History
The league initially consisted of six teams based in Texas, Arizona and New Mexico: the Albuquerque Dukes, Douglas Miners, El Paso Mackmen, Las Cruces Farmers, Phoenix Senators and Tucson Old Pueblos. By May 24, the Miners and Farmers had disbanded and on July 6, the league<|fim_middle|>10.
The league officially started after a meeting held at the Hotel Sheldon, at El Paso, Texas, February 18, 1915.
On May 4 the league was officially accepted into the National Association of Professional Baseball Leagues. Tucson hosted Opening day April 26, Tucson defeated Phoenix 10-2.
Nearly a month into the season, May 24, the Douglas and Las Cruces teams were dropped from the league due to financial difficulties. The teams' records were 5-13 and 5-14 respectively.
At a league meeting held at El Paso, July 5, it was decided to close the league because of sustaining losses.
The league featured multiple notable players and managers, including those who would attain major league experience and those who had major league experience. They include Kitty Brashear, Frank Huelsman (who led the league with ten home runs), Rudy Kallio, Stoney McGlynn and Herb Hall.
Cities Represented
Albuquerque, NM: Albuquerque Dukes 1915
Douglas, AZ: Douglas Miners 1915
El Paso, TX: El Paso Mackmen 1915
Las Cruces, NM: Las Cruces Farmers 1915
Phoenix, AZ: Phoenix Senators 1915
Tucson, AZ: Tucson Old Pueblos 1915
1915 Rio Grande Association
Douglas and Las Cruces disbanded May 24. The league disbanded July 6.
References
Defunct minor baseball leagues in the United States
Baseball leagues in Texas
Baseball leagues in Arizona
Baseball leagues in New Mexico
Sports leagues established in 1915
Sports leagues disestablished in 1915 | disbanded. The league was founded by John McCloskey, who also founded the Texas League.
Each team that appeared in the Rio Grande Association was the first professional baseball team to come out of their respective cities, often predating their successors by many years. For example, after its appearance in the Association, Phoenix and Tucson did not again have a professional team until 1928; El Paso until 1930; Albuquerque until 1932; Douglas until 1948 and Las Cruces until 20 | 111 |
Kennan is now one year old and Blind Baby Daddy doesn't know whether to celebrate the fact that he has survived one year under my oversight or to be fearful of what is to come. As you know, my vision is quite limited and therefore I like to keep all living blobs in my small world of workable vision. This has become increasingly more difficult as he now is not only walking but running and climbing on everything. In a small way, I almost feel like I have become more similar to my Vizsla dog Gunther, head always on a swivel and trying to attend to every stimuli in the environment. This may be a<|fim_middle|> Rocky. Part of you is amazed on how he did that and the other part of you is saying "Hold S####," what did he just do?
As if he doesn't have enough things to entertain himself with, he has been fixated on getting to the stairs or the toilet. He figured out how to move aside the barrier to the stairs and therefore I have had to resort to placing a 45lbs weightlifting plate to prevent him from getting to the stairs. He has discovered that lids open his world up to a whole new set of treasures. He has already attempted to eat dog food and to be honest if that's the worst he puts in his mouth, that is totally fine with me.
Kennan is learning words and how to read basic books so he can read them to daddy.
He now can say a handful of words, a few of which are dog and ball. This is helpful as he thinks it is absolutely hilarious to pick up the ball and through it to the dogs. He also knows book but his daddy still hasn't quite figured out how to read the books to him without totally making up the words. I do have a few memorized such as "Where is Baby,"and "That's not my Puppy." The other books are either read by mommy or contribute to the random clutter all over the house. A few other words that he knows are "more" and "no no" but he has quite learned how to say please and thank you. We will continue working on those as he is the child of a SouthernLady so those manners better improve quickly. | small exaggeration as those that have met Gunther know that he is like an ADHD child on cocaine and coffee. Needless to say, I don't do much sitting around anymore.
Not an exact representation of my blurry world but think about navigating through a storm of toys through this windshield.
All those parents reading this blog, remember back when your child was one year old and remember the efforts you made to child proof the house. Now, put the icy opaque windshield over your car directly in front of your and chase around that little Tasmanian Devil. What you will find is that you trip and hurt yourself more than he does and that your hands work better than the kitchen broom because you constantly have them in front of you sweeping all of the debris and remains of the little monster that just stormed through.
My typical day begins with waking up to Kennan screaming to be rescued from what he believes is a prison (his crib), but in reality is a safe haven. I pick the little chunker up and walk down the hall, stepping on Duplo blocks or Little People characters on the way. I ask Kennan, "Did you have a stinky?" If so, he will respond with the universal sign for, "what stinks," waving his hand in front of his face. After changing him, I put him in the high chair to eat. This is seriously the only place where I can take my head off of a swivel and relax for a minute. He typically eats a banana and a Clif Bar Kids for breakfast with a nice cup of milk. He is a good little eater until he gets done nd begins feeding the dogs that are eagerly awaiting any food droppings. It got so bad though that we had to place baby barriers around the high air to keep the dogs back. From an outsider he looks like a celebrity in his high chair with barricades to thwart off the paparazzi of fans.
Once eating is complete, the terrorization of the house begins. I open the dishwasher and before I can get all of the glass bowls out he has already taken out spoons and plates and is throwing them on the ground. I leave the kitchen for a second to use the bathroom and come back and he is inside the dishwasher. The attempt to sanitize the house is not even a thought anymore. I am just damage control. I no longer worry to much about him falling but rather how far he falls. The kid face plants and I just shrug it off as standard practice. It is his climbing that is more concerning to me as just a week ago I left the room for a mere minute and he had somehow managed to climb to the top of his high chair and was standing on top with his hands raised about his head like | 554 |
The iPhone 6 has a 4.7-inch screen with 1334 x 750 pixels. If you're thinking this is an odd resolution, you're right. It only exists to improve compatibility with apps made for older iPhones. The 4.7-inch display is smaller than those offered by other flagships, such as the GS5, HTC One, LG G3, and Moto X. Those competing models also go with full HD (or, in the G3's case, quad HD) resolution. That said, the iPhone 6's screen looks really, really good. It's not quite as impressive as the display of the 6 Plus, but it still packs in enough pixels to exceed 720p HD. Viewing angles are great. There's no brightness drop<|fim_middle|>ertime. Power users might run into trouble slightly sooner than 11PM. The 6 Plus gets about a half-day more uptime from a single charge, so that might be worth weighing if you're on the fence about which iPhone to choose. Competing models from Samsung, HTC, and LG offer slightly better battery life.
iOS 8 doesn't offer advanced power-saving tools, but it does offer a guide to help you discover what's been chewing through your battery life. This way you can deactivate or disable those apps to conserve power.
Next page: Basic | off and no color shift. I really like that colors are accurate and not over-saturated as on some AMOLED screens. I was able to use the iPhone 6 outdoors under a sunny sky with no trouble. It's a very good screen.
We tested the Verizon variant of the iPhone 6. It did well on Verizon's LTE 4G network in and around the New York City area. It maintained a connection to 4G without fail, even in areas with weak coverage. It always showed several bars of signal strength and was able to connect calls and pass data with no problem no matter where I took it. The iPhone 6 didn't drop any calls during nearly a week of use, nor did it miss any. Data speeds were consistently good. I noticed only the slightest of slowdowns in LTE when in weak coverage areas. Most of the time it was really fast.
The 6 on Verizon performs about as well as the 6 Plus did on AT&T. That is to say, phone calls were slightly below average in terms of quality and volume. The quality of voices coming through the earpiece ranged between awful and decent; it never impressed. Earpiece volume is not where it should be. It's better than older iPhones, but doesn't match other flagship devices, such as the HTC One. I was able to hear calls in coffee shops and when hanging out with several friends, but screaming kids and a loud TV were enough to drown it out. The speakerphone actually improves voice quality a little bit, but is also short of excellent when it comes to volume. I was able to maintain conversations in my home and office, but road noise made it harder to hear in the car. Those with whom I conversed through the 6 said I sounded far away and somewhat muffled.
Ringtones are audible in your home or office, but crowded coffee shops made the 6 hard to hear. I wouldn't be surprised if people missed calls because they couldn't hear the ringer. On the flip side, the vibrate alert is among the strongest ever. In fact, it's too strong. The point of a vibrate alert is to be somewhat subtle. There's nothing subtle about the 6's vibrate alert. You can hear it loud and clear in a range of settings. Apple needs to dial it back a bit.
The 6 makes significant improvements in the battery department. I was able to coax an entire day out of the 6, though I often went to bed with just 20% power left. In other words, regular users shouldn't have a problem getting from breakfast to bedtime on a single charge. This is somewhat better than the iPhone 5/5s, which could kill off a battery closer to dinn | 561 |
Google News is maybe the largest and most popular news aggregator in the whole world. What's for sure at the moment is that Google News is one class above other similar portals such as Bing News. However, that doesn't mean that the platform is free of bugs and other issues, but Google is working to solve out the most annoying ones. Now, Google News 5.8.0 rolled out<|fim_middle|> of critical events, FAQs, essential people for the story, and more. Google News would organize the coverage on specific news for you to access only what's significant.
Google News is promising to list only those credible sources which post quality content from a diverse set of reliable publishers. Also, you can set up the application to only display those topics that interest you. That's one excellent feature if you just don't want to browse an entire category for the news you care about.
Now, Google News 5.8.0 rolled out with new enhancements and issues fixes. According to Google, the latest version of Google News, which is already available on the Google Play Store, comes with bug fixes and several stability and performance improvements. | with some bug fixes and improvements.
With lots of new features added since Google News changed its interface and integrated AI features, the portal is now boasting some functions to help each user stay updated with stories he/she cares about. "With Your Briefing feature, easily stay in the know about what's important and relevant to you. Your briefing updates throughout the day are bringing you the top stories you need to know, including local stories, national news, and world content," Googe News description reads.
Besides, to understand the full context of a story, tap on Full Coverage and access everything that's online about a story, including different perspectives, a timeline | 130 |
The 11 Best Game Recording Software In 2021 (Free & Paid)
By Stephen MalipUpdated: May 24, 2021 13 Mins Read
While some of the gamers use recording software to boast of their kill-streaks others are interested in creating game walkthroughs. In either case, recording software that doesn't impact the actual gaming performance is hotcakes.
We have taken care of the hard part of going through the number of game recording software available in the market.
Latest recording software supports all sorts of video resolutions from HD to 4K recording. While most free streaming software supports up to HD recording, you will need premium software for recording Full HD and 4K.
Moreover, your system should have an i5 3rd gen / Ryzen 3 2200 or the latest processor for<|fim_middle|> of Gaming
Aim Controllers Review- Are The Paddles Worth The Money?
Vortex Cloud Gaming Review: Hit or Miss?
Zygor Guides Review: Your Personal Sensei for Leveling Up
No More Heroes 1 Review: The Unconventional Game We All Want | a smooth recording and gaming experience.
Game Recording Software: User's Guide
Considering the number of software options available to you, opting for any one software while making an informed decision is vital. These are the things you need to consider to make the best choice for you –
Frames Per Second (FPS)
This is the most important word in the gaming industry. How much FPS your system can churn will play a major part in your gaming experience. With a game recording software in the midst, note that your PC will churn lower FPS. While competitive games can go up to 200 frames per second, DOTA 2 or Warzone or even Fortnite should run at 80 FPS if you want to win more than losing.
Not everybody needs professional recording software. Going for the pro game recording software is a waste of money for beginners. Paid tools definitely provide better outputs in comparison to free ones but you need to make sure your PC can handle it in the first place!
PC Performance
Your game preference will determine which software is the best suitable for you. As a general rule of thumb, you should choose software that can record higher frames than what your system can generate.
So, now that you know what you're getting into, let's dive right in!
Best Gaming Game Recording Software in 2021
11. XSplit Gamecaster
Xsplit Gamecaster by SplitmediaLabs is a good recording software, offering both recording and content streaming for free. It has a simple user-interface, a perfect choice for first-time users.
XSplit Gamecaster is simple to install and is ready to use after a few simple steps like connecting to Twitch, Facebook, or youtube.
You can even save the recording in a capture card or a separate application. Xsplit Gamecaster will also allow you to use your webcam feed into the recorded video while simultaneously saving your microphone audio.
It offers you to download @1080 P resolution video at a base rate of 25 FPS and a max FPS of 60.
Xsplit Gamecaster even stores all your files on the cloud, making it easier to access this application from any device.
It provides you with a large number of pre-designed overlays and widgets to give a professional touch to your recording. You also get third-party software integrations such as Elgato, Spotify, and Restream.
XSplit is currently available only on Windows.
Download here!
10. Dxtory
Dxtory screen recorder is perfect for capturing gameplay with applications using OpenGL and DirectX frameworks. The developer's Exkode puts a higher emphasis on capturing the pixels as in the original file to create a lossless video of the gameplay.
This application supports separate audio sources recording directly from game audio, mike sound, and two other sources as per the user's choice. Users can also access the source files and mark them for broadcasting purposes.
Apart from screen recording, audio mixing, Dxtory is capable of taking a screenshot using simple shortcuts. Users can pre-set the format of these screenshots before using the application. It supports all the windows systems currently in use, from 64-bit Windows XP to 64-bit Windows 10.
Dxtory also supports a wide range of APIs, and until a premium version is purchased, it inserts the Dxtory Logo on both screenshots and videos. The premium version is available for 3800 JPY, roughly $38.
9. Fraps
Fraps is a popular game recording software, dominating the entire recording domain for over a decade. It is a very compressed and small application with an old-age user interface. Installation takes less than a minute to complete.
Fraps offer three features – Benchmarking, Movies, and Screenshots. Under Movies, you will be allowed to record a video in many pre-set video settings at a maximum of 60 FPS and a custom minimum frame option.
Here you will also get to save your sound from Stereo and Multichannel with options to hide the mouse cursor and lock frame rate in the video.
While the free version has not been updated since 2013, you can get the latest updates after registering for an amount of $37. It offers bundled packages for multiple users, and the price per user decreases with higher orders.
One registered user can download the latest version of Fraps on any device after entering their login credentials used during purchase.
Fraps supports all intel processors released after Pentium 4.
8. CamStudio
Although CamStudio launched its stable release in 2016, it has been in the screen recording business since 2001. A series of successive acquisitions and mergers has finally led to ownership under Adobe Macromedia, a subsidiary of Adobe System Inc.
CamStudio is an open-source screen recorder that allows you to capture video, screenshots, and audio through a mic, which makes it perfect for creating game walkthrough tutorials.
It offers a custom crop to dictate the area you intend to capture and select from multiple formats (You don't get this feature everywhere!) The key highlight of this software is restriction-free recording length.
This software also contains advanced drawing and watermarking tools to prevent others from using your work.
Make sure to uncheck the browser and search engine extensions while installing the CamStudio application. You can download a video at up to 70 frames per second.
Despite having a fair share of controversy to contain malware after its stable release, the company has consistently worked towards its reputation. As of April 2017, out of 79 malware scanners, only 1 reported CamStudio to be infected with malware. Users should not download this application from anywhere but from the official website.
7. Movavi Screen Recorder
Movavi screen recorder is a free trial software that provides premium services available in 3 different packs, Screen Recorder, Recorder with Editor, and Complete Video Suite. By default, these packs come in a one-year plan, just as the anti-virus software.
Movavi supports both Windows and macOS. It can record live streams and webinars apart from games. Movavi allows you to record sounds either through the speakers or microphones. You get freedom from the watermarks only after purchasing the software.
Here you can choose to stream a selected part of your screen by cropping the video, capture your webcam feed, record only Audio, Schedule recording for reminders, or downloading the videos of your favorite streamer.
It records your keyboard and mouse strokes as well, an added boon for subscribers (ogling newbies!)
The premium plans begin from $39.95 per year and increase for bundled plans. Overall, the user interface is simple and makes it easy for new users, unlike the overwhelming applications with loads of professional features.
6. Nvidia GeForce Experience
Nvidia GeForce Experience is proprietary software, which offers a host of facilities including, gameplay recording. Apart from recording, it is also capable of streaming live videos, updating your gaming drivers, and optimizing your game settings.
This software is optimized to work using your GeForce card's processing power instead of eating your CPU performance.
Since it uses GPU to record, the frame drops are below 10 FPS, which makes this software a one-stop solution for the entire gaming and streaming-related performance issues.
The downside with GeForce Experience is its limited game support and capability to work with only Nvidia Graphics. Guess What? You can't complain about its incompatibility with AMD cards.
At least you now have a manufacturer-optimized game recorder and one of the best game recording software around!
Experience doesn't have any hardcore system requirements and works perfectly with Windows 7 or later. We recommend using this application with the Geforce 700 series or later.
5. AMD Radeon Relive
With Nvidia and its own recording software, how can AMD be far behind? AMD Radeon ReLive is the proprietary recording and downloading software specifically for AMD graphics cards.
Radeon Relive downloads gameplay videos at a default 60 FPS and follows the footsteps of Nvidia's GeForce Experience using the GPU for recording.
Radeon Relive can also record upscaled videos. You will be able to download in higher resolution as compared to the actual gameplay. Game at 720P and record 1080P videos!
Radeon Relive can record at up to 4K resolutions so you can offer the best resolutions to your subscribers. You should expect a performance drop of 5-10% in general but above 10% in graphic intensive games such as Control.
Radeon Relive has extensive recording options and controls, from creating multiple Profiles to selecting Video Resolutions, Audio bitrate, FPS, and Instant GIFs. Instant GIF files can be maximum of 15 seconds.
This application works only with AMD RX 400 and RX 500 or later series cards and 64-bit Windows 7 or above.
If you have a compatible AMD card, this is one of the best free game recording software around!
4. Bandicam
Bandicam is one of the best free game recording software with an amazing bundle of three-in-one recorder. It is capable of Screen Recording, Game Recording, and Application recording.
This software is available to use as crippleware, to lure you into purchasing the premium version and that's even better.
Bandicam has extensive recording settings, including FPS tuning and multiple video settings. It supports both AVI and MP4 modes and uses a compressive recording technology that requires less storage space without compromising on resolution.
Bandicam can also record at a maximum of 192 bitrate audio in both Stereo and Mono settings.
But there's a catch:
The Game Recording Mode initiates only while running applications or software using Directx/ OpenGL.
All recorded files are downloaded in the Documents folder. It displays available and/to used space on the top right corner with convenient access to controls to Record, Pause, Camera, Microphone, and Webcam.
You can record at up to a whopping 480 FPS! (You will need hardware acceleration though)
The premium version of this application comes at a one-time payment of $39.95 for 1 PC and $59.96 for 2 PCs.
3. OBS Studio
OBS Studio is the ace in the hole for new users to keep up with pro streamers. Today, just live streaming via the available software is not enough to keep notching more subscribers.
You also need editing software on top of downloading software, OBS Studio can be the perfect go-to solution. It is free-to-use open-source software created with help from small contributions and sponsorships.
OBS Studios provides high-performance audio/ video mixing, Modular UI, Pre-set broadcasting configurations, and a host of pro-grade features. Some of these features are not even provided by leading premium services!
The reason behind its open source is sponsorship from Facebook and Twitch, Api Video, and Own3D pro.
Being free is not the only big thing about OBS Studio. It is compatible with all 3 operating systems, Windows, Mac, and Linux. Users get to use 8 different scenes with easy transitions between them.
It also has a nifty feature called Studio Mode, which lets you preview before steaming the videos.
There's more:
OBS studio offers API integration, plugins, and scripts for extra customization and fine-tuning everything as per your expectations.
You can use Python or Lua scripts to improve the integrations. Is this the best free game recording software? With its editing and casting tools, it might just be!
2. WonderShare
Filmora WonderShare is here to empower the video creator hiding inside you. It is another crippleware with amazing audio and video editing features. You name an editing task and Filmora Wondershare must have it.
Wondershare works perfectly with the latest devices but this is a performance-hungry tool. We recommend having at least 4 GB of RAM, which goes to 8GB for HD and 4K videos.
Wondershare recommends at least 2GB of VRAM for AMD processors or Intel HD 5000 or later for basic image rendering. You should have at least an intel i3 6th generation or AMD equivalent processor with a 64-bit Windows 7 operating system.
Coming to its features, well, there's loads. You get Speed Control, Color Grading, Split Screen, Multiple live streams with one setup, and a lot of keyboard shortcuts. Your trial version will provide all the features of a premium service, except the Wondershare watermark.
This software is compatible with both Windows and macOS and has 3 premium plans to offer. Monthly plans begin at $7.99, with an Annual subscription available at just $39.99, and a Lifetime membership for roughly $70.
A lifetime purchase keeps getting the latest updates. You also get advanced encryption with purchased plans for better security.
Any purchase is liable for 30 days of money-back guarantees. This is among the best game recording software for PCs, especially gaming PCs.
1. Streamlab OBS
While the name Streamlabs OBS sounds relatable to OBS, there is a ton of difference between the two. Streamlabs OBS or SLOBS offers unique features, an easy to interface and has slowly become the go-to game recording software for first-timers and semi-pros alike.
The prime highlight of Streamlabs OBS is its integration-friendly user code, which enables you to integrate youtube and Twitch chat within the streaming screen.
SLOBS also supports live streaming to Facebook, Twitch, and Facebook with layout support. There are over 100s of layouts to select for your video.
Its dynamic in-game overlay enables game chatting and controlling without compromising the screen space. The most talked-about feature of this software is the Live Tab, which provides a clean dashboard showing recent events, live previews, and chat in a single tab.
Streamlabs OBS has a bevy of widgets that you can directly upload to your video stream. These widgets can transform your video into a professional one.
You can even set stream Twitch alerts for integrating donations. SLOBS can undisputedly claim itself to be the best game recording software available in 2021. And it's free!
Perhaps the first thing you need to consider before downloading a free game recording software to get things started is whether your PC can take. Expect at least a 30% FPS drop while live streaming your game. That's the last thing you want to happen when you start streaming.
All said, if your PC can still manage 120 FPS while streaming, you're good to go. Now consider whether you want to live stream or stream later after editing the gameplay recording. Either way, don't let streaming hamper your game.
Upgrade your PC first in case of performance issues. Then, just download any of these best game recording software and you are good to go.
Previous ArticleThe 5 Best Motherboard for Ryzen 7 3800x In 2021
Next Article 17 Games Like Stardew Valley You Must Play Right now
Green Man Gaming Review? Legit or not?
Best Cloud Gaming Services in 2022: The Future | 3,102 |
Leeds United v Newcastle United: Is it on TV? kick-off time, head-to-head record and more
SportFootballLeeds United
Leeds United's players celebrate the last-gasp equaliser against Wolves at Elland Road. Pic: Getty
Leeds United's predicted line-up at Arsenal - Marcelo Bielsa to make changes for League Cup clash?
Leeds United travel to face Arsenal in the League Cup on Tuesday night at the Emirates - but what line-up could Marcelo Bielsa select?
By Joe Urquhart
Monday, 25th October 2021, 12:01 pm
The Whites' injury crisis refused to ease over the weekend against Wolverhampton Wanderers in the Premier League.
Leeds saw just one player return to action in the form of wide man Raphinha for the top flight outing.
The Brazilian, though, limped off during the 1-1 draw at Elland Road and briefly added to the treatment room worries for United until he put nerves at rest with a social media update post-match.
Raphinha posted a photograph of himself smiling together with the message: "Hello guys, just coming to say I'm fine. It was nothing serious so I'm back soon. Thank you for all the messages and concern of all."
Despite his apparent all clear, it is unlikely Bielsa will risk one of his key players in the capital for the midweek clash with the Gunners.
United are into the Round of 16 of the Carabao Cup but will still be without a number of first team players for the fixture against Mikel Arteta's side.
Patrick Bamford (ankle), Luke Ayling (knee), Junior Firpo (muscle) and Robin Koch (hip) all remain out while Kalvin Phillips returned to the bench on Saturday following a calf and hip problem.
The England midfielder could be<|fim_middle|>lich a rest in the middle of the park.
8. Roberts - AM
Did well when he came on against Wolves, Leeds need more of that - another opportunity to show what he can do.
Marcelo BielsaRaphinhaArsenalPremier League
Sign up to our Leeds United newsletter | handed a few minutes by his head coach in London as he steps up his return to full fitness. Bielsa - despite being down to a thin squad - could also make a few changes for the trip south.
Here, we take a look at how the Whites may opt to line-up for the visit to the Emirates on Tuesday night...
5. Dallas - LWB
Left-back options are short at the moment, so you'd expect Dallas to get the nod here.
6. Phillips - CDM
He was fit enough for the bench on Saturday and needs minutes in his legs, according to Bielsa. Could be the perfect chance to get them going.
7. Forshaw - CM
Has found game time in the cup competitions so far. Another possibility here, which would allow K | 160 |
Join me for a lively adventure down the rabbit hole into the world of "Folk Art Fusion."
My "Play Dates" are designed to inspire individual creativity with projects that can actually be completed and not end up in your UFO pile! I will share my signature "reverse wool applique" technique, as well as, loads of ideas and inspiration on how to embellish your creations. Each student will leave with their own unique piece<|fim_middle|> to bring two pair of scissors to class. I bring the wool felt, Valdani threads, embellishments and everything else you need. Kit fee $35 per student.
My classes are stress free and filled with friendship, conversation and some good laughs. Join me!
"Beekeeper Pincushion" play date (measures 8").
Five flower designs. Four are EXCLUSIVE for my students.
For more information, send me an email and I will forward my contract. I also give a one hour "Chat" (lecture) on my adventures Down the Rabbit Hole, which includes a trunk show. | .
There are no sewing machines required for my Play Dates. Students only need | 15 |
Holisticescapes is happy to welcome you to the most natural & scenic part of the Akamas Peninsula, a short 35 minute drive from main city of Paphos in the south of Cyprus. Here you will be able to explore places of interest, churches, traditional craft museums, wineries, cheese & olive oil factories & picturesque small villages dotted around the Akamas peninsula.
If you wish to just relax locally you can spend some of your time learning from the locals about the lives in<|fim_middle|> plenty of local produce is available, full of a flavour of the land. | this area going back to the last century, where working the land was one of the best ways to earn a living & protect the environment. For the more energetic - you hire a mountain bike with GPS & visit many places off the beaten track & talk to local resident mountain bike expert who can help you plan your outings, as well as hire you your bikes!
Based within the Akamas peninsula we can offer you guided walks/hiking tours or mountain biking use (by prior arrangement) or will advise where the best places to visit are & give you interesting routes to follow, depending on the type of terrain you enjoy.
From Latchi to Polis, Argaka to Pomos there are many beaches and wild coastline for you to explore and plenty of quiet places to chill/mediate and blow all the cobwebs away. We can arrange to take you to visit permeable farms, meet the farmer & see his crop growing over a hillside facing the sea & taste how good his produce is first hand. He will be delighted to discuss how the farm came into being & how he is developing the land to host a huge range of produce.
You may also visit the local organic herb & produce gardens, where you will meet a local Naturopath - who has a whole host of interesting remedies, natural body & home products to take home. Plus she can arrange to give you a one to one consultation with follow-ups once you return home. There is a very nice coffee & delicious snacks shop on site to relax & take in the sprawling garden views.
Car Hire available with opportunity to visit numerous churches, places of interest including UNESCO sites through-out the island.
Quaint unspoilt villages and experience first had the local wineries, cheese factory, olive oil production, and plenty of typical craft museums.
Craft Museum at Inea - full of interesting local crafts & displays of authentic local manufacturing.
The producers of the local herbs, spices, dried fruit & nut display their wares in the local village markets each weekend for you to try & then choose from their hand crafted wares.
We are situated in one of the main fruit & vegetable farming areas, so | 432 |
LaserMaxx Lasergames is world's premier laser tag supplier. With 1+<|fim_middle|> marginal costs, it requires just a few employees to operate and therefore the return on investment is high. The extreme strength, the modern functions, the advanced features and the extensive support of LaserMaxx ensure you of a maximized potential.
Through our experience we have distilled information with demographics such as age and gender of the actual players of our customers, group sizes, visits, arena types, favorite game types and much more. We have bundled this information in a factsheet available for download here (.pdf - 229 kb)! | million monthly players in 350+ locations in over 50 countries worldwide, ranging from Germany to Jamaica and from Mexico to Thailand, LaserMaxx is firmly established as the premier global laser tag supplier. Founded in 1995, the global expansion of LaserMaxx Lasergames B.V. boils down to an absolute unique strength of the LaserMaxx system and perception within its service: as a laser tag operator your sales will be directly depending on the reliability of our products and this is, was and will always be our utmost concern. With the LaserMaxx system you are ensured of maximized uptime, usage of the strongest materials and the most reliable system. Together with options for integrated social media, special game types, interactive arena control the absolute strength of LaserMaxx makes it the best professional laser tag equipment available.
Laser tag is generally seen as one of the most diverse entertainment activities available. The harmless lasers combined with the competitive element of laser tag make it a fun entertainment activity for young, old and everybody in between. The advantages of laser tag are distinctive as an extreme large majority of the plays occur in groups, there are limited to no | 236 |
In affiliation with HIV.gov
What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient
Guidelines search
Archived Guidelines (1)
Guidelines for Caring for Persons with HIV in Disaster Areas (4)
HIV Clinical Guidelines: Adult and Adolescent ARV (19)
HIV Clinical Guidelines: Adult and Adolescent Opportunistic Infections (33)
HIV Clinical Guidelines: Pediatric ARV (17)
HIV Clinical Guidelines: Pediatric Opportunistic Infections (31)
Interim Guidance for COVID-19 and Persons with HIV (1)
Perinatal HIV Clinical Guidelines (17)
Key Considerations and Recommendations Regarding Initial Combination Regimens for the Antiretroviral-Naive Patient
Key Considerations and Recommendations
An antiretroviral (ARV) regimen for a treatment-naive patient generally consists of two nucleoside reverse transcriptase inhibitors (NRTIs) administered in combination with a third active ARV drug from one of three drug classes: an integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a protease inhibitor (PI) with a pharmacokinetic (PK) enhancer (also known as a booster; the two drugs used for this purpose are cobicistat and ritonavir).
Data also support the use of the two-drug regimen, dolutegravir plus lamivudine, for initial treatment.
Before initiating antiretroviral therapy (ART) in a person of childbearing potential, a pregnancy test should be performed (AIII). Before prescribing ART to a person of childbearing potential, please refer to Table 6b for information about safety of different INSTI-based regimens taken around the time of conception.
The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) classifies the following regimens as Recommended Initial Regimens for Most People with HIV (in alphabetical order):
Bictegravir/tenofovir alafenamide/emtricitabine (AI)
Dolutegravir/abacavir/lamivudine—only for individuals who are HLA-B*5701 negative and without chronic hepatitis B virus (HBV) coinfection (AI)
Dolutegravir plus (emtricitabine or lamivudine) plus (tenofovir alafenamide or tenofovir disoproxil fumarate)a (AI)
Dolutegravir/lamivudine (AI)—except for individuals with HIV RNA >500,000 copies/mL, HBV co-infection, or in whom ART is to be started before the results of HIV genotypic resistance testing for reverse transcriptase or HBV testing are available.
Raltegravir plus (emtricitabine or lamivudine) plus (tenofovir alafenamide [TAF] or tenofovir disoproxil fumarate [TDF])a (BI for TDF, BII for TAF)
To address individual patient characteristics and needs, the Panel also provides a list of Recommended Initial Regimens in Certain Clinical Situations (Table 6a).
Given the many excellent options for initial therapy, selection of a regimen for a particular patient should be guided by factors such as virologic efficacy, toxicity, pill burden, dosing frequency, drug-drug interaction potential, resistance test results, comorbid conditions, access, and cost. Table 7 provides guidance on choosing an ARV regimen based on selected clinical case scenarios. Table 9 highlights the advantages and disadvantages of different components in a regimen.
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials, observational cohort studies with long-term clinical outcomes, relative bioavailability/bioequivalence studies, or regimen comparisons from randomized switch studies; III = Expert opinion
a TAF and TDF are two forms of tenofovir that are approved by the Food and Drug Administration. TAF has fewer bone and kidney toxicities than TDF, while TDF is associated with lower lipid levels. Safety, cost, and access are among the factors to consider when choosing between these drugs.
More than 30 antiretroviral (ARV) drugs in seven mechanistic classes are Food and Drug Administration (FDA)-approved for treatment of HIV infection. These seven classes include the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), a fusion inhibitor, a CCR5 antagonist, and a CD4 T lymphocyte (CD4) post-attachment inhibitor. In addition, two drugs, ritonavir (RTV) and cobicistat (COBI) are used as pharmacokinetic (PK) enhancers (or boosters) to improve the PK profiles of PIs and the INSTI elvitegravir (EVG).
The initial ARV regimen for a treatment-naive patient generally consists of two NRTIs, usually abacavir/lamivudine (ABC/3TC) or either tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), plus a drug from one of three drug classes: an INSTI, an NNRTI, or a boosted PI. As shown in clinical trials and by retrospective evaluation of cohorts of patients in clinical care, this strategy for initial treatment has resulted in suppression of HIV replication and CD4 count increases in most persons with HIV.1-3 Additional data now support the use of the two-drug regimen dolutegravir (DTG) plus 3TC for initial treatment of people with HIV.4
Supporting Evidence and Rationale Used for the Panel's Recommendations
The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel)'s recommendations are primarily based on clinical trial data published in peer-reviewed journals and data prepared by drug manufacturers for FDA review. In select cases, the Panel considers data from abstracts presented at major scientific meetings. The Panel considers published information from a randomized, prospective clinical trial with an adequate sample size that demonstrates that an ARV regimen produces high rates of viral suppression, increases CD4 count, and has a favorable safety profile to be the strongest evidence on which to base recommendations. Comparative clinical trials of initial treatments generally show no significant differences in HIV-related clinical endpoints or survival. Thus, assessment of regimen efficacy and safety are primarily based on surrogate marker endpoints (especially rates of HIV RNA suppression) and the incidence and severity of adverse events.
In some instances, the Panel recommends regimens that include medications approved by FDA based on bioequivalence or relative bioavailability studies demonstrating that the exposure of the drug(s) in the new formulation or combination is comparable to the exposure of a reference drug(s) that has demonstrated safety and efficacy in randomized clinical trials. When developing recommendations, the Panel may also consider data from randomized switch studies in which a medication in an initial regimen that suppressed patients' viral loads is replaced by a new medication from the same class. Switch trials do not evaluate the ability of a drug or regimen to induce viral suppression; they only examine the drug or regimen's ability to maintain suppression. Therefore, results from switch trials may not be directly applicable to the selection of an initial regimen and should be considered in conjunction with other data, including data from trials conducted in treatment-naive patients and bioequivalence/bioavailability studies. In this section of the guidelines, the definition of an evidence rating of II is expanded to include supporting data from bioavailability/bioequivalence studies or randomized switch studies.
When developing recommendations, the Panel also considers tolerability and toxicity profiles, pill burden and dosing frequency, drug interaction potential, cost and access, post-marketing safety data, observational cohort data published in peer-reviewed publications, and the experience of clinicians and community members who are actively engaged in patient care.
The Panel reviewed the available data to arrive at two regimen classifications for ARV-naive patients: (1) Recommended Initial Regimens for Most People with HIV and (2) Recommended Initial Regimens in Certain Clinical Situations (Table 6a). Recommended Initial Regimens for Most People with HIV are those regimens with demonstrated durable virologic efficacy, favorable tolerability and toxicity profiles, and ease of use. The Panel also recognizes that, in certain clinical situations, other regimens may be preferred; these options are included in Table 6a in the category of Recommended Initial Regimens in Certain Clinical Situations. Examples of clinical scenarios in which certain drugs in these regimens may be particularly advantageous are outlined in Table 7.
There are many other ARV regimens that are effective for initial therapy but have disadvantages when compared with the regimens listed in Table 6a. These disadvantages include greater toxicity, higher pill burden, less supporting data from large comparative clinical trials, or limitations for use in certain patient populations. These other regimens are no longer included in Table 6a. A person with HIV who has a suppressed viral load and is not experiencing any adverse effects while on a regimen that is not listed in Table 6a need not necessarily change to one that is listed in the table. Clinicians should refer to Optimizing Antiretroviral Therapy in the Setting of Viral Suppression for further guidance if switching to a new regimen is desired.
Regimens and medications listed in Table 10 below are not recommended as initial therapy. In most instances, a clinician is urged to consider switching a patient who is on one of the regimens listed in Table 10 to a recommended regimen.
In addition to these tables, several tables presented below and at the end of these guidelines provide clinicians with guidance on selecting and prescribing an optimal regimen for an individual patient. Table 9 lists the potential advantages and disadvantages of the different ARV drug components. Appendix B, Tables 3–9 list characteristics of individual ARV agents (e.g., formulations, dosing recommendations, PKs, common adverse effects). Appendix B, Table 10 provides ARV dosing recommendations for patients who have renal or hepatic insufficiency.
Changes Since the Last Revision of the Guidelines
Since the last revision of these guidelines, the Panel has made several important changes to the recommendations for initial therapy in people with HIV. Among these changes, the following deserve emphasis:
On the basis of 96-week data from the GEMINI-1 and GEMINI-2 trials showing that the efficacy of the two-drug regimen DTG plus 3TC is similar to that of the three-drug regimen DTG plus TDF/FTC,4 the Panel has added DTG/3TC as one of the regimens Recommended for Initial Treatment of Most People with HIV (except for individuals with HIV RNA >500,000 copies/mL, hepatitis B virus (HBV) coinfection, or in whom antiretroviral therapy (ART) is to be started before the results of HIV genotypic resistance testing for reverse transcriptase or HBV testing are available).
In the previous version of these guidelines, because of preliminary data raising concern that DTG use around the time of conception may be associated with an increased risk of infant neural tube defects (NTDs),5 the Panel recommended against the use of DTG during the first trimester of pregnancy and in those of childbearing potential who are trying to conceive or who are sexually active and not using effective contraception. Now, additional results have shown that the prevalence of infant NTDs in association with DTG exposure at conception is lower than shown in the preliminary data6,7 but still higher than with non-DTG containing regimens. These updated findings led to revisions in the Panel's recommendation for individuals of childbearing potential. Clinicians should review recommendations in Table 6b before prescribing INSTIs to these patients.
The Panels' changes to the list of Recommended Initial Regimens in Certain Clinical Situations (Table 6a) include the following:
Efavirenz (EFV) 400 mg/TDF/3TC has been added based on additional data on the regimen's efficacy (BI).8
Raltegravir (RAL) plus ABC/3TC and lopinavir/ritonavir (LPV/r) plus 3TC have been removed because other regimens have advantages or more supporting data than these (relatively) less commonly used options.
Table 7, which outlines clinical situations in which certain medications may be particularly advantageous, has been updated and revised.
Data from studies showing increased weight gain with particular ARV medications, including some INSTIs and TAF, and especially in certain patient populations (i.e., women, Black people, and Hispanic people), are summarized.
The section Other Antiretroviral Regimens for Initial Therapy When Abacavir, Tenofovir Alafenamide, and Tenofovir Disoproxil Fumarate Cannot Be Used or Are Not Optimal has been updated. DTG/3TC is the preferred regimen because it has the most robust clinical data among the two-drug options in this situation.
The discussions on clinical trial and safety data in the sections on INSTIs, NRTIs, NNRTIs and PIs have been updated.
Given the growing number of FDA-approved generic ARV medications, cost and access are increasingly important factors to consider when choosing an ARV regimen (see Cost Considerations and Antiretroviral Therapy).
Table 6a. Recommended Antiretroviral Regimens for Initial Therapy
Selection of a regimen should be individualized based on virologic efficacy, potential adverse effects, childbearing potential and use of effective contraception, pill burden, dosing frequency, drug-drug interaction potential, comorbid conditions, cost, access, and resistance test results. Drug classes and regimens within each class are arranged first by evidence rating, and, when ratings are equal, in alphabetical order. Table 7 provides ARV recommendations based on specific clinical scenarios.
Recommended Initial Regimens for Most People with HIV
Recommended regimens are those with demonstrated durable virologic efficacy, favorable tolerability and toxicity profiles, and ease of use.
INSTI plus 2 NRTIs:
Note: For individuals of childbearing potential, see Table 6b before prescribing one of these regimens.
BIC/TAF/FTC (AI)
DTG/ABC/3TC (AI)—if HLA-B*5701 negative
DTG plus (TAF or TDF)a plus (FTC or 3TC) (AI)
RAL plus (TAF or TDF)a plus (FTC or 3TC) (BI for TDF/[FTC or 3TC], BII for TAF/FTC)
INSTI plus 1 NRTI:
DTG/3TC (AI), except for individuals with HIV RNA >500,000 copies/mL, HBV coinfection, or in whom ART is to be started before the results of HIV genotypic resistance testing for reverse transcriptase or HBV testing are available
Recommended Initial Regimens in Certain Clinical Situations
These regimens are effective and tolerable but have some disadvantages when compared with the regimens listed above or have less supporting data from randomized clinical trials. However, in certain clinical situations, one of these regimens may be preferred (see Table 7 for examples).
EVG/c/(TAF or TDF)a/FTC (BI)
Boosted PI plus 2 NRTIs:
In general, boosted DRV is preferred over boosted ATV
(DRV/c or DRV/r) plus (TAF or TDF)a plus (FTC or 3TC) (AI)
(ATV/c or ATV/r) plus (TAF or TDF)a plus (FTC or 3TC) (BI)
(DRV/c or DRV/r) plus ABC/3TC—if HLA-B*5701 negative (BII)
NNRTI plus 2 NRTIs:
DOR/TDFa/3TC (BI) or DOR plus TAFa/FTC (BIII)
EFV plus (TAF or TDF)a plus (FTC or 3TC)
EFV 600 mg plus TDF plus (FTC or 3TC) (BI)
EFV 400 mg/TDF/3TC (BI)
EFV 600 mg plus TAF/FTC (BII)
RPV/(TAF or TDF)/FTC (BI)—if HIV RNA <100,000 copies/mL and CD4 count >200 cells/mm3
Regimens to Consider when ABC, TAF, and TDF Cannot be Used or Are Not Optimal:
DRV/r plus RAL twice a day (CI)—if HIV RNA <100,000 copies/mL and CD4 count >200 cells/mm3
DRV/r once daily plus 3TCa (CI)
a TAF and TDF are two forms of TFV approved by FDA. TAF has fewer bone and kidney toxicities than TDF, while TDF is associated with lower lipid levels. Safety, cost, and access are among the factors to consider when choosing between these drugs.
Note: The following are available as coformulated drugs: ABC/3TC, ATV/c, BIC/TAF/FTC, DOR/TDF/3TC, DRV/c, DRV/c/TAF/FTC, DTG/3TC, DTG/ABC/3TC, EFV (400 mg or 600 mg)/TDF/3TC, EFV/TDF/FTC, EVG/c/TAF/FTC, EVG/c/TDF/FTC, RPV/TAF/FTC, RPV/TDF/FTC, TAF/FTC, TDF/3TC, and TDF/FTC.
Key: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; ATV = atazanavir; ATV/c = atazanavir/cobicistat; ATV/r = atazanavir/ritonavir; BIC = bictegravir; CD4 = CD4 T lymphocyte; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat<|fim_middle|>logic failure has also been reported with DOR. EFV has a long track record of widespread use, is considered safe in persons of childbearing potential, and has minimal PK interaction with rifamycins, making it an attractive option for patients who require TB treatment. EFV-based regimens (using either 400 mg or 600 mg dosing) have excellent virologic efficacy,35 including in patients with high HIV RNA (except when EFV is used with ABC/3TC); however, the relatively high rate of central nervous system (CNS)-related side effects reduces the tolerability of EFV-based regimens. As an STR, EFV 600 mg is available with TDF/FTC or TDF/3TC; EFV 400 mg is available with TDF/3TC. RPV has fewer adverse effects than EFV, is available as one of the smallest tablet sizes among STRs that also include TAF/FTC or TDF/FTC, and has a favorable lipid profile. However, RPV has lower virologic efficacy in patients with baseline HIV RNA levels >100,000 copies/mL and CD4 counts <200 cells/mm3. DOR is available both as a single-drug tablet to be used with two NRTIs and as part of an STR with TDF/3TC. In randomized trials, DOR was noninferior to both EFV and DRV/r when either of these drugs were taken in combination with two NRTIs.36,37 DOR has CNS tolerability advantages over EFV and more favorable lipid effects than DRV/r and EFV. DOR also has fewer potential drug interactions than EFV or RPV, and unlike with RPV, the virologic efficacy of DOR is not compromised in patients with high HIV RNA levels and low CD4 counts.
Regimens When Abacavir, Tenofovir Alafenamide, and Tenofovir Disoproxil Fumarate Cannot Be Used or Are Not Optimal
In those patients in whom ABC, TDF, or TAF cannot be used or are not optimal, there are several two-drug options that do not contain these agents. Two-drug options should not be used in individuals with HBV coinfection or known pre-existing resistance to either ARV in the combination. Among the two-drug regimens, DTG/3TC is preferred because there are substantial data for this combination in initial therapy, with the caveat that people with HIV RNA >500,000 copies/mL were excluded from the largest trial.4,16 Another two-drug treatment option that can be considered is the combination of DRV/r (once daily) plus RAL (twice daily), but this combination should only be used in those with baseline CD4 counts >200 cells/mm3 and HIV RNA levels <100,000 copies/mL.38 A small, randomized trial indicated that once-daily DRV/r plus 3TC had similar efficacy to once-daily DRV/r plus TDF/3TC, although this study has yet to be published.39
Table 7. Antiretroviral Regimen Considerations for Initial Therapy Based on Specific Clinical Scenarios
This table guides clinicians in choosing an initial ARV regimen according to various patient and regimen characteristics and specific clinical scenarios. When more than one scenario applies to a person with HIV, clinicians should review considerations for each relevant scenario and use their clinical judgment to select the most appropriate regimen. This table is intended to guide the initial choice of regimen. However, if a person is doing well on a particular regimen, it is not necessary to switch to another regimen based on the scenarios outlined in this table. Please see Table 9 for additional information regarding the advantages and disadvantages of particular ARV medications. Before initiating an INSTI-based regimen in a person of childbearing potential, review Table 6b for considerations in choosing the regimen.
Patient or Regimen Characteristics
Consideration(s)
Rationale/Comments
Pre-ART Characteristics CD4 count <200 cells/mm3 Do Not Use the Following Regimens:
RPV-based regimens
DRV/r plus RAL
A higher rate of virologic failure has been observed in those with low pretreatment CD4 counts.
HIV RNA >100,000 copies/mL (also see next row if HIV RNA >500,000 copies/mL) Do Not Use the Following Regimens:
ABC/3TC with EFV or ATV/r
Higher rates of virologic failure have been observed in those with high pretreatment HIV RNA levels
HIV RNA >500,000 copies/mL Do Not Use the Following Regimens:
DTG/3TC
For DTG/3TC, limited data are available in patients above this viral load threshold.
HLA-B*5701 positive or result unknown Do not use ABC-containing regimens. ABC hypersensitivity, a potentially fatal reaction, is highly associated with the presence of the HLA-B*5701 allele.
ARV should be started before HIV drug resistance results are available (e.g., in a person with acute HIV) or when ART is being initiated rapidly. Avoid NNRTI-based regimens and DTG/3TC.
Avoid ABC.
Recommended ART Regimens:
BIC/TAF/FTC
DTG plus (TAF or TDF)a plus (3TC or FTC)
(DRV/r or DRV/c) plus (TAF or TDF)a plus (3TC or FTC)
Transmitted mutations conferring NNRTI and NRTI resistance are more likely than mutations associated with PI or INSTI resistance.
HLA-B*5701 results may not be available rapidly.
Transmitted resistance to DRV, BIC, and DTG is rare, and these drugs have high barriers to resistance.
ART-Specific Characteristics A one-pill, once-daily regimen is desired STR Options as Initial ART Include:
DOR/TDF/3TC
DRV/c/TAF/FTC
DTG/ABC/3TC
EFV/TDF/FTC
EFV/TDF/3TC
EVG/c/TAF/FTC
EVG/c/TDF/FTC
RPV/TAF/FTC
RPV/TDF/FTC
Do not use DTG/ABC/3TC if patient is HLA-B*5701 positive.
DTG/3TC is not recommended if HIV RNA is >500,000 copies/mL.
Do not use DTG/ABC/3TC or DTG/3TC in the setting of HBV coinfection or unknown HBV status.
Do not use RPV-based regimens if HIV RNA is >100,000 copies/mL and CD4 count is <200/mm3.
See Appendix B, Table 10 for ARV dose recommendations in the setting of renal impairment.
Food effects
Regimens that Can be Taken Without Regard to Food:
BIC-, DOR-, DTG-, or RAL-based regimens
Oral bioavailability of these regimens is not significantly affected by food.
Regimens that Should be Taken with Food:
ATV/r- or ATV/c-based regimens
DRV/r- or DRV/c-based regimens
EVG/c/TAF/FTCa
EVG/c/TDF/FTCa
Food improves absorption of these regimens. RPV-containing regimens should be taken with ≥390 calories of food.
Regimens that Should be Taken on an Empty Stomach:
EFV-based regimen
Food increases EFV absorption and may increase CNS side effects.
Presence of Other Conditions Chronic kidney disease (defined as CrCl <60 mL/min) In general, avoid TDF.
ABC may be used if patient is HLA-B*5701 negative. If HIV RNA is >100,000 copies/mL, do not use ABC/3TC plus (EFV or ATV/r).
TAF may be used if CrCl >30 mL/min or if patient is on chronic hemodialysis (only studied with EVG/c/TAF/FTC).
Consider avoiding ATV.
ART Options When ABC, TAF, or TDF Cannot be Used:
DTG/3TC (if HIV RNA <500,000 copies/mL and without HBV coinfection)
DRV/r plus 3TC
DRV/r plus RAL (if CD4 count >200 cells/mm3 and HIV RNA <100,000 copies/mL)
TDF has been associated with proximal renal tubulopathy. Higher rates of renal dysfunction have been reported in patients using TDF in conjunction with RTV-containing regimens.
An adjusted dose of TDF can be used in patients with ESRD or in those who are on hemodialysis. Refer to Appendix B, Table 10 for specific dosing recommendations.
TAF has less impact on renal function and lower rates of proteinuria than TDF.
ATV has been associated with chronic kidney disease in some observational studies.
ABC has not been associated with renal dysfunction.
Liver disease with cirrhosis Some ARVs are contraindicated or may require dosage modification in patients with Child-Pugh class B or C disease. Refer to Appendix B, Table 10 for specific dosing recommendations.
Patients with cirrhosis should be carefully evaluated by an expert in advanced liver disease.
Osteoporosis Avoid TDF.a
ABC may be used if patient is HLA-B*5701 negative. If HIV RNA is >100,000 copies/mL, do not use ABC/3TC plus (EFV or ATV/r). TDF is associated with decreases in BMD along with renal tubulopathy, urine phosphate wasting, and resultant osteomalacia. TAFa and ABC are associated with smaller declines in BMD than TDF.
Psychiatric illnesses Consider avoiding EFV- and RPV-based regimens.
Patients on INSTI-based regimens who have pre-existing psychiatric conditions should be closely monitored.
Some ARVs are contraindicated, and some psychiatric medications need dose adjustments when coadministered with certain ARVs. EFV and RPV can exacerbate psychiatric symptoms and may be associated with suicidality.
INSTIs have been associated with adverse neuropsychiatric effects in some retrospective cohort studies and case series.
See the drug-drug interaction tables (Tables 21a, 21b, and 21d) for dosing recommendations when drugs used for psychiatric illnesses are used with certain ARVs.
HIV-associated dementia (HAD) Avoid EFV-based regimens if possible. The beneficial effects of ART on HAD-symptoms may be confounded by EFV-related neuropsychiatric effects.
Medication-assisted treatment for opioid use disorder Opioid withdrawal may occur when EFV is initiated in patients who are on a stable dose of methadone.
Clinical monitoring is recommended, as medications used to treat opioid dependence may need to be adjusted in some patients. EFV reduces methadone concentrations and may lead to withdrawal symptoms.
See the drug-drug interaction tables (Tables 21a, 21b, and 21d) for dosing recommendations.
Cardiac QTc interval prolongation Consider avoiding EFV- or RPV-based regimens if patient is taking other medications with known risk of Torsades de Pointes, or in patients at higher risk of Torsades de Pointes. High EFV or RPV concentrations may cause QT prolongation.
High cardiac risk Consider avoiding ABC- and LPV/r -based regimens.
If a boosted PI is the desired option, an ATV-based regimen may have advantages over a DRV-based regimen.
Refer to Hyperlipidemia below for regimens associated with more favorable lipid profiles. An increased risk of CV events with ABC has been observed in some studies.
Observational cohort studies reported an association between some PIs (DRV, IDV, FPV, and LPV/r) and an increased risk of CV events; this risk has not been seen with ATV (see text). Further study is needed.
Certain ART regimens are associated with more favorable lipid profiles than other regimens, although evidence on whether this improves CV outcomes is lacking.
Hyperlipidemia The Following ARV Drugs Have Been Associated with Dyslipidemia:
PI/r or PI/c
EVG/c
BIC, DOR, DTG, RAL, and RPV have fewer lipid effects.
TDF lowers lipids; therefore, switching from TDF to TAF is associated with increased lipids. TDF has been associated with lower lipid levels than ABC or TAF.
Patients with history of poor adherence to non-ARV medications or inconsistent engagement in care Consider using regimens with a boosted PI or BIC or DTG. These regimens have a high genetic barrier to resistance.
Pregnancy Refer to Table 6b and the Perinatal Guidelines for further guidance on ARV use during pregnancy.
Patients of childbearing potential who are planning to become pregnant or who are sexually active and not using effective contraception Refer to Table 6b for further guidance.
Presence of Coinfections
HBV infection Use TDF or TAF, with FTC or 3TC
If TDF and TAF Are Contraindicated:
For treatment of HBV, use FTC or 3TC with entecavir and a suppressive ART regimen (see HBV/HIV Coinfection).
TDF, TAF, FTC, and 3TC are active against both HIV and HBV. 3TC- or FTC-associated HBV mutations can emerge rapidly when these drugs are used without another drug that is active against HBV.
HCV treatment required Refer to recommendations in HCV/HIV Coinfection, with special attention to potential interactions between ARV drugs and HCV drugs.
Treating TB disease with rifamycin antibiotics (rifabutin, rifampin, and rifapentine) Recommended regimens may require dose adjustment. See the drug-drug interaction tables (Tables 21a-e) and TB/HIV Coinfection for information on ARV use with rifamycin antibiotics. Rifamycin antibiotics are inducers of CYP3A4 and UGT1A1 enzymes, causing significant decreases in concentrations of PIs, INSTIs, and RPV.
a TAF and TDF are two FDA-approved forms of TFV. TAF has fewer bone and kidney toxicities than TDF, whereas TDF is associated with lower lipid levels. Safety, cost, and access are among the factors to consider when choosing between these drugs.
Key: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; ATV = atazanavir; ATV/c = atazanavir/cobicistat; ATV/r = atazanavir/ritonavir; BIC = bictegravir; BID = twice daily; BMD = bone mineral density; COBI = cobicistat; CD4 = CD4 T lymphocyte; CNS = central nervous system; CrCl = creatinine clearance; CV = cardiovascular; CYP = cytochrome P; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; ESRD = end stage renal disease; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FDA = Food and Drug Administration; FPV = fosamprenavir; FTC = emtricitabine; HAD = HIV-associated dementia; HBV = hepatitis B virus; HCV = hepatitis C virus; HLA = human leukocyte antigen; IDV = indinavir; INSTI = integrase strand transfer inhibitor; LPV = lopinavir; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NTD = neural tube defect; PI = protease inhibitor; PI/c = cobicistat-boosted protease inhibitor; PI/r = ritonavir-boosted protease inhibitor RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; STR = single-tablet regimen; TAF = tenofovir alafenamide; TB = tuberculosis; TDF = tenofovir disoproxil fumarate; TFV = tenofovir; UGT = uridine diphosphate glucuronosyltransferase
Characteristics of Antiretroviral Drugs Recommended for Initial Therapy
The following sections provide detailed information on ARV drugs that the Panel recommends for initial therapy for persons with HIV, including the drugs' characteristics and adverse effects profiles, results from related clinical trials, and Panel recommendations on their use.
Nucleoside Reverse Transcriptase Inhibitor Options as Part of Initial Therapy
Table 8a. Characteristics of Nucleoside Reverse Transcriptase Inhibitor Options Recommended for Antiretroviral Therapy-Naive Patients
ABC/3TC
3TCa
TDF/3TC
TAF/FTC
TDF/FTC
Dosing Frequency Once daily Once daily Once daily Once daily Once daily
Available Coformulations for ART-Naive Patients
EFV 600 mg/TDF/3TC
TAF 25 mg/FTC
BIC/TAF 25 mg/FTC
DRV/c/TAF 10 mg/FTC
EVG/c/TAF 10 mg/FTC
RPV/TAF 25 mg/FTC
Adverse Effects ABC:
HSR to ABC is associated with the presence of HLA-B*5701 allele.
Increase in CV events is associated with ABC use in some, but not all, cohort studies.
See below TDF:
Renal insufficiency, proximal renal tubulopathy
Decrease in BMD
Renal and bone toxicity are exacerbated by pharmacologic boosters.
TAF:
Renal insufficiency, proximal renal tubulopathy (less frequent than with TDF)
Decrease in BMD (less than with TDF; similar to with ABC)
TDF:
3TC: No significant adverse effects FTC: Skin discoloration
Other Considerations ABC:
Perform HLA-B*5701 testing before initiating ABC; if result is positive, do not start ABC and add ABC to patient's allergy list.
3TC:
Epivir HBV™ is for the treatment of HBV and contains a different dose of 3TC than the formulation for ART. Thus, Epivir HBV™ should not be used for HIV treatment.
Coadministration of 3TC with sorbitol-containing drugs decreases 3TC concentration and should be avoided.
FTC should not be used as sole treatment for HBV due to development of resistance. Discontinuation may precipitate HBV flare if no other agents active against HBV are present.
3TC or ABC/3TC should not be used as treatment for HBV due to development of resistance. Discontinuation may precipitate HBV flare if no other agents active against HBV are present. Also used for HBV treatment. Discontinuation may precipitate HBV flare.
See Appendix B, Table 10 for dose recommendations in patients with renal insufficiency.
a 3TC is recommended for use with DTG in ART-naive persons, and with DRV/r if ABC, TDF, and TAF are not optimal. Otherwise, dual-NRTI backbones are recommended.
Key: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; BIC = bictegravir; BMD = bone mineral density; CV = cardiovascular; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; HBV = hepatitis B virus; HLA = human leukocyte antigen; HSR = hypersensitivity reaction; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate
FDA-approved NRTIs include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), ABC, TDF, TAF, 3TC, and FTC. Older NRTIs (ZDV, d4T, ddI) are no longer recommended for use in clinical practice in the United States because of high rates of serious toxicities, including peripheral neuropathy and mitochondrial toxicity that may lead to myopathy, hepatic steatosis, lactic acidosis, lipoatrophy, and bone marrow suppression from ZDV use. The incidence of these complications is much lower with 3TC, FTC, ABC, TDF, and TAF than with older NRTIs.40,41
ABC/3TC, TAF/FTC, TDF/3TC, and TDF/FTC are NRTI combinations that are recommended as components of initial therapy. In addition, 3TC may be used as a single NRTI with DTG, or, in select circumstances, with boosted DRV. Table 6a provides recommendations and ratings for the individual regimens. These recommendations are based on the virologic potency and durability, short- and long-term toxicity, and dosing convenience of these drugs. TDF has been associated with bone and kidney toxicities, especially when used with a pharmacologic booster.42 TAF is less likely to cause kidney and bone toxicities than TDF. TDF is associated with lower lipid levels than TAF. Safety, cost, and access are among the factors to consider when choosing between these drugs. ABC/3TC, TDF/3TC, and 3TC are available as generic formulations.
Clinical Trials Comparing Nucleoside Reverse Transcriptase Inhibitors
Abacavir/Lamivudine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine
Several randomized controlled trials in ART-naive participants compared ABC/3TC to TDF/FTC, each administered in combination with a third ARV drug43-45 (see also the discussion in the Dolutegravir section).46
The ACTG 5202 study, a randomized controlled trial in >1,800 participants, evaluated the efficacy and safety of ABC/3TC and TDF/FTC when each combination was used with either EFV or ATV/r. In patients with baseline HIV RNA ≥100,00 copies/mL, the time to virologic failure was significantly shorter with ABC/3TC than with TDF/FTC, regardless of whether the third active drug was EFV or ATV/r.43 In the HEAT study, 688 participants received ABC/3TC or TDF/FTC in with once-daily LPV/r. Virologic efficacy was similar in the two study arms, including in a subgroup of participants with HIV RNA ≥100,000 copies/mL.45
The ASSERT study compared open-label ABC/3TC with TDF/FTC in 385 HLA-B*5701-negative, ART-naive patients; all participants also received EFV. The primary study endpoint was renal safety of the regimens. At week 48, the proportion of participants with HIV RNA <50 copies/mL was lower among ABC/3TC-treated participants than among TDF/FTC-treated participants.44
Lamivudine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine
An STR of DTG/3TC has now been approved as an initial ART regimen. Please refer to the INSTI section for full discussion.
GEMINI 1 and GEMINI 2 were identically designed randomized, double-blind clinical trials that found DTG plus 3TC noninferior to DTG plus TDF/FTC in ART-naive adults with HIV RNA <500,000 copies/mL and estimated glomerular filtration rate (eGFR) ≥50 mL/min.4,16
Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate
Two randomized double-blind Phase 3 clinical trials compared the safety and efficacy of EVG/c/TDF/FTC and EVG/c/TAF/FTC in 1,733 ART-naive adults with eGFR ≥50 mL/min.
TAF/FTC was virologically noninferior to TDF/FTC at week 48 (92% vs. 90% of participants had plasma HIV RNA <50 copies/mL, respectively),47 but TAF/FTC was superior to TDF/FTC at week 144 (84.2% vs. 80% of participants with plasma HIV RNA <50 copies/mL), largely driven by a higher rate of treatment discontinuation in the TDF arm.48
Participants in the TAF arm had significantly smaller reductions in BMD at the spine and hip than those in the TDF arm through 144 weeks.48 Those receiving TAF also had less pronounced changes in eGFR and renal biomarkers and fewer clinically significant renal events through week 96.49 Conversely, levels of fasting low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides increased more in the TAF group than in the TDF group at 96 weeks, with no change in total cholesterol to HDL ratio.50
Two randomized studies have compared the safety and efficacy of TAF/FTC to TDF/FTC each combination administered with boosted DRV in ART-naive participants:
A Phase 2 study of coformulated darunavir/cobicistat (DRV/c) plus TAF/FTC versus DRV/c plus TDF/FTC in treatment-naive patients demonstrated similar virologic suppression rates in both arms (75% vs. 74%).51 In the TAF arm, fewer participants developed proteinuria. Changes in BMD were also less pronounced among participants in the TAF group.
The AMBER study randomized ART-naive participants to receive either coformulated DRV/c/TAF/FTC or DRV/c plus TDF/FTC. At 48 weeks, HIV RNA <50 copies/mL was achieved in 91% of the DRV/c/TAF/FTC participants versus 88% of the DRV/c plus TDF/FTC participants. Participants in the TAF/FTC arm showed less decline in hip and spine BMD and eGFR than participants in the TDF/FTC arm.52
One analysis evaluated data from 11 randomized trials that compared the virologic efficacy, frequency of renal events, and bone density changes associated with the use of TDF and of TAF when either drug was taken with or without PK boosters (RTV or COBI). There were no significant differences between unboosted TDF and TAF in terms of virologic efficacy or in the number of participants who discontinued treatment because of renal or bone adverse events or fractures. However, bone- and renal-related toxicities were more pronounced when TDF was used with RTV or COBI.42
To assess the ability of TAF to maintain HIV and HBV suppression, 72 patients with HIV/HBV coinfection who had HIV RNA <50 copies/mL and HBV DNA <9 log10 IU/mL on a stable regimen were switched to EVG/c/TAF/FTC.53 In this study, 96% of participants were on a TDF/FTC-containing regimen before the switch. Key results of the study showed that:
Among those who switched to EVG/c/TAF/FTC, HIV suppression was maintained in 94.4% and 91.7% of participants at 24 and 48 weeks, respectively. At 24 and 48 weeks, 86.1% and 91.7% of participants, respectively, had HBV DNA <29 log10 IU/mL.
Markers of proximal tubular proteinuria and biomarkers of bone turnover decreased in those who switched to EVG/c/TAF/FTC.53
Nucleoside Reverse Transcriptase Inhibitor Options for Initial Therapy
In alphabetical order.
Abacavir/Lamivudine (ABC/3TC)
ABC plus 3TC has been studied in combination with EFV, several PIs, and DTG in ART-naive patients.46,54-56
Hypersensitivity Reactions:
Clinically suspected hypersensitivity reactions (HSRs) were observed in 5% to 8% of individuals who started ABC in clinical trials conducted before the use of HLA-B*5701 testing. The risk of HSRs is highly associated with the presence of the HLA-B*5701 allele; approximately 50% of HLA-B*5701-positive patients, if given ABC, will have a related HSR.57,58 HLA-B*5701 testing should be done if the use of ABC is being considered. A patient who tests positive for HLA-B*5701 should not be given ABC and ABC hypersensitivity should be noted on the patient's allergy list. Patients who are HLA-B*5701 negative are far less likely to experience an HSR, but they should be counseled about the symptoms of the reaction. Patients who discontinue ABC because of a suspected HSR should never be rechallenged, regardless of their HLA-B*5701 status.
Cardiovascular Risk:
An association between ABC use and myocardial infarction (MI) was first reported in the D:A:D study. This large, multinational, observational study group found that recent (i.e., within 6 months) or current use of ABC was associated with an increased risk of an MI, particularly in participants with pre-existing cardiac risk factors.30,59
Since the D:A:D report, several studies have evaluated the relationship between ABC therapy and cardiovascular events. Some studies have found an association.60-66 Others, including an FDA meta-analysis of 26 randomized clinical trials that evaluated ABC, have not.29,67-70
An analysis of data from NA-ACCORD found that use of ABC in the previous 6 months was associated with an increased risk of both type 1 and type 2 MIs after adjusting for cardiovascular disease risk factors.71
No consensus has been reached on the association between ABC use and MI risk or the mechanism for such an association.
Other Factors and Considerations:
ABC/3TC is available as a coformulated tablet and as a coformulated STR with DTG.
ABC and 3TC are available separately and as a coformulated tablet in generic tablet formulations.
ABC does not cause renal dysfunction and can be used instead of TDF in patients with underlying renal dysfunction or in those who are at high risk for renal effects. No dose adjustment is required in patients with renal dysfunction.
The Panel's Recommendations:
ABC should only be prescribed for patients who are HLA-B*5701 negative.
On the basis of clinical trial safety and efficacy data, experience in clinical practice, and the availability of DTG/ABC/3TC as an FDC, the Panel classifies DTG/ABC/3TC as a Recommended Initial Regimen for Most People with HIV (AI) (see the discussion of DTG in this section regarding the clinical efficacy data for ABC/3TC plus DTG).
ABC/3TC use with EFV, ATV/r, atazanavir/cobicistat (ATV/c), DRV/c, DRV/r, or RAL is only recommended for patients with pretreatment HIV RNA levels <100,000 copies/mL. See Table 6a for more detailed recommendations on the use of ABC/3TC with these drugs.
ABC should be used with caution or avoided in patients with known high cardiovascular risk.
Lamivudine (3TC) as Single NRTI
3TC was approved for HIV treatment in 1995 and is often used in combination with ABC or TDF. Based on the GEMINI-1 and GEMINI-2 studies4 that found DTG plus 3TC noninferior to DTG plus TDF/FTC in ART-naive patients with HIV RNA <500,000 copies/mL, 3TC may be used as a single NRTI with DTG (for more information, please refer to INSTI section). In addition, based on the ANDES trial, if ABC, TDF, and TAF cannot be used, 3TC can be used as a single NRTI with DRV/r39 (please refer to Other Antiretroviral Regimens for Initial Therapy When Abacavir, Tenofovir Alafenamide, and Tenofovir Disoproxil Fumarate Cannot Be Used or Are Not Optimal.)
Adverse Effects:
Long-term experience with 3TC has shown that it is well tolerated with no significant adverse effects.
3TC is available as an STR with DTG.
3TC has activity against HBV but is insufficient for HBV treatment when used alone due to the emergence of resistance. Discontinuation of 3TC can precipitate a flare in HBV if no other HBV-active drugs are in the regimen.
There are two brand-name formulations of 3TC (one for HIV and the other for HBV), but doses are different. The dose for HIV treatment is 3TC 300 mg daily.
The dose of 3TC should be adjusted in patients with creatinine clearance (CrCl) <50 mL/min.
Sorbitol-containing drugs can decrease 3TC concentration and co-administration should be avoided.
The Panel recommends the use of DTG/3TC (AI) as a Recommended Initial Regimen for Most People with HIV with three exceptions. DTC/3TC is not recommended for:
Individuals with HIV RNA >500,000 copies/mL;
Individuals with HBV coinfection or whose HBV status is unknown; and
Individuals starting ART before the results of genotypic resistance testing for reverse transcriptase are available.
Tenofovir Alafenamide/Emtricitabine (TAF/FTC)
TAF, an oral prodrug of tenofovir (TFV), is hydrolyzed to TFV in plasma and then converted to TFV-diphosphate (TFV-DP) intracellularly, where it exerts its activity as an NRTI. Unlike TDF, which readily converts to TFV in plasma after oral absorption, TAF remains relatively stable in plasma, resulting in lower plasma and higher intracellular TFV concentrations. After oral administration, TAF 25 mg resulted in plasma TFV concentrations that were 90% lower than those seen with TDF 300 mg. Intracellular TFV-DP concentrations, however, were substantially higher with TAF.
Renal and Bone Effects:
The potential for adverse kidney and bone effects is lower with TAF than with TDF. In randomized controlled trials that compared TAF and TDF in treatment-naive or virologically suppressed patients, TAF had more favorable effects on renal biomarkers and bone density than TDF (described below).
Lipid Effects:
In randomized controlled trials in ART-naive patients, as well as in switch studies (described below), levels of LDL and HDL cholesterol and triglycerides were higher in patients receiving TAF than in patients receiving TDF. However, total cholesterol to HDL ratios did not differ between patients receiving TAF and those receiving TDF. The clinical significance of this finding is not clear.47,72,73
Weight Gain:
Initiation of TAF in ART-naive individuals has been associated with greater weight gain than initiation of TDF23,24 and ABC.23 Significant weight gain was initially reported in a cohort of patients switching from TDF-containing to TAF-containing regimens.74 In ADVANCE, an open-label trial conducted in South Africa that compared EFV/TDF/FTC versus DTG plus TDF/FTC versus DTG plus TAF/FTC in ART-naive patients, there was a greater increase in body weight with initiation of TAF than with TDF.24 Weight gain was most pronounced in black women (10 kg over 96 weeks). This is an area of intense investigation and the clinical significance of the effect is still uncertain. It is also unclear whether change of therapy results in reversal of weight gain.
TAF/FTC is available in FDCs with bictegravir (BIC), DRV/c, EVG/c, or RPV, allowing the regimens to be administered as a single pill taken once daily with food.
In Phase 3 randomized trials, BIC/TAF/FTC was comparable to DTG/ABC/3TC and to DTG plus TAF/FTC (see the INSTI section below).
TAF-containing regimens are approved for patients with eGFR ≥30 mL/min. Renal function, urine glucose, and urine protein should be assessed before initiating treatment with TAF, and these assessments should be repeated periodically during treatment. EVG/c/FTC/TAF was safe and effective in a single-arm switch study that was conducted in patients on hemodialysis with eGFR <15 mL/min.75
Both TAF and FTC are active against HBV. In patients with HIV/HBV coinfection, TAF/FTC may be used as the NRTI pair in an ART regimen because these drugs have activity against both viruses (see HBV/HIV Coinfection).53
The Panel's Recommendation:
On the basis of clinical trial safety and efficacy data, supportive bioequivalence data,76 and its availability as a component of various FDCs, the Panel considers TAF/FTC a recommended NRTI combination for initial ART in most persons with HIV when prescribed with BIC, DTG, and RAL.
Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) and Tenofovir Disoproxil Fumarate/Lamivudine (TDF/3TC)
TDF, with either 3TC or FTC, has been studied in combination with DOR, EFV, RPV, several boosted PIs, EVG/c, RAL, and DTG in randomized clinical trials.77-86 In a 10-day, open-label, randomized, monotherapy trial that was not powered to find a difference between study arms, the reduction in viral load from baseline was 1.7 log10 for FTC 200 mg once daily and 1.5 log10 for 3TC 150 mg twice daily.87 In a meta-analysis of 12 trials, there was no significant difference in treatment success between 3TC and FTC.88 In the ATHENA cohort, virologic efficacy of TDF/FTC was compared to TDF/3TC when either was combined with an NNRTI (EFV or nevirapine [NVP])89 or with a boosted PI.90 TDF/3TC was associated with higher rates of virologic failure than TDF/FTC in the NNRTI analysis. However, it is noteworthy that the participants in the NNRTI cohort who were taking 3TC generally had higher viral loads, lower CD4 counts, and were more likely to be using injection drugs at the start of the study than those taking FTC.89 There was no difference in the rates of virologic failure in people who were taking TDF/FTC and people who were taking TDF/3TC when these drug combinations were used with a boosted PI.90 A retrospective analysis of an Italian national database found that viral resistance was more common with TDF/3TC than with TDF/FTC, but this was not observed in clinical trials.91
Renal Effects:
New onset or worsening renal impairment has been associated with TDF use.92,93 Risk factors may include advanced HIV disease, longer treatment history, low body weight (especially in women),94 and pre-existing renal impairment.95 Concomitant use of a PK-enhanced regimen (with a PI or EVG) can increase TDF concentrations; studies have suggested that the risk of renal dysfunction is greater when TDF is used in these regimens. As previously noted, adverse effects on renal biomarkers such as proteinuria, especially tubular proteinuria, were more frequent with TDF than with TAF.93,95-99
Adverse renal outcomes are more likely when TDF/FTC is coadministered with PK boosters (RTV or COBI). A meta-analysis of randomized trials found that discontinuation due to renal adverse events is more frequent in people who take TDF/FTC with PK boosting.42
Bone Effects:
While initiation of all NRTI-containing regimens has been associated with a decrease in BMD, the loss of BMD is greater with TDF-containing regimens. For example, in two randomized studies that compared TDF/FTC with ABC/3TC, participants who received TDF/FTC experienced a significantly greater decline in BMD than ABC/3TC-treated participants.100,101 BMD generally stabilizes following an early decline after ART initiation. Loss of BMD with TDF is also greater than with TAF (see above).
Cases of osteomalacia associated with proximal renal tubulopathy have been reported with the use of TDF.102
Adverse bone outcomes are more likely when TDF/FTC is coadministered with PK boosters (RTV or COBI). A meta-analysis of randomized trials found that fractures and study discontinuations due to bone adverse events occured more frequently among patients who took TDF/FTC with PK boosting than among those who took TAF/FTC with PK boosting.42
TDF/FTC is available in FDCs with EFV, EVG/c, and RPV, allowing the regimens to be administered as a single pill taken once daily.
TDF/3TC is available in FDCs with DOR 100 mg, EFV 600 mg, and EFV 400 mg.
Renal function, urine glucose, and urine protein should be assessed before initiating treatment with TDF and periodically during treatment (see Laboratory Testing for Initial Assessment and Monitoring). In patients who have pre-existing renal insufficiency (CrCl <60 mL/min),103 use of TDF should generally be avoided. If TDF is used, a dose adjustment is required if the patient's CrCl falls below 50 mL/min (see Appendix B, Table 10 for dose recommendations).
TDF, FTC, and 3TC are active against HBV. In patients with HBV/HIV coinfection, TDF/FTC or TDF/3TC may be used as the NRTI pair of the ART regimen because these drugs have activity against both viruses (see HBV/HIV Coinfection).
On the basis of clinical trial safety and efficacy data, long-term experience in clinical practice, and the combination's availability as a component of FDC drugs, the Panel considers TDF/FTC and TDF/3TC as recommended NRTI combinations for initial ART in most persons with HIV when combined with DTG or RAL. See Table 6a for recommendations regarding use of TDF/FTC with other drugs.
TDF should be used with caution or avoided in patients with renal disease and osteoporosis.
When TDF is used, especially in conjunction with a PK booster, clinicians should monitor for renal and bone safety during therapy. Boosters should be avoided when possible in patients taking TDF.
Integrase Strand Transfer Inhibitor–Based Regimens
Table 8b. Characteristics of Integrase Strand Transfer Inhibitors That Are Recommended for Antiretroviral Therapy-Naive Patients
Before starting an INSTI-based regimen in a person of childbearing potential, clinicians should refer to Table 6b for further guidance.
Dosing Frequency Once daily Once Daily:
In ART-naive or INSTI-naive persons
Twice Daily:
If used with certain CYP3A4 and UGT1A1 inducers; or
In INSTI-experienced persons with certain INSTI drug resistance mutations
Once daily; requires boosting with COBI
400 mg twice daily, or
1,200 mg (two 600-mg tablets) once daily
STR Available for ART-Naive Patients BIC/TAF/FTC
Available as a Single-Drug Tablet No Yes No Yes
Approved for ART-Experienced Patients No Yes, with twice-daily dosing for patients with certain INSTI drug resistance mutations No, but sometimes used in combination with DRV and TAF/FTC as part of a simplification regimen in patients with resistance. Yes, for patients with drug resistance mutations to RTV-boosted PIs or NNRTIs, but not to INSTIs
Virologic Efficacy Against EVG- or RAL-Resistant HIV In vitro data indicate activity, but clinical trial data are not available. Yes, for some isolates; effective with DTG 50 mg twice-daily dose No No
Adverse Effects Nausea, diarrhea (GI disturbance greater with EVG/c), headache, insomnia. Among ARV-naive individuals, initiation of INSTI-containing regimens has been associated with greater weight gain than NNRTI or boosted-PI regimens (see text). Depression and suicidality are rare, occurring primarily in patients with pre-existing psychiatric conditions.
↑ CPK (4%) Hypersensitivity, hepatotoxicity, ↑ CPK, myositis ↑ TG, ↑ LDL ↑ CPK, myopathy, hypersensitivity, SJS/TEN
CYP3A4 Drug-Drug Interactions CYP3A4 substrate CYP3A4 substrate (minor) EVG is a CYP3A4 substrate; COBI is a CYP3A4 inhibitor No
Chelation with Polyvalent Cation Supplements and Antacids Oral absorption of all INSTIs may be reduced by polyvalent cations. See Table 21d for recommendations regarding dosing separation of INSTIs and these drugs.
Other Key Potential Drug Interactions UGT1A1 substrate, OCT2 and MATE1 inhibitor P-gp substrate, UGT1A1 substrate EVG is a UGT1A1 substrate; COBI is a P-gp inhibitor. UGT1A1 substrate
Key: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; BIC = bictegravir; BID = twice daily; COBI = cobicistat; CPK = creatine phosphokinase; CYP = cytochrome P; DRV = darunavir; DTG = dolutegravir; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; GI = gastrointestinal; INSTI = integrase strand transfer inhibitor; LDL = low density lipoprotein; MATE = multidrug and toxic compound extrusion; NNRTI = non-nucleoside reverse transcriptase inhibitor; NTD = neural tube defect; OAT = organic cation transporter; P-gp = p-glycoprotein; PI = protease inhibitor; PI/r = ritonavir-boosted protease inhibitor; RAL = raltegravir; SJS/TEN = Stevens Johnson Syndrome/toxic epidermal necrolysis; STR = single-tablet regimen; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TG = triglyceride; UGT = uridine diphosphate glucuronosyltransferase
Four INSTIs—BIC, DTG, EVG, and RAL—are approved for use in ART-naive patients with HIV.
The Panel recommends one of the following INSTI-based regimens for most people with HIV:
DTG plus (TAF or TDF) with (FTC or 3TC) (AI)
RAL plus (TAF or TDF) with (FTC or 3TC) (BI for TDF/[FTC or 3TC], BII for TAF/FTC)
DTG/3TC (AI), except for those with HIV RNA >500,000 copies/mL, with HBV coinfection, or in whom ART is to be started before the results of HIV genotypic resistance testing for reverse transcriptase or HBV testing are available.
Among the INSTI-based regimens, RAL-containing regimens have the longest clinical experience, and they have been shown to have durable virologic efficacy; however, they have a higher pill burden than BIC- and DTG-containing regimens. EVG and RAL have lower barriers to resistance than BIC and DTG. Because of its high barrier to resistance, DTG plus two NRTI or BIC/TAF/FTC may be considered for patients who must start ART before resistance test results are available. EVG-based regimens require boosting with COBI, which results in a greater potential for interaction with concomitant medications, Therefore, EVG-based regimens are now considered Recommended Initial Regimens in Certain Clinical Situations.
All INSTIs are generally well tolerated, though there are reports of insomnia in some patients. Depression and suicidal ideation, primarily in patients with a history of psychiatric illnesses, have rarely been reported in patients receiving INSTI-based regimens.104-107
Among ARV-naive individuals, initiation of INSTI-containing regimens has been associated with greater weight gain than NNRTI- or boosted PI-regimens.23-26,108,109 In randomized trials of ARV-naive individuals, the mean increase in weight from baseline associated with BIC and DTG was similar and greater than with EVG/c.23 Greater weight gain has also been observed after initiation of TAF,20,23,24 or with a switch from TDF to TAF74 especially in conjunction with INSTIs. While ARV-associated weight gain appears to disproportionately affect women, Blacks and Hispanics,23,24,108,110 predictors and mechanism(s) for the weight gain are still unclear. Further questions that need to be clarified include regional distribution of the weight gain,22 whether it is associated with significant cardio-metabolic risk,111 and whether it is reversible upon discontinuation of the offending agent.
Preliminary data from an observational study in Botswana suggested that there may be an increased risk of NTDs in infants born to individuals who were receiving DTG at the time of conception.5,9 Additional data show that the prevalence of NTDs in infants who were exposed to DTG at the time of conception is lower than previously reported, but still higher than in infants exposed to non-DTG regimens.6,7 Before initiating an INSTI-based regimen in a person of childbearing potential, clinicians should review the information in Table 6b.
Integrase Strand Transfer Inhibitors Recommended as Part of an Initial Regimen for Most People with HIV
Bictegravir (BIC)
BIC is an INSTI that is approved by FDA for initial therapy in adults with HIV as a component of a single-tablet, once-daily regimen with TAF and FTC.
Efficacy in Clinical Trials:
The efficacy of BIC in ART-naive adults has been evaluated in two large Phase 3 randomized double-blind clinical trials that compared BIC to DTG administered in combination with two NRTIs. The primary efficacy endpoint was the proportion of participants with plasma HIV RNA <50 copies/mL at week 48.
The GS-US-380-1490 trial randomized participants 1:1 to receive either BIC/TAF/FTC or DTG with coformulated TAF/FTC. Both regimens were given once daily. At week 96, 84% of participants in the BIC arm and 86% of those in the DTG arm achieved HIV RNA <50 copies/mL.20
The GS-US-380-1489 trial randomized participants 1:1 to receive BIC/TAF/FTC or coformulated DTG/ABC/3TC once daily. At week 96, 88% of participants in the BIC/TAF/FTC arm and 90% of those in the DTG/ABC/3TC arm achieved HIV RNA <50 copies/mL.21
BIC is generally well tolerated. In clinical trials, the most commonly reported adverse reactions of any grade with an incidence ≥5% included diarrhea, nausea, and headache. Some studies have shown greater weight gain among people initiating INSTI-based regimens, particularly Black women. In a pooled analysis of eight randomized, controlled trials in ART-naive individuals, the weight gain at 96 weeks with BIC- and DTG-based regimens was similar (approximately 3.5 kg).23
BIC is a CYP3A4 substrate and a UGT1A1 substrate, and its metabolism may be affected by concomitant use of CYP3A4 and UGT1A1 inducers or inhibitors. Rifampin or other rifamycins may decrease BIC or TAF concentrations, which may result in a loss of therapeutic effect. For patients who require rifamycins, BIC/FTC/TAF should not be used. Use of certain anticonvulsants and St. John's wort should also be avoided.112
BIC is an inhibitor of the drug transporters OCT2 and MATE1, which may lead to increased concentrations of drugs that are substrates of these transporters. For this reason, dofetilide is contraindicated with BIC/TAF/FTC.
BIC is not a CYP3A4 inducer or inhibitor; thus, unlike EVG/c, BIC is unlikely to affect the metabolism of medications that are CYP3A4 substrates.
Like other INSTIs, oral absorption of BIC may be reduced when BIC is coadministered with polyvalent cations (e.g., aluminum-, magnesium-, or calcium-containing antacids, or calcium or iron supplements). See the BIC product label for dosing recommendations when using BIC with these products.112
BIC decreases tubular secretion of creatinine without affecting glomerular function. Increases in serum creatinine are typically observed within the first 4 weeks of BIC therapy (with a median increase of 0.10 mg/dL after 48 weeks). This increase is comparable to that seen with other drugs that have a similar effect on creatinine secretion, including DTG, RPV, and COBI.
Treatment-emergent mutations that confer BIC resistance have not yet been reported in people receiving BIC for initial therapy. BIC has not been studied in people with prior INSTI failure or INSTI-related resistance mutations, and BIC should not be used in these individuals until more data are available.
On the basis of clinical trial data, the Panel categorizes the combination of BIC/TAF/FTC administered once daily as a Recommended Initial Regimen for Most People with HIV (AI).
Before prescribing BIC to a person of childbearing potential, review Table 6b. BIC should not be used in pregnancy because of insufficient safety data.
Dolutegravir (DTG)
DTG is an INSTI with a higher barrier to resistance than EVG or RAL. In ART-naive patients, DTG plus two NRTIs demonstrated high efficacy in achieving HIV suppression. DTG is given once daily, with or without food. Preliminary data from Botswana suggested that there may be an increased risk of NTDs in infants born to women who were receiving DTG at the time of conception,5,9 but additional data indicate the risk is lower than previously reported.6,7 More detailed discussions of this potential risk and recommendations for the use of DTG are found below and in Table 6b.
The efficacy of DTG in ART-naive patients has been evaluated in several fully powered randomized controlled clinical trials. In these trials, DTG-based regimens were noninferior or superior to a comparator INSTI-, NNRTI-, or PI-based regimen. The primary efficacy endpoint in these clinical trials was the proportion of participants with plasma HIV RNA <50 copies/mL.
DTG plus Two NRTIs versus Other INSTIs plus Two NRTIs:
DTG-based regimens (with TAF/FTC or ABC/3TC) have been compared to BIC/TAF/FTC in two randomized controlled trials. These regimens have shown virologic efficacy that is similar to BIC/TAF/FTC (see the discussion in the BIC section above).20,21,113,114
The SPRING-2 trial compared DTG 50 mg once daily to RAL 400 mg twice daily. Each drug was administered in combination with an investigator-selected, two-NRTI combination (ABC/3TC or TDF/FTC) to 822 participants. At week 96, DTG was noninferior to RAL.86
DTG plus Two NRTIs versus EFV plus Two NRTIs:
The SINGLE trial compared DTG 50 mg once daily plus ABC/3TC to EFV/TDF/FTC in 833 participants. At week 48, DTG plus ABC/3TC was superior to EFV/TDF/FTC, primarily because the study treatment discontinuation rate was higher in the EFV arm than in the DTG arm.46 At week 144, DTG plus ABC/3TC remained superior to EFV/TDF/FTC.115
The ADVANCE trial, an open label, noninferiority trial conducted in South Africa, compared DTG with either TDF/FTC or TAF/FTC to EFV/TDF/FTC. At week 48, the DTG-based regimens were noninferior to the EFV regimen based on the proportion of participants with HIV-RNA levels <50 copies/mL. More participants discontinued the trial regimen in the EFV group than in the DTG group.24
The NAMSAL ANRS 12313 study, an open-label, multicenter randomized noninferiority trial conducted in Cameroon, compared DTG to EFV 400 mg, both combined with TDF/3TC. At week 48, DTG was noninferior to EFV 400 mg, with HIV RNA <50 copies/mL in 74.5% and 69.0% of participants in the DTG and EFV arms respectively.8
DTG plus Two NRTIs versus PI/r plus Two NRTIs:
The FLAMINGO study, a randomized open-label clinical trial, compared DTG 50 mg once daily to DRV/r 800 mg/100 mg once daily, each administered in combination with investigator-selected ABC/3TC or TDF/FTC. At week 48, DTG was superior to DRV/r, with 90% and 83% of participants achieving HIV RNA <50 copies/mL, respectively. The rate of participants who discontinued their assigned regimen was higher in the DRV/r arm.116 The difference in efficacy between the DTG and DRV/r regimens was more pronounced in patients with pretreatment HIV RNA levels >100,000 copies/mL. At week 96, DTG remained superior to DRV/r.117
The ARIA trial, an open-label, Phase 3b randomized controlled trial, compared the efficacy and safety of DTG/ABC/3TC to ATV/r plus TDF/FTC in ART-naive, nonpregnant women. At week 48, 82% of participants in the DTG group and 71% in the ATV group (P = 0.005) achieved HIV RNA viral loads <50 copies/mL. The difference was driven by a lower rate of virologic nonresponse and fewer withdrawals due to adverse events in the DTG group.118
DTG/3TC:
In the GEMINI-1 and GEMINI-2 trials, 1,433 ART-naive participants with baseline HIV RNA <500,000 copies/mL and no evidence of HBV infection were randomized to receive DTG plus 3TC or DTG plus TDF/FTC. At week 96, DTG plus 3TC was noninferior to DTG plus TDF/FTC based on the proportion of participants with viral loads <50 copies/mL (86% in DTG plus 3TC group and 89.5% in DTG plus TDF/FTC group).4 Virologic nonresponse was uncommon, occurring in 3.1% of participants who received DTG plus 3TC and 2% of participants who received DTG plus TDF/FTC. No instances of treatment-emergent NRTI or INSTI resistance occurred in either treatment group. Among participants who started the study with CD4 counts <200 cells/mm3, the rate of those with HIV RNA <50 copies/mL at week 96 was lower in the DTG plus 3TC group than in the DTG plus TDF/FTC group; however, the difference was not related to a higher rate of virologic failures in the two-drug group.
Two other small, non-randomized single-arm studies showed similar rates of viral suppression with DTG plus 3TC.119,120
DTG is generally well tolerated. The most commonly reported adverse reactions of moderate-to-severe intensity were insomnia and headache. As discussed earlier, some studies have shown greater weight gain among people initiating INSTI-based regimens, including regimens with DTG.23-26
Case series of neuropsychiatric adverse events (e.g., sleep disturbances, depression, anxiety, suicidal ideation) associated with the initiation of DTG and RAL have been reported.104,105 Two observational cohort studies reported a higher frequency of neuropsychiatric adverse events leading to treatment discontinuation in patients receiving DTG than in patients receiving other INSTIs.106,107 However, analyses of data from large randomized controlled trials and a health care database demonstrated similar rates of neuropsychiatric adverse events between DTG-based regimens and other ARV regimens,121 with neuropsychiatric events rarely leading to DTG discontinuation. Another report from the World Health Organization international pharmacovigilance database reported neuropsychiatric events with all approved INSTIs,122 not just DTG. Further studies will be needed to clarify the true incidence and implications of these neuropsychiatric events. A pathophysiologic mechanism for these neuropsychiatric adverse events has not been defined.
An observational surveillance study of birth outcomes among pregnant women on ART in Botswana identified five cases of NTDs among infants born to 1,683 women (0.3%) who initiated a DTG-based regimen around the time of conception. The incidence of NTDs among infants born to women who were receiving other ARV drugs at the time of conception was 0.1%, although data were limited for all other ARV agents except EFV.9 See Table 6b for recommendations on prescribing INSTIs as part of initial therapy, including for people of childbearing potential.
Weight gain has been reported with INSTIs, including DTG, as discussed in the Summary of this INSTI section.
DTG, like BIC, decreases tubular secretion of creatinine without affecting glomerular function, with increases in serum creatinine observed within the first 4 weeks of treatment.
DTG has fewer drug interactions than EVG/c. See Drug-Drug Interactions for specific drug-drug interactions that require dosage adjustment.
DTG absorption, like absorption for other INSTIs, may be reduced when the ARV is coadministered with polyvalent cations (see Drug-Drug Interactions). DTG should be taken at least 2 hours before or 6 hours after cation-containing antacids or laxatives are taken. Alternatively, DTG and supplements containing calcium or iron can be taken simultaneously with food.
Treatment-emergent mutations that confer DTG resistance have been rarely reported in patients receiving DTG as part of a three-drug regimen for initial therapy.17-19 The incidence of resistance with DTG is much lower than with EVG or RAL, which suggests that DTG, like BIC, has a higher barrier to resistance than EVG or RAL.
On the basis of clinical trial data, the Panel categorizes DTG in combination with ABC/3TC (AI), TAF/FTC (AI), or TDF/(FTC or 3TC) (AI) as a Recommended Initial Regimen for Most People with HIV.
The Panel also recommends the use of DTG/3TC (AI) as a Recommended Initial Regimen for Most People with HIV except for those with HIV RNA >500,000 copies/mL, with HBV coinfection, or in whom ART is to be started before the results of HIV genotypic resistance testing for reverse transcriptase or of HBV testing are available.
Individuals of childbearing potential should have a pregnancy test before initiating DTG (AIII).
A DTG-based regimen can be considered for individuals of childbearing potential who are using effective contraception after a discussion of the risks and benefits of the regimen so that individuals can make informed decisions (see Table 6b for details) (BIII).
For initial therapy of individuals of childbearing potential who are trying to conceive or are sexually active and not using contraception, please see Table 6b for recommendations.
Raltegravir (RAL)
RAL was the first INSTI approved for use in both ARV-naive and ARV-experienced patients.
Efficacy in Clinical Trials
RAL 400 mg Twice Daily plus Two NRTIs versus Comparator Drug plus Two NRTIs:
The efficacy of RAL at a dose of 400 mg twice daily (with either TDF/FTC or ABC/3TC) as initial therapy was evaluated in two randomized, double-blind, controlled clinical trials and a third open-label, randomized trial.
STARTMRK compared RAL 400 mg twice daily to EFV 600 mg once daily, each administered in combination with TDF/FTC. RAL was noninferior to EFV at 48 weeks.82 RAL was superior to EFV at 4 and 5 years,85,123 in part because of more frequent discontinuations due to adverse events in the EFV group than in the RAL group.
The SPRING-2 trial compared DTG 50 mg once daily to RAL 400 mg twice daily, each administered in combination with investigator-selected ABC/3TC or TDF/FTC. At week 96, DTG was noninferior to RAL.
The SPRING-2 trial also provided nonrandomized data on the efficacy of RAL plus ABC/3TC. In this trial, 164 participants (39 participants with baseline viral loads ≥100,000 copies/mL and 125 participants with baseline viral loads <100,000 copies/mL) received RAL in combination with ABC/3TC. After 96 weeks, there was no difference in virologic response between the ABC/3TC and TDF/FTC groups when RAL was given as the third drug.86
ACTG A5257, a large randomized open-label trial, compared three NNRTI-sparing regimens that contained RAL, ATV/r, or DRV/r, each given with TDF/FTC. At week 96, all three regimens had similar virologic efficacy, but RAL was superior to both ATV/r and DRV/r for the combined endpoints of virologic efficacy and tolerability. Participants had greater increases in lipid levels in the ritonavir-boosted protease inhibitor (PI/r) arms than in the RAL arm, and BMD decreased to a greater extent in participants in the PI/r arms than in participants in the RAL arm.13
RAL 1,200 mg Once Daily plus TDF/FTC versus RAL 400 mg Twice Daily plus TDF/FTC:
In a Phase 3, randomized, double-blind, active comparator-controlled trial (the ONCEMRK trial), the efficacy of once-daily RAL 1,200 mg (formulated as two 600-mg tablets) was compared to RAL 400 mg twice daily, each administered with TDF/FTC. At 96 weeks, a similar proportion of participants in both groups achieved HIV RNA suppression (81.5% in the once-daily arm vs. 80.1% in the twice-daily arm). The responses were similar regardless of baseline HIV RNA or CD4 count.124
RAL, when compared in a randomized trial to DRV/r or ATV/r, all with TDF/FTC, led to a greater mean increase in waist circumference.125
RAL use has been associated with creatine kinase elevations. Myositis and rhabdomyolysis have been reported.
Rare cases of severe skin reactions and systemic HSRs in patients who received RAL have been reported during post-marketing surveillance.126
Neuropsychiatric adverse events (e.g., insomnia, headache, depression, and suicidal ideation) have been reported in people receiving INSTIs (see the discussion under DTG).121,127
RAL can be administered as 1,200 mg (two 600-mg tablets) once daily or as 400 mg twice daily with or without food in ART-naive patients.
Coadministration of RAL as either 400 mg twice daily or 1,200 mg once daily with aluminum-containing and/or magnesium-containing antacids is not recommended. Calcium carbonate-containing antacids may be coadministered with RAL 400 mg twice daily, but not with RAL 1,200 mg once daily. Polyvalent cation-containing supplements may also reduce absorption of RAL. See Table 21d for dosing recommendations.
RAL has a lower barrier to resistance than RTV-boosted PIs, BIC, and DTG.
Among those who received RAL during pregnancy, the rate of fetal malformations is within the expected range for pregnancy outcomes in the United States.10-12 Data on RAL use around the time of conception is limited. Thus far, based on data collected from Antiretroviral Pregnancy Registry, the manufacturer and in a cohort study from the United States and other countries, no case of NTD has been reported.10-12
On the basis of these clinical trial data, the Panel considers RAL given as 1,200 mg (two 600-mg tablets) once daily or as 400 mg twice daily plus TDF/FTC (BI) or TAF/FTC (BII) as a Recommended Initial Regimen for Most People with HIV.
Integrase Strand Transfer Inhibitors Recommended as Part of an Initial Regimen in Certain Clinical Situations
Elvitegravir (EVG)
EVG is available as a component of two STRs: EVG/c/TDF/FTC and EVG/c/TAF/FTC. COBI is a specific, potent CYP3A inhibitor that has no activity against HIV. It acts as a PK enhancer of EVG, which allows for once-daily dosing of the combination but increases the likelihood of significant drug interactions.
The efficacy of EVG/c/TDF/FTC in ART-naive participants has been evaluated in two randomized, double-blind active-controlled trials.
At 144 weeks, EVG/c/TDF/FTC was noninferior to fixed-dose EFV/TDF/FTC.128
EVG/c/TDF/FTC was also found to be noninferior to ATV/r plus TDF/FTC.129
In a randomized, blinded trial that compared EVG/c/TDF/FTC to ATV/r plus TDF/FTC in women with HIV, EVG/c/TDF/FTC had superior efficacy, in part because of a lower rate of treatment discontinuation.15
The efficacy of EVG/c/TAF/FTC in ART-naive participants has been evaluated in two randomized, double-blind controlled trials in adults with eGFR ≥50 mL/min.47,50
At 48 and 96 weeks, TAF was noninferior to TDF when both drugs were combined with EVG/c/FTC; at 144 weeks, EVG/c/TAF/FTC was superior to EVG/c/TDF/FTC.48
The most common adverse events reported with EVG/c/TDF/FTC were diarrhea, nausea, upper respiratory infection, and headache.128,129
The most common adverse events reported with EVG/c/TAF/FTC were nausea, diarrhea, headache, and fatigue.130
Neuropsychiatric adverse events have been reported in people receiving INSTIs (see the discussion under DTG).
EVG is metabolized primarily by CYP3A enzymes; as a result, CYP3A inducers or inhibitors may alter EVG concentrations.
Because COBI is a PK enhancer, it is a CYP3A enzyme inhibitor, which may lead to significant interactions with medications that are metabolized by this enzyme (see Drug-Drug Interactions).131
Administration of EVG simultaneously with polyvalent cation-containing antacids or supplements lowers EVG plasma concentrations (see Drug-Drug Interactions). Separate EVG/c/TDF/FTC or EVG/c/TAF/FTC and polyvalent antacid administration by at least 2 hours; administer polyvalent cation-containing supplements at least 2 hours before or 6 hours after EVG.
COBI inhibits active tubular secretion of creatinine, resulting in increases in serum creatinine and a reduction in estimated CrCl without reducing glomerular function.132 Patients with a confirmed increase in serum creatinine >0.4 mg/dL from baseline while taking EVG/c/TDF/FTC should be closely monitored and evaluated for evidence of TDF-related proximal renal tubulopathy.99
EVG/c/TDF/FTC is not recommended for patients with pretreatment estimated CrCl <70 mL/min.99
EVG/c/TAF/FTC is not recommended for patients with estimated CrCl <30 mL/min unless they are on chronic hemodialysis. An observational study of 55 people with HIV who were on hemodialysis suggested that EVG/c/TAF/FTC given once daily (after hemodialysis on dialysis days) can be used safely in persons with no resistance to any of the ARV drugs in this STR.133
At the time of virologic failure, INSTI-associated mutations were detected in some EVG/c/TDF/FTC-treated patients whose therapy failed.128,129 These mutations conferred cross-resistance to RAL, with most patients retaining susceptibility to DTG.
EVG/c is not recommended during pregnancy because of low drug exposure when taken during the second and third trimesters.134
On the basis of the above considerations, the Panel classifies EVG/c/TAF/FTC and EVG/c/TDF/FTC as Recommended Initial Regimens in Certain Clinical Situations (BI). EVG/c/TAF/FTC should only be used in people with estimated CrCl ≥30 mL/min, unless they are on chronic hemodialysis. EVG/c/TDF/FTC should only be used in people with estimated CrCl ≥70 mL/min.
Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens
Table 8c. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors that are Recommended for Antiretroviral Therapy-Naive Patients
RPV
Dosing Frequency Once daily Once daily Once daily
Food Requirement With or without food On an empty stomach With a meal
STR Available for ART-Naive Patients DOR/TDF/3TC
EFV 600 mg/TDF/FTC
Available as a Single-Drug Tablet Yes Yes Yes
Adverse Effects Generally well tolerated
CNS side effects, including dizziness, abnormal dreams, headache, depression, suicidality, insomnia, somnolence
QTc prolongation
Depression, headache
CYP3A4 Drug-Drug Interactions CYP3A4 substrate CYP3A4 substrate, mixed inducer/inhibitor CYP3A4 substrate
Other Significant Drug Interactions None CYP2B6 and 2C19 inducer RPV oral absorption is reduced with increased gastric pH. Use of RPV with PPIs is not recommended; see Drug-Drug Interactions for dosing recommendations when RPV is coadministered with H2 blocker or antacids.
Key: 3TC = lamivudine; CNS = central nervous system; CYP = cytochrome P; DOR = doravirine; EFV = efavirenz; FTC = emtricitabine; H2 = histamine 2; PPI = proton pump inhibitor; RPV = rilpivirine; STR = single-tablet regimen; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate
Five NNRTIs (delavirdine [DLV], DOR, EFV, etravirine [ETR], NVP, and RPV) are currently approved by FDA for the treatment of HIV when used in combination with other ARV drugs.
NNRTI-based regimens have demonstrated virologic potency and durability. The major disadvantages of currently available NNRTIs (especially EFV and RPV) are the prevalence of NNRTI-resistant viral strains in ART-naive patients135 and the drugs' low barrier for the development of resistance. Resistance testing should be performed before initiation of an NNRTI-based regimen in ART-naive patients. High-level resistance to all NNRTIs (except ETR or DOR) may occur with a single mutation. In RPV-treated patients, the presence of RPV resistance mutations at virologic failure may confer cross-resistance to other NNRTIs, including ETR.136,137 DOR-, EFV-, and RPV-based regimens are now categorized as Recommended Initial Regimens in Certain Clinical Situations for ART-naive patients.
Doravirine (DOR)
The efficacy of DOR-based therapy for treatment of HIV in ART-naive individuals was demonstrated in two randomized, double-blind, placebo-controlled trials.
DOR-Based Regimen versus EFV-Based Regimen:
In DRIVE-AHEAD, 734 participants received either DOR/TDF/3TC or EFV/TDF/FTC, both as FDCs.36
At 48 weeks, DOR/TDF/3TC was noninferior to EFV/TDF/FTC, with 84.3% of participants who received DOR/TDF/3TC and 80.8% of those who received EFV/TDF/FTC achieving HIV RNA <50 copies/mL. Although virologic responses to ART overall were lower in participants with pre-ART HIV RNA >100,000 copies/mL, there was no difference between the DOR-treated and EFV-treated participants. Virologic responses overall were lower in participants with pre-ART HIV RNA >100,000 copies/mL, but there was no difference between the DOR and EFV groups.
A greater proportion of participants in the EFV arm discontinued their assigned ART due to adverse events than in the DOR arm (6.3% vs. 2.7%). Neuropsychiatric side effects were more common in the EFV arm.
Genotype resistance results were reported for 13 participants with virologic failure in the DOR arm and 10 participants in the EFV arm. For the DOR arm, seven out of 13 participants had NNRTI resistance and five out of 13 had NRTI resistance; for EFV, nine out of 10 participants had NNRTI resistance and five out of 10 had NRTI resistance.
LDL cholesterol and non-HDL cholesterol did not change with DOR use, whereas both increased with EFV use.
At 96 weeks, 77.5% and 73.6% of participants in the DOR arm and the EFV arm had maintained HIV RNA <50 copies/mL, respectively.138
DOR-Based Regimen versus DRV/r-Based Regimen:
In DRIVE-FORWARD, 769 participants received DOR or DRV/r once daily along with two investigator-selected NRTIs, either ABC/3TC or TDF/FTC.37
At 48 weeks, DOR was found to be noninferior to DRV/r when these drugs were administered with two NRTIs, with 84% of study participants receiving DOR versus 80% of those receiving DRV/r achieving HIV RNA <50 copies/mL at 48 weeks.
Participants who received DOR plus ABC/3TC (n = 48) and those who received DOR plus TDF/FTC (n = 316) had similar virologic responses.
At week 96, DOR was superior to DRV/r in terms of virologic suppression,139 with a higher rate of discontinuation in the DRV/r group.
Genotype resistance results were reported for seven and eight participants with virologic failure in the DOR and DRV/r arms, respectively. No drug resistance mutations were detected in either group.
Treatment-related diarrhea was more frequently reported in the DRV/r arm, and greater increases in fasting LDL cholesterol and triglycerides were seen in the participants who received DRV/r than in those who received DOR.
DOR is available as a single-drug, 100-mg tablet140 and as part of an STR that contains DOR/TDF/3TC 100 mg/300 mg/300 mg141 and is dosed once daily, with or without food.
DOR is primarily metabolized by the CYP3A4 enzyme and should not be coadministered with strong CYP3A4 inducers. DOR concentration may increase in the presence of a CYP3A4 inhibitor (see Table 21b). DOR is not a CYP3A4 inducer or inhibitor, so it is not expected to affect the concentrations of concomitant CYP3A4 substrates.
Treatment-emergent resistance mutations to DOR may confer cross-resistance to certain other NNRTIs. Most isolates with DOR mutations remain susceptible to ETR.142
DOR-based regimens have not been directly compared to INSTI-based regimens in clinical trials.
There are currently no data on the safety of DOR use during pregnancy.
On the basis of the clinical trial data discussed above, the Panel classifies DOR/TDF/3TC (BI) and DOR plus two NRTIs (BI for TDF/FTC and BIII for TAF/FTC) as Recommended Initial Regimens in Certain Clinical Situations.
Because the number of clinical trial participants who received DOR plus ABC/3TC is much lower than the number who received TDF/FTC plus DOR, the Panel considers ABC/3TC plus DOR to be an option for initial therapy (CI).
Efavirenz (EFV)
Efficacy of EFV 600 mg Daily Dose in Clinical Trials:
Large randomized controlled trials and cohort studies in ART-naive patients have demonstrated potent and durable viral suppression in patients treated with EFV plus two NRTIs. EFV-based regimens have demonstrated superiority or noninferiority to a number of comparator regimens in ART-naive patients in several randomized controlled trials.
In ACTG 5202, EFV was comparable to ATV/r when each was given with either TDF/FTC or ABC/3TC.143
In the ECHO and THRIVE studies, EFV was noninferior to RPV, with less virologic failure. However, EFV caused more discontinuations due to adverse events. The virologic advantage of EFV was most notable in participants with pre-ART viral loads >100,000 copies/mL, and NRTI and NNRTI resistance occurred more frequently in patients who experienced failure on a regimen that included RPV.144
In the GS 102 study, EFV/TDF/FTC was noninferior to EVG/c/TDF/FTC.128
The DRIVE-AHEAD study compared EFV/TDF/FTC to DOR/TDF/3TC in ART-naive patients. At 48 weeks, DOR/TDF/3TC was found to be noninferior to EFV/TDF/FTC, as discussed in the DOR section. Neuropsychiatric side effects were more common in the EFV arm.
ADVANCE, an open label, noninferiority trial, compared TDF/FTC/EFV 600 mg to DTG combined with either TDF/FTC or TAF/FTC. At week 48, the DTG regimens were noninferior to the EFV regimen based on the proportion of participants with HIV-RNA levels <50 copies/mL. More participants in the EFV group than in the DTG group discontinued the trial regimen.24
In clinical trials, some regimens have demonstrated superiority to those with EFV, based primarily on fewer discontinuations because of adverse events:
In the SINGLE trial, a DTG-based regimen was superior to an EFV regimen at the primary endpoint of viral suppression at week 48.46
In the STARTMRK trial, RAL was noninferior to EFV at 48 weeks,82 but RAL was superior to EFV at 4 and 5 years,85,123 in part because of more frequent discontinuations due to adverse events in the EFV group than in the RAL group.
In the open-label STaR trial, participants with baseline viral loads ≤100,000 copies/mL had higher rates of treatment success on RPV than on EFV.145
Efficacy of Low-Dose Efavirenz (EFV 400 mg Daily) in Clinical Trials:
ENCORE 1, a multinational, randomized, placebo-controlled trial, compared two once-daily doses of EFV (combined with TDF/FTC): EFV 600 mg (standard dose) versus EFV 400 mg (reduced dose). At 96 weeks, EFV 400 mg was noninferior to EFV 600 mg for rate of viral suppression.35 While the frequency of overall adverse events was not different between groups, EFV-related adverse events and treatment-related discontinuations occurred less frequently in the EFV 400 mg group than in the EFV 600 mg group. Although there were fewer self-reported CNS events in the 400 mg group, the groups had similar rates of psychiatric events. The 400-mg dose of EFV is now approved in the United States for initial treatment of HIV infection and is coformulated with TDF and 3TC in an FDC tablet.
NAMSAL ANRS 12313 (an open-label, multicenter randomized noninferiority trial) compared EFV 400 mg to DTG, both combined with TDF/3TC. At week 48, EFV 400 mg was noninferior to DTG based on percentage of participants with viral suppression to HIV RNA <50 copies/mL (69.0% in EFV group vs. 74.5% in DTG group).8
In an open label trial, 25 pregnant women with HIV and HIV RNA <50 copies/mL while on an EFV-based regimen were switched from EFV 600 mg to EFV 400 mg daily (the TDF and FTC or 3TC components of the regimen did not change). Participants were monitored closely with EFV concentrations measured weekly and viral loads biweekly during pregnancy and postpartum. Stopping criteria were HIV RNA >50 copies/mL on two consecutive occasions or random EFV concentration <800 ng/mL on three consecutive occasions. All participants maintained viral load suppression to HIV RNA <50 copies/mL throughout the study.146
A PK study enrolled 22 persons with HIV (without TB) who were on an EFV-based regimen and had HIV RNA levels <50 copies/mL. Participants were switched from EFV 600 mg to EFV 400 mg. Fourteen days after the switch, isoniazid and rifampin were started for 12 weeks. The combination resulted in only minimal reduction in EFV 400 mg PK parameters, which were within the range of concentrations seen in the ENCORE 1 trial. HIV RNA levels <50 copies/ mL were maintained in all participants during the study.147
EFV can cause CNS side effects (e.g., abnormal dreams, dizziness, headache, and depression) that resolve over a period of days to weeks in most patients. However, subtler, long-term neuropsychiatric effects can occur.
EFV use has also been associated with suicidality; however, evidence for this association has differed among various large studies. An analysis of four ACTG comparative trials showed a higher rate of suicidality (i.e., reported suicidal ideation or attempted or completed suicide) among EFV-treated patients than among patients taking comparator regimens (LPV/r, ATV, ATV/r, or ABC-based regimens).148 Similarly, a subgroup analysis of the START trial revealed higher risk of suicidal or self-injurious behavior among participants in the immediate ART group who took EFV than among ART-naive controls; the risk increased for those with previous psychiatric diagnoses.149 This association, however, was not found in analyses of three large observational cohorts150,151 or in a retrospective cohort study that used U.S. administrative pharmacy claims data.152 A prospective observational cohort study among people with HIV in Uganda revealed no evidence that EFV carried a greater risk of suicidal ideation or depression than NVP.153
Delayed onset neurotoxicities, including ataxia and encephalopathy, have been reported months to years after EFV use.154,155
EFV may cause elevation in LDL cholesterol and triglycerides.
QTc interval prolongation has been observed with EFV use.156,157 Consider an alternative to EFV in patients taking medications known to increase the risk of Torsades de Pointes, or in patients at higher risk of Torsades de Pointes.
EFV is formulated both as a single-drug, 600-mg tablet and in an FDC tablet of EFV/TDF/FTC that allows for once-daily dosing.
EFV is also available as a generic single-drug, 600-mg tablet and as a generic once-daily FDC tablet that includes 3TC, TDF, and either 600 mg or 400 mg of EFV; the lower-dose EFV/TDF/3TC tablet is approved for treating adults and children weighing ≥35 kg.158,159
EFV is a substrate of CYP3A4 and an inducer of CYP3A4 and 2D6, and therefore, may potentially interact with other drugs that use the same pathways (see Tables 21b, 22a, and 22b).
EFV has been associated with CNS birth defects in nonhuman primates, and cases of NTDs have been reported after first-trimester exposure in humans.160 A link between EFV and birth defects in humans has not been supported in meta-analyses (see the Perinatal Guidelines).161
People with HIV who are taking a regimen that includes EFV should be screened for depression and suicidality.
Given the availability of regimens with fewer treatment-limiting adverse events and noninferior or superior efficacy, the Panel classifies EFV 600 mg/TDF/FTC or EFV 600 mg/TDF/3TC (BI) or EFV 600 mg plus TAF/FTC (BII) as Recommended Initial Regimens in Certain Clinical Situations.
Randomized clinical trial data have demonstrated the noninferiority of EFV 400 mg compared to EFV 600 mg35 and to DTG.8 This dose has not been studied in a U.S. population. The Panel classifies EFV 400 mg/TDF/3TC as a Recommended Initial Regimen in Certain Clinical Situations (BI).
Rilpivirine (RPV)
RPV is an NNRTI that is approved for use in combination with NRTIs for ART-naive patients with pretreatment viral loads <100,000 copies/mL.
Two Phase 3 randomized, double-blind clinical trials—ECHO and THRIVE—compared RPV and EFV, each combined with two NRTIs.144 At 96 weeks, the following findings were reported:
RPV was noninferior to EFV overall.
Among participants with pre-ART viral loads >100,000 copies/mL, more RPV-treated participants than EFV-treated participants experienced virologic failure. Moreover, in this subgroup of participants with virologic failure, NNRTI and NRTI resistance were more frequently identified in those treated with RPV.
Among the RPV-treated participants, the rate of virologic failure was greater in those with pretreatment CD4 counts <200 cells/mm3 than in those with CD4 counts ≥200 cells/mm3.
STaR, a Phase 3b, open-label study, compared the FDCs of RPV/TDF/FTC and of EFV/TDF/FTC in 786 treatment-naive patients. The results at 96 weeks162 were similar to those reported at 48 weeks.145
RPV was superior to EFV in patients with pre-ART viral loads ≤100,000 copies/mL and noninferior in those with pre-ART viral loads >100,000 copies/mL. Among patients with pre-ART viral loads >500,000 copies/mL, virologic failure was more common in RPV-treated patients than in EFV-treated patients.
There were more participants with emergent resistance in the RPV/FTC/TDF arm than in the EFV/FTC/TDF arm (4% vs. 1%, respectively).
The STR of RPV/TAF/FTC was approved by FDA based on results from a bioequivalence study. In this study, plasma concentrations of RPV, FTC, and TAF 25 mg in participants taking the coformulated drug were similar to those seen in participants who received RPV as the single-drug tablet and TAF/FTC as part of the STR of EVG/c/TAF 10 mg/FTC.76
RPV is generally well tolerated. In the ECHO, THRIVE, and STaR trials, fewer instances of CNS adverse events (e.g., abnormal dreams, dizziness, psychiatric side effects), skin rash, and dyslipidemia were reported in the RPV arms than in the EFV arms, and fewer patients in the RPV arms discontinued therapy due to adverse events. However, up to 9% of clinical trial participants experienced depressive disorders, including approximately 1% of participants who had suicidal thoughts or who attempted suicide. Patients receiving RPV who have severe depressive symptoms should be evaluated to assess whether the symptoms may be due to RPV and if the risks of continuing the same regimen outweigh the benefits.
RPV is formulated both as a single-drug tablet and in STRs with TAF/FTC and with TDF/FTC. Among available STRs, RPV/TAF/FTC is the smallest tablet.
RPV/TAF/FTC and RPV/TDF/FTC are given once daily and must be administered with a meal (containing at least 390 kcal).
RPV is also coformulated as a once-daily FDC tablet with DTG that is used as continuation therapy for persons with HIV who have achieved viral suppression.163 However, this combination has not been studied in ART-naive individuals, and it is not recommended for initial therapy (see Optimizing Antiretroviral Therapy in the Setting of Viral Suppression).
The oral drug absorption of RPV can be significantly reduced in the presence of acid-lowering agents. RPV is contraindicated in patients who are receiving proton pump inhibitors (PPIs), and should be used with caution in those receiving H2 antagonists or antacids (see Drug-Drug Interactions for dosing recommendations).
RPV is primarily metabolized in the liver by the CYP3A enzyme; its plasma concentration may be affected in the presence of CYP3A inhibitors or inducers (see Drug-Drug Interactions).
At doses above the approved dose of 25 mg, RPV may cause QTc interval prolongation. RPV should be used with caution when coadministered with a drug known to increase the risk of Torsades de Pointes.
Given the availability of other effective regimens that do not have virologic and immunologic prerequisites to initiate treatment, the Panel recommends RPV/TDF/FTC and RPV/TAF/FTC as Recommended Initial Regimens in Certain Clinical Situations.
Use of RPV with TAF/FTC (BII) or TDF/FTC (BI) should be limited to ART-naive patients with pretreatment viral loads <100,000 copies/mL and CD4 counts >200 cells/mm3.
Data on RPV plus ABC/3TC are insufficient to consider recommending this regimen.
Table 8d. Characteristics of Protease Inhibitor Options that are Recommended for Antiretroviral Therapy-Naive Patients
Dosing Frequency Once daily
Once daily for PI-naive patients
Twice daily for PI-experienced patients with certain PI mutations
PK Boosting PK-boosting with RTV or COBI is generally recommended. Unboosted ATV is also FDA-approved for ART-naive patients. DRV should only be used with a PK booster (i.e., RTV or COBI).
Fixed-Dose Formulation
ATV/c
DRV/c
Available as a Single-Drug Tablet Yes Yes
Indirect hyperbilirubinemia
Cholelithiasis
Nephrolithiasis
PR prolongation
Increase in serum transaminases
A higher cardiovascular risk was reported in participants taking DRV-based regimens than in those taking ATV-based regimens in an observational cohort study.
CYP3A4 Drug-Drug Interactions CYP3A4 substrate, inhibitor CYP34A substrate, inhibitor
Other Significant Drug Interactions ATV absorption is reduced when ATV is given with acid-lowering therapies. See Table 21a for ATV dosing recommendations when the drug is coadministered with acid-lowering agents. N/A
Key: ART = antiretroviral therapy; ATV = atazanavir; ATV/c = atazanavir/cobicistat; COBI = cobicistat; CYP = cytochrome P; DRV = darunavir; DRV/c = darunavir/cobicistat; FDA = Food and Drug Administration; FTC = emtricitabine; N/A = not applicable; PI = protease inhibitor; PK = pharmacokinetic; RTV = ritonavir; TAF = tenofovir alafenamide
FDA-approved PIs include ATV, atazanavir/cobicistat (ATV/c), DRV, DRV/c, FPV, IDV, LPV/r, nelfinavir, RTV, saquinavir (SQV), and tipranavir. PI-based regimens with PK enhancement (also called boosting) have demonstrated virologic potency, durability in treatment-naive patients, and a high barrier to resistance. Because transmitted PI resistance is uncommon, PI-based regimens are generally recommended if early ART initiation is necessary, before resistance test results are available. Few or no PI mutations are detected when a patient's first PI-based regimen fails, which is not the case with NNRTI-based regimens and some INSTI-based regimens.164,165 For this reason, PI-based regimens may be useful for patients at risk for intermittent therapy because of poor adherence. All PIs (boosted by either RTV or COBI) inhibit the CYP3A4 isoenzyme, which may lead to significant drug-drug interactions (see Drug-Drug Interactions). Each PI has specific characteristics related to its virologic potency, adverse effects profile, and PK properties. The characteristics of recommended PIs are listed in Table 9 and Appendix B, Table 5.
PI-based regimens that are recommended for use in ART-naive patients should have proven virologic efficacy, once-daily dosing, a lower pill count than older PI-based regimens, and good tolerability. On the basis of these criteria, the Panel considers once-daily DRV/r, DRV/c, ATV/c, or ATV/r, each administered in combination with with two NRTIs, as PI-based regimen options in the category of Recommended Initial Regimens in Certain Clinical Situations. DRV/c/TAF/FTC is now available as an STR. In a large, randomized controlled trial comparing DRV/r, ATV/r, and RAL, each administered in combination with TDF/FTC, all three regimens achieved similar virologic suppression rates; however, the proportion of patients who discontinued their assigned treatment because of adverse effects, mainly hyperbilirubinemia, was greater in the ATV/r arm than in the other two arms.13
Several metabolic abnormalities, including dyslipidemia and insulin resistance, have been associated with PI use. The currently available PIs differ in their propensity to cause these metabolic complications, which also depends on the dose of RTV used as a PK-enhancing agent. Large observational cohort studies found an association between some PIs (i.e., DRV/r, FPV, IDV, and LPV/r) and an increased risk of cardiovascular events; this risk was not seen with ATV.29-31,34 Another observational cohort study of predominantly male participants found a lower rate of cardiovascular events in those receiving ATV-containing regimens than in those receiving other regimens.33 Further study is needed.
Compared to other PIs, LPV/r, FPV/r, unboosted ATV, and SQV/r have disadvantages such as greater pill burden, lower efficacy, or increased toxicity, and thus are no longer recommended as options for initial therapy.
Darunavir/Ritonavir (DRV/r)
The ARTEMIS study compared DRV/r (800 mg/100 mg once daily) with LPV/r (800 mg/200 mg once daily or 400 mg/100 mg twice daily), both administered in combination with TDF/FTC, in a randomized, open-label, noninferiority trial. DRV/r was noninferior to LPV/r at week 48,80 and superior at week 192.166 Among participants with baseline HIV RNA levels >100,000 copies/mL, virologic response rates were lower in the LPV/r arm than in the DRV/r arm.
The FLAMINGO study compared DRV/r with DTG, each administered in combination with two NRTIs, in 488 ART-naive participants. The rate of virologic suppression at week 96 was significantly greater among those who received DTG than in those who received DRV/r. The higher rate of virologic failure observed in the DRV/r group was primarily related to the great number of failures among those with a viral load >100,000 copies/mL, and secondarily because there were more drug discontinuations in the DRV/r group.14
ACTG A5257, a large, randomized, open-label trial, compared ATV/r to DRV/r or RAL, each given with TDF/FTC. The trial showed similar virologic efficacy for DRV/r, ATV/r, and RAL, but more participants in the ATV/r group discontinued randomized treatment because of adverse events.13
The DRIVE-FORWARD study compared DRV/r to DOR, both administered with two investigator-selected NRTIs, in ART-naive participants. At 48 weeks, DOR was found to be noninferior to DRV/r, with 80% of participants who received DOR and 84% of participants who received DRV/r achieving HIV RNA levels <50 copies/mL.
Patients taking DRV/r may develop a skin rash, which is usually mild-to-moderate in severity and self-limited. Treatment discontinuation is necessary on rare occasions when severe rash with fever or elevated transaminases occur.
ACTG A5257 showed similar lipid changes in participants in the ATV/r and DRV/r arms. BMD decreased to a greater extent in participants in the ATV/r and DRV/r arms than in participants in the RAL arm.13 The likelihood of developing metabolic syndrome was equivalent between the three arms, although a larger increase in waist circumference was observed at 96 weeks in participants assigned to the RAL arm than in those assigned to the DRV/r arm (P ≤ 0.02).167
An observational cohort study suggested that DRV/r is associated with increased rates of cardiovascular disease.34
DRV/r is administered once daily with food in treatment-naive patients.
DRV has a sulfonamide moiety and should be used with caution in patients with severe sulfonamide allergies. In clinical trials, the incidence and severity of rash were similar in participants with and without a history of sulfonamide allergy. Most patients with sulfonamide allergy are able to tolerate DRV.
DRV/r is a potent CYP3A4 inhibitor, and this may lead to significant interactions with other medications metabolized through this same pathway (see Drug-Drug Interactions).
On the basis of efficacy and safety data from clinical trials and clinical experience, the Panel classifies DRV/r with TDF/FTC (AI), with TAF/FTC (AII), or with ABC/3TC (BII) as Recommended Initial Regimens in Certain Clinical Situations.
Darunavir/Cobicistat (DRV/c)
In a study in healthy volunteers, DRV 800 mg with COBI 150 mg was bioequivalent to DRV 800 mg with RTV 100 mg based on the maximum concentration and area under the concentration time curve for DRV.168 Because the minimum concentration (Cmin) of DRV combined with COBI was 31% lower than that of DRV combined with RTV, bioequivalence for the Cmin was not achieved.169
The AMBER trial enrolled 725 ART-naive participants in a Phase 3 randomized controlled trial that compared the STR DRV/c/TAF/FTC and DRV/c plus TDF/FTC. At 48 weeks, similar virologic suppression rates among participants were achieved in both arms of the study (91% and 88% had HIV RNA < 50 copies/mL, respectively). No treatment-emergent mutations associated with DRV or TAF/TDF resistance were observed in either group. In the DRV plus TAF/FTC arm, fewer participants developed proteinuria. Changes in BMD were also less pronounced among these participants.52 At 96 weeks, 85% of participants on the STR maintained HIV RNA levels <50 copies/mL.170
In a single-arm trial in which most of the patients were treatment-naive (94%), the coformulated DRV/c 800 mg/150 mg tablet was evaluated in combination with two investigator-selected NRTIs (99% of participants were given TDF/FTC). At week 48, 83% of treatment-naive participants achieved HIV RNA <50 copies/mL; 5% of participants discontinued treatment because of adverse events.171
The most common drug-related adverse events were diarrhea, nausea, fatigue, flatulence, rash, and headache.
Other Factors:
DRV/c 800 mg/150 mg is available as a coformulated boosted PI or as an STR with TAF/FTC 10 mg/200 mg.
The Panel recommends DRV/c plus TAF/FTC or TDF/FTC (AI) and DRV/c plus ABC/3TC (BII) as Recommended Initial Regimens in Certain Clinical Situations.
DRV/c plus TDF/FTC is not recommended for patients with CrCl <70 mL/min, whereas DRV/c plus TAF/FTC is not recommended for patients with CrCl <30 mL/min.
Atazanavir/Ritonavir (ATV/r) or Atazanavir/Cobicistat (ATV/c)
ATV/r plus Two NRTIs versus LPV/r plus Two NRTIs
The CASTLE study compared once-daily ATV/r (300 mg/100 mg) with twice-daily LPV/r (400 mg/100 mg), each administered in combination with TDF/FTC. In this open-label, noninferiority study, the two regimens showed similar virologic and CD4 responses at 96 weeks.172
ATV/r plus Two NRTIs versus EFV plus Two NRTIs
The ACTG A5202 study compared open-label ATV/r and EFV, each given in combination with placebo-controlled TDF/FTC or ABC/3TC. Efficacy was similar in the ATV/r and EFV groups.143 In a separate analysis, women assigned to receive ATV/r were found to have a higher risk of virologic failure than women assigned to receive EFV or men assigned to receive ATV/r.173
ATV/r plus Two NRTIs versus INSTI plus Two NRTIs
In a study that compared ATV/r plus TDF/FTC to EVG/c/TDF/FTC, virologic suppression rates through 144 weeks were similar among participants in the two groups.129 A Phase 3 clinical trial of 575 women evaluated EVG/c plus FTC/TDF versus ATV/r plus FTC/TDF.15 At week 48, the virologic suppression rate in the EVG/c arm was superior to that in the ATV/r arm. Nineteen women in the PI arm and five women in the INSTI arm discontinued therapy because of an adverse event.
In a Phase 3 trial, 499 ART-naive women were randomized to receive either ATV/r plus TDF/FTC or DTG/ABC/3TC. At 48 weeks, the rate of virologic suppression (HIV RNA <50 copies/mL) in the DTG arm was noninferior to that in the ATV/r arm, and fewer drug-related adverse events occurred in the DTG arm.118
ATV/r plus Two NRTIs versus DRV/r plus Two NRTIs versus RAL plus Two NRTIs
In ACTG A5257, a significantly higher proportion of patients in the ATV/r arm discontinued randomized treatment because of adverse events, mostly for elevated indirect bilirubin/jaundice or gastrointestinal toxicities. Lipid changes in participants in the ATV/r and DRV/r arms were similar. BMD decreased to a greater extent in participants in the ATV/r and DRV/r arms than in participants in the RAL arm.13
ATV/c versus ATV/r plus Two NRTIs
In the Gilead Study 114, all patients received TDF/FTC and ATV and were randomized to receive either RTV or COBI as PK enhancers. Both RTV and COBI were given as a separate tablet with matching placebos.174 Through 144 weeks, the percentage of patients who achieved virologic suppression was similar in both study arms. The percentage of adverse events that caused patients to discontinue treatment, and changes in serum creatinine and indirect bilirubin levels were comparable.175
The main adverse effect associated with ATV/c or ATV/r is reversible indirect hyperbilirubinemia, with or without jaundice or scleral icterus, but without concomitant hepatic transaminase elevations. The risk for treatment-limiting indirect hyperbilirubinemia is greatest for patients who carry two UGT1A1 decreased-function alleles.176
Nephrolithiasis,177-179 nephrotoxicity,32 and cholelithiasis180 have also been reported in patients who received ATV.
Both ATV/c and ATV/r can cause gastrointestinal side effects, including diarrhea.
ATV/c and ATV/r are dosed once daily and with food.
ATV requires acidic gastric pH for dissolution. As a result, concomitant use of drugs that raise gastric pH (e.g., antacids, H2 antagonists, and particularly PPIs) may impair absorption of ATV. Table 21a provides recommendations for use of ATV/c or ATV/r with these agents.
ATV/c and ATV/r are potent CYP3A4 inhibitors and may have significant interactions with other medications that are metabolized through this same pathway (see Drug-Drug Interactions).
Large observational cohort studies found an association between some PIs (DRV/r, FPV, IDV, and LPV/r) and an increased risk of cardiovascular events; this risk was not seen with ATV.29-31,34 Another study of an observational cohort of predominantly male participants found a lower rate of cardiovascular events in participants receiving ATV-containing regimens than in participants receiving other regimens.33 Further study is needed.
On the basis of clinical trial safety and efficacy data, the Panel classifies ATV/r and ATV/c plus TAF/FTC (BII) or TDF/FTC (BI) as Recommended Initial Regimens in Certain Clinical Situations.
ATV/c or ATV/r plus ABC/3TC is no longer included in the list of Recommended Initial Regimens in Certain Clinical Situations, because it has disadvantages when compared with other regimens in this category. In a randomized trial, when combined with ATV/r, ABC/3TC was less potent than TDF/FTC in people with HIV RNA >100,000 copies/mL;43 in a separate randomized trial, ATV/r was not as well tolerated as DRV/r.13
ATV/c plus TDF/FTC is not recommended for patients with CrCl <70 mL/min, whereas ATV/c plus TAF/FTC is not recommended for patients with CrCl <30 mL/min.
Other Antiretroviral Regimens for Initial Therapy When Abacavir, Tenofovir Alafenamide, and Tenofovir Disoproxil Fumarate Cannot Be Used or Are Not Optimal
Most currently recommended ARV regimens consist of two NRTIs plus a third active drug. In some clinical situations, it is preferable to avoid ABC, TAF, and TDF, such as in patients who are HLA-B*5701 positive or at high risk of cardiovascular disease and with significant renal impairment. In this situation, DTC/3TC, which is recommended for most people with HIV, is the preferred option. In addition, several other NRTI-limiting two-drug regimens have been evaluated in clinical studies. Of note, two-drug regimens should not be used in people with HBV/HIV coinfection or during pregnancy. Clinicians should refer to HBV/HIV Coinfection for guidance on treatment of patients with HBV infection when TAF or TDF cannot be used as part of the ARV regimen.
Strategies Supported by Evidence from Clinical Trials
Dolutegravir/Lamivudine (DTG/3TC)
Among the two-drug regimens for initial therapy, the combination of DTG/3TC has the most clinical data supporting its use;4,120,181 therefore, it is recommended over the other two-drug regimens listed below. Clinicians should refer to the INSTI section above for a summary of the data supporting the use of DTG/3TC as initial therapy for ART-naive people with HIV.
The Panel recommends DTG/3TC as an initial regimen for most people with HIV (AI); as such, this is the preferred regimen when use of ABC, TAF, or TDF is not optimal. DTG/3TC is not recommended for individuals with HIV RNA >500,000 copies/mL, HBV coinfection, or in whom ART is to be started before the results of HIV genotypic resistance testing for reverse transcriptase or HBV testing are available. Before prescribing DTG/3TC for a person of childbearing potential, review Table 6b for a discussion of important considerations.
Darunavir/Ritonavir plus Lamivudine (DRV/r plus 3TC)
In the ANDES trial, 145 participants were randomized 1:1 to receive open-label, once-daily dual therapy with DRV/r plus 3TC or triple therapy with DRV/r plus TDF/3TC. This study was conducted in Argentina, and the researchers used an FDC of DRV/r 800 mg/100 mg that is available in that country. The median baseline HIV RNA was 4.5 log10 copies, and 24% of participants had HIV RNA >100,000 copies/mL. At week 48, 93% of the participants in the dual-therapy group and 94% of the participants in the triple-therapy group achieved an HIV RNA <50 copies/mL; dual therapy was noninferior to triple therapy.39 The rates of virologic suppression among study participants who had pre-therapy HIV RNA levels >100,000 copies/mL were similar in the dual- and triple-therapy groups (91% and 92%, respectively).
On the basis of results from a small study with a relatively short follow-up period, DRV/r plus 3TC can be considered for use in people who cannot take ABC, TAF, or TDF (CI). Although the ANDES trial supports the use of DRV/r plus 3TC, it is smaller than other trials of NRTI-limiting regimens, and larger studies are warranted.
Darunavir/Ritonavir plus Raltegravir (DRV/r plus RAL)
In the NEAT/ANRS 143 study, 805 treatment-naive participants were randomized to receive twice-daily RAL or once-daily TDF/FTC, each with DRV/r (800 mg/100 mg once daily). At week 96, DRV/r plus RAL was noninferior to DRV/r plus TDF/FTC based on the primary endpoint of proportion of patients with virologic or clinical failure. Among those with baseline CD4 counts <200 cells/mm3, however, there were more virologic failures in the two-drug arm; a trend towards more failure was also observed among those with pretreatment HIV RNA ≥100,000 copies/mL.38 High rates of virologic failure in patients with HIV RNA >100,000 copies/mL were also seen in two smaller studies of DRV/r plus RAL.182,183
On the basis of these study results, the Panel recommends that DRV/r plus RAL be considered for use only in patients with HIV RNA <100,000 copies/mL and CD4 counts >200 cells/mm3, and only in those patients who cannot take ABC, TAF, or TDF (CI).
A Nucleoside-Limiting Regimen with Insufficient Supporting Data
Darunavir/Ritonavir plus Rilpivirine (DRV/r plus RPV)
In a single-arm, open-label, pilot study, 36 ART-naive participants without genotypic evidence of resistance to DRV or RPV received DRV/r plus RPV for 48 weeks. Half of the participants (18 of 36) had baseline HIV viral loads >100,000 copies/ml. By week 36, 97% of participants (35 of 36) achieved HIV RNA <50 copies/ml, and by week 48, all achieved viral suppression (HIV RNA <50 copies/ml).184
At this time, the Panel does not recommend DRV/r plus RPV given the small sample size of the study described above and the lack of comparative data evaluating DRV/r plus RPV as initial therapy for people with HIV.
Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy
Note: All drugs within an ARV class are listed in alphabetical order.
ARV Class
ARV Agent(s)
Advantage(s)
Disadvantage(s)
Dual-NRTI Regimens ABC/3TC
Coformulated with DTG
Generic formulations are available for ABC/3TC, ABC, and 3TC.
May cause life-threatening HSRs in patients who test positive for the HLA-B*5701 allele. As a result, HLA-B*5701 testing is required before use.
In the ACTG 5202 study, patients with baseline HIV RNA ≥100,000 copies/mL showed inferior virologic responses when ABC/3TC was given with EFV or ATV/r as opposed to TDF/FTC. This difference was not seen when ABC/3TC was used in combination with DTG.
ABC use has been associated with CV disease and cardiac events in some, but not all, observational studies.
Coformulated with BIC, DRV/c, EVG/c, or RPV
Active against HBV; a recommended dual-NRTI option for patients with HBV/HIV coinfection
Smaller decline in renal function, less proteinuria, and smaller reductions in BMD than TDF/FTC
Approved for patients with eGFR ≥30 mL/min
Can be used in patients with eGFR <30 mL/min and on chronic hemodialysis
TDF is associated with lower lipid levels than TAF, perhaps because TDF results in higher plasma levels of tenofovir, which lowers lipids.
Not recommended in pregnancy.
Coformulated with DOR
Generic formulations are available for TDF, 3TC, TDF/3TC, and EFV/TDF/3TC.
Long-term clinical experience
Active against HBV
Renal toxicity, including proximal tubulopathy and acute or chronic renal insufficiency, especially when combined with pharmacologic boosters.
Osteomalacia has been reported as a consequence of proximal tubulopathy.
Decreased BMD has been associated with use of TDF, especially when combined with pharmacologic boosters.
Coformulated with EFV, EVG/c, and RPV as STRs
Active against HBV; a recommended dual-NRTI option for patients with HIV/HBV coinfection
Better virologic responses than ABC/3TC in patients with baseline viral loads ≥100,000 copies/mL when combined with ATV/r or EFV
Associated with lower lipid levels than ABC or TAF
Single NRTI 3TC
Coformulated with DTG as STR
Avoids potential toxicities associated with TDF, TAF, ABC
DTG/3TC is not recommended for individuals with HIV RNA >500,000 copies/mL, HBV co-infection, or in whom ART is to be started before the results of HIV genotypic resistance testing for reverse transcriptase or HBV testing are available.
INSTI BIC
Coformulated with TAF/FTC
Higher barrier to resistance than EVG and RAL
No food requirement
See Table 6b for considerations related to prescribing an INSTI-based regimen to people of childbearing potential.
Oral absorption of BIC can be reduced by simultaneous administration with drugs or supplements containing polyvalent cations (e.g., Al-, Ca-, or Mg-containing antacids or supplements, or multivitamin tablets with minerals). See dosing recommendations in Table 21d.
Inhibits tubular secretion of Cr without affecting glomerular function.
CYP3A4 and UGT1A1 substrate (but not a CYP3A4 inducer or inhibitor); potential for drug-drug interactions.
Should not be used in pregnancy because of lack of data and coformulation with TAF.
See discussion in text regarding weight gain related to INSTIs.
Higher barrier to resistance than EVG or RAL
Coformulated with ABC/3TC and 3TC
Minimal CYP3A4 interactions
Favorable lipid profile
Data from Botswana suggest that DTG exposure during conception may be associated with risk of NTDs in the infant (0.3% vs. 0.1% with non-DTG ARV drugs).
See Table 6b for considerations related to prescribing an INSTI-based regimen for a person of childbearing potential.
Oral absorption of DTG can be reduced by simultaneous administration with drugs containing polyvalent cations (e.g., Al-, Ca-, or Mg-containing antacids or supplements, or multivitamin tablets with minerals). See dosing recommendations in Table 21d.
Inhibits renal tubular secretion of Cr and can increase serum Cr without affecting glomerular function.
UGT1A1 substrate; potential for drug interactions (see Table 21d).
Depression and suicidal ideation (rare; usually in patients with pre-existing psychiatric conditions).
Coformulated with TDF/FTC or TAF/FTC
Compared with ATV/r, EVG/c causes smaller increases in total and LDL cholesterol.
EVG/c/TAF/FTC can be used in patients on chronic hemodialysis.
EVG/c/TDF/FTC is only recommended for patients with baseline CrCl ≥70 mL/min; this regimen should be discontinued if CrCl decreases to <50 mL/min.
COBI is a potent CYP3A4 inhibitor, which can result in significant interactions with CYP3A substrates.
Oral absorption of EVG can be reduced by simultaneous administration with drugs containing polyvalent cations (e.g., Al-, Ca-, or Mg-containing antacids or supplements, or multivitamin tablets with minerals). See dosing recommendations in Table 21d.
COBI inhibits active tubular secretion of Cr and can increase serum Cr without affecting renal glomerular function.
Has a lower barrier to resistance than boosted PI-, BIC-, or DTG-based regimens.
Food requirement.
Should not be used in pregnancy because of low drug exposure.
Compared to other INSTIs, has longest post-marketing experience
No CYP3A4 interactions
Increases in creatine kinase, myopathy, and rhabdomyolysis have been reported.
Rare cases of severe HSRs (including SJS and TEN) have been reported.
Higher pill burden than other INSTI-based regimens.
No FDC formulation.
Oral absorption of RAL can be reduced by simultaneous administration with drugs containing polyvalent cations (e.g., Al-, Ca-, or Mg-containing antacids or supplements, or multivitamin tablets with minerals). See dosing recommendations in Table 21d.
NNRTI DOR
Coformulated with TDF/3TC
Compared to EFV, fewer CNS side effects
Shorter-term clinical experience than with EFV and RPV.
Potential for CYP450 drug interactions (see Tables 21b, 22a and 22b).
Treatment-emergent DOR resistance mutations may confer resistance to certain NNRTIs.
EFV 600 mg is coformulated with TDF/FTC and TDF/3TC.
EFV 400 mg is coformulated with TDF/3TC.
EFV 600-mg dose has long-term clinical experience and EFV-based regimens (except for EFV plus ABC/3TC) have well-documented efficacy in patients with high HIV RNA.
EFV 400 mg has fewer CNS side effects than EFV 600 mg.
EFV 600 mg can be given with rifamycin antibiotics (rifampin, rifabutin, or rifapentine).
Short- and long-term neuropsychiatric (CNS) side effects, including depression and, in some studies, suicidality and catatonia. Late onset ataxia and encephalopathy have also been reported.
Periodic screening for depression and suicidality is recommended in people with HIV who are taking a regimen that includes EFV.
QTc interval prolongation; consider using an alternative to EFV in patients taking medications with known risk of causing Torsades de Pointes or in those at higher risk of Torsades de Pointes.
Transmitted resistance is more common than with PIs and INSTIs.
Greater risk of resistance at the time of treatment failure than with PIs.
Potential for CYP450 drug interactions (see Tables 21b and 22a).
Should be taken on an empty stomach (food increases drug absorption and CNS toxicities).
Coformulated with TDF/FTC and TAF/FTC
RPV/TDF/FTC and RPV/TAF/FTC have smaller pill sizes than other coformulated ARV drugs
Compared with EFV:
Fewer CNS adverse effects
Fewer lipid effects
Fewer rashes
Not recommended in patients with pre-ART HIV RNA >100,000 copies/mL or CD4 counts <200 cells/mm3 because of higher rate of virologic failure in these patients.
Depression and suicidality
QTc interval prolongation; consider using an alternative to RPV in patients taking medications with known risk of causing Torsades de Pointes or in those at higher risk of Torsades de Pointes.
More NNRTI-, TDF-, and 3TC-associated mutations at virologic failure than with regimens that contain EFV and 2 NRTIs.
Meal requirement (>390 kcal)
Requires acid for adequate absorption.
Contraindicated with PPIs.
Use with H2 antagonists or antacids with caution (see Table 21a for detailed dosing information).
PI ATV/c
ATV/r
Higher barrier to resistance than NNRTIs, EVG, and RAL
PI resistance at the time of treatment failure is uncommon with PK-enhanced PIs.
ATV/c and ATV/r have similar virologic activity and toxicity profiles.
Observational cohort studies have found an association between some PIs (DRV, LPV/r, FPV, IDV) and an increased risk of CV events; this risk has not been seen with ATV. Further study is needed. See text for discussion.
Individual ATV and RTV components are available as generics.
Commonly causes indirect hyperbilirubinemia, which may manifest as scleral icterus or jaundice.
Food requirement
Absorption depends on food and low gastric pH (see Table 21a for interactions with H2 antagonists, antacids, and PPIs).
Nephrolithiasis, cholelithiasis, nephrotoxicity
GI adverse effects
CYP3A4 inhibitors and substrates: potential for drug interactions (see Table 21a).
Specific considerations Coformulated tablet
Coadministration with TDF is not recommended in patients with CrCl <70 mL/min.
COBI (like RTV) is a potent CYP3A4 inhibitor, which can result in significant interactions with CYP3A substrates.
COBI is not recommended in pregnancy because of low drug levels.
DRV/r
Increased CV risk reported in one observational cohort study.
Hepatotoxicity has been reported, especially in those with pre-existing liver disease.
Specific considerations
Coformulated as DRV/c and DRV/c/TAF/FTC
Key: 3TC = lamivudine; ABC = abacavir; Al = aluminum; ART = antiretroviral therapy; ARV = antiretroviral; ATV = atazanavir; ATV/c = atazanavir/cobicistat; ATV/r = atazanavir/ritonavir; BIC = bictegravir; BMD = bone mineral density; Ca = calcium; CD4 = CD4 T lymphocyte; CNS = central nervous system; COBI = cobicistat; Cr = creatinine; CrCl = creatinine clearance; CV = cardiovascular; CYP = cytochrome P; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; eGFR = estimated glomerular filtration rate; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FDC = fixed-dose combination; FPV = fosamprenavir; FTC = emtricitabine; GI = gastrointestinal; HBV = hepatitis B virus; HLA = human leukocyte antigen; HSR = hypersensitivity reaction; IDV = indinavir; INSTI = integrase strand transfer inhibitor; LDL = low-density lipoprotein; LPV/r = lopinavir/ritonavir; Mg = magnesium; MI = myocardial infarction; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NTD = neural tube defect; PI = protease inhibitor; PK = pharmacokinetic; PPI = proton pump inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SJS = Stevens-Johnson syndrome; STR = single-tablet regimen; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TEN = toxic epidermal necrosis; UGT = uridine diphosphate glucuronosyltransferase
ARV Components or Regimens
Reasons for Not Recommending as Initial Therapy
ABC/3TC/ZDV (Coformulated)
As triple-NRTI combination regimen
Inferior virologic efficacy
ABC/3TC/ZDV plus TDF
As quadruple-NRTI combination regimen
d4T plus 3TC
Significant toxicities (including lipoatrophy, peripheral neuropathy) and hyperlactatemia (including symptomatic and life-threatening lactic acidosis, hepatic steatosis, and pancreatitis)
ddI plus 3TC (or FTC)
Limited clinical trial experience in ART-naive patients
ddI toxicities, such as pancreatitis and peripheral neuropathy
ddI plus TDF
High rate of early virologic failure
Rapid selection of resistance mutations
Potential for immunologic nonresponse/CD4 cell decline
Increased ddI drug exposure and toxicities
ZDV/3TC
Greater toxicities (including bone marrow suppression, GI toxicities, skeletal muscle myopathy, cardiomyopathy, and mitochondrial toxicities such as lipoatrophy, lactic acidosis, and hepatic steatosis) than recommended NRTIs
Inconvenient (three times daily) dosing
Insufficient data in ART-naive patients
Associated with serious and potentially fatal toxicity (hepatic events and severe rash, including SJS and TEN)
When compared to EFV, NVP did not meet noninferiority criteria
ATV (Unboosted)
Less potent than boosted ATV
DRV (Unboosted)
Use without RTV or COBI has not been studied
FPV (Unboosted) or FPV/r
Virologic failure with unboosted FPV-based regimen may result in selection of mutations that confer resistance to FPV and DRV
Less clinical trial data for FPV/r than for other RTV-boosted PIs
IDV (Unboosted)
Inconvenient dosing (3 times daily with meal restrictions)
Fluid requirement
IDV toxicities, such as nephrolithiasis and crystalluria
IDV/r
LPV/r
Higher pill burden than other PI-based regimens
Higher RTV dose than other PI-based regimens
GI intolerance
RTV as sole PI
High pill burden
Metabolic toxicity
SQV (Unboosted)
Inadequate bioavailability
SQV/r
Can cause QT and PR prolongation; requires pretreatment and follow-up ECG
TPV/r
Higher rate of adverse events than other RTV-boosted PIs
Higher dose of RTV required for boosting than other RTV-boosted PIs
Entry Inhibitors
Only studied in patients with virologic failure
Twice-daily subcutaneous injections
High rate of injection site reactions
Only studied in a very small number of patients with virologic failure
Requires IV therapy
High cost
Requires testing for CCR5 tropism before initiation of therapy
No virologic benefit when compared with other recommended regimens
Requires twice-daily dosing
Key: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; ATV = atazanavir; CD4 = CD4 T lymphocyte; COBI = cobicistat; d4T = stavudine; ddI = didanosine; DLV = delavirdine; DRV = darunavir; ECG = electrocardiogram; EFV = efavirenz; ETR = etravirine; FPV = fosamprenavir; FPV/r = fosamprenavir/ritonavir; FTC = emtricitabine; GI = gastrointestinal; IBA = ibalizumab; IDV = indinavir; IDV/r = indinavir/ritonavir; IV = intravenous; LPV = lopinavir; LPV/r = lopinavir/ritonavir; MVC = maraviroc; NFV = nelfinavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RTV = ritonavir; SJS = Stevens Johnson Syndrome; SQV = saquinavir; SQV/r = saquinavir/ritonavir; T20 = enfuvirtide; TDF = tenofovir disoproxil fumarate; TEN = toxic epidermal necrolysis; TPV = tipranavir; TPV/r = tipranavir/ritonavir; ZDV = zidovudine
Moore RD, Bartlett JG. Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice. Clin Infect Dis. 2011;53(6):600-604. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21844006.
Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis. 2010;50(1):98-105. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19951169.
Lee FJ, Amin J, Carr A. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up. PLoS One. 2014;9(5):e97482. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24830290.
Cahn P, Madero JS, Arribas JR, et al. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. J Acquir Immune Defic Syndr. 2019. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31834000.
Zash R, Makhema J, Shapiro RL. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. N Engl J Med. 2018;379(10):979-981. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30037297.
Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 2019;381(9):827-840. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31329379.
Raesima MM, Ogbuabo CM, Thomas V, et al. Dolutegravir use at conception - additional surveillance data from Botswana. N Engl J Med. 2019;381(9):885-887. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31329378.
NAMSAL ANRS Study Group, Kouanfack C, Mpoudi-Etame M, et al. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. N Engl J Med. 2019;381(9):816-826. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31339676.
Zash R, Holmes L, Makhema J, et al. Surveillance for neural tube defects following antiretroviral exposure from conception. Presented at: 22nd International AIDS Conference (AIDS 2018); 2018; Amsterdam.
Shamsuddin H, Raudenbush C, Sciba B, et al. Pregnancy outcome following raltegravir exposure. Presented at: ID Week; 2019; Washington, DC. Available at: https://www.eventscribe.com/2019/IDWeek/fsPopup.asp?Mode=presInfo&PresentationID=582846.
Gantner P, Sylla B, Morand-Joubert L, et al. "Real life" use of raltegravir during pregnancy in France: the Coferal-IMEA048 cohort study. PLoS One. 2019;14(4):e0216010. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31017957.
Rasi V, Cortina-Borja M, Peters H, Sconza R, Thorne C. Brief report: surveillance of congenital anomalies after exposure to raltegravir or elvitegravir during pregnancy in the United Kingdom and Ireland, 2008-2018. J Acquir Immune Defic Syndr. 2019;80(3):264-268. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30531300.
Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014;161(7):461-471. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25285539.
Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2(4):e127-136. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26424673.
Squires K, Kityo C, Hodder S, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV. 2016;3(9):e410-e420. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27562742.
Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143-155. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30420123.
Fulcher JA, Du Y, Zhang TH, Sun R, Landovitz RJ. Emergence of integrase resistance mutations during initial therapy containing dolutegravir. Clin Infect Dis. 2018;67(5):791-794. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29933437.
Pena MJ, Chueca N, D'Avolio A, Zarzalejos JM, Garcia F. Virological failure in HIV to triple therapy with dolutegravir-based firstline treatment: rare but possible. Open Forum Infect Dis. 2019;6(1):ofy332. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30631792.
Lubke N, Jensen B, Huttig F, et al. Failure of dolutegravir first-line ART with selection of virus carrying R263K and G118R. N Engl J Med. 2019;381(9):887-889. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31461601.
Stellbrink HJ, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: Week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e364-e372. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31068272.
Wohl DA, Yazdanpanah Y, Baumgarten A, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e355-e363. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31068270.
Bhagwat P, Ofotokun I, McComsey GA, et al. Changes in waist circumference in HIV-infected individuals initiating a raltegravir or protease inhibitor regimen: effects of sex and race. Open Forum Infect Dis. 2018;5(11):ofy201. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30465010.
Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2019. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31606734.
Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803-815. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31339677.
Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2019. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31100116.
Bourgi K, Jenkins C, Rebeiro PF, et al. Greater weight gain among treatment-naive persons starting integrase inhibitors. Presented at: Conference on Retroviruses and Opportunistic Infections; 2019; Seattle, Washington. Available at: https://www.croiconference.org/sessions/greater-weight-gain-among-treatment-naive-persons-starting-integrase-inhibitors.
Stein JH, Ribaudo HJ, Hodis HN, et al. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS. 2015;29(14):1775-1783. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26372383.
de Saint-Martin L, Bressollette L, Perfezou P, et al. Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort. AIDS. 2010;24(18):2797-2801. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21063175.
Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170(14):1228-1238. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20660842.
Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201(3):318-330. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20039804.
Monforte AD, Reiss P, Ryom L, et al. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AIDS. 2013;27(3):407-415. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23291539.
Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 2013;207(9):1359-1369. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23382571.
LaFleur J, Bress AP, Rosenblatt L, et al. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS. 2017;31(15):2095-2106. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28692532.
Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 2018;5(6):e291-e300. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29731407.
ENCORE Study Group, Carey D, Puls R, et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015;15(7):793-802. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25877963.
Orkin C, Squires KE, Molina JM, et al. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019;68(4):535-544. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30184165.
Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5(5):e211-e220. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29592840.
Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384(9958):1942-1951. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25103176.
Figueroa MI, Sued OG, Gun AM, et al. DRV/R/3TC FDC for HIV-1 treatment naive patients: week 48 results of the ANDES study. Presented at: Conference on Retroviruses and Opportunistic Infections; 2018; Boston, MA.
Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46(3):716-723. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11850253.
Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem. 2001;276(44):40847-40857. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11526116.
Hill A, Hughes SL, Gotham D, Pozniak AL. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? J Virus Erad. 2018;4(2):72-79. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29682298.
Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361(23):2230-2240. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19952143.
Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55(1):49-57. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20431394.
Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23(12):1547-1556. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19542866.
Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807-1818. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24195548.
Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606-2615. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25890673.
Arribas JR, Thompson M, Sax PE, et al. Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results. J Acquir Immune Defic Syndr. 2017;75(2):211-218. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28282300.
Rijnders BJ, Post FA, Rieger A, et al. Longer-term renal safety of tenofovir alafenamide vs tenofovir disoproxil fumarate. Presented at: Conference on Retroviruses and Opportunistic Infections; 2016; Boston, MA. Available at: http://www.croiconference.org/sessions/longer-term-renal-safety-tenofovir-alafenamide-vs-tenofovir-disoproxil-fumarate.
Wohl D, Oka S, Clumeck N, et al. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr. 2016;72(1):58-64. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26829661.
Mills A, Crofoot GJ, McDonald C, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2015;69(4):439-445. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25867913.
Eron JJ, Orkin C, Gallant J, et al. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2018;32(11):1431-1442. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29683855.
Gallant J, Brunetta J, Crofoot G, et al. Efficacy and safety of switching to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-1/hepatitis B coinfected adults. J Acquir Immune Defic Syndr. 2016. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27171740.
DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004;39(7):1038-1046. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15472858.
Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35(1):22-32. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14707788.
Gathe JC, Jr., Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004;18(11):1529-1537. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15238771.
Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46(7):1111-1118. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18444831.
Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-579. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18256392.
Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417-1426. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18387667.
The SMART/INSIGHT and the D:A:D Study Groups TSIatDADSG. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22(14):F17-24. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18753925.
Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med. 2010;11(2):130-136. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19682101.
Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS. 2011;25(10):1289-1298. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21516027.
Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database. J Acquir Immune Defic Syndr. 2011;57(3):245-253. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21499115.
Young J, Xiao Y, Moodie EE, et al. Effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2015;69(4):413-421. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25932884.
Marcus JL, Neugebauer RS, Leyden WA, et al. Use of abacavir and risk of cardiovascular disease among HIV-infected individuals. J Acquir Immune Defic Syndr. 2016;71(4):413-419. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26536316.
Sabin CA, Reiss P, Ryom L, et al. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Med. 2016;14:61. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27036962.
Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51(1):20-28. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19282778.
Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011;53(1):84-91. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21653308.
Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011;52(7):929-940. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21427402.
Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012;61(4):441-447. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22932321.
Elion RA, Althoff KN, Zhang J, et al. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr. 2018;78(1):62-72. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29419568.
Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3(4):e158-165. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27036991.
Wohl D, Thalme A, Finlayson R, et al. Renal safety of tenofovir alafenamide in patients at high risk of kidney disease. Presented at: Conference on Retroviruses and Opportunistic Infections; 2016; Boston, MA. Available at: http://www.croiconference.org/sessions/renal-safety-tenofovir-alafenamide-patients-high-risk-kidney-disease.
Gomez M, Seybold U, Roider J, Harter G, Bogner JR. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017. Infection. 2019;47(1):95-102. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30269210.
Eron JJ, Lelievre JD, Kalayjian R, et al. Safety and efficacy of E/C/F/TAF in HIV-infected adults on chronic hemodialysis. Presented at: Conference on Retroviruses and Opportunistic Infections; 2018; Boston, MA.
Zack J, Chuck S, Chu H, et al. Bioequivalence of the rilpivirine/emtricitabine/tenofovir alafenamide single-tablet regimen. J Bioequiv Availab. 2016;8(2):49-54. Available at: http://www.omicsonline.org/open-access/bioequivalence-of-the-rilpivirineemtricitabinetenofovir-alafenamidesingletablet-regimen-jbb-1000266.pdf.
Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2007;8(3):164-172. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17621463.
Molina JM, Podsadecki TJ, Johnson MA, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses. 2007;23(12):1505-1514. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18160008.
Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646-655. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18722869.
Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22(12):1389-1397. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18614861.
Smith KY, Weinberg WG, Dejesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther. 2008;5:5. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18373851.
Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796-806. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19647866.
DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379(9835):2429-2438. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22748590.
Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439-2448. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22748591.
DeJesus E, Rockstroh JK, Lennox JL, et al. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. HIV Clin Trials. 2012;13(4):228-232. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22849964.
Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927-935. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24074642.
Rousseau FS, Wakeford C, Mommeja-Marin H, et al. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis. 2003;188(11):1652-1658. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14639535.
Ford N, Shubber Z, Hill A, et al. Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials. PLoS One. 2013;8(11):e79981. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24244586.
Rokx C, Fibriani A, van de Vijver DA, et al. Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort. Clin Infect Dis. 2015;60(1):143-153. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25273080.
Rokx C, Gras L, van de Vijver D, Verbon A, Rijnders B, Study ANOC. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naive HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort. HIV Med. 2016;17(8):571-580. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26842457.
Maserati R, De Silvestri A, Uglietti A, et al. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. AIDS. 2010;24(7):1013-1018. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20124969.
Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36(8):1070-1073. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12684922.
Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42(2):283-290. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16355343.
Gervasoni C, Meraviglia P, Landonio S, et al. Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. PLoS One. 2013;8(12):e80242. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24312465.
Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 2009;23(15):1971-1975. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19696652.
Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;43(3):278-283. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17079992.
Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197(1):102-108. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18171292.
Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83(2):265-272. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17597712.
Stribild package insert [package insert]. Gilead. 2017. Available at: http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/stribild/stribild_pi.pdf.
Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963-972. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20828304.
McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791-1801. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21606537.
Perrot S, Aslangul E, Szwebel T, Caillat-Vigneron N, Le Jeunne C. Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol. 2009;15(2):72-74. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19265350.
Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(9):e96-138. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25234519.
Kheloufi F, Allemand J, Mokhtari S, Default A. Psychiatric disorders after starting dolutegravir: report of four cases. AIDS. 2015;29(13):1723-1725. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26372287.
Harris M, Larsen G, Montaner JS. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22(14):1890-1892. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18753871.
Penafiel J, de Lazzari E, Padilla M, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother. 2017;72(6):1752-1759. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28333231.
Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56-63. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27860104.
Bernardino JI, Mocroft A, Wallet C, et al. Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial. PLoS One. 2019;14(1):e0209911. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30689664.
Bedimo R, Li X, Adams-Huet B, et al. Differential BMI changes following PI- and InSTI-based ART initiation by sex and race. Presented at: Conference on Retroviruses and Opportunistic Infections; 2019; Seattle, WA.
Bedimo R, Adams-Huet B, Taylor BS, Lake J, Luque A. Integrase inhibitor-based HAART is associated with greater BMI gains in blacks, hispanics and women. Presented at: IDWeek; 2018; San Fransisco, CA. Available at: https://idsa.confex.com/idsa/2018/webprogram/Paper71208.html.
Schafer JJ, Sassa KN, O'Connor JR, Shimada A, Keith SW, DeSimone JA. Changes in body mass index and atherosclerotic disease risk score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide. Open Forum Infect Dis. 2019;6(10):ofz414. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31660372.
Biktarvy Product Label [package insert]. Gilead Sciences. 2018. Available at: http://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf.
Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073-2082. Available at: http://www.ncbi.nlm.nih.gov/pubmed/28867499.
Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063-2072. Available at: http://www.ncbi.nlm.nih.gov/pubmed/28867497.
Walmsley S, Baumgarten A, Berenguer J, et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70(5):515-519. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26262777.
Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24698485.
Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naive HIV-1-positive individuals: 96 week results from FLAMINGO. J Int AIDS Soc. 2014;17(4 Suppl 3):19490. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25393999.
Orrell C, Hagins DP, Belonosova E, et al. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Lancet HIV. 2017. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28729158.
Cahn P, Rolon MJ, Figueroa MI, Gun A, Patterson P, Sued O. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc. 2017;20(1):1-7. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28537061.
Nyaku AN, Zheng L, Gulick RM, et al. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353. J Antimicrob Chemother. 2019;74(5):1376-1380. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30668695.
Fettiplace A, Stainsby C, Winston A, et al. Psychiatric symptoms in patients receiving dolutegravir. J Acquir Immune Defic Syndr. 2017;74(4):423-431. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27984559.
Kheloufi F, Boucherie Q, Blin O, Micallef J. Neuropsychiatric events and dolutegravir in HIV patients: a worldwide issue involving a class effect. AIDS. 2017;31(12):1775-1777. Available at: http://www.ncbi.nlm.nih.gov/pubmed/28700395.
Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63(1):77-85. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23412015.
Cahn P, Sax PE, Squires K, et al. Raltegravir 1200 mg once daily vs 400 mg twice daily, with emtricitabine and tenofovir disoproxil fumarate, for previously untreated HIV-1 Infection: Week 96 results from ONCEMRK, a randomized, double-blind, noninferiority Trial. J Acquir Immune Defic Syndr. 2018;78(5):589-598. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29771789.
Bhagwat P, Ofotokun I, McComsey GA, et al. Predictors of severe weight/body mass index gain following antiretroviral initiation. Presented at: Conference on Retroviruses and Opportunistic Infections; 2017; Seattle, Washington. Available at: https://www.croiconference.org/sessions/predictors-severe-weightbody-mass-index-gain-following-antiretroviral-initiation.
Isentress package insert [package insert]. Merck Sharp & Dohme Corp. 2017. Available at: http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf.
Gray J, Young B. Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review. AIDS Patient Care STDS. 2009;23(9):689-690. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19663717.
Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e118-120. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24256630.
Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e121-124. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24346640.
Genvoya package insert [package insert]. Gilead. 2017. Available at: http://www.gilead.com/~/media/files/pdfs/medicines/hiv/genvoya/genvoya_pi.pdf.
Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther. 2009;85(1):64-70. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18815591.
German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61(1):32-40. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22732469.
Eron JJ, Jr., Lelievre JD, Kalayjian R, et al. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. Lancet HIV. 2018. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30555051.
Momper JD, Best BM, Wang J, et al. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30134297.
Snedecor SJ, Khachatryan A, Nedrow K, et al. The prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patients. PLoS One. 2013;8(8):e72784. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23991151.
Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr. 2012;60(1):33-42. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22343174.
Edurant package insert [package insert]. Janssen Therapeutics. 2017.
Orkin C, Squires K, Molina JM, et al. Doravirine/Lamivudine/Tenofovir DF continues to be non-inferior to Efavirenz/Emtricitabine/Tenofovir DF in treatment-naive adults with HIV-1 infection: week 96 results of the DRIVE-AHEAD trial. Presented at: ID Week; 2018; San Francisco, CA.
Molina JM, Squires K, Sax P, et al. Doravirine (DOR) versus ritonavir-boosted darunavir (DRV+r): 96-week results of the randomized, double-blind, phase 3 DRIVE-FORWARD Noninferiority trial Presented at: 22nd International AIDS Conference (AIDS 2018); 2018; Amsterdam, Netherlands.
Inc MC. Pifeltro prescribing information. In:2018.
Inc MC. Delstrigo prescribing information. In:2018.
Lai MT, Xu M, Ngo W, et al. Characterization of doravirine-selected resistance patterns from participants in treatment-naive Phase 3 clinical trials. Presented at: 22nd International AIDS Conference (AIDS 2018); 2018; Amsterdam, Netherlands.
Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445-456. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21320923.
Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS. 2013;27(6):939-950. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23211772.
Cohen C, Wohl D, Arribas JR, et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS. 2014;28(7):989-997. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24508782.
Lamorde M, Wang X, Neary M, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of efavirenz 400 mg once daily during pregnancy and post-partum. Clin Infect Dis. 2018;67(5):785-790. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30124823.
Cerrone M, Wang X, Neary M, et al. Pharmacokinetics of efavirenz 400 mg once daily coadministered with isoniazid and rifampicin in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2019;68(3):446-452. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30084943.
Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014;161(1):1-10. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24979445.
Arenas-Pinto A, Grund B, Sharma S, et al. Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial. Clin Infect Dis. 2018;67(3):420-429. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29538636.
Smith C, Ryom L, Monforte A, et al. Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. J Int AIDS Soc. 2014;17(4 Suppl 3):19512. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25394021.
Napoli AA, Wood JJ, Coumbis JJ, Soitkar AM, Seekins DW, Tilson HH. No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. J Int AIDS Soc. 2014;17:19214. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25192857.
Nkhoma ET, Coumbis J, Farr AM, et al. No evidence of an association between efavirenz exposure and suicidality among HIV patients initiating antiretroviral therapy in a retrospective cohort study of real world data. Medicine (Baltimore). 2016;95(3):e2480. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26817882.
Chang JL, Tsai AC, Musinguzi N, et al. Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study. Ann Intern Med. 2018;169(3):146-155. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29946683.
Cross HM, Chetty S, Asukile MT, Hussey HS, Lee Pan EB, Tucker LM. A proposed management algorithm for late-onset efavirenz neurotoxicity. S Afr Med J. 2018;108(4):271-274. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29629676.
Variava E, Sigauke FR, Norman J, et al. Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series. J Acquir Immune Defic Syndr. 2017;75(5):577-579. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28520619.
Sustiva package insert [package insert]. Bristol-Myers Squibb. 2016. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020972s049-021360s038lbl.pdf.
Abdelhady AM, Shugg T, Thong N, et al. Efavirenz inhibits the human ether-a-go-go related current (hERG) and induces QT interval prolongation in CYP2B6*6*6 allele carriers. J Cardiovasc Electrophysiol. 2016;27(10):1206-1213. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27333947.
Pharmaceuticals M. Symfi prescibing information. In:2018.
Pharmaceuticals M. Symfi Lo prescribing information. In:2018.
Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16(2):299-300. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11807320.
Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2011;25(18):2301-2304. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21918421.
van Lunzen J, Antinori A, Cohen CJ, et al. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study. AIDS. 2016;30(2):251-259. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26684822.
ViiV Healthcare. Juluca prescribing information. In:2017.
Lathouwers E, De Meyer S, Dierynck I, et al. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis. Antivir Ther. 2011;16(1):99-108. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21311113.
Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther. 2011;16(3):339-348. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21555816.
Orkin C, Dejesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013;14(1):49-59. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23088336.
Ofotokun I, Na LH, Landovitz RJ, et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015;60(12):1842-1851. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25767256.
Tybost package insert [package insert]. Gilead. 2017. Available at: http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/tybost/tybost_pi.pdf.
Prezcobix package insert [package insert]. Janssen Therapeutics. 2017. Available at: https://www.prezcobix.com/sites/www.prezcobix.com/files/prescribing-information-prezcobix.pdf.
Orkin C, Eron JJ, Rockstroh J, et al. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2019. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31833849.
Tashima K, Crofoot G, Tomaka FL, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014;11:39. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25926858.
Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53(3):323-332. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20032785.
Smith KY, Tierney C, Mollan K, et al. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis. 2014;58(4):555-563. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24253247.
Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis. 2013;208(1):32-39. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23532097.
Gallant JE, Koenig E, Andrade-Villanueva JF, et al. Brief report: cobicistat compared with ritonavir as a pharmacoenhancer for atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate: week 144 results. J Acquir Immune Defic Syndr. 2015;69(3):338-340. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26181707.
Gammal RS, Court MH, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and atazanavir prescribing. Clin Pharmacol Ther. 2016;99(4):363-369. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26417955.
Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS. 2007;21(9):1215-1218. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17502736.
Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson M. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS. 2011;25(13):1671-1673. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21716074.
Hamada Y, Nishijima T, Watanabe K, et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis. 2012;55(9):1262-1269. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22820542.
Rakotondravelo S, Poinsignon Y, Borsa-Lebas F, et al. Complicated atazanavir-associated cholelithiasis: a report of 14 cases. Clin Infect Dis. 2012;55(9):1270-1272. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22820540.
Figueroa MI, Rolón MJ, Patterson P, Gun A, Cahn P, Sued O. Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: 96 week results of the PADDLE trial. Presented at: IAS Conference on HIV Science; 2017; Paris, France. Available at: http://www.ias2017.org/Portals/1/Files/IAS2017_LO.compressed.pdf?ver=2017-07-27-211231-197.
Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011;25(17):2113-2122. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21857490.
Bedimo RJ, Drechsler H, Jain M, et al. The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health. PLoS One. 2014;9(8):e106221. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25170938.
Jackson A, Else L, Higgs C, et al. Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naive HIV-1-infected individuals. HIV Clin Trials. 2018;19(1):31-37. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29189101.
Provided in collaboration with NIH's Office of AIDS Research. | ; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FDA = Food and Drug Administration; FTC = emtricitabine; HLA = human leukocyte antigen; INSTI = integrase strand transfer inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; STR = single-tablet regimen; TAF = tenofovir alafenamide; TFV = tenofovir; TDF = tenofovir disoproxil fumarate
Table 6b. Considerations Before Initiating Dolutegravir and Other Integrase Strand Transfer Inhibitors as Initial Therapy for Persons of Childbearing Potential
Preliminary data from a study in Botswana suggested that there is an increased risk of NTDs (0.9%) in infants born to women who were receiving DTG at the time of conception.5,9 Updated results have shown that the prevalence of NTDs in infants who were exposed to DTG at the time of conception is lower (0.3%) than reported in the preliminary data, but still higher than in infants who were exposed to ART that did not contain DTG (0.1%).6,7
It is not yet known whether use of other INSTIs around the time of conception also poses a risk of NTDs (i.e., a class effect).
There are insufficient data to determine whether use of BIC around the time of conception and during pregnancy is safe.
There is limited data on RAL use around the time of conception. Thus far, based on data collected from the Antiretroviral Pregnancy Registry, the drug manufacturer, and in a cohort study from the United States and other countries, no case of NTD has been reported.10-12 Among those receiving RAL during pregnancy, the rate of fetal malformations is within the expected range for pregnancy outcomes in the United States.10-12
Before Initiating an INSTI-Containing Regimen in a Person of Childbearing Potential:
A pregnancy test should be performed (AIII).
To enable individuals of childbearing potential to make informed decisions, providers should discuss the benefits and risks of using DTG around the time of conception, including the low risk of NTDs and the relative lack of information on the safety of using other commonly prescribed ARV drugs, including other INSTIs, around the time of conception (AIII).
For individuals who are trying to conceive, the Panel recommends initiating one of the following regimens, which are designated as Preferred regimens during pregnancy in the Perinatal Guidelines: RAL, ATV/r or DRV/r plus TDF/FTC, TDF/3TC, or ABC/3TC. DTG would be an Alternative, rather than a Preferred, option (BII).
For individuals who are not planning to conceive but who are sexually active and not using contraception, consider a regimen's effectiveness and tolerability, the available data on potential teratogenicity, and the person's preferences (e.g., low pill burden) when choosing among regimens recommended for initial therapy (Table 6a). In this situation, DTG would be an Alternative, rather than Preferred, option (BII). If the person becomes pregnant, changes to the ARV regimen may be warranted. Clinicians should refer to the Perinatal Guidelines for recommendations.
For individuals who are using effective contraception, a DTG-based regimen is one of the recommended options; however, clinicians should discuss the risks and benefits of using DTG with patients to allow them to make an informed decision (AIII).
An approach similar to that outlined for DTG should be considered for BIC-containing ART (AIII).
EVG/c should not be used during pregnancy because of inadequate drug concentrations in the second and third trimesters (AII).
Clinicians should refer to the Perinatal Guidelines when prescribing ART for a pregnant person with HIV.
Key: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ATV/r = atazanavir/ritonavir; BIC = bictegravir; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; INSTI = integrase strand transfer inhibitor; NTD = neural tube defect; RAL = raltegravir; TDF = tenofovir disoproxil fumarate
Selecting an Initial Antiretroviral Regimen
The goal of ART is to provide a potent, safe, tolerable, and easy-to-adhere-to regimen in order to achieve sustained virologic control. Initial therapy should be with two NRTIs combined with an INSTI, the combination of DTG/3TC or, in some individuals, a combination including two NRTIs plus an NNRTI or an RTV- or COBI-boosted PI. When selecting a regimen for a person with HIV, a number of patient- and regimen-specific characteristics should be considered. Some of the factors can be grouped into the categories listed below and may influence the choice of recommended regimens listed in Table 6a or the decision to consider alternative regimens. Table 7 includes recommendations for additional regimens to use in specific clinical scenarios.
Initial Characteristics to Consider in All Persons with HIV:
Pretreatment HIV RNA level (viral load)
Pretreatment CD4 count
HIV genotypic drug resistance test results. Based on current rates of transmitted drug resistance to different ARV medications, standard genotypic drug-resistance testing in ARV-naive persons should focus on testing for mutations in the reverse transcriptase (RT) and protease (PR) genes. If transmitted INSTI resistance is a concern, providers should consider also testing for resistance mutations to this class of drugs.
HLA-B*5701 status. Those who are HLA-B*5701 positive should not receive ABC. Regimens that do not include ABC can be initiated if HLA-B*5701 test results are not yet available; see Table 7 for regimens to initiate.
Individual preferences
Anticipated adherence to the regimen
Timing of ART initiation after diagnosis (i.e., immediate versus delayed)
Note that results of pretreatment HIV RNA, CD4 count, and resistance testing do not need to be available before starting ART. See Table 7 for regimens to initiate if these results are not available.
Presence of Specific Conditions:
Comorbid conditions: Cardiovascular disease; hyperlipidemia; renal disease; liver disease; osteopenia, osteoporosis, or other conditions associated with bone mineral density (BMD) loss; psychiatric illness; neurologic disease; drug abuse or dependency requiring narcotic replacement therapy
Pregnancy or potential to become pregnant: Clinicians should refer to Table 6b and the Perinatal Guidelines for more detailed recommendations on the safety and effectiveness of ARV drugs during conception and throughout pregnancy.
Coinfections: HBV, hepatitis C virus, tuberculosis (TB)
Regimen-Specific Considerations:
Regimen's barrier to resistance
Potential adverse effects and drug toxicities, including risk for development of comorbid diseases.
Known or potential drug interactions with other medications (see Drug-Drug Interactions)
Convenience (e.g., pill burden, dosing frequency, availability of a fixed-dose combination [FDC] or single-tablet regimen [STR] formulations, food requirements)
Cost and access (see Cost Considerations and Antiretroviral Therapy)
General Considerations for INSTI-, PI-, or NNRTI-Based Regimens
The choice between an INSTI, PI, or NNRTI in an initial ARV regimen should be guided by the ARV drug's efficacy, barrier to resistance, and adverse effects profile; convenience; the patient's comorbidities and concomitant medications; and the potential for drug-drug interactions (see Tables 7 and 9).
INSTI-Based Regimens
The Panel's Recommended Initial Regimens for Most People with HIV as listed in Table 6a include one of three INSTIs (BIC, DTG, or RAL) plus two NRTIs or DTG/3TC. For most patients, these INSTI-containing regimens will be highly effective and have relatively infrequent adverse effects and few drug interactions. In several head-to-head comparisons between boosted PI- and INSTI-containing regimens, the INSTI-based regimens were better tolerated and caused fewer treatment discontinuations.13-15 The Panel now recommends a two-drug regimen of DTG/3TC for initial therapy if certain criteria are met. Data from two randomized trials showed that, in terms of virologic efficacy, DTG plus 3TC was noninferior to a three-drug regimen of DTG plus TDF/FTC. No treatment-emergent resistance was seen in either the two-drug or the three-drug group. The study inclusion criteria limited enrollment to participants with HIV RNA levels <500,000 copies/mL; no known major NRTI, PI, or NNRTI resistance; and without active hepatitis B.4,16
Among the INSTI-based regimens, BIC- and DTG-containing regimens have a higher barrier to resistance and lower pill burden than RAL-containing regimens. However, RAL-containing regimens may be preferred for individuals who wish to become pregnant (see Table 6b for further discussion). Treatment-emergent resistance has been reported very rarely in individuals receiving three-drug DTG-based therapy17-19 and has not been reported in those receiving BIC-based regimens. In addition, transmitted resistance to BIC and DTG is rare. Because of this high barrier to resistance and tolerability, BIC- and DTG-containing regimens may be considered for patients who plan to start ART before resistance test results are available (e.g., with rapid initiation of ART after diagnosis). BIC-based regimens have been shown to be noninferior to DTG-based regimens in clinical trials.20,21
Recent studies have shown that the prevalence of infant NTDs in association with DTG exposure at conception is still higher than with non-DTG containing regimens (0.3% vs. 0.1%, respectively).6,7 For individuals of childbearing potential who are trying to conceive, DTG would be an Alternative, rather than a Preferred, option, as recommended in the Perinatal Guidelines. Clinicians should review the revised Table 6b before prescribing ART to a person of childbearing potential.
There are now data suggesting greater weight gain with certain INSTI-based regimens and TAF than with other ARV drugs. The clinical significance of these findings is still unknown.22-26 EVG-based regimens have the advantage of also being available as STRs and are recommended for certain clinical situations (see Table 7). However, EVG-based regimens have the potential disadvantages of a lower barrier to resistance than DTG- or BIC-containing regimens and, importantly, a greater potential for drug interactions because EVG is combined with COBI, a strong cytochrome P (CYP) 3A4 inhibitor.
Protease Inhibitor-Based Regimens
PK-enhanced PI-based regimens are recommended in certain clinical situations. Similar to elvitegravir/cobicistat (EVG/c), they carry the disadvantage of greater drug interaction potential than other ARV drugs. For those individuals in whom ART needs to begin urgently before resistance test results are available, boosted DRV may be an appropriate choice because the rate of transmitted PI resistance is low and boosted DRV has a high barrier to resistance and a low rate of treatment-emergent resistance. DRV/c/TAF/FTC is available as an STR. Boosted ATV, like boosted DRV, has relatively few metabolic adverse effects in comparison to older boosted-PI regimens; however, ATV/r had a higher rate of adverse effect-associated drug discontinuation than darunavir/ritonavir (DRV/r) or RAL in a randomized clinical trial.13 In a substudy of this trial, and in a separate cohort study, atazanavir/ritonavir (ATV/r) use was associated with slower progression of atherosclerosis, as measured by carotid artery intima medial thickness.27,28 Large observational cohorts found an association between some PIs (DRV/r, fosamprenavir [FPV], indinavir [IDV], and LPV/r) and an increased risk of cardiovascular events; however, this association was not seen with ATV.29-34 Further study is needed.
NNRTI-Based Regimens
NNRTI-based regimens (which include doravirine [DOR], EFV, or rilpivirine [RPV]) may be options for some patients, although these drugs, especially EFV and RPV, have low barriers to resistance. The emergence of resistance at the time of viro | 2,788 |
In 2017, Arizona State University's School of Politics and<|fim_middle|> pursue a variety of careers. | Global Studies, with the Center on the Future of War, launched an online master's degree program in global security and now, one year later, the program is celebrating its first graduating class.
The MA educates students from different backgrounds who study at their own pace, from anywhere in the world, often while working. Students range in age from their early 20s to mid-70s, around half are active duty U.S. military or veterans, and the participants vary widely in terms of their professional experiences and career interests. Some are deeply involved in human rights and international development, others are focused on intelligence and defense issues and still others on training and higher education.
Timothy Ayers, a 2018 graduate of the MA, worked full-time for the State Department while balancing home life and his coursework. Prior to pursuing graduate school, Ayers spent more than a decade overseas dealing with security matters and international trade relations which he cites as key motivations for selecting the program.
"I was going through the VA's website and, since I was using the GI Bill to pay for my education, I searched for international relations programs and found the master of arts in global security program," he said.
The program features lectures and content by some of the nation's most influential global security thinkers including general officers, former high-ranking officials at the State Department and the National Security Council, Pulitzer Prize-winning journalists, human rights activists, retired special operations officers and best-selling authors.
"The strongest aspect of the MA is the instructor depth. After that, it is the diverse student body which allowed for intelligent discussion boards each and every week," Ayers said.
The MA includes a required capstone course in which students produce individual projects that build on skills and issues they learned while in the program. This year, a group of students briefed United States Special Operations Command on a collaborative research project focusing on the role of big data in international security.
"There are few, if any, online programs that can offer the experience to take part in applying theory and coursework you learned to problems that government or private industries have asked for your input on," said DJ Gering, a graduate of the program.
The master's degree program provides excellent career training for students who are working in or who aspire to careers in diplomacy, international development, the military, security, global management and humanitarian aid.
"I was interested in international relations and homeland security during my search for programs. This program seemed to blend those fields and helped to enhance my background in emergency management," global security graduate Alexander Suggs said.
The program is based on the idea that understanding the rapidly changing nature of conflict and international relations requires a strong grounding in foundational ideas and concepts along with focused intellectual and writing skills to support complex interdisciplinary analysis. The master's program graduates have gained useful training and knowledge to grapple with today's global security challenges and | 575 |
Find all your photos, videos, and other types of documents from a secure, centralized solution.
Store your media from your own servers or on a high availability private cloud infrastructure hosted by Amise in France.
Stop to the files scattered in trees and under trees, duplicated on several servers.
Import your files easily without any duplicates. Define your tree, tag your media with keywords so you can find them with a click.
We help you to migrate your media to Amise. For free.
View and preview your media thumbnails in an elegant and intuitive interface. Create media collections to organize your thoughts and projects.
Define your own keyword dictionaries with the multilingual company thesaurus. Using keyword dictionaries provides search suggestions and avoids misspellings related to search terms.
Automatically add the<|fim_middle|> in the most secure way possible. As a result, Amise is routinely audited to ensure that your data is kept secure.
Your data is automatically backed up every day and all our customers benefit from regular updates and new features throughout the year.
We provide you with tools such as video tutorials that will allow your users to take Amise quickly.
Our support team is always at your disposal to advise you and help you in case of problems. We are experts in pre-media solution for over 10 years and have only one goal: to take care of you! | appropriate metadata to the assets to find them more easily and spend less time tagging them. Your metadata can be keywords, as well as author names, a drop-down menu, GPS coordinates, file usage rights, and more.
Say goodbye to attachments in the e-mail. Put the validated assets at the disposal of each one (internal teams, external agencies, partners, resellers), on request. In just a few clicks and in a secure way.
A virtual work room, invite your employees to comment on your work in a workflow integrated in the multimedia library.
Share your files via FTP, Facebook, Twitter and Slack without ever leaving your workspace.
Resize your images and videos in web and mobile formats.
Amise supports a wide range of file types and formats. See the full list here.
You also benefit from automatic editing tools that allow you to generate a multitude of variants by modifying the size, color, format, resolution and framing.
No installation required, your users access Amise via the browser.
Create, preview, and stream interactive video content. Amise has a video player in which you can also define your chapters and cut a video into several sub videos. Subtitling is also managed.
The quality of the video adapts automatically according to the speed of connection of your users; Useful for sites in the region or internet access is not very fast.
Publish your videos on social networks, on all screens and devices with a single URL.
Thanks to its application structure, Amise knows how to communicate natively with other applications such as Salesforce, Photoshop, Illustrator, InDesign. Work with your media directly from Wordpress, Drupal and other CMS through a plugin system.
Configure Amise to match the visual identity of your brand: logos, colors, typographies, etc. Also make these assets available to your employees in order to maintain a consistent brand image.
Add and remove accounts with their own brand images.
Identify the most used assets, that is, those that generate the greatest number of consultations and downloads in order to design campaigns that are always more efficient. Find the best performing assets and reuse them on new channels.
Give your users tools to create templates without any programming or help from the IT department. Whether it is a simple web page or a landing page in responsive design, users can quickly create templates that meet their needs and control the structure and appearance of pages.
Control the lifecycle of your users, their roles and privileges such as the rights to download, consult, change, etc.
Monitor the behavior of your users to know who is accessing or editing such and such content and when. Create custom reports so you can see at a glance which users download the most. For example.
Amise was created | 541 |
The most surprising names on the ballot All MLB
There are 121 players nominated for the 2022 All-MLB Team. If you've followed what has happened in the Majors throughout the season, you probably understand why everyone on this long list is being considered. Only 32 will end up on the First or Second team, and fans can vote now for your favorites once every 24 hours until 5 pm ET on November 22.
But try to go back to Opening Day and look again at that list. Many players would still be obvious picks, but there are many others who weren't top of mind in early April. But still, over the course of six months and 162 games, those initially underrated earned your attention.
In fact, you could put together a very good starting lineup with those types of players, and that's what we're going to do. Here's a player from each position on the All-MLB Team that surprised us this year.
Catcher: Cal Raleigh, Mariners
Though always a powerhouse prospect throughout his time in the minors, Raleigh homered just twice for the Mariners in 2021 and began 2022 with a 24-2 slump that sent him back to Triple-A. But he returned in May and responded in a big way, hitting 26 homers in his last 105 games.
First base: Nathaniel Lowe, Rangers
In his second season with Texas, the left-handed slugger was among the AL leaders in several categories, including hits (4th,<|fim_middle|>16, and his wRC+ of 143 was the best by a club player since Josh Hamilton (175) and his 2010 MVP campaign. a jump after hitting .264 with 18 homers in 2021.
Second base: Andrés Giménez, Guardians
When the season began, Gimenez was best known for being one of the pieces sent to Cleveland in the Francisco Lindor trade. But in six months that perception completely changed, hitting .297 with 17 home runs, 25 stolen bases and an OPS+ of 141, in addition to exhibiting a luxury defense, ranking second in Defensive Runs Saved (16) and third in Outs Above Average (13 ) in its position. All of that helped the 23-year-old earn his first Gold Glove and his first All-Star trip. And his 7.4 bWAR was a full point above his closest pursuer among bartenders (Tommy Edman, 6.4).
Shortstop: Jeremy Pena, Astros
Phenomenal newbie. Horse in postseason. Sure, we all know by now who the Dominican Peña is. But seven months ago, he was a prospect with a lot to prove and some very big shoes to fill after the departure of Puerto Rican Carlos Correa. When the season ended, Peña had the same number of home runs as Correa (22) and had done a better job defensively. And that was before they shined big in October/November.
Third base: Brandon Drury, Padres
Drury signed a minor league contract with the Reds in March and paid off quickly, hitting 18 home runs with a .528 slugging percentage before the All-Star break. He was traded to the Padres two weeks later and although his bat didn't make as much noise in San Diego, he set career highs in different categories and won a Silver Slugger, thus setting the stage for a multi-year deal at the agency. free.
Designated hitter: Albert Pujols, Cardinals
What started as the beautiful story of a legend returning to his origins became an incredible farewell for the future Hall of Famer. Wearing a St. Louis uniform for the first time since 2011, the 42-year-old hit just .215 with six hits in the first half, but somewhere between the Home Run Derby and his 11th All-Star Game he found a way to back off. the clock 15 years. He again became one of the most fearsome hitters in the league, hitting 18 home runs and posting a .715 slugging percentage, a 1.103 OPS and a 206 wRC+ in the second half. Of course, the crowning glory of it all were the two home runs he hit at Dodger Stadium on September 23 to become the fourth member of the 700-homer club.
Outfielder: Taylor Ward, Angels
After hitting .230 with 15 home runs in his first four years with the Angels, the 28-year-old slugger kicked it off and come June, he was hitting .347 with 10 home runs and leading the MLB in on-base percentage (.459) and slugging percentage. (.686). Ward cooled off in the final months, but his torrid start justifies putting him here.
Starting pitcher: Kyle Wright, Braves
Wright had the talent and the opportunity to have such a year; he just needed him to make all of that come true before considering him for the All-MLB Team, as he began this season with a 6.56 career ERA in 70 regular-season innings. But this summer he became a key part of Atlanta's rotation, posting a 3.19 ERA in 30 starts and 180.1 innings, also becoming the first Braves pitcher to lead MLB in wins since Hall of Famer Tom Glavine did. in 2000.
Relief Pitcher: Evan Phillips, Dodgers
Among many candidates, it's hard to find a bigger surprise than Phillips. Selected in the 17th round of the 2015 Draft, Phillips had a 5.07 ERA in college and his major league ERA prior to this season was 6.68. This year? 1.14 in 63 innings, thanks to him using his slider more and his four-seamer less.
We would like to thank the author of this write-up for this awesome content
Categories Baseball Tags ballot, Baseball, Major League Baseball, MLB, names, surprising
Basketball: Olympic champion Walter Herrmann led a campus for girls and boys from the city
Week 11 of the NFL 2022-2023, who are the favorites to win? | 179), total bases reached (6th, 292) and OPS (8th, .850). He became the first Ranger to hit at least .300 with 25 home runs since Adrian Beltre in 20 | 55 |
We have a great free guide that tells you how to get started with automating your home!
UK Automation are a leading retailer for a wide range of home automation products at great prices. We sell home automation equipment<|fim_middle|>! | from leading brands such as Fibaro who we are an authorised dealer for, Haibrain formerly Marmitek, X10, Z-Wave, Home Easy, Insteon, Systemline, Russound distributed multi-room audio solutions, energy saving devices, wireless sockets & lighting control, and home security systems.
UK Automation are specialists in X10 and Z-Wave home automation. We are a Preferred Partner for the supply of quality Haibrain X10 Products within the UK. Haibrain is the X10 Home Automation market leader in Europe and chooses to sell exclusively through selected partners. For Z-wave we stock a range of the best products from different manufacturers to ensure you end up with a good reliable system.
If you need help in choosing the right home automation equipment for your project, or you're new to home automation, then please check out our home automation articles or contact us with your questions - we're happy to help | 192 |
In our last series of posts Zach and I talked about using SQL Server's new FILESTREAM support to store, manage and retrieve media in SQL Server to enable rich user experiences. We've been at it again this week trying to get some traction with the new spatial data types and query semantics in SQL Server 2008. This new functionality makes it possible to integrate location awareness into just about any type of application. What could be more compelling than allowing a user to interact with information that is relevant to locations that they care about, like home, work, school or vacation destinations? This technology has long been the domain of sophisticated GIS applications, but by integrating spatial capabilities into SQL Server 2008, Microsoft is making location awareness available to the average database developer.
Zach has some experience with GIS applications, but I have none at all. So the challenge was whether a couple of database geeks could figure out how to leverage this spatial stuff in an application in a couple of days. I'm happy to say that we made great progress and we'd like to share some of our experiences in hopes that it will demystify the spatial functionality in SQL Server 2008. Rather than regurgitate the same stuff you can read in books online when CTP5 comes out, I'm going to try to focus on some of the key discoveries we made in hopes that it might save you some time.
The scenario we focused on was "geo-locating" the media we stored in SQL Server 2008 in our previous FILESTREAM sample. By tagging these images and videos with some location information, it's possible to do spatial queries that retrieve all the pictures that were taken in a particular geographic area. There are a ton of cool applications for this kind of functionality, I'll leave it to your imagination to think of some.
Next I started thinking about how to get shapes into our new geography column. Turns out it was a whole lot easier than I expected. Under the covers, the geography type is implemented as a UDT. That means geography is not a scalar type like an integer or date, rather its an object with methods and properties. This is a great example of how the .NET Framework Common Language Runtime integration introduced in SQL Server 2005 is now enabling a whole new generation of features and capabilities in SQL Server 2008.
In this example the point shape's coordinates are the latitude and longitude of my old apartment building in Philadelphia. It's worth mentioning that the geography type utilizes a default coordinate system known as WGS 84 which is used by most GPS systems. Once you've initialized a geography instance, there's a ton of methods and properties you can use to interrogate them, compare them, and create new instances from existing ones. Most of these capabilities are defined in the OGC's Simple Features for SQL Specification.
Next we started thinking about what kind of shapes to load into our new geography column. My first inclination was to start loading a bunch of map data. Zach and I really didn't want to write a bunch of graphics code to draw maps, there are great services out there like Virtual Earth that draw maps way better than we could. We quickly realized that there really wasn't any need to load a whole map, all we needed to demonstrate "geo-locating" our media files was to create some shapes that represent the map and regions that we are interested in, then tag each of our media files with a specific location within that map. To keep things simple, we decided to store those shapes in the same table as our media files so we could query them all in the same place.
Map row: There is only one of these. It's a rectangle represented as a geography POLYGON instance whose four points are the lat/long coordinates of our total map area. For good measure we store an image of the map region from a map drawn in Microsoft Streets & Trips. I simply drew a rectangle on top of an existing map in Streets and Trips, then used the location sensor tool in Streets & Trips to get the lat/long coordinates of the four corners.
Region rows: There are three of these. They are irregular closed polygons that define regions of interest contained within the overall map. Like the map, we store an image of the region I created in Streets & Trips along with the lat/long coordinates for each of the points in the polygons.
Media rows: There are several of these, which represent pictures stored as varbinary(max) FILESTREAM instances. We tag them with location information using a geography POINT shape whose lat/long coordinates correspond to the location where the picture was taken. By comparing these points to our regions, the demo shows how you can retrieve media based upon its location within a map or region of interest.
For the demo we decided to focus on the Pro Cycling Tour International Championship in Philadelphia, PA. It's relatively self-contained and has some cool sections that correspond neatly to our concept of "regions of interest".
Description This is the total map area we will deal with in this sample. This helps constrain things to a specific geography in Philadelphia rather than the whole earth. The entire Pro Cycling Championship race route is contained inside this irregular polygon. One of the most interesting parts of the race route. Contains the infamous 17% grade climb known as the "Manayunk Wall". The race starts and finishes here on the Benjamin Franklin Parkway.
Description Taken on the Ben Franklin Parkway near the finish line. This shot was taken from the bottom of the Manayunk Wall. This shot was taken at the top of the Manayunk Wall. This is another shot from the Benjamin Franklin Parkway.
Microsoft.SqlServer.Types.GLArgumentException: 24205: The specified input does not represent a valid geography instance because it exceeds a single hemisphere. Each geography instance must fit inside a single hemisphere. A common reason for this error is that a polygon has the wrong ring orientation.
I don't confess to understand this 100%, but Ed Katibah told me its kind of like turning the world inside-out. Ed also mentioned that sister data type geometry polygons don't have this limitation and can be loaded in either order (clockwise or counter-clockwise). Without getting into too much detail here, that led to a conversation about what the right type was to use for our demo. I had thought that geometry was limited to standard x and y coordinates and wouldn't handle lat/long coordinates, but was surprised to learn that it does. The basic difference between the two is that geography types account for the curvature of the earth, while geometry types don't. That means for relatively small surface areas they are roughly equivalent, but if you are dealing with larger surface areas you will definitely want to stick with the geography type.
System.FormatException: 24119: The Polygon input is not valid because the start and end points of the exterior ring are not the same. Each ring of a polygon must have the same start and end points.
This points out one of my few beefs about the CLR implementation in SQL Server, and that is that CLR exceptions always generate the same Transact-SQL error number (6522). Somebody on the CLR team once explained to me why it has to be this way, I think it has to do with limitations of the existing Transact-SQL error handling framework and RAISERROR in comparison to the extremely rich exception handling capabilities in the .NET Framework. I'm sure my buddy Bob Beauchemin would be able to explain this in gory detail.
One last tip about polygons, and any other shape that uses lat/long coordinates. I made several typos when initially recording my lat/long coordinates, resulting in less than satisfying results for the demo. I called Ed to get some debugging recommendations. Ed mentioned a great spatial partner named Safe Software who is working on a beta version of their spatial ETL tool named FME, which can be used to move spatial data in and out of SQL Server 2008 from other formats. One of their components will actually allow you to visualize shapes stored in a geography column, making it a heck of a lot easier to determine if the polygon you thought you created is actually the polygon you created.
Anyway back to the matter at hand, we created a .NET Framework command-line utility named FileStreamLoader designed to populate our eventMedia table. This was the easiest way for us to pump in all of our pictures and videos using FILESTREAM. It's tough to do that kind of stuff in a Transact-SQL script, so database geeks please go learn .NET programming it will make your life a whole lot easier. I'll post the code for FileStreamLoader up on CodePlex once CTP5 ships.
While I don't discuss it in this blog post, its important to note that the STIntersects() method supports usage of the new spatial index type in SQL Server 2008. We didn't really need one for such a small number of rows, but when dealing with larger scale GIS systems indexing can become critical.
And there we have it! These are the two pictures that were taken in the Manayunk<|fim_middle|>NET scripting (including IronPython), etc.
The result is that right now, today, you can combine SQL Server 2008 spatial and Virtual Earth using seamless Manifold GIS running 64-bit in Windows Vista x64 on a quad-core processor and you will have a GIS / spatial DBMS tool of unprecendented power that works with data from just about any spatial data source known and scales from individual desktop use to thousands of simultaneous users within the largest enterprise. That's a real credit to the synergies of the Microsoft ecosystem.
We're really excited about SQL Server 2008 spatial capability. We are so excited about this that Manifold support for SQL Server 2008 spatial is built in at no additional cost into every Manifold edition from Enterprise Edition ($395 a seat) on up. We want our customers to consider SQL Server 2008 spatial a fundamental, standard building block for both server-side spatial applications and also for everyday desktop GIS. | Wall area. Obviously the demo gets more interesting with more photos and more regions.
Now you know how to use the new spatial functionality in SQL Server 2008 to geo-locate media files in your application. Hopefully all you database developers out there won't be afraid to dive in and start using this amazing new functionality. Zach is going to do some additional posts in our spatial series which discuss how to leverage these new spatial features within a WPF application.
[Fair warning… this is a long post.] Great blog! I see you are using FME. FME is good stuff, but FME is not a GIS and so is very limited compared to using a full featured GIS for work with either GIS data or with SQL Server 2008 spatial.
I'll use Manifold as the GIS example in this post, since I'm a product manager for Manifold and most familiar with that. As far as I know, Manifold is the only production GIS that is shipping today with built-in support for SQL Server 2008 spatial capabilities (since August, 2007 – See the announcement at http://www.manifold.net/info/news.shtml ).
Manifold has a lot of spatial DBMS experience supporting other vendors, including Oracle Spatial, IBM DB2 with IBM's Spatial Extender, PostgreSQL/PostGIS, SQL Server 2005 using the Manifold Spatial Extender, and "generic" spatial DBMS capability for virtually any DBMS. I hope these comments, drawn from our experience with many tens of thousands of spatial DBMS applications, will help novice spatial DBMS users avoid re-inventing the wheel when putting the mighty power of SQL Server 2008 spatial to use.
GIS data often requires significant work besides simple format translations to be useful within spatial DBMS, and such work is usually best done in the visual / analytic / editing context provided by a real GIS. That speeds up workflow, and allows analytic processes that can transform data into the most useful form, which is what you want if you are going to be storing it within your SQL Server 2008 spatial data warehouse. It is rarely the case that data from legacy formats should be uploaded into a spatial DBMS like SQL Server 2008 without substantial alteration and editing.
A simple example: Let's say you want to grab data from a variety of different formats and different spatial DBMS servers for upload into SQL Server 2008 spatial storage. If you bring the data as layers into a real GIS that can do reprojection on the fly, and combine it with existing layers within SQL Server, you can see to what degree they overlay. Errors in projections will be immediately evident, especially if your GIS has the capability of combining layers from radically different sources, such as images, terrain elevation surfaces and many different formats of vector data, as Manifold automatically does.
What often causes trouble with data not seen in context is not something that can be solved by a simple act of reprojection, it is missing small nuances in matters such as datums or specific coordinate system parameters so that the data to be uploaded is slightly off even though the coordinate system (projection) information appears OK. Such problems are easiest to catch in a visual setting but cause no end of chaos once they get embedded into your corporate geospatial data warehouse.
An example where you might need to do more serious work before uploading: Suppose you have a data set which consists of boundary lines created with AutoCAD and stored in a DXF without any geographic context. That's a classic situation that afflicts about 300,000 jurisdictions in the US with civic spatial data as well as endless commercial users such as utilities with corporate CAD data.
Before uploading into SQL Server 2008 you'll need to get that data set georeferenced, you'll want to get it cleaned up to be free of classic CAD errors (dangles, overshoots, unclosed boundary lines, etc.), you'll most likely want to create area objects instead of boundary lines, assign data attributes automatically to the resultant area parcels and only then export into SQL Server 2008 spatial storage. Manifold can do all that in a highly visual, point-and-click environment using a variety of layers, such as automatically streamed-in Virtual Earth satellite or road map backgrounds, to assist the process. You can use hundreds of editing and analytic tools to assist as well. If a problem is not caught before upload, you can easily fix it afterwards because all those tools still work even after the data is in SQL Server 2008.
When a GIS like Manifold has strong DBMS capabilities, you can also slice and dice your data into desired form using data attributes as well as visual or spatial characteristics to control the process. For example, you might want to use spatial SQL to dynamically create new objects based upon spatial relationships such as intersections between buffer zones and existing objects that also take into account the heights of surfaces in the region or the value of data attributes within nearby polygons. In fact, with Manifold you can do that with data before it uploads into SQL Server 2008 or you can do it later, editing data stored in SQL Server 2008 as if it were a local layer.
A GIS like Manifold that can connect directly to a spatial DBMS and visually, seamlessly work with data using a full power, visual GUI brings a lot of additional value to the data stored in the DBMS. For every user whose choice of interface is SQL, there are many more who prefer a visual GUI using something like Manifold. Having both spatial SQL as well as a visual interface makes it a lot easier to manage data in the DBMS and to develop spatial applications because you can choose when you want to write code for server-side, DBMS processing and when you would prefer a more visual, point-and-click process to do the job.
For example, if you want to grab photos within a given area of interest it is a lot easier for most users to simply "lasso" such points with a mouse on a visual map than it is to write SQL to select them. A GIS like Manifold will give you such visual capabilities and will allow you to dynamically edit what's in your SQL Server 2008 spatial storage and to manage that storage using visual means. If you are developing applications, you can use the GIS as a visual workbench while you try out SQL or .NET scripts within Manifold to help you create a spatial application much faster, even if that application ultimately will be implemented exclusively within server-side code.
Keep in mind that getting data into a spatial DBMS is just the beginning. What comes after is use within applications. While there are plenty of big applications that merit server-side coding to create each application individually, there are far many more applications that become instantly available when people use existing, modern GIS capabilities to manipulate data stored within spatial DBMS in an ad hoc, interactive manner. In most cases, it is much easier and faster to simply point-and-click to accomplish the desired task than to write an application that does it.
The above tutorial shows an example where favorite restaurants are marked as points of interest using Virtual Earth background images and maps. That tutorial and any of the other hundreds of visual examples in the user manual can be done as layers within SQL Server 2008.
Everything works: full multiuser editing of drawings in SQL Server, direct connect to IMS web applications, interaction with images and surfaces, visual copy and paste from Oracle Spatial or other spatial DBMS products to Katmai, zillions of editing and other tools, reprojection on the fly, etc.
CUrrent support in the shipping Manifold product is for Katmai pre-releases that are not public. When Microsoft issues a public SQL Server 2008 CTP that includes spatial capabilities, Manifold will immediately issue a free update that supports the public CTP as well. That update will also include detailed, visual examples featuring SQL Server 2008 to help users new to GIS get started.
As mentioned earlier, Manifold supports essentially supports all other spatial DBMS products as well as SQL Server 2008 spatial.
Having the ability to simultaneously connect to just about any other spatial DBMS is extremely useful when moving data into SQL Server 2008. For example, you could have four different windows simultaneously open showing a drawing each in Oracle, DB2, PostgreSQL and SQL Server 2008 and simply copy and paste between windows to move, say, parcel data, from DB2 into SQL Server 2008. Manifold will automatically match projections, do reprojection on the fly if need be, change geometry types into SQL Server 2008 native types and adjust attribute data so that the spatial data is correctly stored within SQL Server 2008.
Prior experience has also helped Manifold assure that support for SQL Server 2008 spatial includes mature support right from the beginning for other key technologies like native 64-bit Windows code, total support for Vista, automatic usage of Virtual Earth, automatic multicore and multiprocessor support, use of NVIDIA CUDA, integrated . | 1,874 |
Brandeis University Press
Palestine between Politics and Terror, 1945–1947
Motti Golani
The Schusterman Series in Israel Studies
2013 • 27<|fim_middle|>8-1-61168-388-2
Check your ebook retailer or local library for ebook availability.
A fascinating look at the end of British rule in Palestine, through the eyes of its final high commissioner
British General Sir Allan Cunningham was appointed in 1945 as high commissioner of Palestine, and served in this capacity until the end of the British mandate on May 15, 1948. The three years of Cunningham's tenure were tremendously complex politically: players included the British government in London, the British army, the British administration in Jerusalem, and diverse military forces within the Zionist establishment, both Jew and Arab. Golani revisits this period from the perspective of the high commissioner, examining understudied official documents as well as Cunningham's letters, notes, and cables. He emphasizes especially the challenges of navigating Jewish and Arab terrorists, on the one hand, and the multiple layers of British institutional bureaucracies, on the other, and does an excellent job of establishing Sir Allan's daily trials within the broad frame of the collapse of the British Empire following World War II.
Click here for TABLE OF CONTENTS
Reviews / Endorsements
"In this skillful blend of biography and political history, Motti Golani presents British Palestine's last High Commissioner as a decent man beset by insuperable obstacles. A determined advocate of the partition of Palestine, Sir Alan Cunningham faced intransigent Jews and Arabs, bull-headed British officials, and the British Empire's rapid post-war collapse. Meticulously researched and gracefully written, Golani's book is required reading for anyone interested in the origins of the state of Israel and the Israel–Palestine conflict."—Derek Penslar, University of Oxford
"A masterful study of the British retreat from Palestine through the eyes of the last High Commissioner, Sir Alan Cunningham. Golani has once more produced a work of the highest quality that reminds us of his standing as one of the leading scholars in the field."—Rory Miller, King's College London
"An account of Sir Alan Cunningham's years as High Commissioner is long overdue, as is a considered and balanced history of the last years of the British Mandate. Motti Golani, one of the preeminent historians of Israel, has presented us with a first rate account of the man, the period, and the end of the Mandate. Both the narrative and the analysis presented in this book ensure that it will be widely read. Palestine between Politics and Terror will be indispensable for anyone interested in the history of the Arabs and Jews in Palestine and the failed British efforts to find a solution to their problems." —Ronald Zweig, New York University
MOTTI GOLANI is a professor in the Department of Land of Israel Studies at the University of Haifa. | 2 pp. 6 x 9"
History of Israel & Palestine / Middle East Studies
$40.00 Paperback, 978-1-61168-450-6
$7.99 Ebook, 97 | 56 |
2 min read August 12, 2012
I have already posted this on FaceBook and Twitter and told family and friends, nonetheless I want to mark the occasion here on my blog:
On Monday the 23rd July 2012 my girlfriend of some 10 years Tash gave birth to our twins, and our daughter Luca and son Finlay were born at 04:51 and 04:53 respectively.
Our hospital was Kings in London, England (for the benefit of any international readers). Tash and I had made a birthing plan which included using a birthing pool for pain relief and delivering the twins naturally unless there was a medical reason not to at any point. Unfortunately during the later stages of labour Finn's heart rate became elevated and didn't return to normal after a period of monitoring, so our best made plans somewhat went out of the window as<|fim_middle|> thing I will not miss was sleeping on the hospital floor for the 4 or 5 nights we were at the hospital, that combined with the lack of sleep, canteen food and the constant activity of the staff coming in and out made it a pretty tough few days in terms of keeping our heads together whilst we were adapting to being new parents, so we were pleased when we were told that everything was in order for us to be discharged and to go home and start our new family life together.
As I'm writing this we have now been home for 2 weeks, Tash and I are absolutely knackered but despite the lack of sleep we are loving every moment of getting to know the twins. They don't do much other than eat and sleep at the moment but already their individual personalities are so apparent and we're loving getting to know them whilst we learn the parenting ropes. I have been really fortunate that my current client has agreed to me taking 3 weeks leave from the project, this has been an invaluable time and I am feeling both sad and yet also super excited to be returning to work this coming Monday.
So without further ado I would like to welcome Finlay and Luca to the world and our family, here's to many many happy years together!
I'm growing a Mo for Movember | an emergency c-section suddenly became our only option to ensure safe delivery of the twins. Tash was an absolute soldier and the staff at Kings mostly did a fantastic job, apart from the moment when they left me waiting alone outside theatre without first having told me what the plan was (i.e. that someone was getting me some scrubs and I would be able to enter theatre shortly to support Tash). Our midwife Jean from the Paxton Group Practice was an absolute hero in providing fantastic continuity of care to Tash, before, during and after the labour. Jean's colleagues Jackie, Emma and Veronica have also provided fantastic post natal support and advice for which we are incredibly grateful.
We ended up staying in the post-natal ward for a few days before being discharged, Little Finn had some blood sugar issues at birth and had to spend a couple of days in the special care ward (SCBU), however he was quickly put right and was discharged from SCBU so he could rejoin his sister and us in the post-natal ward. Tash has coped with everything brilliantly and is recovering really well from her c-section, she was up and moving around the day after the birth which is testament both to her courage and the advances in c-section techniques.
One | 255 |
Jerry Kozlowski, Dean of The BEST Center, Invited to Albany for ACME Formation Meeting By SUNY Chancellor Robert King
Jerry Kozlowski, Dean of The BEST Center of Genesee Community College, was invited by Robert L. King, the Chancellor of the State University of New York, to participate in the ongoing discussion and planning process to form an Advisory Council on Military Education (ACME) in New York State. Similar councils have already been established in several other states and have proven very effective in supporting the educational objectives of military families. The meeting was held Monday, June 6, 2005 in Albany and included more than 50 representatives from educational and military groups from across the state.
The purpose of the meeting was to learn more about educational opportunities, increase the college enrollment of the military and their families in New York colleges and universities, and address the challenges faced by these families who wish to attend college.
For several years, soldiers and their families at Fort Drum near Watertown, New York have recognized the need for improved networking and communication between education and military organizations. ACME could help develop partnerships among New York State colleges with the National Guard and Reserve; support tuition assistance programs targeted to working spouses of soldiers; and help the young adult children of soldiers who wish to remain in New York State and attend college even when their family moves to an assignment that is out-of-state or out-of-country. In addition, ACME could also be a prime motivator for a "Troops to Teachers" initiative with the State Education Department.
Last summer, interested individuals met to discuss the feasibility of establishing ACME resulting in a draft of by-laws. This year, ACME is poised for implementation.
"It is very exciting to see an organization with<|fim_middle|> as a legally recognized nonprofit organization this fall. The overriding mission of the new organization will be to improve educational opportunities not only for the actively enlisted New York State servicemen and women, but also to their spouses and children. ACME plans to develop partnerships and communication networks with SUNY campuses and various government bodies to explore a wide range of possibilities. From effectively utilizing the online SUNY Learning Network (http://sln.suny.edu/) to provide coursework to military bases around the globe, to expanding the availability of TAP (Tuition Assistance Program) to the spouses and children of our soldiers-these are among the potential opportunities ACME will investigate.
Mr. Kozlowski brings a wealth of experience and service for the successful implementation of ACME. In addition to his current responsibility as Dean of The BEST Center and overseeing the College's five campus center locations, Jerry served honorably in the United States Air Force for 25 years. He began his distinguished military career in 1971 as a training instructor, assumed the role of Commander, Executive Officer, computer program development manager, and finished his tenure as a speech writer and executive aid to the Commander-In-Chief of U.S. Space Command.
In addition, Jerry is a member of the Leadership Genesee Class of 2004, and serves on numerous area boards and committees including: Chairman, Genesee County Chamber of Commerce Business Development Committee; Chairman, Genesee County Chamber of Commerce Economic Development Committee; Member, Genesee County Empire Zone Board; and Member, Genesee County Economic Development Center (GCEDC) Economic Development Focus Group. He also writes a monthly business column for The Daily News.
Editor's note: A photograph of Mr. Kozlowski is available at the following Internet site:http://marketing.genesee.edu/images/kozlowskijerry.jpg | such an important mission and focus come together. New York State has the best educational network in the country, if not the world-and who else deserves to be part of this system more than the families and soldiers in our military," Kozlowski said. "I was personally honored to be invited to this excellent forum and I am delighted to lend the support and interest of Genesee Community College to help launch ACME."
It is hoped that ACME will be formally established | 95 |
Tag Archives: Sy<|fim_middle|> 9-hectare site, but these were demolished by the end of the 1970s and the area returned to a woodland state (with a few Victorian era plants thrown in for good measure). It has been managed by the London Wildlife Trust since 1982.
Although it was the folly that drew me to Sydenham Hill Wood, this little slice of woodland also has several other points of interest. As difficult as it is to believe given its rather pristine current state, a railway line once ran right through this area – and not just any line, but the Crystal Palace line transporting people from Nunhead to the Crystal Palace. Camille Pissarro painted the view from the Cox's Walk Footbridge in the wood in 1871 (see picture below left), which looks remarkably different today (below right). You can also see the 1865 tunnel mouth that the railway once passed through – now home to a colony of bats. Much like the story in Vauxhall, this is an open space that has reverted to type, in this case with the wood and its inhabitants reclaiming the space.
Sydenham Hill Wood is located in SE26 – there are entry points on Crescent Wood Road and Sydenham Hill. Forest Hill and Sydenham Overground are the closest stations, while the buses that will get you here are the 363 and 356. It even has its own Twitter account: @SydenhamWoodLWT
London Wildlife Trust Sydenham Hill Wood page
If you'd like to see more photos of the folly you can visit the Londonphile's Flickr set.
Posted in Follies and grottoes, Parks/gardens/open spaces | Tagged follies, James Pulham, London follies, Pulhamite, Sydenham Hill Wood, Sydenham Hill Wood folly, Sydenham wood folly | 2 Replies | denham Hill Wood folly
Sydenham Hill Wood and Folly
'A folly might be defined as a useless building erected for ornament on a gentleman's estate' – Barbara Jones.
'The mark of a true folly is that it was erected to satisfy and give pleasure to the builder, and greatly to surprise the stranger' – Sir Hugh Casson.
While there is much debate about how exactly to define a folly, there's little doubt that many visitors must be fooled by this folly in Sydenham Hill Wood. These 'ruins' actually only date back to the Victorian era, and were built as an impressive garden feature in the grounds of a large house once on the site – Fairwood, which was built around 1864. Its owner, Alderman David Henry Stone (later a Lord Mayor of London), contracted the firm of James Pulham & Son (inventor of the artificial Pulhamite rock) to construct these sham ruins. Ruins had been a popular type of folly since the late seventeenth and eighteenth centuries, when wealthy landowners inspired by their Grand Tours of Europe wanted to re-create some of the classical sights in their own gardens.
The folly and rockery
The Sydenham folly depicts a ruined church or monastery – apparently remains of stained glass were still present in the windows back in the 1950s and early 1960s. It's thought that the arch would once have been complete – although it's hard to be precise when you're talking about ruins, and fake ones at that! There are also the remains of a rockery leading down to what was once an ornamental stream. Previously a group of six or seven large houses, including Fairwood, had been built on this | 356 |
According to its clever advertising slogan: "You never actually own a Patek Philippe; you just look after it for the next generation". Within those 16 words is summed up the longevity, desirability and heritage that make Patek the untouchable brand it is today.
The Swiss giant is the world's oldest watchmaker, widely acknowledged for their exemplar watchmaking and clean, timeless designs.
Independence, tradition, innovation, quality and craftsmanship are among the fundamental values of the Genevan watchmaker. What it doesn't know about watchmaking simply isn't worth knowing and the company is proud to own impressive repertoire of more than 80 patents.
But don't think innovation equals over-complication, the firm strives for simplicity and is known for the pared-back elegance of its design as can be seen by the Calatrava, Patek Philippe's signature model, in rose gold with hidden dust-cover (above).
In 2009 Patek Philippe launched its proprietary quality label for mechanical watches. The 'Patek Philippe Seal' attests to the utmost quality of its timepieces, far above and beyond official standards, by integrating all competencies and features of relevance in manufacturing, precision and lifelong maintenance.
Did You Know? On 1 May 2014, Patek Philippe celebrated 175 years of watchmaking, which will be celebrated with<|fim_middle|> during the Great Exhibition of London in 1851. | Grand Exhibition from May 27 – June 7 at the Saatchi Gallery in London.
Brand Friends: Former French President Nicolas Sarkozy wore his white gold Patek Philippe Triple Date Perpetual Calendar, Reference 3940 during his presidency. Queen Victoria and Prince Albert were also supplied watches by Patek Philippe. The Queen also acquired a key-wound Patek Philippe pendant-style watch | 84 |
Football agents
Where does your data come from?
How long do we keep your data?
What part of the General Data Protection Regulation (GDPR) covers this?
You're fundamental for the development of the game's stars. We use your data to comply with the rules of football and in particular the FIFA Football Agent Regulations. In this regard, the data that you enter on the FIFA Agent Platform is necessary for you to become a licensed agent and to centralise the reporting with regard to football agents' activities. Some of your data is made available on the FIFA Legal Hub and the FIFA Agent Platform in order to ensure transparency, and information of public interest might be published on fifa.com. We also use your data to create the stats that are of interest to our fans – for example, we may refer to the amounts earned linked to player transfers.
Your data comes directly from you.
Agent ID number
National identification/passport number
Office phone number
Social media account details
Information on authorisation to work with minors
Information on remuneration received
Dates of transactions
Details of compliance background check
Details of services provided
Details of sanctions imposed
We keep your data for as long as you are a licensed agent, or as required for legal or regulatory purposes.
Single-entity leagues
The general public
Article 6 paragraph 1 (a) GDPR (consent)
Article 6 paragraph 1 (c) GDPR (compliance with legal obligation)
Article 6 paragraph 1 (e) GDPR (public interest)
Article 6 paragraph 1 (f) GDPR (legitimate interests)
Data Subjects
Before the first whistle<|fim_middle|>. We use your data to comply with the rules of football and the Regulations on the Status and Transfer of Players.
Keeping the game clean
It is everyone's responsibility to play by the rules and ensure the beautiful game is a doping-free sport.
eFootball players
Passionate fans from all over the world tune in to watch the action online. You are the stars. We use your data to give you access to the platform where the game is played.
Whistle-blowers
Fair play is the name of the game. You must blow the whistle when you see foul play on or off the pitch. | , you should know that we use your data to provide customer service, manage our relationship and allow you to pay for your ticket.
We can't wait to welcome you to one of our events to share our love of the beautiful game!
Event team members and volunteers
Thanks for being part of the team of staff and volunteers who make our events happen. We couldn't do it without you!
Without our hard-working officials, there's no game, so thanks for everything you do for the sake of football around the world.
Thanks for helping us tell football's story! We use your data to manage access to the FIFA Media Channel and accredit the journalists, photographers and broadcast reporters who help us bring football to the world.
Match agents
Match agents help us bring communities, countries, clubs and national teams together – you embody FIFA's Living Football philosophy.
You're fundamental for the development of the game's stars. We use your data to comply with the rules of football and in particular the FIFA Football Agent Regulations.
Without fans like you, there's no football. Your enthusiasm gets us up in the morning and drives us to make football truly global.
Players under the age of 18
You're the future of the game. We use your data to help keep football safe and open, protect young players, comply with the rules of football, distribute funds and support payments, and share information between member associations and FIFA.
Amateur players
You're the beating heart of the game, the players who turn out for local glory come rain or shine.
Professional players
You're the stars of the game and role models for millions of people. We salute you | 331 |
To provide a forum for member companies to develop, discuss and respond to issues that affect us in our responsible management of contaminated lands.
To establish and maintain a strong working relationship with regulatory authorities and other related agencies that have an interest in the management of contaminated lands.
To encourage others to accept ACLCA-WA as the consulting industry's peak representative group on contaminated land issues in WA.
To assist in the development and maintenance of appropriate indsutry practices and encourage members to adopt these practices.
To promote and encourage the open exchange of information between members and<|fim_middle|>AFE students and based on academic merit, project / research relevance and community involvement. To manage Scholarship funds, report to the ACLCA WA Executive and follow directions as instructed by the ACLCA WA.
The WA NPG focus area group is made up of contaminated land consultants within their first five years of consulting. The aim of the group is to provide the opportunity to network with other consultants within the industry, keep up to date with the goings on within our industry, attend monthly meetings and organize the ACLCA social functions! New events are always being introduced so joining the NPG allows individuals to have their say and assist with organising events and information sessions that will benefit ACLCA members.
For more information, events, news and presentations, refer to the NPG webpage. | other interested bodies.
To promote an awareness and provide information to outside parties on the professional skills in the area of contaminated land management.
To facilitate and / or run training events for member, regulatory agencies, industry and non-members oganisations.
To coordinate professional and social development opportunties for younger members of the ACLCA-WA or potential members, through the Paul Turner Scholarship.
Charter: to develop criteria and monitor procedures for maintaining a high standard of integrity for ACLCA WA as the peak body association for contaminated land consultants. To review membership applications and deliver a quality service to member companies.
Charter: to manage and run the annual Paul Turner Scholarship awarded to University and / or T | 138 |
CANNON BEACH — Best-selling author and Oregon Coast devotee Matt Love will headline the roster for the seventh annual Summer in Words Writing Conference held at the Hallmark Inn &<|fim_middle|>, June 19 to 22. A full weekend of workshops, presentations and keynote addresses by speakers, best-selling authors and industry experts will focus on the craft and business of writing. The theme for this year's conference is Craft, Connection & Community. Summer in Words provides aspiring and established writers the opportunity to hone their writing skills, learn the latest insights about the ever-changing publishing world, and network with fellow writers and professionals. Cost for all three days is $285; single-day or single-event pricing is also available.
The conference kicks off Thursday evening, June 19 with a chance for participants to meet and mingle. On Friday, June 20 workshops will be taught by John Ellis, Jessica Morrell, Randall Platt and Love. Friday's workshops will be followed by a reception and book signing with books from Cloud & Leaf Bookstore and a talk by bestselling fantasy author Karen Azinger. Her talk, "A Fearless Path to Publishing!" will describe her path from a mailbox full of rejections to a five-figure deal from one of the Big Six publishing houses, to then taking her destiny into her own hands, forming her own publishing company, and gaining avid fans around the world.
To read the entire story on CoastWeekend.com, click here. | Resort in Cannon Beach | 4 |
Natalia Jessa is on the forefront of becoming the new face of Portuguese wines and one of the hardest working people around. Having relocated for love from Poland via Ireland to Oporto, Natalia Jessa has really taken grasp of what is virtually<|fim_middle|> management and winemaking to marketing. Antonio also leads oenology teams in various wineries in Lisboa, Tejo and Alentejo where his signature can be tasted in some millions of Portuguese wine bottles, exported throughout the world.
Having been a buyer at one of England's top food and wine markets, Tesco, for years where she studied wine through WSET, when she arrived to live in Portugal, Natalia developed her own distribution company to fulfill the needs of her various employers and clients over the years. She quickly recognized an opportunity to collaborate with some of the country's best vintners to bottle lovely expressions from wineries in each region, using only local varieties. All of these wines named themselves. After releasing their bouquets, Natalia chose the floral names and designs to represent how the wines have developed aromatically. | an underserved market for inexpensive and incredibly delicious wine. She says it herself in the most adorable broken Portu/Polish English accent: "Drink it, don't overthink it." And these wines over deliver in a BIG way.
Since the year 2000, Antonio is the golden child of Provintage, a winemaking consulting company where he is the General Manager and Chief-Winemaker, encompassing a large range of winery services, from vineyard | 97 |
here and I guess maybe they don't know about this place or perhaps it seems more wonderful to me than it really is on<|fim_middle|> one of them, but Bob said he would rather I stubbed my toe than have a lot of men staring at me, but he was awfully nice about my toe and kept asking me how it felt.
Bob is a wonderful swimmer and I tried to make him go out and enjoy himself in the deep water, but he wouldn't leave me for a second and he said he would never forgive himself if he left me and something happened to me. I told him I would stay in shallow water and there would be no danger, but he said he had heard that sharks and baracudas sometimes came right up to the beach and bit women if they were alone. | account of being here with Bob and that is what makes it so wonderful. Anyway I was never so happy in my life and am already dreading the time when it will be time to start home.
The first day we got here there was a young couple introduced themselves to Bob after dinner that evening and wanted to know did we want to play bridge with them. As you know I don't play bridge and Bob says he can't take any interest in games unless I am in them so he told these people we were going out for a sail and after we were alone he said he hated to tell a lie so we would have to go out for a sail so he would not have told those people a lie, so he hired a sail boat and it was simply heavenly sailing in the moonlight just Bob and I and the man sailing the boat who never looked at us.
The moonlight here is heavenly and I don't believe there is any other place where it is so wonderful and it was so wonderful that Bob and I had to laugh at the idea of staying in a stuffy hotel and playing cards when you could be out sailing in the moonlight though I suppose it would bore some people.
The next morning we got on the hotel boat and went over to the bathing beach and went in swimming and the water was wonderful but Bob didn't like it at first as he said there was too many people around and he hated to have other men see me in my bathing suit so he and I walked away along the beach where there was nobody else and we went in the water there. It was kind of weedy and not as nice as the regular beach as there was also some rocks in the place we went in and I stubbed my toe on | 349 |
High-pressure behavior...
American Mineralogist
Journal of Earth and Planetary Materials
Ed. by Baker, Don / Xu, Hongwu / Swainson, Ian
€ [D] 862.00 / US$ 1034.00 / GBP 708.00*
€ [D] 1034.00 / US$ 1241.00 / GBP 848.00*
Presidential Address. Nano- and micro-geochronology in Hadean and Archean zircons by atom-probe tomography and SIMS: New tools for old minerals by Valley, John W./ Reinhard, David A./ Cavosie, Aaron J./ Ushikubo, Takayuki/ Lawrence, Daniel F./ Larson, David J./ Kelly, Thomas F./ Snoeyenbos, David R. and Strickland, Ariel
Particle size effects on transformation kinetics and phase stability in nanocrystalline TiO2 by Gribb, Amy A. and Banfield, Jillian F.
The application of electron backscatter diffraction and orientation contrast imaging in the SEM to textural problems in rocks by Prior, David J./ Boyle, Alan P./ Brenker, Frank/ Cheadle, Michael C./ Day, Austin/ Lopez, Gloria/ Peruzzo, Luca/ Potts, Graham J./ Reddy, Steve/ Spiess, Richard/ Timms, Nick E./ Trimby, Pat/ Wheeler, John and Zetterström, Lena
Magmatic volatiles (H, C, N, F, S, Cl) in the lunar mantle, crust, and regolith: Abundances, distributions, processes, and reservoirs by McCubbin, Francis M./ Kaaden, Kathleen E. Vander/ Tartèse, Romain/ Klima, Rachel L./ Liu, Yang/ Mortimer, James/ Barnes, Jessica J./ Shearer, Charles K./ Treiman, Allan H./ Lawrence, David J./ Elardo, Stephen M./ Hurley, Dana M./ Boyce, Jeremy W. and A...
Interpretation of XPS Mn(2p) spectra of Mn oxyhydroxides and constraints on the mechanism of MnO2 precipitation by Nesbitt, H.W. and Banerjee, D.
The American Mineralogist at 100 years, and a mineralogy renaissance by Putirka, Keith
Structure and elasticity of MgO at high pressure by Karki, B.B./ Stixrude, L./ Clark, S.J./ Warren, M.C./ Ackland, G.J. and Crain, J.
A route for the direct crystallization of dolomite by Rodriguez-Blanco, Juan Diego/ Shaw, Samuel and Benning, Liane G.
Oxidation state of gold and arsenic in gold-bearing arsenian pyrite by Simon, Grigore/ Huang, Hui/ Penner-Hahn, James E./ Kesler, Stephen E. and Kao, Li-Shun
Structure and crystal-field spectra of Co3Al2(SiO4)3 and (Mg,Ni)3Al2(SiO4)3 garnet by Ross, Charles R./ Keppler, Hans/ Canil, Dante and O'Neill, Hugh St. C.
Reactions of aqueous Au1+ sulfide species with pyrite as a function of pH and temperature by Scaini, M.J./ Bancroft, G.M. and Knipe, S.W.
Book Review by Rust, Alison
The origin and implications of clay minerals from Yellowknife Bay, Gale crater, Mars by Bristow, Thomas F./ Bish, David L./ Vaniman, David T./ Morris, Richard V./ Blake, David F./ Grotzinger, John P./ Rampe, Elizabeth B./ Crisp, Joy A./ Achilles, Cherie N./ Ming, Doug W./ Ehlmann, Bethany L./ King, Penelope L./ Bridges, John C./ Eigenbrod...
Data, ideas, and the nature of scientific progress by Putirka, Keith
What Lurks in the martian Rocks and Soil? Investigations of Sulfates, Phosphates, and Perchlorates. Gypsum in modern Kamchatka volcanic hot springs and the Lower Cambrian black shale: Applied to the microbial-mediated precipitation of su.. by Tang, Min/ Ehreiser, Anouk and Li, Yi-Liang
A novel technique for fluorapatite synthesis and the thermodynamic mixing behavior of F-OH apatite crystalline solutions by Hovis, Guy L./ McCubbin, Francis M./ Nekvasil, Hanna/ Ustunisik, Gokce/ Woerner, William R. and Lindsley, D.H.
Oriented attachment and growth, twinning, polytypism, and formation of metastable phases: Insights from nanocrystalline TiO2 by Penn, R. Lee and Banfield, Jillian F.
Structure of synthetic monoclinic Na-rich birnessite and hexagonal birnessite: I. Results from X-ray diffraction and selected-area electron diffraction by Drits, Victor A./ Silvester, Ewen/ Gorshkov, Anatoli I. and Manceau, Alain
Modification of garnet by fluid infiltration during regional metamorphism in garnet through sillimanite-zone rocks, Dutchess County, New York by Whitney, Donna L./ Mechum, Trudy A./ Dilek, Yildirim and Kuehner, Scott M.
Experimental phase-equilibrium study of Al- and Ti-contents of calcic amphibole in MORB—A semiquantitative thermobarometer by Ernst, W.G. and Liu, Jun
Volume 104 (2019)
Issue 7 (Jul 2019) , pp. 917-1063
Issue 3 (Mar 2019) , pp. 317-463
Issue 2 (Feb 2019) , pp. 165-315
Issue 12 (Dec 2018) , pp. 1877-2049
Issue 11 (Nov 2018) , pp. 1717-1876
Issue 10 (Oct 2018) , pp. 1521-1715
Issue 9 (Sep 2018) , pp. 1353-1520
Issue 8 (Aug 2018) , pp. 1173-1351
Issue 7 (Jul 2018) , pp. 1009-1171
Issue 6 (Jun 2018) , pp. 837-1007
Issue 6 (Jun 2017) , pp. 1149-1367
Issue 5 (May 2017) , pp. 925-1148
Issue 5 (May 2016) , pp. 1021-1243
Issue 4 (Apr 2016) , pp. 753-1020
Issue 11-12 (Nov 2015) , pp. 2365-2756
Issue 8-9 (Aug 2015) , pp. 1657-2016
Issue 5-6 (May 2015) , pp. 1017-1332
Issue 2-3 (Feb 2015) , pp. 341-668
Issue 5-6 (May 2014) , pp. 877-1192
Issue 5-6 (May 2011) , pp. 697-935
Issue 9 (Aug 2001) , pp. 957-1111
Issue 7-8 (Jul 2001) , pp. 773-938
Issue 7-8 (Jul 2000) , pp. 881-1091
Issue 3-4 (Apr 2000) , pp. 397-626
Issue 9-10 (Sep 1998) , pp. 937-1132
Issue 3-4 (Mar 1998) , pp. 193-418
Issue 9-10 (Sep 1996) , pp. 1021-1300
On the nature and significance of rarity in mineralogy
Zircon saturation and Zr diffusion in rhyolitic melts, and zircon growth geospeedometer
On silica-rich granitoids and their eruptive equivalents
Discovery of in situ super-reducing, ultrahigh-pressure phases in the Luobusa ophiolitic chromitites, Tibet: new insights into the deep upper mantle and mantle transition zone
Uraninite from the Olympic Dam IOCG-U-Ag deposit: linking textural and compositional variation to temporal evolution
A story of olivine from the McIvor Hill complex (Tasmania, Australia): Clues to the origin of the Avebury metasomatic Ni sulfide deposit
The origin of extensive Neoarchean high-silica batholiths and the nature of intrusive complements to silicic ignimbrites: Insights from the Wyoming batholith, U.S.A.
From the Hadean to the Himalaya: 4.4 Ga of felsic terrestrial magmatism
Compositional effects on the solubility of minor and trace elements in oxide spinel minerals: insights from crystal-crystal partition coefficients in chromite exsolution
An X-ray magnetic circular dichroism (XMCD) study of Fe ordering in a synthetic MgAlO-FeO (spinel-magnetite) solid-solution series: Implications for magnetic properties and cation site ordering
High concentrations of manganese and sulfur in deposits on Murray Ridge, Endeavour Crater, Mars
A Cr luminescence study of spodumene at high pressures: effects of site geometry, a phase transition, and a level-crossing
Phase transitions between high- and low-temperature orthopyroxene in the MgSiO-FeSiO system
High-temperature and high-pressure behavior of carbonates in the ternary diagram CaCO-MgCO-FeCO
Natural Mg-Fe clinochlores: enthalpies of formation and dehydroxylation derived from calorimetric study
Trace element thermometry of garnet-clinopyroxene pairs
Constraints on the solid solubility of Hg, Tl, and Cd in arsenian pyrite
Ni-phyllosilicates (garnierites) from the Falcondo Ni-laterite deposit (Dominican Republic): mineralogy, nanotextures, and formation mechanisms by HRTEM and AEM
Cu diffusion in a basaltic melt
High-pressure behavior of the polymorphs of FeOOH
New Mineral Names
Mary M. Reagan
Department of Geological Sciences, Stanford University, Stanford, California 94305, U.S.A
Other articles by this author:
De Gruyter OnlineGoogle Scholar
/ Arianna E. Gleason
Shock and Detonation Physics, LANL, Los Alamos, New Mexico 87545, U.S.A
/ Luke Daemen
Spallation Neutron Source, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, U.S.A
/ Yuming Xiao
Advanced Photon Source, Argonne National Laboratory, Lemont, Illinois 60439, U.S.A
/ Wendy L. Mao
Photon Science, SLAC National Accelerator Laboratory, Menlo Park, California 94025, U.S.A
Published Online: 2016-06-03 | DOI: https://doi.org/10.2138/am-2016-5449
The high-pressure structural and electronic behavior of α-, β-, and g-FeOOH were studied in situ using a combination of synchrotron X ray diffraction (XRD) and X ray emission spectroscopy (XES). We monitored α-FeOOH by XES as a function of pressure up to 85 GPa and observed an electronic spin transition that began at approximately 50 GPa, which is consistent with previous results. In the γ-FeOOH sample, we see the initiation of a spin transition at 35 GPa that remains incomplete up to 65 GPa. β-FeOOH does not show any indication of a spin transition up to 65 GPa. Analysis of the high-pressure XRD data shows that neither β-FeOOH nor γ-FeOOH transform to new crystal structures, and both amorphize above 20 GPa. Comparing our EOS results for the b and g phases with recently published data on the a and e phases, we found that β-FeOOH exhibits distinct behavior from the other three polymorphs, as it is significantly less compressible and does not undergo a spin transition. A systematic examination of these iron hydroxide polymorphs as a function of pressure can provide insight into the relationship between electronic spin transitions and structural transitions in these OH- and Fe3+-bearing phases that may have implications on our understanding of the water content and oxidation state of the mantle.
Key words: Spin transitions; high-pressure studies; XES; FeOOH; XRD data
Benoit, M., Marx, D., and Parrinello, M. (1998) Tunnelling and zero-point motion in high-pressure ice. Nature, 392, 258–261.Google Scholar
Birch, F. (1978) Finite strain isotherm and velocities for single-crystal and polycrystalline NaCl at high pressures and 300°K. Journal of Geophysical Research, 83, 1257–1268.Google Scholar
Bolotina, N., Molchanov, V., Dyuzheva, T., Lityagina, L., and Bendeliani, N. (2008) Single-crystal structures of high-pressure phases FeOOH, FeOOD, and GaOOH. Crystallography Reports, 53, 960–965.Web of ScienceGoogle Scholar
Friedrich, A., Haussül, E., Boehler, R., Morgenroth, W., Juarez-Arellano, E.A., and Winkler, B. (2007) Single-crystal structure refinement of diaspore at 50 GPa. American Mineralogist, 92, 1640–1644.Web of ScienceGoogle Scholar
Frost, D.J., and McCammon, C.A. (2008) The redox state of Earth's mantle. Annual Review of Earth and Planetary Sciences, 36, 389–420.Google Scholar
Gerth, J. (1990) Unit-cell dimensions of pure and trace metal-associated goethites. Geochimica et Cosmochimica Acta, 54, 363–371.Google Scholar
Gilli, G., and Gilli, P. (2009) The Nature of the Hydrogen Bond. Oxford University Press, New York.Google Scholar
Gleason, A.E., Jeanloz, R., and Kunz, M. (2008) Pressure-temperature stability studies of FeOOH using X ray diffraction. American Mineralogist, 93, 1882–1885.Web of ScienceGoogle Scholar
Gleason, A.E., Quiroga, C.E., Suzuki, A., Pentcheva, R., and Mao, W.L. (2013) Symmetrization driven spin transition in e-FeOOH at high pressure. Earth and Planetary Science Letters, 379, 49–55.Google Scholar
Hammersley, A.P. (1998) Fit2D: V99.129 Reference Manual Version 3.1. Internal Report ESRF-98-HA01.Google Scholar
Heinz, D., and Jeanloz, R. (1984) The equation of state of the gold calibration standard. Journal of Applied Physics, 55, 885–893.Google Scholar
Holzapfel, W.B. (1972) Symmetry of the hydrogen bonds in Ice VII. Journal of Chemical Physics, 56, 712–715.Google Scholar
Kosmulski, M., Maczka, E., Jartych, E., and<|fim_middle|>89–96.Google Scholar
Wang, X., Chen, X., Gao, L., Zheng, H., Ji, M., Tang, C., Shen, T., and Zhang, Z. (2004) Synthesis of β-FeOOH and α-Fe2O3 nanorods and electrochemical properties of β-FeOOH. Journal of Material Chemistry, 905–907.Google Scholar
Williams, Q., and Hemley, R. (2001) Hydrogen in the deep earth. Annual Review of Earth and Planetary Sciences, 29, 365–418.Google Scholar
Xu, W., Greenberg, E., Rozenberg, G.K., Pasternak, M.P., Bykova, E., Boffa-Ballaran, T., Dubrovinsky, L., Prakapenka, V., Hanfland, M., Vekliova, O., and others. (2013) Pressure-induced hydrogen bond symmetrization in iron oxyhydroxide. Physical Review Letters, 111, 175501.Web of ScienceGoogle Scholar
About the article
Received: 2015-06-05
Accepted: 2016-02-16
Published in Print: 2016-06-01
Citation Information: American Mineralogist, Volume 101, Issue 6, Pages 1483–1488, ISSN (Online) 1945-3027, ISSN (Print) 0003-004X, DOI: https://doi.org/10.2138/am-2016-5449.
© 2016 by Walter de Gruyter Berlin/Boston. | Rosenholm, J.B. (2003) Synthesis and characterization of goethite and goethite-hematite composite: Experimental study and literature survey. Advances in Colloid and Interface Science, 103, 57–76.Google Scholar
Lin, J.F., and Tsuchiya, T. (2008) Spin transition of iron in the Earth's lower mantle. Physics of the Earth and Planetary Interiors, 170, 248–259.Google Scholar
Lin, J.F., Vankó, G., Jacobsen, S.D., Iota, V., Struzhkin, V.V., Prakapenka, V.B., Kuznetsov, A., and Yoo, C.-S. (2007) Spin transition zone in Earth's lower mantle. Science, 317, 1740–1743.Google Scholar
Lin, J.F., Speziale, S., Mao, Z., and Marquardt, H. (2013) Effects of the electronic spin transitions of iron in lower mantle minerals: Implications for deep mantle geophysics and geochemistry. Reviews of Geophysics, 51, 244–275.Web of ScienceGoogle Scholar
Lutterotti, L., Matthies, S., Wenk, H.-R., Schultz, A.S., and Richardson, J.W. (1997) Combined texture and structure analysis of deformed limestone from time-of-flight neutron diffraction spectra. Journal of Appied Physics, 81, 594–600.Google Scholar
Mao, H.K., Xu, J., and Bell, P.M. (1978) High pressure physics: Sustained static generation of 1.36 to 1.72 megabars. Science, 200, 1145–1147.Google Scholar
Mattila, A., Pylkkänen, T., Rueff, J-P., Huotari, S., Vankó, G., Hanfland, M., Lehtinen, M., and Hämäläinen, K. (2007) Pressure induced magnetic transition in siderite FeCO3 studied by X ray emission spectroscopy. Journal of Physics, 19, 386206.Google Scholar
Momma, K., and Izumi, F. (2008) VESTA: a three-dimensional visualization system for electronic and structural analysis. Journal of Appied Crystallography, 41, 653–658.Google Scholar
Otte, K., Pentcheva, R., Schmahl, W.W., and Rustad, J.R. (2009) Pressure-induced structural and electronic transitions in FeOOH from first principles. Physical Review B, 80, 205116.Google Scholar
Sano, A., Ohtani, E., Kubo, T., and Funakoshi, K.I. (2004) In situ X ray observation of decomposition of hydrous aluminum silicate AlSiO3OH and aluminum oxide hydroxide d-AlOOH at high pressure and temperature. Journal of Physics and Chemistry of Solids, 65, 1547–1554.Google Scholar
Skoog, D.A., West, D.M., and Holler, F.J. (1996) Fundamentals of Analytical Chemistry, 7th ed. Thomson, Belmont, California.Google Scholar
Speziale, S., Milner, A, Lee, V.E., Clark, S.M., Pasternak, M.P., and Jeanloz, R. (2005) Iron spin transition in Earth's mantle. Proceedings of the National Academy of Sciences, 102, 17918–17922.Google Scholar
Stackhouse, S., Brodholt, J.P., and Price, G.D. (2007) Electronic spin transitions in iron-bearing MgSiO3 perovskite. Earth and Planetary Science Letters, 253, 282–290.Web of ScienceGoogle Scholar
Suzuki, A. (2010) High-pressure X ray diffraction study of ∊-FeOOH. Physics and Chemistry of Minerals, 37, 153–157.Google Scholar
Schwertmann, U., and Cornell, R.M. (2000) The Iron Oxides in the Laboratory, 2nd ed. Wiley-VCH, Weinheim.Google Scholar
Voigt, R., and Will, G. (1981) The system Fe2O3-H2O under high pressures. Neues Jahrbuch für Mineralogie, 2, | 1,041 |
Home | Fitness | Dear Foodie: How Do I Get Motivated to Work Out?
Dear Foodie: How Do I Get Motivated to Work Out?
How do I get motivated to start exercising?
Don't (necessarily) exercise, be active! In my case, I found ways to move my body without doing the gym rat thing. I love to walk so that's my main form of exercise. There are so many benefits to just being active. Most experts agree you should get about an hour of physical activity a day but that does not mean you have to do a structured exercise program. Walk, dance, chase the kids, whatever!
Find something you love doing and do it! I realize this can be daunting for someone who was morbidly obese, and may not have been used to moving his/her body with any great regularity. But think about what kind of movement makes you happy and then focus on doing that. If you love it<|fim_middle|> like you are doing all you can to provide a supportive environment. Have you asked him why he doesn't put in the effort? If so, what does he say?
Thank you so much for this. I'm 11 month post op and I find it so hard to motivate myself. In my head I think that I have to spend 3 hour at the gym, and when I don't do that, I tend to beat myself up.
When Iwas younger, and much skinnier, I was very active. Over years of weight gain and lack of movement from arthritis in knees I became VERY sedentary. In the last five years I have had both knees replaced and had my bypass June 2015. I love walking the beautiful trails we have here in Alaska during the ice and snow free months. With snow and ice I have to be careful in not falling and damaging my new knee implants. As winter is approaching I'm just having a hard time getting my mind wrapped around going to gym. Oh yes….I have been paying for my membership for a year and a half now and haven't been for a year! I love the weight machines and know the toning the flabby areas would be beyond awesome!
I love the idea about the Xbox videos since we do have the Kinect (was for my kids) might be a cool way to go about this. I love to dance and thought Zumba would be fun. I found Zumba for the Xbox Kinect! So will purchase this and give it a shot. Plus, I can learn routines at home without feeling lost in the classes at gym. I'll let you know how it goes. | , you'll keep doing it!
Start slowly! Nobody is expecting you to run a marathon, or whatever, immediately. And you shouldn't expect that of yourself either (confession: I'm terrible for putting that sort of pressure on myself, that I didn't go far enough, hard enough, whatever, when you, and I, need to remember to be kind to yourself!).
Try an assortment of things, especially if you don't have a clue what you'll like. Cycling (outside or check out a spin class), swimming, walking, kayaking, belly-dance, even games for your X-box or Wii…whatever! This also has the added benefit of safe-guarding you against stalls. Keep those muscles guessing as you figure out what you like!
As I said before, I started off with walking. And I didn't go far at first but slowly I pushed myself to go further and further. Soon I was surprising myself with the number of miles I was logging. And, on a recent weekend, I was shocked that I actually ran on a treadmill. Me? Formerly obese me!
I would be remiss not to point out (cuz Nik said so) that anytime you plan to start a physical activity routine you should check with your doctor and heed common safety tips.
But in the end you just have to commit to start. That's the hardest part. I've heard it said before that the hardest part about exercise is showing up. That's so true! But if you can focus on showing up, doing things you like to do and progressing slowly but steadily, you may just come to love moving more.
"Dear Foodie" is Julia Weaver, who is 20 months post-op from RNY gastric bypass surgery and has lost 180 lbs. and counting!
Do you have a question about post-op life to ask Dear Foodie? Email your questions (with the subject line "Dear Foodie") to [email protected].
Thanks for writing. I know that has to be a bit frustrating! Unfortunately, you can't make him change if he doesn't want to do it for himself. It sounds to me | 436 |
Luxembourg Herald
Fresh News from the heart of Grand Duchy of Luxembourg
Trump admits that his son met with a Russian in 2016 to obtain information about Clinton
7th August 2018 Politics 24833
Donald trump first admitted that his son met with a Kremlin-related lawyer in 2016 to gather information about Hillary Clinton, but insists that the meeting was legal.
In one of a series of Sunday morning tweets issued in apparent reaction to a CNN report, the US president wrote: "Fake News reporting, a complete fabrication, that I am concerned about the meeting my wonderful son, Donald, had in Trump Tower. This was a meeting to get information on an opponent, totally legal and done all the time in politics – and it went nowhere. I did not know about it!"
That explanation differs entirely from one given by Trump 13 months ago, when a statement dictated by the president but released under the name of Donald Trump Jr read: "We primarily discussed a program about the adoption of Russian children that was active and popular with American families years ago."
The 2016 meeting is pivotal to the special counsel Robert Mueller's Russia collusion investigation, though Trump's tweets appeared aimed at conveying the message that he is not worried about Donald Trump Jr's exposure to the inquiry.
He made the remarks as one of his lawyers warned the special counsel against trying to force the president to be interviewed.
Trump has launched a series of new public attacks on Mueller and his team in recent weeks, which has been interpreted as possible signs the president is anxious about the inquiry reaching his family.
Trump, who is currently ensconced at his Bedlington, New Jersey, golf course for an 11-day "working holiday", has a decision to make over whether to sit for an interview with Mueller – or risk being issued a subpoena.
Trump's legal team have gone back and forth on the issue, playing each scenario out in the court of public opinion to see how it plays.
On Sunday, a Trump lawyer, Jay Sekulow, told ABC News' George Stephanopoulos that if Mueller subpoenas Trump to testify, it would spark a legal battle that would go to the supreme court.
"A subpoena for live testimony has never been tested in court as to the president of the United States," Sekulow said.
In Trump's early Sunday Twitter barrage, he again sought to link Mueller's investigation with the motives of his political opponents, government law enforcement agencies and the media's reporting of his presidency.
"Why aren't Mueller and the 17 Angry Democrats looking at the meetings concerning the Fake Dossier and all of the lying that went on in the FBI and DOJ? This is the most one sided Witch Hunt in the history of our country. Fortunately, the facts are all coming out, and fast!".
Trump Jr's exposure to the Mueller investigation stems from a meeting with a Kremlin-connected Russian lawyer promising damaging information on Hillary Clinton that he and Trump son-in-law Jared Kushner attended at Trump Tower in July 2016.
Trump Jr's claim to a Senate committee that he never told his father about the meeting have been contradicted by others in Trump's circle, including Trump's lawyer and fixer Michael Cohen, who is believed to be cooperating with the investigation.
The former White House communications director Anthony Scaramucci and the former White House chief strategist Steve Bannon have suggested that Trump, at a minimum, knew of the meeting soon after it took place.
Senior Republicans have sought to distance themselves from Trump's attempt to protect Trump Jr by claiming he, too, is the victim of a witch-hunt, a phrase Trump has tweeted 46 times over the past two months in connection to Mueller.
In private, Trump reportedly believes his son may have inadvertently exposed himself to legal jeopardy.
Last week, the Iowa Republican Chuck Grassley, chairman of the Senate judiciary committee, told CNN: "If he misled the committee, he's lying to Congress. That's a crime. And that'd be up to the prosecutors, not me."
Still, Trump's concern for his son, and his efforts to protect him, speaks to a larger sense of frustration that is beginning to envelop the presidency. Trump is believed to be aggrieved by Mueller's treatment of Paul Manafort, his former campaign chairman, who went on trial last week on tax evasion and bank fraud charges.
"He is completely outraged by the way Manafort has been treated, with the solitary confinement and all of that," Trump's legal counsel Rudy Giuliani told the Washington Post. "It's obvious to him that they're all but torturing Manafort in order to try to get him to flip."
Last week, Trump called on his attorney general, Jeff Sessions, to end the investigation, a position White House communications staff had then to describe as "a personal opinion".
"With his great feel for public opinion and how to deal with it, he has a sense about what would work, what to say," Giuliani said this week. "He sort of determines the public strategy, and we get his approval and input for the legal strategy."
Breakfast briefing: Italian Mafia trial, Estonia PM quits, Brussels riots and top sandwiches
New Ohio covid variant, global and local roundup, Estonia PM quits, Navalny will return to Russia, Flint water crisis charges, Mafia trial, Brussels riots and top sandwiches. Our breakfast [...]
Trump riots: Democrats plan to introduce article of impeachment
Patrick de la Hamette: Leaving no one behind in the digital transformation
Healthcare workers aren't sure about the vaccine
Almost six out of ten staff at the Robert Schuman Hospital group said they want to be vaccinated against [...]
People over 75 next in Lux vaccination drive
EU begins vaccinations to end Covid nightmare<|fim_middle|>]
Two people killed in a Baptist church in San Jose
Viking Grace liner safely towed from Åland Islands
Choice supporters hold largest protest in history against the Polish government
Luxembourg on ITB 2020
Best IT in the country
CC BY ND 2.0 Luxembourg Herald 2013-2016 [email protected] |
Covid-19 immunity can help guide pandemic management
Three judges overseeing Italy's mega-mafia trial ask to be recused on the first day as 350 'Ndrangheta mob suspects prepare to face justice
Three judges assigned to oversee Italy's largest mafia trial in more than 30 years today asked to be [... | 71 |
Anne Phillips, The Politics of the Human
Authors Leila Faghfouri Azar
Leila Faghfouri Azar, "Anne<|fim_middle|> rooted in an unclear distinction that Arendt draws between the political and the social, according to which the only form of community through which equality could be established is a political community. Phillips argues that this understanding of the political overlooks the important role of social differences in claiming equality against the political community (which has denied the equality of certain groups of people). This criticism gives rise to what is at the heart of Phillips' account on the human: the claim to be recognized as equal, and the commitment to recognize each other as equal within and against the political community (p. 78).
But what does it mean to consider the claim and commitment to equality as central in understanding the human? To address this question, Phillips engages in a critical reading of different understandings of human dignity in different discourses, since she sees this as one major challenge to her argument on the political understanding of the human. Phillips argues that dignity, most often, is just another way of theorizing what it means to treat others as equals. Theories of human dignity that go beyond this will engage with offering a substantive idea about what it is to be human, which should be avoided in her view. Therefore, instead of referring to a substantial characteristic, it is better to rely on equality, both as a claim and as commitment. Equality, in terms of the right to be regarded as an equal member of the category of the human, is neither a matter of justification nor an empirical claim. Phillips believes that detaching the notion of the human from what it essentially means to be human would protect us from distinguishing humans on the ground of their cognitive capacities. This would also protect us from making sentimental, non-political claims. In addition, a more claim-based account of what it means to be human moves the attention from those who are at the moment secure in the status of being equal to those who are still about to achieve it. The politics of the human which understands equality in terms of the human's claim and commitment would have a greater political force than the politics in which equality is seen as what should be given to the human.
Phillips devotes the final chapter of this book to discuss her position's distance from discourses on humanism and post-humanism in order to substantiate her equality-claim based understanding of the human. Although critical of both discourses, Phillips argues that her position is neither anti-humanist nor post-humanist. She is critical of humanism, basically because this discourse's essentialist approach to understanding the human moves the focus away from particularities and differences in understanding what the human is. Besides, she argues that post-humanism, ranging from an oversimplified anti-humanism to more complex versions, will potentially decrease the central role and importance of equality and the politics of the human.
Some scholars affirm that The Politics of the Human is a significant contribution to set political theory free from the search for foundation(s). I also believe it is a valuable contribution to the contemporary literature on emancipatory politics, the politics of difference, and the politics of inclusion. This, of course, has advantages, especially when it comes to issues and questions regarding contemporary human crises on a normative level. However, I am still skeptical about taking the move to normative accounts in politics without having addressed questions on grounding and definition. Philips attempts to offer a normative account of the human, which is substantiated by the concept of equality. And equality, according to her, is not founded on anything, and therefore, there is no need to prove or justify it. Equality, on this view, is taken as a central and predominant value. But before turning to defend and substantiate the politics of the human in terms of a claim and commitment to equality, she needs to clarify who this human is. For she will always be asked about this human who is supposed to claim and be committed to equality. Phillips' only reflection with regard to this question, which is not very easy to be grasped from the lines of her argument, suggests that the human is the one who has the capacity to (at least initially) recognize herself and others as equal. In other words, the capacity to recognize humans as equal is the condition to be considered as human. Here, I think, Phillips is defining the human in a way she herself is critical of. For this defining condition sets limits on membership of the category of the human as long as we could imagine (and introduce examples) of people who cannot exhibit this capacity. Yet, Phillips' political account of the human and equality is supposed to offer a framework of the politics of the human which is free from exclusionary and essentialist characteristics in defining the human. For that reason, one could raise the question how her politics of the human would locate groups of people who cannot/do not exhibit the capacity to recognize humans as equal within the realm of politics. | Phillips, The Politics of the Human", Netherlands Journal of Legal Philosophy, 1, (2016):75-77
Leila Faghfouri Azar
Leila Faghfouri Azar (LL.M., M.A.) is a post-graduate candidate in Socio-Legal Studies at the University of Oxford, Faculty of Law.
Anne Phillips (2015), The Politics of the Human, Cambridge: Cambridge University Press, viii+150 pp, ISBN: 978-1107475830
In The Politics of the Human, Anne Phillips develops a political account in which the human is understood through her particular differences; an account which is neither humanist nor foundationalist. This book basically relies on the lectures she delivered in the John Robert Seeley Series at Cambridge in 2013. A major part of this book revolves around criticizing those conceptions of common humanity that go beyond or beneath human particularities including gender, race, color, and so on. The significance attached to the notion of the human, as she puts it, pertains to its central role in three prevailing contemporary politico-ethical discourses: human rights, global justice, and humanitarianism. In order to critically reflect on these discourses, she criticizes the way the human is understood in them. Firstly, she challenges what she calls an 'abstract' or 'content-less' understanding of the human. The human, on this view, is understood based on the idea of commonality and some shared essentially human characteristics, which is a powerful ethical idea enforced by the universal human rights discourse. Nevertheless, this conception's shortcoming reveals when we invoke some qualifications such as rationality, empathy, or considering the human as a political animal to substantiate this common humanity. As soon as we understand the common humanity on these grounds, some groups of people are considered to be excluded from this category due to not being able to exhibit these qualifications to some extent.
Secondly, Phillips criticizes the 'substantive' or 'content-overloaded' understanding of the human. On this account, the human is conceived of on the ground of a kind of co-humanity, despite the differences that people carry in regard to their gender, color, race, etc. In this framework, the notion of the human, in one sense, is interchangeable with equality. The human, as understood in this manner, is mostly central to cosmopolitan projects of global justice, which, according to Phillips, are 'in some ways an amalgam of humanitarianism and human rights' (p. 4). This discourse employs justice-based arguments in order to convince those who are securely established in their enjoyment of equality and rights to support vulnerable others in the name of a shared humanity. However, Phillips believes this argumentation dissuades people to challenge hierarchies and their corresponding violence, because it sees differences and particularities to be less significant than the general demand for justice. The third account of the human, as approached in humanitarianism, is also associated with equality. Viewed from this standpoint, those who are more privileged and have more fortune should act on behalf of less privileged people in order to serve humanity. Phillips argues that stipulating an obligation of one part of humanity to another part of humanity, even if involving the notion of equality, is very close to ideas of charity and compassion. Although it is not the intention, acting on behalf of those who are not (yet) equal might end up with confirming what humanitarianism asserts to fight against: hierarchies, inequalities, and power-relations.
Phillips' critique of humanitarianism is closely linked to her critique of Rorty's anti-foundationalism, presented in chapter 3. She believes that the implementation of justice by those who are privileged out of empathy disregards what is most radical in the notion of the human: claiming equality by those who have been denied equality on the basis of the claim that they are on a same fully equal standing. Acting on behalf of the other out of empathy, Phillips contends, reflects a non-political understanding of the human. This leads her to discuss Arendt's anti-foundationalism, which though reliable to some extent, is still contestable. Phillips basically tackles Arendt's narrow understanding of politics. This narrowness is | 883 |
Adam<|fim_middle|> that, he has more than 15 years of experience in several field of computer engineering. He has experience in several roles including software engineer, research scientist, consultant, lecturer and technical manager. He has more than 60 publications and 26 issued patents.
Most importantly, Adam is known as a co-founder of Siri. As a startup, Siri won the Innovative Web Technologies award at SXSW and was chosen a Top Ten Emerging Technology by MIT's Technology Review.
In 2012, he left Siri team and founded Viv Labs. It is a startup simplifying the world by providing an intelligent interact to everything. He is also a founding member and adviser of Change.org. It is a social network for positive social change. | Cheyer Net Worth- How Rich is Adam Cheyer Actually?
Adam Cheyer is an American Computer Engineer and Investor. He is the co-founder of Siri Inc and formerly worked as a director of engineering in the iPhone group at Apple. Although Adam Cheyer net worth (exact) is hard to breakdown, what we know is that he is a multi-millionaire.
Adam received his bachelor's degree in computer science from Brandeis University in 1988 and earned a master's degree in computer science and artificial intelligence from UCLA in 1993. He received "Outstanding Masters Student" award from UCLA's School of Engineering.
Adam started his career as a Program Director in SRI's Artificial Intelligence Center where he worked as Chief Architect of CALO/PAL project. He was VP of Engineering at Dejima where he was responsible for managing engineering staff, technology, strategy and guiding the company to move forward.
In-addition to | 191 |
The Knot's first COUTURE: Las Vegas Bridal Market, is rapidly approaching, set for downtown Las Vegas at World Market Center Pavilion I from August 27th through August 29th.
Show hours are 10 - 7 on Sunday and Monday and 10 - 6 on Tuesday.
The Las Vegas show will connect more than 150 top bridal collections and more than a thousand retail buyers from the West Coast and beyond for a first look at forthcoming collections and, ultimately, providing brides with the most current bridal fashions all over the country.
Buyers can shop top lines and learn from renowned industry expert and salon trainer, Wendy Rivera ("Do You Speak Bride?"), during seminars held from 9 - 10 am Monday and Tuesday. Attend the always festive and fun<|fim_middle|> Blanche, House of Wu, Bonny Bridal, Ashley & Justin, Chic Nostalgia, Eddy K, Badgley Mischka Bridal, Alfred Angelo, Venus, Rachel Allen, Modeca, among many others.
For more information, visit: www.coutureshow.com or contact Susan Cain, Director of Couture, at scain@xogrp.com or Brett Olsen, Sales Manager, at bolsen@xogrp.com. | Knot Party at The W pool for cocktails and hors d'oeuvres on Sunday night.
During show hours, The Knot lounge, centrally located on the show floor, offers a coffee bar, lite bites and a place to relax. And shuttle service available to and from The W, The Bellagio, SLS Las Vegas and The Wynn hotels.
Exhibitors include Maggie Sottero, Allure Bridals, Mori Lee, Mon Cheri Bridals, Casablanca Bridal, JLM Couture, Jovani, Blush Prom, Justin Alexander, Jasmine, Moonlight Bridal, Azul by Liancarlo, Enzoani, Kenneth Winston, Calla | 142 |
Posted on August 22, 2020 August 22, 2020 by UntamedS
The eighties and nineties were the most glorious peak era of Xiangjiang.
At that time, the total GDP of a small city like Hong Kong was equivalent to 20% of the total GDP of the entire Chinese mainland.
The richest men in Asia were still in their infancy, the Pao family, the Huo family, and the "legendary" generation of thirty years later, were still in their prime.
Most importantly, Novartis, Pfizer, Ro<|fim_middle|> Sitian didn't wait for Li Zheng to object, and had already turned around and entered the house.
Li Zheng….
Li Zheng forced himself to calm down and raised his head to give Zhang Bingkun a polite smile, "Uncle Zhang, let's go."
Zhang Bingkun nodded and the two of them walked towards the Qinghe Town Cemetery in silence, one after the other.
Since he had just been buried, there were still flowers as well as wine glasses in front of Father Li's grave, but the flowers had already thanked him and the wine in the glasses had evaporated and dried up.
The moment he saw the tombstone, Zhang Bingkun knelt heavily on the ground before Li Zheng could speak, his knees colliding with the stone slab, making a clear crashing sound.
"Brother Li, I'm sorry to you…"
Zhang Bingkun and Father Li's relationship was quite deep, Zhang Bingkun had been running a black boat, walking the line of Shenzhen, Zhuhai, Xiangjiang, some years ago, when the crackdown, he was found by the marine police when running a black boat at night, he abandoned ship and jumped into the sea, it was father Li who saved him. In order to help him, Father Li embezzled the production team supplies, although it was only two bundles of gauze, but still because of this, he was caught by Yang Sheng, and resigned from the position of production team captain by taking the blame.
"I didn't know, I really didn't know that my sister-in-law was also on the boat, otherwise I wouldn't have sailed that boat." Ironically, Father Li saved Zhang Bingkun, but Mother Li left Qinghe town with Zhang Bingkun's boat and went to Xiangjiang.
Knowing this, Zhang Bingkun never went near the Li family again until he heard the news of Father Li's death.
"Uncle Zhang, I'm sorry." It could be heard from Zhou Sitian that Mother Li was not a person who was comfortable with firewood, she had nothing in common with Father Li, and it was only a matter of time before she left.
After paying his respects to Father Li, Zhang Bingkun didn't go to Li's family for dinner, and he stuffed Li Zheng with a large sum of money, which Li Zheng counted to be three or four thousand.
Li Zheng shook his head and laughed bitterly, but now he had all the money for the route and road expenses. Could it be that the heavens were hinting at him as well? Pushing this ridiculous thought down. Zhou Sitian was already a senior in high school, her grades were good, he couldn't be so selfish.
Even so, the idea of going to Hong Kong had already been planted in Li Zheng's heart, and it would take root as soon as the time was right.
It was the weekend, and last night, Li stayed up late to write a paper on "Butanotine Drug Production Catalyst". The annual sales of Danotin in Europe and North America alone amounted to nearly 5 billion U.S. dollars, and demand exceeded supply.
Its supply was limited by a lack of production capacity, but the main ingredient of tylenol was a crystalline compound extracted from animal liver, and often only a few dozen grams of crystals could be extracted from dozens of kilograms of animal liver, resulting in an extremely low conversion rate.
The catalyst mentioned in Li Zheng's thesis could increase the extraction rate of crystals from animal livers by 30%-50%, that is to say, under the same raw materials and production conditions, after using the catalyst, the output of nordin could be increased by 30%-50%, which was converted into sales of nearly two billion dollars, which was enough to make any pharmaceutical predator crazy.
When Li Zheng finished writing, he carefully folded up the letter paper, put it in an envelope with a good stamp, and pressed it under his pillow, which was his original capital.
However, his dream of a day's sleep was soon shattered.
Li Chaoyang's gibbering voice sounded outside the door, and not long after, Li Zheng only felt a pair of cold hands reach into his blanket.
Li Zheng fiercely opened his eyes.
"Hi, Li Zheng, good morning." Li Chaoyang smiled innocently.
Good…good your sister! Lab dogs have temperaments too!
Getting up, brushing his teeth, washing his face, Li Zheng was filled with low pressure, while Li Chaoyang seemed to be unaware of it, and was vigorously talking in Li Zheng's ear about a big official returning to his hometown or something.
Big official, where was the big official, even if there really was a big official, who cared what he did. In his last life, when he gave up his work at Cold Spring Harbor Laboratory to return to China, the State Academy General, Premier of the State Council even met him personally and praised him as a pillar of the nation!
By the time they were dragged to the auditorium, it was packed with people, townspeople stuck their necks out one by one to look at it upside down, many of the women still had babies in their arms, the cries of the babies echoed throughout the auditorium.
"What's the point of carrying a baby in this environment." Li Zheng frowned and said, "There are so many people and so many germs, it's very dangerous for a child who is just a few months old and has a weak immune system."
"It's just that they want to get a taste of Xie Wenjie's culture, that's the one who scored the best among the first batch of university students in our Qinghe Town, he's now in the Huaying Ministry of Health, this time he's accompanying the big leader to talk about some kind of project, I heard that if it's done, our entire Qinghe Town will be like Huaying Town, everyone will be able to live in big buildings!" Lee Chaoyang danced around and said.
The Ministry of Health? Project? A thought flashed through Li Zheng's mind and his eyes flashed, was it what he guessed…he would find out soon enough.
"Knock knock knock" the big gong sounded, the county and town leaders took the stage in turn, a young man with an upright stature among a group of old men with white hair looked particularly striking, and before Li Zheng could think about who this person was, an excited Li Chaoyang had already given his answer.
"Xie Wenjie, it's Xie Wenjie!" The frenzied look was similar to that of a young girl in later years seeing her idol.
On the auditorium stage, the county leader clapped his horn and began to speak.
"Folks, I've invited you here today to tell you two good news. First, our Xie Wenjie is back, Xie Wenjie is the pride of our Qinghe Town who went out and is now working at the Ministry of Health in Huaying . Second, he has brought a big project to our hometown! An investment by a large foreign corporation, Screw, it's called Screw isn't it, although the name of the corporation is a bit odd! But it is indeed a very big business! If this project succeeds, our economy in Qinghe Town will be even better!"
A round of applause broke out in the auditorium.
"Screw … The names of big foreign companies are so strange?" Li Chaoyang muttered softly.
Li Zheng's mouth twitched, screw, it was Roche, a Swiss pharmaceutical company, which had been ranked in the top ten in the global pharmaceutical companies. A few years before his sudden death in his previous life, Roche squeezed into the top three in the global pharmaceutical companies because of its advantages in cancer drugs.
Coincidentally, it was Roche who cooperated most closely with Li Zheng in his previous life, and he remembered that … David Andorio, his partner and future executive vice president of Roche Asia, seemed to be in Xiangjiang, living what he called the darkest "exile " in his life.
"Good folks, I'm glad to be back in Qinghe town again. Roche is the largest pharmaceutical company in Switzerland, one of the largest pharmaceutical companies in the world, and one of the top 500 in the world. Roche's visit to Yantian County is to find a suitable pharmaceutical factory site, which is one of the most important projects of the Ministry of Health this year, and it is also a great opportunity for Yantian County as a whole. As a native of Qinghe Town, I certainly hope that Qinghe Town can be selected among the birds. But this is inseparable from the help of the villagers … "
Life Zheng didn't listen to what Xie Wenjie said later. He searched in his mind. He didn't remember that Roche had a pharmaceutical factory in Shenzhen. Either it was closed, or the project was not successful at all. Li Zheng felt that most of it might be the latter.
Navleu says: Reply
Ohhh how can Li Zheng grasp this opportunity?!
C7—- Kill The Emperor[7] | che, Sanofi, Mertz, GlaxoSmithKline, and other top pharmaceutical companies all had offices in Hong Kong, which was much more convenient than the mainland where it took a month or two to send a letter.
It was just that in '82, Hong Kong was still under the control of the British Empire, and it was almost impossible for a minor without a guardian to get a permit to go to Hong Kong. What was more, even if one were to go to Xiangjiang, it wasn't easy to start all over again when one was unfamiliar with life.
"What are you a kid thinking so much about, you ah, just study hard. If you get into university, you won't have to worry about anything in the future!" Zhou Sitian poked her brother's head, then patted the back seat of the bike, "Come on up, no one will laugh at you now that no one is here."
Li Zheng was dumbfounded, it turned out that she thought he didn't sit in the back seat of the car because he was afraid of his classmates seeing it. He…he was unable to overcome the shame!
It was a good idea to sit on it, as Dongliu Town was five or six kilometers away from Qinghe Town, so they couldn't really walk back.
Passing through an alley, the younger brother and sister saw a man standing at the door of the house with his head down and a cigarette in his mouth.
Li Zheng got off the bike and swept his gaze around the man, seven or eight cigarette butts were messily distributed on the ground, it seemed like he had been waiting for a long time.
"Uncle Zhang?" Zhou Sitian called out slightly hesitantly.
Zhang Bingkun's head snapped up, saw Li Zheng and Zhou Sitian, and casually threw his cigarette to the ground, stomping it out.
"Sitian, little Zheng…" he opened his mouth, seemingly unsure of what to say. His eyes were a little red, his beard hadn't been shaved for days, and his mouth was ringed with fine stubble.
"Uncle Zhang, go sit at inside." Zhou Sitiain said as she stepped forward to open the door.
"No…no." Zhang Bingkun shook his head, "I'm here to see Brother Li. Take me to see him." His voice was suppressed with sadness.
Li Zheng lowered his head like an ostrich, the last thing he wanted right now was to see an acquaintance of the original owner, especially one that was not easy to fool at a glance. But Zhou Sitian clearly didn't pick up his signal.
"Little Zheng, you should accompany Uncle Zhang, I'll go prepare dinner." Zhou | 562 |
Two sculptures were installed in Geneva, NY (USA) as a part of Geneva's just-completed Phase I Lakefront Access Improvement Project. The two pieces were<|fim_middle|> so much time! Unfolding was generously donated by the George D. and Freida B. Abraham Foundation.
This instal comes on the heels of the installation of "On Upward Wing" at Miichagn College (St. Joesph, MI) just a week prior. These three are joined by one other piece of public art at The Hartsbrook School (Hadley, MA) and Urban Rising (2014) which is to be installed at Hobart and William Smith Colleges (Geneva, NY)!
Lake Michigan College recently installed, "On Upward Wing" at their main campus in St. Joseph, Michigan. On Upward Wing was initially shown at the Krasl Arts Center's 2012 Biennial Sculpture Invitational. | selected by the city's Public Art Committee.
To have two more sculptures in the shared public realm is an honour, especially in a place where I have spent | 31 |
OSHA Upgrades its Small Business Assistance Web Site
OSHA has unveiled an enhanced Office of Small Business Assistance (OSBA) Web site. The site includes an improved "Safety Pays" eTool and a new Spanish language safety link. "OSHA continues to be at the forefront in developing and making resources and tools available to help employers provide a safe and healthful work environment," said Assistant Secretary of Labor for OSHA Edwin G. Foulke Jr. "The 'Safety Pays' eTool and the Spanish language safety link are examples of our commitment to better serve the needs of the small business community."
The /dcsp/smallbusiness/index.html Web site has been redesigned to highlight categorical pages, or tabs, for easier navigation and data access. The new format showcases focal points, new products, and links. The site provides a wide variety of safety and health tools, products, and information for small businesses. The OSBA Web site features an updated "Safety Pays" eTool to help employers estimate the costs of occupational injuries and illnesses and the estimated impact on a company's profitability. This Web-based application allows businesses to identify direct and indirect costs of injuries and calculate the sales<|fim_middle|>. Visitors may access this link from the Small Business Assistance Web page. | needed to make up for these losses. Advantages of the "Safety Pays" tool include no downloading; access to updated loss-injury figures; automatic results after entering data in the appropriate fields; and the option to create and print additional forms online.
A new addition to the site, the Spanish link contains useful Spanish-language compliance assistance resources and tools developed by OSHA's State Consultation programs. The page provides small businesses with access to Spanish-language safety cards, booklets, and posters | 97 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.